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2 
Abstract 
 
Interferon Regulatory Factor 5 (IRF5) is a key transcription factor that regulates 
inflammatory responses by acting as a mediator of macrophage plasticity.  IRF5 is 
expressed at high levels in pro-inflammatory (M1) macrophages where it drives 
expression of characteristic M1 markers, such as IL-12p40, IL-12p35 and IL-23p19, 
and inhibits expression of typical markers of anti-inflammatory (M2) macrophages, 
like IL-10.  In this way, IRF5 polarises macrophages towards a pro-inflammatory 
phenotype. 
 
There are two modes of IRF5 activity: 1) direct binding to Interferon Stimulated 
Response Element (ISRE) sites in the DNA, and 2) indirect recruitment via protein-
protein interactions.  IRF5 can be indirectly recruited via interactions with the RelA 
subunit of Nuclear Factor kappa B (NFκB) at multiple inflammatory loci genome-
wide, including Tnf.  This suggests protein-protein interactions between the two 
factors are of great importance for driving inflammatory gene expression.  My 
research shows the IRF Association Domain (IAD) of IRF5 and the Dimerisation 
Domain (DD) of RelA form an interaction interface between the two proteins.  I have 
identified a short peptide, a region of IRF5 IAD sequence, that can bind to RelA, and 
hypothesise this peptide could block IRF5-RelA interactions, potentially dampening 
expression of inflammatory mediators co-regulated by these two factors.   
 
I have also identified a novel co-factor of IRF5: Krüppel Associated Protein 1 (KAP1) 
by a proteomic screen consisting of affinity purification coupled to mass 
spectrometry.  The IRF5-KAP1 complex is present in M1 macrophages, and absence 
of KAP1 in this cell type results in prolonged TNF secretion, suggesting that KAP1 is 
important for ‘switching off’ Tnf gene expression.  Further investigation showed KAP1 
is important for regulation of a heterochromatin (H3K9me3) environment downstream 
of the Tnf locus. 
 
By understanding the IRF5 interactome, we hope to unravel and potentially 
manipulate the determinants of IRF5’s key role in inflammation in a cell-type and 
activity-specific manner. 
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1.0 – Introduction  
 
1.1 – The Immune System 
The immune system has evolved to protect the body from pathogenic invasion and 
infection; and does so by detecting the presence of foreign or ‘non-self’ antigens, 
belonging to microorganisms including bacteria, viruses, fungi and parasites, and 
ultimately eliminating these threats from the healthy ‘self’ tissues.  In order to be 
successful in this endeavour, the immune system is constantly adapting new 
mechanisms to prevent pathogen infiltration and disease progression, which could 
ultimately threaten host viability.  As a result, the vertebrate immune system is highly 
complex, consisting of multiple levels of both short- and long-term defences, 
involving anatomical, humoral and cellular components.  In line with this, pathogens 
themselves strive to develop novel means to evade immune responses in order to 
persist in the otherwise optimal survival conditions provided by the host.  In this 
manner, a delicate evolutionary balance exists between the survival needs of both 
the host and the pathogen.  Alongside this activity, the immune system also protects 
the body from damaged ‘self’ tissues, which also need to be eliminated to ensure the 
body remains healthy.  In some instances, known as ‘autoimmunity’, dysregulation of 
the immune system can occur, due to an inability to distinguish between ‘self’ and 
‘non-self’ antigens.  As a result, immune responses are directed toward healthy 
tissues, resulting in currently incurable conditions such as Rheumatoid Arthritis: an 
impromptu immune response directed at joint synovial tissue, leading to chronic 
inflammation and excessive joint damage (see Section 1.4.3). 
 
1.1.1 – Innate Immune Responses 
Innate immunity is the most primitive form of immunity, forming the first line of 
defence against invading pathogens in all classes of plant and animal life.  The 
innate immune response consists of a non-specific surveillance system that acts 
rapidly in response to infection to remove pathogens from the body via acute 
inflammation.  Inflammation is characterised by increased permeability of local blood 
vessels and enhanced blood flow to the infected region, resulting in heat, redness, 
swelling and pain.  Such conditions are driven by both cellular and humoral aspects 
of innate immunity, which together direct the second arm of immunity – the ‘adaptive’ 
immune system (vertebrates only) – to mediate a longer-lasting memorable approach 
to protection against the pathogen in question (see Section 1.1.3). 
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1.1.1.1 – Cellular Innate Immunity 
Innate immune responses are activated by phagocytic white blood cells – primarily 
macrophages and dendritic cells, but also granulocytes and monocytes to a certain 
degree (see Section 1.1.2).  Such phagocytes or their precursors migrate from the 
bloodstream and patrol tissues in order to identify infection, by means of recognising 
characteristic molecules on the surface of microbial pathogens by receptor-ligand 
interactions.  These invariant pathogen-associated molecular patterns (PAMPs), 
such as lipopolysaccharide (LPS) on the surface of gram-negative bacteria, are 
detected by germline-encoded pattern recognition receptors (PRRs) on the surface 
of the patrolling innate immune cells [1].  In addition, PRRs also recognise damage-
associated molecular patterns (DAMPs) from ‘self’ cells, resulting in a non-infectious 
inflammatory response.  DAMPs include cytosolic or nuclear proteins released by 
necrotic cells during tissue injury, or extracellular matrix molecules upregulated upon 
injury, such as tenascin-C [2].  The recognition of both PAMPs and DAMPs by PRRs 
means the innate immune system is activated by a large variety of pathogen/damage 
signals, making the initial phase of immunity a non-specific process.   
 
There are three types of PRR associated with the innate immune system – 1) 
transmembrane receptors, such as the Toll-like receptors (TLRs) and C-type lectins; 
2) cytosolic receptors, such as the retinoic acid-inducible gene I (RIG-I)-like receptors 
(RLRs) and nucleotide-binding domain and leucine-rich repeat-containing receptors 
(NLRs); and 3) secretory receptors, which act as part of the humoral aspect of innate 
immunity.  13 mammalian TLRs are currently described [3], each recognising a 
different range of microbial PAMPs and exhibiting differential expression across a 
range of cell types.  This enables different immune cells to specialise in the 
elimination of different pathogens via TLR recognition [4].  TLRs can be associated 
with the plasma membrane, from which they detect microbial cell surface marker 
PAMPs; or with endosomal/lysosomal organelles, from which they detect intracellular 
microbial nucleic acid PAMPs.  TLR signalling following receptor ligation can be 
divided into two main pathways – the MyD88-dependent pathway and the MyD88-
independent, or TRIF pathway, according to the adaptor protein that each TLR 
utilises via reciprocal TIR (Toll/Interleukin-1 receptor) domain interactions [5].  Most 
TLRs signal via MyD88, however TLR3 signals exclusively via the TRIF pathway, 
and TLR4 signals via both MyD88 and TRIF [6] (see Figure 1.5), providing specificity 
in the transcriptional responses triggered by each TLR.  In comparison to the large 
TLR family, the C-type lectins consist of Dectin-1 and Dectin-2, which detect fungal 
cell wall components [7].  Cytosolic RLRs are expressed by most cell types, 
Chapter 1 - Introduction 
16 
functioning in the detection of viral pathogens [8]; and NLRs activate the multi-protein 
inflammasome complex following detection of pathogen degradation products and 
‘self’ stress signals (DAMPs) [9]. 
 
Downstream signalling events following PRR ligation lead to the activation of 
transcription factors, such as Nuclear Factor kappa B (NFκB) and the Interferon 
Regulatory Factors (IRFs), which drive gene expression of pro-inflammatory 
mediators, such as the cytokines TNF and IL-1β, chemokines like IL-8 and anti-viral 
factors such as Type I Interferons (IFN).  Upon release of these inflammatory factors, 
other immune cells - including those of the adaptive immune system (B-cells and T-
cells) - become recruited to the site of infection by chemotactic attraction and 
activated; hence the swelling and redness associated with inflamed tissue (see 
Section 1.1.3).  Whilst the immune response is being propagated, the innate 
phagocytes then begin the elimination process of invading microbial pathogens by 
engulfing them by endocytosis and digesting them intracellularly via lysosome fusion. 
 
1.1.1.2 – Humoral Innate Immunity 
The humoral arm of innate immunity includes the production of anti-microbial 
peptides by innate immune cells, which circulate in the bloodstream/tissues and can 
bind electrostatically to bacterial surfaces in order to disrupt the cell membrane and 
eliminate pathogens by cell lysis [10].  Opsonisation is also an important aspect of 
humoral innate immunity, in which the binding of B-cell produced antibodies (see 
Section 1.1.3.2) such as IgG, and liver-derived complement molecules such as C3b, 
to microbial antigens marks a pathogen for engulfment and digestion by specialised 
phagocytic innate immune cells.  Opsonisation is effective as antibody/complement 
molecule binding overrides the charge of the antigen membrane, making optimal 
attachment sites for Fc receptor/CR1 docking by phagocytic cells [11, 12]. 
 
1.1.2 – Cells of the innate immune system 
As the vertebrate immune system has evolved over time, so has its repertoire of 
immune cells, in order to shift the evolutionary balance in favour of the host by 
increasing the efficiency of immune responses and preventing pathogen survival. 
 
1.1.2.1 – Monocytes 
Monocytes constitute 5-10% of circulating lymphocytes and are derived from 
common myeloid progenitors (CMPs) that originate from haematopoietic stem cells 
(HSCs) in the bone marrow (see Figure 1.1). The growth factor M-CSF (macrophage 
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colony-stimulating factor) has been shown to be crucial for monocyte development, 
as demonstrated by the fact that Csf1-/- (M-CSF) or Csf1r-/- (M-CSFR/CD115) mice 
exhibit a severe reduction in monocyte cell numbers [13, 14].  Consequently, 
monocytes can be characterised by their expression of CD115, as well as a lack of 
expression of CD4 and CD19 (T-cell and B-cell markers respectively).   
 
Following migration from the circulation, monocytes act as precursors to 
macrophages and dendritic cells, which differentiate in situ according to the local 
cytokine milieu of the resident tissue [15, 16].  There are several sub-types of 
monocytes described, each with varying abilities to perform phagocytosis and 
produce inflammatory mediators.  80% of monocytes in the blood are CD14+CD16-, 
and can be described as anti-inflammatory due to their ability to produce IL-10, which 
can down-regulate the M1 phenotype of macrophages (see Section 1.1.2.2) [17-19].  
A high proportion of CD14+CD16+ monocytes, which are able to produce the pro-
inflammatory cytokines TNF and IL-1β upon LPS stimulation, have been identified at 
sites of inflammation [20].  Both CD14+CD16- and CD14+CD16+ monocytes are able 
to efficiently perform phagocytosis [21].  In contrast, CD14dimCD16+ monocytes are 
poor phagocytes due to a lack of Fc receptor expression, and are only activated to 
produce TNF and IL-1β by viral DNA and DNA-containing immune complexes [22]. 
 
1.1.2.2 – Macrophages 
Macrophages are phagocytic cells (from the Greek meaning ‘large eater’) that were 
first identified in 1884 by Elie Metchnikoff, forming the basis of innate immunity.  
Macrophages are differentiated from monocytes, and demonstrate a great degree of 
plasticity in terms of their phenotype in response to stimulation by cytokines and 
infection, making them a very heterogeneous cell population, which responds 
specifically according to the local tissue microenvironment to dynamically transition 
between different functional states.  Similarly to the TH1/TH2 polarisation concept of 
T-cells [23] (see Section 1.1.3.1), macrophages can be classified as either M1 
(classically activated) or M2 (alternatively activated) according to their phenotype 
(see Figure 1.1) [24].  M1 macrophages produce high levels of the pro-inflammatory 
cytokines IL-12 and IL-23, and low levels of IL-10; whereas M2 macrophages 
produce the converse – high levels of IL-10 and minimal amounts of IL-12 and IL-23, 
thus promoting tissue-repair and remodelling activity rather than inflammation [25].  
M1 macrophages also express MHC class II for antigen presentation, IL-1R1 and the 
T-cell co-stimulatory molecules CD80/CD86; whereas M2 macrophages express the 
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mannose receptor CD206, the TLR4 co-receptor CD14 and the scavenger receptors 
CD163/CD204/CD36 [26-28]. 
 
M1 macrophages can be generated by activation of resting cells with the TH1 
cytokine IFNγ, which results in increased production of pro-inflammatory cytokines, 
and an increased capacity for antigen-presentation and killing of intracellular 
pathogens [29].  M1 macrophage gene expression is therefore associated with acute 
infections that induce strong TH1/TH17 (IFNγ-producing) responses, such as 
Mycobacterium tuberculosis, Salmonella typhi (typhoid fever) and Salmonella 
typhimurium (gastroenteritis) [30, 31].  As IL-12 and it’s family member IL-23 activate 
naïve T-cells toward TH1/TH17 phenotypes respectively, the protective role of M1 
macrophages in such infections can be highlighted by mice deficient in constituents 
of the IL-12 family signalling pathway [32].  Although effective in controlling TH1/TH17-
activating infections, prolonged or excessive M1 polarisation of macrophages can 
also be harmful to the host, such as in the case of E.coli-induced sepsis.  High 
concentrations of M1-characteristic cytokines - which are also produced by E.coli-
derived LPS stimulation of macrophages in vitro – are observed in the serum of 
patients with sepsis, which results in tissue and organ damage driven by systemic 
inflammation [33, 34].  
 
Conversely to M1 macrophages, M2 macrophages are associated with TH2 
responses to parasitic infections such as the nematode Nippostrongylus, resulting in 
effector functions such as encapsulation.  Tumour-associated macrophages are 
considered to have an M2 phenotype due to their expression of M2-associated 
markers such as IL-10 and TGFβ [35].   The M2 macrophage phenotype can be 
generated by priming with IL-4 and IL-13; which are produced by activated TH2 cells 
and both signal via the IL-4Rα chain [36-38].  There is some controversy associated 
with this differentiation protocol in vitro, when used in combination with IFNγ priming 
to produce M2/M1 macrophages respectively; as while IFNγ alone induces M1 
cytokine expression, IL-4/IL-13 priming requires additional TLR stimulation with LPS 
to drive M2 gene expression.  As a result, many labs use the alternative 
differentiation protocol of GM-CSF+LPS for M1 macrophages and M-CSF+LPS for 
M2 macrophages (see Figure 1.1), as these are considered more comparable due to 
both phenotypes receiving LPS stimulation [39].  Whereas M-CSF is crucial for 
monocyte/macrophage differentiation, Csf2-/- (GM-CSF) mice show only defective 
alveolar macrophage differentiation, which suggests that GM-CSF plays a role in 
macrophage plasticity but not myeloid lineage commitment [40].  It is likely that in the 
Chapter 1 - Introduction 
19 
complex environment in vivo, macrophages are exposed to multiple differentiation 
stimuli at a given moment, and therefore adopt less-defined functional profiles that 
are merged across the M1-M2 spectrum, rather than stable differentiation (see 
Section 1.3.5 /Figure 1.1 for transcriptional regulation of macrophage polarisation). 
Figure 1.1: Macrophage differentiation and polarisation 
Common Myeloid Progenitor (CMP) cells in the bone marrow are differentiated to peripheral blood 
mononuclear cells, including monocytes and neutrophils, which migrate from the bone marrow to 
circulate in the blood.  Differentiation of CMPs into monocytes is driven by the lineage-defining factors 
PU.1 and IRF8, in combination with IRF4.  In contrast, IRF8 inhibits the differentiation of CMPs into 
neutrophils, thus polarising differentiation of CMPs toward monocytes/macrophages.  Monocytes in the 
blood migrate into tissues where they come into contact with growth factors, which are produced in the 
tissue environment by local cells.  Under normal homeostatic conditions, monocytes come into contact 
with M2-driving factors such as M-CSF, IL-4 and IL-13, leading to their differentiation to M2 
macrophages.   The expression of phenotypic M2 markers is driven by IRF4, and inhibited by IRF5.  
Under inflammatory conditions, monocytes come into contact with M1-driving factors such as GM-CSF 
and IFNγ, which are produced locally by immune cells responding to the infection, thus leading to M1 
macrophage differentiation.  The expression of phenotypic M1 markers is driven by IRF5.  PU.1 and 
IRF8 act as markers for IRF4/IRF5 recruitment to the promoters/enhancers of characteristic 
macrophage marker genes. 
 
1.1.2.3 – Dendritic cells 
Dendritic cells, like macrophages, are derived from monocytes and are highly 
phagocytic.  As they mature upon stimulation, they have an increased capacity to 
secrete cytokines and express MHC class II for antigen presentation to the adaptive 
immune system (see Section 1.1.3) [41].  They are also highly migratory, moving 
from tissues to the lymphoid organs in both steady state and inflammatory 
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conditions, according to the expression of CCR7 on the dendritic cell surface [42].  
Steady state dendritic cells can be categorised into two groups – conventional 
dendritic cells (cDCs), which have the ability to secrete IL-12 and can be further 
categorised according to their anatomical location (for example Langerhans cells in 
the skin epidermis); and plasmacytoid dendritic cells (pDCs), which secrete large 
amounts of Type I IFN in response to viral infections [43]. 
 
1.1.2.4 – NK cells 
Natural killer (NK) cells are cytotoxic lymphocytes that function in innate immunity 
and contribute 15% to total lymphocyte numbers.  NK cell development depends on 
the cytokine IL-15, which can be produced by monocytes and macrophages, and the 
downstream transcriptional activity of E4BP4, a member of the basic leucine zipper 
(bZIP) family [44].  NK cells are unique in the fact that they can detect stressed or 
infected cells that are lacking MHC class I expression (present on healthy cells), and 
are therefore crucial for tumour immunosurveillance.  They can also attack antibody-
opsonised pathogens as they express Fc receptors on the cell surface [45]. The 
primary mode of NK action is degranulation – the release of the contents of 
cytoplasmic granules, including perforin and proteases, in order to induce apoptosis 
or lysis of the invading pathogen.  NK cells provide an early source of pro-
inflammatory mediators such as TNF, GM-CSF and IFNγ, which propagate innate 
immune responses by activating the other cellular compartments [46]. 
 
1.1.2.5 – Granulocytes 
Granulocytes are innate polymorphonuclear cells that include neutrophils (60% of 
total white blood cells), eosinophils (1-6%) and basophils (0.3%).  Like monocytes, 
granulocytes originate from CMPs, from which they differentiate in the bone marrow 
before entering the bloodstream and migrating to infected tissues.  Granulocytes 
function as phagocytic first responders to infection, and also possess the ability to 
degranulate to release cytoplasmic granules containing numerous toxic compounds 
and enzymes that are harmful to bacteria, fungi and large multicellular pathogens 
that cannot be phagocytosed.  Granules can contain proteases, reactive oxygen 
species and perforins, which function to create pores in pathogens to mediate cell 
lysis or intracellular exposure to other granule components.  Basophil granules in 
particular can also contain histamine and heparin to increase vasodilation and blood 
flow to enhance inflammatory responses [47].  Eosinophil granules can also contain 
RNases, which function in anti-viral responses [48].  Neutrophils also have a unique 
function of releasing extracellular traps (NETs) composed of chromatin and 
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proteases, which can trap and kill microbes extracellularly [49].  During inflammatory 
responses granulocytes, similarly to macrophages, secrete multiple cytokines and 
chemokines that drive the further recruitment of innate and adaptive immune cells.  
In particular, basophils are thought to be the primary source of IL-4, which polarises 
naïve T-cells to a TH2 phenotype [50] (see Section 1.1.3.1).  Basophils and 
eosinophils in addition are important cellular components of allergic immune 
responses. 
 
1.1.3 – Activation of adaptive immunity by innate immunity 
Following phagocytosis of pathogens by innate cells such as macrophages and 
dendritic cells, antigens are processed at the endoplasmic reticulum and a molecular 
fraction of the antigen (the ‘epitope’) is transported to the cell surface within an MHC 
class II molecule for presentation to the adaptive immune system.  Intracellular 
antigens, such as viral nucleic acids, are processed in the same way, but epitopes 
are presented in the context of MHC class I rather than MHC class II.  Macrophages 
and dendritic cells are therefore described as antigen-presenting cells (APCs) [51]. 
 
1.1.3.1 – T-cell-mediated adaptive immunity 
T-lymphocytes, or T-cells, originate from bone marrow precursors, which migrate to 
the thymus where differentiation into naïve T-cells (T0) occurs.  T-cells express a T-
cell receptor (TCR), which is capable of recognising a wide range of epitopes 
presented on the surface of APCs due to its generation by random V(D)J 
recombination of the TCR gene segments [52, 53].  Whilst in the thymus, negative 
selection of naïve T-cells is performed, during which apoptosis occurs if the TCR 
recognises a ‘self’ antigen presented by an APC, in order to prevent the occurrence 
of autoimmunity.  Once this check has occurred, the naïve T-cells migrate to the 
peripheral lymphoid organs as either CD4+ T-helper cells or CD8+ cytotoxic T-cells 
[54], where they are activated during infection by two distinct signals from awaiting 
activated APCs – 1) TCR recognition of the APC epitope, and 2) a signal from the 
co-stimulatory molecules CD80/CD86 on the surface of the activated APC [55].  
Once activated, T0 cells proliferate and differentiate into the appropriate T-cell 
effector subset to respond to the microbial infection, according to the surrounding 
cytokine milieu.  Parallel to this, some of the proliferating T-cells become memory T-
cells, which enable faster future immune responses to the same pathogen, as they 
persist in an inactive state in the host for long periods [56]. 
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CD4+ T0 cells can differentiate into either TH1/TH2/TH17 or Treg cells.  TH1 cells 
differentiate in the presence of the cytokine IL-12, according to the activity of the 
transcription factor T-bet, which drives the expression of characteristic TH1 markers 
[57].  TH1 cells secrete IFNγ to activate macrophages (become M1 phenotype, see 
Section 1.1.2.2), dendritic cells and NK cells to increase their effector activity [58].  
TH2 cells differentiate in the presence of IL-4, as per the activity of the transcription 
factor GATA3 [59].  TH2 cells secrete IL-4, IL-5 and IL-13, which stimulate 
macrophages (become M2 phenotype, see Section 1.1.2.2), B-cells and eosinophils 
to drive allergic immune responses and eliminate large extracellular pathogens [60].  
TH17 cells are expanded by the cytokine IL-23 as mediated by the transcriptional 
activity of RORγT [61]; and secrete IL-17, which promotes tissue inflammation and 
neutrophil recruitment via the induction of pro-inflammatory cytokines and 
chemokines such as IL-1β, TNF, IL-6 and IL-8 [62].  As the IL-17 receptors are 
expressed on both hematopoietic and non-hematopoietic cells, this allows IL-17 to 
promote inflammation on multiple levels to clear pathogens that cannot be 
adequately eliminated by TH1 cells [62].  IL-17 can therefore be described as acting 
synergistically with pro-inflammatory cytokines like TNF [63].  In contrast to the CD4+ 
effector cell subsets, regulatory T-cells (Treg) suppress immune responses by 
producing IL-10/TGFβ, and are differentiated by the transcription factor FoxP3 [64]. 
 
CD8+ effector cells become cytotoxic T-cells (CTLs), which have similar granule-
related effector functions to NK cells, leading to direct lysis or apoptosis of pathogens 
(viruses in particular).  CTLs detect antigens presented by MHC class I via TCR 
interactions, which are stabilised by the CD8 co-receptor, and like TH cells require 
additional co-stimulatory activation via CD80/CD86 on the APC [65].   CTLs have the 
ability to produce inflammatory mediators such as TNF and IFNγ, and have a 
memory component to protect against future infections by the same pathogen [66]. 
 
1.1.3.2 – B-cell-mediated adaptive immunity 
B-lymphocytes (B-cells) are derived from common lymphoid progenitor (CLP) cells in 
the bone marrow, where they mature before migration to lymphoid tissues as 
transitional B-cells.  B-cells express a specific B-cell receptor (BCR), which has the 
ability to detect native antigens without the requirement of MHC molecules (as is the 
case for the TCR).  Following antigen detection, B-cells require a further signal from 
a TH cell (or in the case of T-cell-independent activation, a second signal from TLRs 
or multiple antigens cross-linking multiple BCRs) before they can proliferate and 
secrete free forms of the BCR, known as antibodies [67].  Mature effector B-cells are 
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either plasma cells (antibody-producing) or memory cells, which persist in the body to 
respond to future infections [68].  Antibodies, like the BCR from which they are 
derived, recognise a specific antigen and function to neutralise pathogen effects by 
marking them for phagocytosis and causing agglutination. 
 
Figure 1.2: Simplified overview of innate and adaptive immunity 
Monocytes migrate from the bloodstream during a microbial infection and differentiate into 
macrophages/dendritic cells in the presence of cytokines/growth factors.  Macrophages/dendritic cells 
detect microbial presence by PRR-PAMP interactions and phagocytose the pathogen, presenting an 
epitope on the cell surface in the context of MHC molecules.  The resulting activated APC produces 
cytokines and migrates to the lymph node where the epitope is detected by the TCR on a naïve T-cell, 
stimulating proliferation and differentiation into a T-helper cell, some of which become a memory 
component.  T-helper cells produce cytokines, which act on the other immune cells to propagate the 
inflammatory response.  B-cells also migrate from the blood and phagocytose pathogens, presenting 
them on the cell surface via the BCR.  Following antigen presentation to the TCR of a T-helper cell, the 
B-cell becomes activation to develop into a plasma cell (antibody-producing) or a memory cell.  
Antibodies opsonise pathogens, targeting them for phagocytosis by innate immune cells such as 
macrophages and neutrophils, which can also degranulate to eliminate infection. 
 
Antibodies are soluble Ig proteins composed structurally of two heavy and two light 
chains.  Like the TCR, antibodies are generated by V(D)J recombination of gene 
segments in order to create diversity in the hypervariable region (light chain) and 
therefore allow B-cells to recognise a huge number of antigens.  The heavy chain 
determines the isotype of the antibody, which is important for effector functions and 
can evolve (class-switching) throughout the B-cell lifespan in order to initiate a 
different effector function to the same antigen [68].  Similarly to T-cells, B-cells are 
tested for autoreactivity before they leave the bone marrow, and are prevented from 
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maturation if they are able to bind to self-antigen.  In this instance, the B-cell 
undergoes apoptosis during clonal selection or the BCR is edited before maturation 
continues.  Interestingly, B-cells are also phagocytic and act as APCs, suggesting 
that B-cells could provide an evolutionary link between innate and adaptive immunity. 
 
1.2 – Regulation of macrophage gene expression 
Transcriptional regulation of characteristic M1/M2 macrophage markers is paramount 
to driving the innate immune response to infection and ultimately resolving 
inflammation following pathogen elimination.  Transcription factors can therefore be 
described as molecular determinants of macrophage diversity. 
 
Transcription factors are DNA-binding proteins that are recruited to defined 
sequences across the genome in order to control the transcription of specific DNA 
loci into mRNA.  ChIP-seq studies have identified that transcription factors have the 
ability to bind to thousands of genomic sites, often in regions that are also associated 
with binding by other transcription factors and co-factors, with which the formation of 
complexes by protein-protein interactions often occur.  Such binding ‘hot-spots’ of 
these trans-acting factors include the cis-regulatory elements known as promoters 
and enhancers.  Promoters are located in close proximity (upstream) to the gene that 
they regulate, whereas enhancers can be located much further away from the 
transcription start site (TSS), and do not even have to be located on the same 
chromosome [69].  Transcription factor binding to regulatory elements can have 
either a positive or negative effect on gene expression, depending on the 
transcription factor protein structure (possession of a transactivation domain) or its 
co-factors, which can affect RNA Polymerase II recruitment. 
 
Amongst the transcription factors present in macrophages, it is clear that there is a 
degree of hierarchy determining transcriptional organisation [70].  Pioneer cell 
lineage-specific transcription factors, such as PU.1, initially influence the epigenetic 
state of the DNA in order to increase chromatin accessibility of enhancer regions 
(see Section 1.2.1).  Following this, static transcription factors are recruited to the 
DNA, such as ATF3, which regulate basal gene expression levels within 
macrophages.  Finally, upon stimulation of macrophages by PAMPs/DAMPs, 
dynamic inducible transcription factors such as NFκB (see Section 1.2.2) and the 
IRFs (see Section 1.3) are recruited to the DNA to activate environmental-specific 
genes [70-72]. 
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1.2.1 – Role of PU.1 and epigenetics in macrophage gene expression  
Via protein-protein interactions, transcription factors can recruit enzymatic co-factors 
to the DNA, in order to alter the chromatin environment and manipulate gene 
expression in an epigenetic manner.  Histone acetylation is a dynamic chromatin 
modification associated with active gene transcription [73, 74]; and is controlled by 
the counteracting effects of histone acetyltransferases (HATs) or histone 
deacetylases (HDACs) recruited to the DNA by transcription factors in response to 
changing environmental signals or position in the cell cycle [75] (see Figure 1.3).   
For example, acetylation of histone 3 at lysine 9 (H3K9Ac) is associated with regions 
of chromatin undergoing transcription (acetylation ‘loosens’ DNA-histone interactions, 
allowing the DNA to be more accessible to transcription factors); and therefore 
deacetylation of H3K9 would suggest transcriptional repression at this region.  
Counter to the enzymes that regulate acetylation, histone methyltransferases (HMTs) 
can also be recruited to the chromatin, resulting in methylation of histone tails, which 
is often associated with transcriptional repression, for example trimethylation of 
histone 3 at lysine 9 (H3K9me3).  Chromatin methylation marks can be removed by 
histone demethylases (HDMs) (see Figure 1.3), which work alongside HATs to 
promote an environment conducive to active transcription. 
Figure 1.3: Enzymatic regulation of the chromatin environment 
Heterochromatin, or ‘closed’ chromatin environments that are conducive to transcriptional repression 
are mediated by HMTs, which deposit methylation marks on histone tails, and HDACs, which remove 
acetylation marks, leading to a compact chromatin phenotype.  Euchromatin, or ‘open’ chromatin allows 
transcriptional activation, as acetylation marks deposited by HATs allow the chromatin to loosen and 
become accessible to transcription factors.  HDMs remove methylation marks to promote euchromatin. 
 
Enhancer sites across the genome (approximately 40,000 sites) are highly cell-type 
specific, and can be identified by their characteristic chromatin environment, which 
includes monomethylation of lysine 4 in histone 3 (H3K4me1) as well as acetylation 
of lysine 27 in histone 3 (H3K27Ac) - a mark of an active enhancer.  Additionally, 
enhancers are DNase hypersensitive due to increased accessibility of the DNA, and 
are often occupied by transcriptional co-activators such as the HAT p300.  PU.1 is 
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associated with nearly all macrophage genomic enhancers, suggesting that PU.1 is 
involved in deposition of H3K4me1 and maintenance of macrophage identity by 
dictating the enhancer repertoire of this cell type [76].  It is undetermined whether 
PU.1 also promotes deposition of H3K4me3 at gene promoters, or whether the PU.1 
regulatory landscape is strictly enhancer-specific. 
 
As well as dictating the enhancer regions to which inducible transcription factors 
should be recruited in macrophages, PU.1 is also required for CMP generation and 
induces myeloid lineage specification, according to the balance of PU.1 levels with 
other antagonising factors [77].  For example, higher levels of PU.1 antagonise the 
activity of C/EBPα to drive monocyte rather than granulocyte differentiation [78].  One 
mode of action of PU.1 to drive monocyte differentiation is to directly transactivate 
the Csf1 (M-CSF) promoter [79].  Accordingly, Spi1-/- (PU.1) myeloid progenitors do 
not express M-CSF and Spi1-/- mice do not possess cells of the 
monocyte/macrophage lineage [80].  PU.1 itself is transcriptionally regulated by 
RUNX1 (Runt-related transcription factor 1), which is also an absolute requirement 
for myeloid lineage specification and differentiation [81, 82]. 
 
1.2.2 – Nuclear Factor kappa B (NFκB) family of transcription factors 
The NFκB family has been extensively studied since its discovery in the 1980’s; and 
has been shown to be involved in numerous pathways, including inflammation, cell 
survival, proliferation and differentiation [83].  The NFκB family consists of five 
subunits, which homo- or heterodimerise to form transcription factors: p50 
(processed from p105), p52 (processed from p100), p65 (also known as RelA), RelB 
and c-Rel.  The subunits present in each NFκB dimer determine the biological activity 
of the complex, due to the presence of different functional domains in the interacting 
proteins.  All five of the NFκB family members contain an N-terminal Rel-homology 
domain (RHD) – a highly conserved domain that has the potential to mediate DNA-
binding at an NFκB (κB) consensus sequence (GGGRNYYYCC) [84]; whereas only 
RelA, RelB and cRel contain C-terminal transactivation domains (TAD) that enable 
interaction with other transcription factors and coactivators [85].  Of the fifteen 
potential dimers of NFκB, three bind to DNA but lack transcriptional activity (p50:p50, 
p52:p52 and p50:p52, due to lack of TAD) and three are not known to bind to DNA 
(RelA:RelB, cRel:RelB and RelB:RelB); leaving nine potential transcriptional 
activators [86].  The most common activating form of NFκB is RelA:p50, which has 
been shown to be present in activated macrophages [87].   
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In unstimulated cells, NFκB is found in the cytosol where it is rendered inactive by 
binding of members of the IκB family (such as IκBα); which mask the NFκB nuclear 
localisation sequence resulting in prevention of nuclear translocation and inhibition of 
transcriptional activation of gene targets [83].  Following IκB phosphorylation by the 
IKK complex (IKKα, IKKβ and IKKγ); IκBα is targeted for degradation by the 
ubiquitin/proteasome pathway and the active NFκB dimer is able to translocate to the 
nucleus [83] (see Figure 1.5).  Down-regulation of NFκB activity coincides with the 
reappearance of IκBα, which enters the nucleus and binds to the NFκB dimer, 
returning the transcription factor to the cytosol, where it is sequestered unless the 
activating stimulus is still present [83].  The IκBα gene promoter contains 11 NFκB 
consensus sequences, making it extremely responsive to NFκB activation; 
highlighting the rapid and transient regulation of the system, which enables 
prevention of a persistent response that could lead to pathogenesis [83].  The C-
termini of p100 and p105 contain ankyrin repeats (like the IκBs) so can also serve as 
inhibitors to sequester NFκB in the cytoplasm [88, 89]. 
 
There are two separate pathways for NFκB activation – the ‘canonical’ pathway, 
triggered by PAMPs and proinflammatory cytokines such as TNF and IL-1β; and the 
‘alternative’ pathway, triggered by TNF-family cytokines (but not TNF) such as 
lymphotoxin β, CD40 ligand, and receptor activator of NFκB ligand (RANKL) [90].  
The canonical pathway usually leads to the activation of RelA- or cRel-containing 
complexes; whereas the alternative pathway results in activation of RelB/p52 
complexes [90].  The NFκB family of transcription factors have been shown to control 
genes encoding many of the pro-inflammatory factors associated with autoimmune 
diseases such as Rheumatoid Arthritis (RA) (see Section 1.4.3.1), including Tnf - the 
gene locus of which is annotated with many putative NFκB binding sites [91, 92].  
This is highlighted by introduction of dominant-negative IκBα into human 
macrophages, which blocks TNF, IL-1β, IL-6 and IL-8 production on stimulation by 
LPS [93].  The introduction of dominant-negative IKKβ into RA synovial cell cultures 
was shown to inhibit IL-6, IL-8 and VEGF production [94], also suggesting the 
importance of the NFκB canonical pathway in RA.  The fact that NFκB is activated by 
most PRRs often leads to being referred to as the ‘master regulator of inflammation’. 
 
1.3 – Transcriptional activity of IRFs in macrophages 
The Interferon Regulatory Factor (IRF) family of transcription factors was originally 
implicated in anti-viral responses and Type I IFN production.  Subsequent studies 
Chapter 1 - Introduction 
28 
revealed their multifaceted role in regulation of anti-microbial responses and cell 
differentiation.  In particular, IRF8 is now known as one of the major factors 
regulating myeloid cell growth and differentiation, while IRF5 and IRF4 are 
associated with M1 and M2 macrophage polarisation respectively.  In addition, IRF 
factors appear to provide a mechanism for conferring signal specificity to expression 
of immune genes regulated by NFκB.  For example, IRF3, whose activation by 
upstream kinases occurs in response to TLR4 stimulation by LPS and TLR3 
stimulation by double stranded RNA (dsRNA) (see Figure 1.5), is not activated in 
many other NFκB inducing signalling pathways.  Another emerging feature of the IRF 
family is that different members of the family seem to target specific gene subsets, 
with IRF3 being essential for anti-viral Type I IFN responses, and IRF5 playing a key 
role in induction of pro-inflammatory cytokines and chemokines.  This section will 
discuss the multifaceted functions of IRF proteins in macrophage biology. 
 
1.3.1 - The IRF family of transcription factors 
The Interferon Regulatory Factor (IRF) family of transcription factors consists of nine 
family members in mammals:  IRF1, IRF2, IRF3, IRF4 (also known as PIP, LSIRF or 
ICSAT), IRF5, IRF6, IRF7, IRF8 (also known as ICSBP) and IRF9 (also known as 
ISGF3γ) [95].  The IRFs were first characterised as transcriptional regulators of Type 
I IFN and IFN-induced genes, but it is becoming clear that they play a pivotal role in 
both the regulation and development of host defence beyond the IFN system, and in 
particular in macrophages.  The members of the IRF family that have been shown to 
have important roles in macrophage biology include IRF1, IRF2, IRF3, IRF4, IRF5, 
IRF7 and IRF8, and will be discussed in this section.  In addition to macrophages, 
IRF1/IRF2 play important roles in NK cells, IRF6 is expressed in keratinocytes, 
IRF3/IRF7 regulate Type I IFN production by pDCs and fibroblasts, IRF1/IRF2/IRF4 
are active in T-cells, and IRF4/IRF5/IRF8 have roles in B-cells.  Further to their roles 
in immune regulation, the IRFs are also involved in regulation of the cell cycle, 
apoptosis and tumour suppression [96] (see Section 1.4.4).  
 
Structurally, the IRFs comprise a 120 amino acid DNA binding domain (DBD) at their 
N-terminus, which consists of five well-conserved tryptophan repeats (see Figure 
1.4), and shares structural homology with the Myb family of oncoproteins [97].  The 
IRF DBD forms a helix-turn-helix motif, and recognises a DNA sequence termed the 
Interferon-Stimulated Response Element (ISRE, A/GNGAAANNGAAACT) [98] of 
which 5’-GAAA-3’ is described as the core binding motif for the domain, as 
determined by analysis of the crystal structure of IRF1 in complex with DNA [99].  
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Virally encoded forms of the IRFs (vIRFs), such as those identified in the genomes of 
Human Herpes Virus 8 (HHV8) and Kaposi Sarcoma Herpes Virus (KHSV) [100, 
101], lack several of the tryptophan residues in the DBD, so cannot bind to DNA and 
act as dominant negative mutants of IRF proteins [102].  This highlights the 
importance of the IRFs in antiviral responses, if viruses are attempting strategies to 
overcome IRF activity in particular in order to propagate.   
Figure 1.4: Interferon Regulatory Factor (IRF) Family of Transcription Factors 
All IRFs are composed of a DNA binding domain (DBD – Orange) at the N-terminus, comprising of 5 
tryptophan residues.  The C-terminal regulatory domain usually contains an IRF Association Domain 
(IAD) of either Type 1 (IAD1 – Pink) or Type 2 (IAD2 – Purple).  Some IRFs contain repression domains 
(Green) and nuclear localisation signals (Dark blue).  Activity of IRF1, IRF3, IRF5 and IRF7 depends on 
phosphorylation events (Yellow).  Figure adapted from [103] 
 
At the C-terminus, most of the IRFs (except IRF1, IRF2 and IRF6) possess an IRF 
Association Domain (IAD) (see Figure 1.4), which is important for homo- and hetero-
dimer formation between IRF family members upon activation, and is structurally 
similar to the Mad-Homology 2 (MH2) domain of the Smad family of transcription 
factors [104, 105].  IRF1 and IRF2 possess a variation of the IAD domain, known as 
IAD2 (see Figure 1.4), which displays similarity to the PEST domain of PU.1.  The 
IAD is also an important interface for protein-protein interactions with unrelated 
proteins, such as PU.1 and STAT proteins, which can further define the nucleotide 
sequences adjacent to the core IRF-binding motif to which IRF complexes can bind. 
 
IRF transcriptional activities are varied, resulting in either activation and/or 
repression, often depending on the protein complexes formed with co-factors.  It can 
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be said that the unique function of an IRF is determined by many elements, 
including: cell-type and stage-specific expression, ability to activate or repress 
transcription of target genes, post-translational modifications, and ability to interact 
with other IRFs and transcriptional activators/repressors.  
 
1.3.2 - IRF1/IRF2: Positive and negative regulators of gene expression 
IRF1 and IRF2 were the first members of the IRF family to be described in 1988, and 
their discovery led to the search for more members of the IRF family, in particular 
those that respond directly to viral infection (IRF3/IRF7). 
 
1.3.2.1 - IRF1 positively regulates gene expression in macrophages 
IRF1 is expressed at low resting levels in many cell types, including T-cells, NK cells 
and macrophages, and is inducible by both IFNα and IFNβ, which highlights the role 
of IRF1 in Type I IFN responses [106].  IRF1 can bind to the ISRE element of the 
enhanceosome structure at the Ifnb1 promoter [99] (see Section 1.3.3.2); yet Irf1-/- 
mice are not impaired in IFNα or IFNβ production following viral infection [107], 
suggesting IRF1 may be involved in later phases of Type I IFN expression, possibly 
as part of an autocrine positive-feedback loop, as for IRF7 in fibroblasts [108]. 
 
IRF1 can also positively regulate expression of the genes encoding IL-12p40 and IL-
12p35 in macrophages; therefore Irf1-/- mice exhibit a severe defect in the production 
of IL-12, an essential cytokine for TH1 differentiation [109].  As a result, Irf1-/- mice 
exhibit a bias towards TH2-type immune responses and are unable to provide 
protection against Leishmania major infection [110].  A lack of NK cells in Irf1-/- mice 
[111] may also be partially responsible for the lack of IL-12 production, as NK cells 
produce IFNγ, which stimulates macrophages to produce IL-12.  The iNOS gene 
(Nos2) also fails to be induced in Irf1-/- macrophages, which means reduced levels of 
nitric oxide catalysis, which is key for the effector phase of TH1 responses [112]. 
 
IRF1 can interact directly with MyD88 [113], and TLR9 engagement induces post-
translational modifications that further activate IRF1 in a process known as ‘IRF1-
licensing’, which leads to more efficient migration into the nucleus than non-MyD88 
associated IRF1.  Irf1-/- macrophages stimulated with IFNγ plus CpG (TLR9 agonist) 
are therefore impaired in their production of IFNβ, iNOS and IL-12p35 [113].  Hence, 
IRF1 is critical for IFNγ enhancement of TLR-dependent gene induction. 
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1.3.2.2 - IRF2 can antagonise and co-operate with IRF1 in macrophages 
IRF2 is constitutively expressed in many cell types including B-cells, T-cells and 
macrophages, and is upregulated by direct binding of IRF1 or IRF9 to the Irf2 
promoter, and by IFNβ (although to a lesser extent than IRF1) [114].  Despite the 
lower inducibility of IRF2, an unstimulated cell normally contains more IRF2 than 
IRF1 protein due to higher stability (8 hours versus 30 minutes half-life respectively 
[115].  Unlike IRF1, IRF2 contains a repression domain (aa325-349), and can 
negatively regulate Type I IFN gene expression by competing with IRF1 for promoter 
binding sites.  IRF2 is therefore often considered an antagonist of IRF1 activity, and 
is important for inhibiting expression of target genes.  For example, IRF1 positively 
regulates caspase-1 (Casp1) gene expression, whereas IRF2 negatively regulates 
the same gene (Irf2-/- macrophages show enhanced expression of caspase-1, which 
may explain accelerated apoptosis upon IFNγ and LPS stimulation) [116].  It is 
thought that IRF2 acts as an inhibitor by acting as a substrate for histone 
acetyltransferase (HAT) enzymes such as PCAF and p300 [117], to inhibit core 
histone acetylation and promotion of an active euchromatin environment for 
transcription.  Similarly, vIRF1 can interact with p300 to inhibit core histone 
acetylation, which results in repressed transcription of IFN-responsive genes [118].   
 
Like IRF1, IRF2 is also important for TH1 differentiation, as Irf2-/- mice show impaired 
production of IL-12 by macrophages [119].  Interestingly, IRF2 may therefore be co-
operating with IRF1 to positively regulate IL-12 gene expression, rather than acting 
as a transcriptional repressor, as described above.  Alternatively, a lack of NK cells in 
Irf2-/- mice [120], like in the Irf1-/- mice, may also contribute to lower levels of IL-12 
production by macrophages, via a lack of IFNγ production.  On the other hand, the 
expansion of basophils in Irf2-/- mice, which results in increased production of IL-4, 
could be polarising macrophages to an M2 (IL-12low) phenotype and T-cells toward a 
TH2 phenotype [121].  In relative terms, IRF2 contributes less to IL-12 production 
than IRF1, and a direct effect of IRF2 at the IL12b promoter has not been detected; 
so it is likely that IRF2 mediates positive gene induction by interactions with IRF1 or 
IRF8 via its IAD2 domain. 
 
1.3.3 - IRF3 and IRF7: Regulation of Type I Interferon (IFN) responses 
IRF3 and IRF7 are important transcription factors that together with NFκB and AP-1 
regulate Type I IFN gene expression in macrophages – the production of anti-viral 
cytokines that are produced in response to viral infection to warn neighbouring cells. 
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1.3.3.1 - Activation of IRF3 and IRF7 in macrophages  
IRF3 is a constitutively expressed protein, which is not itself induced by Type I IFN or 
viral signalling [122].  Instead, IRF3 resides in the cytoplasm in its latent, inactive 
conformation, in which two autoinhibitory domains that flank the IRF3 IAD (aa9-240 
and aa380-427 [123]) are condensed so that the N-terminus and C-terminus of IRF3 
interact, thus masking the DBD and active hydrophobic surface of the IAD [104].  
Upon viral infection, phosphorylation of C-terminal residues of IRF3 occurs, leading 
to re-organisation of these autoinhibitory elements and unfolding of the IRF3 latent 
structure.  Consequently, this mediates realignment of the DBD and increased 
accessibility of the IAD interface, which enables homo- or hetero-dimerisation of 
IRF3 and interactions with co-activator molecules such as CBP/p300, both of which 
are essential for IRF3 transcriptional activity.  Studies in vitro and in fibroblasts have 
identified that the crucial serine residues for alleviation of IRF3 autoinhibition are 
located in two C-terminal clusters: ‘Site 1’ (Ser385-Ser386) and ‘Site 2’ (Ser396-
Ser405) [124, 125].  It has since been determined that IRF5 and IRF7 also possess 
autoinhibitory domains (aa455-504 and aa238-410 respectively); therefore post-
translational phosphorylation events are also crucial for IRF5 and IRF7 activation 
[126, 127].   
 
IRF7 is highly homologous to IRF3, yet unlike IRF3 its expression is strongly induced 
by Type I IFN signalling.  IRF7 is expressed to high levels in plasmacytoid dendritic 
cells (pDCs), and low basal levels are present in many other cell types including 
macrophages [102].  Latent IRF7 molecules reside in the cytoplasm in an 
autoinhibitory conformation, similar to IRF3.  However the majority of IRF7 molecules 
are generated during the onset of viral infection, in particular by Interferon-Stimulated 
Gene Factor 3 (ISGF3), a heterotrimeric transcriptional activator complex consisting 
of IRF9 (induced by IFNγ), STAT1 and STAT2, which is triggered upon binding of 
Type I IFNs to their receptor and goes on to bind to the Irf7 promoter [128] (see 
Figure 1.5).  Newly synthesised and basal IRF7 molecules are activated by 
phosphorylation to induce dimerisation and nuclear translocation, and the region 
Ser471-Ser487 contains the critical phosphorylation sites [129], as mutation of these 
residues results in abrogation of IRF7s ability to transactivate Type I IFN promoters 
in fibroblasts [127].  
 
1.3.3.2 - IRF3/IRF7 are integral to the IFNβ enhanceosome 
Macrophages defective in the expression of both IRF3 and IRF7 completely fail to 
induce Type I IFN responses, and only reconstitution of both of these proteins 
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together results in a normal anti-viral response, demonstrating that IRF3 and IRF7 
have essential and distinct roles in Type I IFN gene expression [130].  IRF3 and IRF7 
can form homo- or hetero-dimers with each other once activated, and in particular 
have been shown to co-operate in IFNβ induction, as part of the enhanceosome 
structure that assembles in a 60bp virus-inducible region of the Ifnb1 promoter [131] 
(see Figure 1.5).  The enhanceosome consists of two IRF dimers (either IRF3 or 
IRF7 homo- or hetero-dimers), one NFκB dimer (RelA/p50) and one AP1 complex 
(ATF2/c-Jun) that independently bind to their respective binding sites, which are 
clustered together and described as the four Positive Regulatory Domains (PRD-IV) 
of Ifnb.  These transcription factor complexes cooperatively interact with one another, 
to form the complete enhanceosome structure, as shown by the crystal structure of 
the complex bound to DNA [131, 132].  This leads to the recruitment of histone acetyl 
transferase enzymes (HATs) and other chromatin remodelling activities that are 
necessary for the initiation of Ifnb1 gene expression [133].  It is thought that the 
enhanceosome complex is more stable and efficient at inducing transcription than 
any of the individual components bound independently to the promoter, therefore the 
enhanceosome is optimal for robust IFNβ production in response to viral infection, 
especially in the situation of limiting concentrations of key transcription factors [134].  
Alternative models of transcriptional regulation of the Ifnb gene have also been 
discussed: for example, in LPS-stimulated MDDCs (monocyte-derived dendritic cells) 
and macrophages, which are characterised by high levels of NFκB, the contribution 
of multiple functional κB (and possibly ISRE) sites outside of the enhanceosome 
region is essential for maximal level of gene induction [135] (see Figure 1.5). This is 
consistent with data that human macrophages rapidly produce IFNβ mRNA upon 
LPS stimulation in a response that subsides after 8 hours and is dependent on both 
IRF3 and NFκB [136].  Genome-wide analysis of gene expression in primary mouse 
B-cells and macrophages demonstrated that LPS induces a subset of ‘interferon 
regulated’ genes, including Ifnb1, Cxcl10, Ccl5, Isg15 and Ifit1 [137, 138].  Moreover, 
the ISRE was identified as the most significant motif enriched in the promoter 
sequences of LPS target genes, many of which were dependent on IRF3 [137].  
LPS-induced IRF3 is recruited to promoters of a subset of tightly regulated primary 
response genes, where it instigates nucleosome remodelling and promotes gene 
expression [139], thus portraying a non-viral role for IRF3 in macrophages. 
 
1.3.3.3 - Activation of IRF3 and IRF7 via the protein kinases TBK1/IKKε 
TBK1 (TANK-binding kinase I) and IKKε (Inhibitor of NFκB kinase ε) have been 
identified as two protein kinases with the ability to directly phosphorylate IRF3 and 
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IRF7 upon viral-activation, which is sufficient to facilitate their nuclear translocation 
and DNA binding [140].  As activation of NFκB is normal in Tbk1-/- and Ikki-/- cells, this 
demonstrates the specificity of these kinases in activating IRF3 and IRF7 and not 
NFκB.  Studies in fibroblasts suggest that TBK1 is principally involved in IRF3 and 
IRF7 activation, whereas IKKε has a more accessory role, in which it regulates only a 
subset of interferon-responsive anti-viral genes [141].  This is highlighted by the fact 
that reconstitution of Tbk1-/- cells with IKKε only partially compensates for the lack of 
TBK1 in terms of IRF3-induced Ifnb1 expression, which demonstrates only a partial 
redundancy between the two kinases [142], however this may be cell type-specific.   
Figure 1.5: Induction of Type I IFN in response to viral and bacterial stimulation in myeloid cells 
Viral dsRNA stimulates both transmembrane TLR3 and intracellular RIG-I/MDA5 receptors, resulting in 
the activation of the protein kinases TBK1 and IKKε.  These kinases are also activated by LPS 
stimulation of TLR4, via the TRIF adaptor protein (also the case for IRF3).  Phosphorylation of latent 
IRF7 (induced by the ISGF3 complex upon Type I/II Interferon signalling) and latent IRF3 by TBK1/IKKε 
leads to homo/hetero-dimerisation of activation IRF3 and IRF7, which translocate to the nucleus to form 
part of the IFNβ enhanceosome structure at the Ifnb1 promoter, along with AP-1 (c-Jun/ATF2) and 
NFκB (p65/p50).  NFκB is activated by both the MyD88-dependent and MyD88-independent (TRIF) 
pathways upon LPS stimulation of TLR4, leading to phosphorylation and degradation of the NFκB 
inhibitor (IκBα) by IKK kinases, which allows NFκB to translocate to the nucleus.  NFκB can form part of 
the enhanceosome structure at the Ifnb1 locus, as well as binding to downstream κB sites, all of which 
are crucial for maximal IFNβ production by myeloid cells. 
 
IRF3/IRF7 can be phosphorylated by TBK1/IKKε by either one of two pathways: the 
TLR-dependent pathway, or the TLR-independent cytosolic pathway, both of which 
converge at the point of TBK1 activation (see Figure 1.5).  Both IKKε and TBK1 
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associate with the PRR adaptor protein TRIF, and these interactions are facilitated 
by NAP1 (NAK-associated protein 1) [143].  IRF3 and IRF7 can therefore be 
activated by ligation of the TLRs that utilise TRIF as an adaptor, namely TLR3 and 
TLR4.  Interestingly, in mouse macrophages, IRF3 can be activated by both LPS and 
the dsRNA analogue poly(I:C), which mimic bacterial and viral infection of TLR4 and 
TLR3 respectively; however in human macrophages, only LPS (not poly(I:C)) seems 
to induce IFNβ via IRF3 [136, 144].  This suggests that in human macrophages, 
poly(I:C) activates alternative IRF3-independent pathways to those activated in 
mouse macrophages in order to induce Type I IFN gene expression. 
 
The TLR3 receptor is activated by viral PAMPs such as dsRNA, which is derived 
either directly from dsRNA viruses or from the replication intermediates of single-
stranded RNA (ssRNA) viruses.  TLR3 signalling is via the MyD88-independent 
pathway, which is dependent on the adaptor protein TRIF as well as TBK1, as Type I 
IFN production is impaired in macrophages from Trif-/- and Tbk1-/- mice stimulated 
with poly(I:C) [142, 145].  TRAF3 forms a complex with both TRIF and TBK1, which 
positively regulates TRIF-dependent Ifnb1 gene induction [146].  A complete immune 
response following TLR3 ligation requires both IRF3 and IRF7, as some gene 
expression is still observed in Irf3-/- cells stimulated with poly(I:C) [147].  
 
The TLR4 cell-surface receptor is activated by PAMPs such as bacterial LPS or viral 
components including the RSV fusion (F) protein.  TLR4 signalling leads to induction 
of the Ifnb1 gene, but not the Ifna genes; suggesting that this pathway activates IRF3 
rather than IRF7, as Irf3-/- cells do not produce IFNβ upon LPS stimulation whereas 
Irf7-/- cells exhibit a normal phenotype [148, 149].  Like TLR3, TLR4 signalling to Ifnb 
predominantly occurs via the MyD88-independent pathway, utilising the adaptor 
proteins TRIF and TRAM (TRIF-related adaptor molecule) to activate TBK1, as Ifnb1 
gene induction is also completely abolished in Tbk1-/- macrophages stimulated with 
LPS [142].  TLR4 activation by LPS also leads to the induction of pro-inflammatory 
cytokines via the MyD88-dependent pathway and the transcription factors 
IRF5/NFκB (see Sections 1.2.2 and 1.3.5). 
 
The cytosolic pathway is initiated when viral PAMPs, such as dsRNA, are detected 
intracellularly by the cytosolic receptors RIG-I and MDA5 (melanoma-differentiation-
associated gene 5) via the C-terminal RNA-helicase domains of these receptors 
[150, 151].  Once the dsRNA interacts with RIG-I/MDA5, the complex moves toward 
the mitochondria where RIG-I/MDA5 interact with their adaptor protein MAVS 
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(mitochondrial antiviral signalling protein) via reciprocal CARD (caspase recruitment 
domain) domains, present at the C-terminus of RIG-I/MDA5 and N-terminus of MAVS 
[152].  This leads to an indirect activation of TBK1, via the protein kinase TRAF3 
[153], resulting in subsequent phosphorylation of IRF3 and IRF7 to induce Type I 
IFNs; as well as recruitment of the signalling proteins FADD, RIP1 and TRAF6 to the 
C-terminal effector domain of MAVS, which leads to activation of NFκB and 
proinflammatory cytokine gene induction [154].  The integral role of MAVS in this 
process is demonstrated by impaired RIG-I/MDA5-mediated Type I IFN production in 
macrophages from MAVS-deficient mice [155].   
 
Figure 1.6: Suppression of IL12b expression by IRF3 via RIG-I signalling 
TLR signalling during a bacterial infection causes nuclear translocation of NFκB and IRF5, which 
activate the IL12b gene.  Activation of RIG-I/MDA5 by dsRNA during a viral infection leads to the 
activation of IRF3, which inhibits IRF5 recruitment to the IL12b locus.  This results in reduced production 
of the p40 subunit of IL-12 and IL-23, cytokines that are important for TH1 and TH17 differentiation and 
elimination of bacterial infection.  Figure adapted from [156]. 
 
Of interest, RIG-I activated IRF3 suppresses IL12b gene transcription via interfering 
with binding of IRF5, at the gene promoter [156] (see Figure 1.6). This results in 
attenuated IRF5-driven TH1 and TH17 cell differentiation (see Section 1.3.5.2), and 
consequently in death of mice at sub-lethal doses of bacterial infection [156]. 
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1.3.4 - IRF8: A lineage-defining factor for macrophages 
IRF8, also known as Interferon Consensus Sequence Binding Protein (ICSBP), was 
originally identified as a nuclear protein that binds to MHC class I genes [157].  IRF8 
is expressed in cells of the monocyte/macrophage lineage, as well as in B-cells and 
activated T-cells.  Irf8 mRNA expression is inducible by IFNγ, via STAT1 binding to 
an IFNγ activation site (GAS) in the Irf8 promoter [158].  IRF8 is also synergistically 
induced by IFNγ in combination with LPS; leading to interactions with TRAF6 [159], 
but not MyD88 [160] downstream of TLR signalling, which suggests suggesting a 
role for IRF8 in the cytoplasm.  Notch and RBP-J have also been recently described 
as regulators of IRF8 protein synthesis via the MNK1-eIF4E axis downstream of 
TLR4 signalling in macrophages [161] (see Figure 1.7).  This leads to enhanced 
expression of a subset of M1-phenotypic genes (see Section 1.1.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Regulation of IRF8 protein synthesis/M1 macrophage polarisation by Notch/RBP-J 
Notch1-RBP-J signalling, which occurs via the enzymatic activities of ADAM10 and γ-secretase, is 
essential for TLR4-induced expression of a subset of M1 macrophage markers.  RBP-J augments the 
activity of the MNK1-eIF4E axis, via IRAK2 and MAPK downstream of TLR4, to promoter IRF8 protein 
synthesis.  Subsequently, IRF8 drives the expression of a subset of M1 genes such as IL12a, IL12b and 
Nos2.  RBP-J is also able to suppress M2 marker gene induction, including the gene Jmjd3, which in 
turn regulates IRF4 expression (a key factor in M2 macrophage polarisation).  Figure adapted from [161] 
 
1.3.4.1 - IRF8 drives macrophage differentiation 
In macrophages, IRF8 is critical for regulation of myeloid cell growth and 
differentiation.  Irf8-/- mice harbour increased numbers of CMP cells, which are hyper-
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responsive to both GM-CSF and G-CSF (granulocyte colony-stimulating factor), and 
display a strong reduction in their response to M-CSF [162].  As a result, Irf8-/- 
myeloid progenitors give rise predominantly to granulocytes and few macrophages, 
even in the presence of M-CSF [162].  Accordingly, there is a reduction in the 
number of bone marrow cells expressing F4/80 and the M-CSF receptor in Irf8-/- mice 
[162], potentially due to accumulation of c-Cbl in the absence of IRF8, which acts as 
a ubiquitin ligase to target activated M-CSF receptor for degradation [163].  
Interestingly, the Nf1 gene (Ras-GFP Neurofibromatosis 1), which encodes a protein 
that inactivates Ras in haematopoietic cells, is reported to be a direct target of IRF8; 
and Nf1-/- mice exhibit myeloproliferative symptoms due to a hypersensitivity to GM-
CSF [164, 165].  A lack of IRF8 transcript has been observed in cells from human 
patients with Chronic Myelogenous Leukemia (CML) [166], a disease that is 
characterised by a marked increase in granulocytes.  The Irf8-/- mice also suffer from 
a syndrome that resembles human CML [167].  Following this, Irf8 expression 
declines as CMPs differentiate into granulocytes, and persists in differentiating 
macrophages, where IRF8 in complex with PU.1 regulates the expression of 
numerous macrophage target genes, including Prdm1 and Ctsc [166, 168].  This 
demonstrates that IRF8 acts as a lineage-selecting factor, and drives CMPs to 
differentiate into mature macrophages, whilst inhibiting granulocytic growth and 
differentiation [169].   
 
1.3.4.2 - Co-operative regulation of gene expression by IRF8 
IRF8 has been shown to both drive and inhibit expression of target genes.  Despite 
possessing the conserved IRF DBD, IRF8 usually only binds to DNA when it 
interacts with other transcription factors via its C-terminal IAD, such as IRF1, IRF2 or 
PU.1.  Conformational changes in IRF8 that occur when such interactions take place 
facilitate enhanced binding of both interaction partners to the DNA [170].  In complex 
with IRF1 or IRF2, IRF8 forms inhibitory complexes that repress IFNα- and IFNβ-
inducible genes in macrophages such as Isg15 by binding to an ISRE.  In contrast, 
when IRF8 (together with IRF1 and/or IRF2) interacts with PU.1 to bind to an IRF-Ets 
Composite Sequence (IECS), the complex induces expression of myeloid target 
genes such as Nox2 [171], Ncf2 [172], IL18 and IL12b [173].  As a consequence,  
Irf8-/- macrophages are defective in the production of IL-12p40 [174], nitric oxide and 
reactive oxygen species [175], thus have impaired development of TH1 responses 
and are highly susceptible to infection by multiple pathogens, including Listeria 
monocytogenes [175], Yersinia enterocolitica [176] and Toxoplasma gondii [177].  
Interestingly, once activated by IFNγ and STAT1, IRF8 as part of a multi-protein 
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complex can also bind to IFNγ activation sites (GAS) and regulate a second wave of 
transcription from GAS-promoters, therefore macrophages from Irf8-/- mice are also 
defective in the induction of some IFNγ-induced genes, even though STAT1 
activation is still intact [178].  As a result of working with co-factors, IRF8 is therefore 
able to bind to a variety of DNA motifs.  Interestingly, more evidence is gradually 
appearing that shows IRF8 is also able to bind directly to DNA, without the need of 
co-factors, for example genome-wide studies in macrophages and THP-1 cells have 
shown IRF8 binding to MHC Class I and II gene loci, and to the Irf9 locus 
independently of PU.1 [179, 180]. 
 
1.3.5 - IRF4/IRF5: Master regulators of M2/M1 macrophage polarisation 
Macrophages are functionally polarised into M1 or M2 cells in response to infection 
by microorganisms, in order to drive the appropriate immune response (see Figure 
1.1).  M1 macrophages are essential for clearing bacterial, viral and fungal infections, 
whereas M2 macrophages have an important role in responses to parasite infection, 
tissue remodelling, angiogenesis and tumour progression [181]. IRF5 and IRF4 have 
been identified as important factors in driving the expression of M1- and M2-related 
genes respectively, and to this effect have mirroring transcriptional roles in 
macrophage polarisation.  Interestingly, recent ChIP-seq studies have shown that 
IRF4 is recruited to the Irf5 promoter in murine bone marrow-derived dendritic cells 
[70].  Taking into account that IRF4 was shown to negatively regulate Irf5 promoter 
reporter activities [182], this may represent a direct mechanism of regulating 
macrophage polarity by inhibition of Irf5 gene expression. 
 
1.3.5.1 - IRF4 regulates macrophage differentiation and M2 polarisation 
IRF4, also known Pip (PU.1 interacting partner) and ICSAT (Interferon consensus 
sequence binding protein for activated T-cells), is expressed in immune cells 
including B-cells, T-cells and macrophages [183].  Like IRF3, activation of 
macrophages by LPS or IFNγ does not induce Irf4 expression, rather it induces 
conformational changes in the latent IRF4 protein to unmask its nuclear localisation 
sequence and drive nuclear translocation [183].  When bound to ISRE motifs, IRF4 
functions as a transcriptional repressor, such as in co-operation with IRF8 at the 
Isg15 promoter in macrophages [184].  Like other members of the IRF family, 
however, IRF4 can also form activating transcriptional complexes, such as with PU.1.  
For example, IRF4/PU.1 binds to an IECS in an upstream enhancer region of the 
IL1b gene in macrophages, which is inducible by LPS [185]. 
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Ectopic expression of IRF4 or IRF8 (which exhibit approximately 70% sequence 
homology) in myeloid progenitor cell lines leads to morphological changes consistent 
with differentiation into macrophages, including expression of CD11b, F4/80 and M-
CSF receptor, and strong phagocytic activity [186].  Interestingly, Irf4-/- mice do not 
exhibit an increase in granulocyte number; despite IRF4 (like IRF8) inhibiting the 
expression of the transcription factor Cebpe, which is essential for neutrophil 
differentiation [186].  Yet a lack of both IRF4 and IRF8 (Irf4-/-Irf8-/- double knock-out 
mice) seems to severely augment granulocyte differentiation and diminish 
macrophage numbers to a greater extent than observed in Irf8-/- single knock-out 
mice.  Concordant with this, Irf4-/-Irf8-/- mice suffer a more severe form of CML than 
Irf8-/- mice [186], and Irf4 transcript levels are also reduced in human CML patients 
[187].  This suggests that although IRF4 is important for macrophage differentiation 
from myeloid progenitors, its role is to co-operate with IRF8, which is the 
predominant factor driving this process.   
 
The fact that Irf4 expression is induced during macrophage differentiation (Irf8 in 
comparison is highly expressed in myeloid progenitors) also suggests a more 
secondary role for IRF4 during these early stages.  To this effect, an important role 
for IRF4 has been identified in the polarisation of macrophages toward an M2 
phenotype, which occurs following differentiation of myeloid progenitors into 
macrophages and migration into tissues.  Both chitin-induced (in vivo) and M-CSF 
differentiated bone marrow-derived (in vitro) macrophages from Irf4-/- mice have 
severely reduced expression of characteristic M2 macrophage markers, including 
Arg1, Chi3l3, Fizz1 and Mrc1 [188].  Consistent with this, ectopic expression of IRF4 
in Irf4-/- bone-marrow macrophages can rescue expression of these characteristic M2 
markers [188].  This therefore indicates that IRF4 specifically regulates macrophage 
polarisation to an M2-phenotype.  As macrophage M1-M2 plasticity is a fine balance, 
the reduced expression of M2 markers observed in the absence of IRF4 also means 
an increase in M1 markers, including TNF, IL-12 and IL-6, resulting in high 
susceptibility of Irf4-/- mice to LPS-induced endotoxic shock due to increased levels of 
pro-inflammatory cytokines [189].  Similarly, under more natural circumstances, the 
microRNA miR-125b can inhibit expression of Irf4 in macrophages, leading to an 
activated phenotype consistent with M1 polarisation [190].  It can therefore be said 
that IRF4 also negatively regulates the production of proinflammatory cytokines in 
response to TLR stimulation.  This is profoundly different to IRF8, which positively 
regulates the proinflammatory cytokine IL-12, showing that despite the high similarity 
of the IRF4 and IRF8 proteins, lower sequence homology at the C-terminus of IRF 
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proteins can lead to diverse transcriptional effects.  Consistent with a shift towards an 
M1 phenotype, Irf4-/- mice also exhibit faulty TH2 responses during Nippostrongylus 
brasiliensis helminth infection [191], for which defective M2 macrophages could be a 
contributing factor. 
 
The Irf4 gene itself is regulated by the histone demethylase JMJD3 (Jumonji domain 
containing-3); as H3K27 is differentially methylated at the Irf4 locus in Jmjd3-/- 
compared to wild-type macrophages [188].  As H3K27 trimethylation (H3K27me3) is 
an epigenetic mark for silenced gene expression, demethylation of H3K27 at the Irf4 
locus by JMJD3 drives Irf4 expression.  This demethylase activity is dependent upon 
the DNA-binding ability of JMJD3, indicating that Irf4 is a JMJD3 target gene.  Chitin-
elicited Jmjd3-/- macrophages are themselves deficient in Arg1, Chi3l3, Fizz1 and 
Mrc1, as are Jmjd3-/- macrophages isolated from the lung following infection with 
Nippostrongylus brasiliensis [188].  Interestingly, ectopic expression of IRF4 in 
Jmjd3-/- M-CSF differentiated bone-marrow macrophages also upregulates 
expression of M2 markers, which confirms that IRF4 is active in M2 macrophage 
polarisation downstream of JMJD3 [188]. 
 
1.3.5.2 - IRF5 regulates M1 macrophage polarisation  
IRF5 is expressed in immune cells including B-cells, dendritic cells and 
macrophages, and is activated by multiple TLRs and their corresponding ligands 
[192].  In particular, a significant fraction of IRF5 becomes detectable in the nucleus 
post-LPS, -ssRNA and –CpG DNA stimulation of murine macrophages, supporting 
the fact that TLR4, TLR7 and TLR9 invoke IRF5 nuclear translocation [193].  Like 
many of the IRF family members, post-translational modifications are crucial to 
switch IRF5 from its autoinhibitory to its active conformation.  In particular, 
phosphorylation of IRF5 at Ser425/427/430 is required for NDV-induced activation 
[126], which involves unfolding of the C-terminus of IRF5 to make the IAD accessible 
for dimerisation and protein-protein interactions.  Phosphorylation of Ser430 in 
particular is important for the structural changes that allow IRF5 to interact with the 
co-activator CBP [194].  IRF5 can be phosphorylated by IKKε and TBK1, like IRF3 
and IRF7, however TBK1 and IKKε do not seem to induce nuclear translocation of 
IRF5, so currently the kinases that activate IRF5 in vivo remain elusive [195]. 
 
Irf5-/- macrophages exhibit severely impaired induction of proinflammatory cytokines, 
a major contributing factor to the observed resistance of Irf5-/- mice to LPS- and CpG-
induced endotoxic shock [193], in stark comparison to the susceptibility observed by 
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Irf4-/- mice.  The Irf5-/- phenotype includes a marked decrease in both mRNA and 
serum protein levels of IL-6, TNF and IL-12p40 in response to TLR activation, which 
therefore suggests direct transcriptional activation of these genes by IRF5 [193].  
This is confirmed by the presence of ISREs in many proinflammatory gene 
promoters, including Tnf, IL12a, IL12b, IL23a, and IL6 to which IRF5 can bind [25, 
193].  Interestingly, IRF5 is also recruited to the promoter of the M2 marker, IL10, in 
M1 macrophages, where it seems to prevent recruitment of RNA polymerase II and 
inhibit IL10 gene induction [25].  IRF5 therefore exhibits diverse modes of 
transcriptional activity, like many other members of the IRF family, so the recruitment 
of IRF5 co-factors is likely to be an important factor in the ability of IRF5 to both 
positively and negatively regulate gene expression.  In this way, IRF5 is able to 
directly polarise macrophages toward a proinflammatory M1 phenotype – the 
opposite activity to IRF4 – and as a result polarises T-cells toward TH1 and TH17 
responses [196] (see Figure 1.1).   
 
Interestingly, many of the pro-inflammatory genes regulated by IRF5 also contain 
binding sites for NFκB in proximity to their promoters, which infers that IRF5 co-
operatively regulates these genes in combination with NFκB [193].  This makes 
sense, as NFκB is the universal regulator of inflammation downstream of all the 
TLRs.  Further investigation at the Tnf locus in particular has revealed two modes of 
transcriptional action of IRF5: both direct binding to ISREs in the Tnf 5’ region, and 
indirect binding of IRF5 to the 3’ of Tnf via protein-protein interactions with the NFκB 
subunit RelA at a κB site [197].  Depletion of IRF5 levels in M1 macrophages 
reduces Tnf gene induction upon LPS-stimulation down to the levels observed in M2 
macrophages, which only express minimal IRF5 protein [197].  This suggests that a 
role of IRF5 in M1 macrophages is to synergistically boost expression of a subset of 
NFκB regulated genes, to levels above those in M2 macrophages; which poses an 
opportunity for therapeutic intervention to reduce such exaggerated cytokine 
production by targeting IRF5 rather than the broader activity of NFκB.   
 
1.3.5.3 - IRF4/IRF5 compete to interact with MyD88 during TLR signalling 
IRF5 is differentially expressed in polarised macrophages, with high levels of 
expression in M1 macrophages and low expression in M2 macrophages, whereas 
IRF4 expression remains the same throughout polarisation [25].  This suggests that 
in order to mediate its proinflammatory transcriptional activity, IRF5 needs to 
overcome the presence of IRF4 and the ‘default’ setting of an M2 phenotype.   
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IRF5 can be activated by the TLR MyD88-dependent signalling pathway, for example 
in response to TLR9 activation, when IRF5 interacts with both MyD88 and TRAF6, 
which facilitates activation and translocation of IRF5 to the nucleus to induce ISRE-
containing gene promoters [193]. Interestingly, IRF4 is also activated by the MyD88-
dependent pathway, and can also directly interact with MyD88 [160].  The fact that 
Irf4-/- mice show enhanced activation of NFκB in response to LPS, as well as 
enhanced proinflammatory cytokine production, highlights the fact that IRF4 
negatively regulates innate immune responses by negatively modulating TLR 
signalling pathways.  Both IRF5 and IRF4 have been shown to bind to the same 
region of the MyD88 protein, which suggests that this is the point of competition for 
polarising activity, therefore TLR-induced IRF5 competes for MyD88-binding during 
inflammation, which leads to M1 polarisation and a proinflammatory response. 
 
1.4 – Interferon Regulatory Factor 5 (IRF5) 
IRF5 is a key transcription factor that modulates macrophage inflammatory 
responses downstream of TLR signalling, by driving the expression of pro-
inflammatory genes and the M1 macrophage phenotype.  How IRF5 itself is 
regulated transcriptionally and on a protein level still remains elusive information, 
however it is clear that dysregulation of IRF5 expression is associated with 
autoimmune disorders such as Rheumatoid Arthritis (RA) and Systemic Lupus 
Erythematosus (SLE).  Modulation of IRF5 expression or activity could therefore 
provide effective alternatives to current autoimmune therapies. 
 
1.4.1 – Irf5 gene structure and expression 
In humans, the Irf5 gene is located on chromosome 7q32 and consists of 9 coding 
exons plus one non-coding exon in the 5’ UTR, of which there are 3 variants (exon 
1A, 1B, and 1C), each encoding an alternative promoter for the Irf5 gene (P-V1, P-
V2, P-V3) [198].  There are nine known Irf5 isoforms created by mRNA splicing 
events (see Section 1.4.2), which have been shown to have differential expression in 
different cell types. IRF5-v1, -v2, and -v3/v4 (result in the same transcript) are 
expressed in human primary pDCs and macrophages, whereas IRF5-v5 and –v6 
were identified in human primary peripheral blood mononuclear cells (PBMCs) from 
healthy donors, and immortalised T-cell/B-cell malignancies [198].  IRF5-v7, -v8 and 
-v9 are only detected in human cancers [198].  The Irf5 isoforms, as shown in Figure 
1.8, have discrete transcription start sites (TSS) due to the utilisation of the described 
different exon 1 promoters.  The majority of Irf5 transcripts (-v1, -v4, -v5, -v6, -v7, -
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v8) derive from exon 1A, which contains an IRF binding site that is stimulated in 
virus-infected cells [198].  Exon 1C, the TSS for –v3, also contains an IRF binding 
site, which is responsive to IFN stimulation via the binding of the ISGF3 complex 
(contains IRF9) [198], so the Irf5 locus is regulated by other IRF family members.   
 
Another characteristic of the Irf5 gene is the strong 700bp CpG island (CGI) that 
spans the promoter region encoded by exon 1A and 1B.  Such GC-rich regions are 
predominantly non-methylated and associated with transcription initiation, so are 
therefore found at approximately 70% of promoters across the genome [199] – 
mostly those associated with housekeeping genes, but also tissue-specific genes 
and those involved in developmental regulation [200, 201].  Methylation of CGIs, 
particularly during development, leads to stable silencing of the associated promoter, 
due to direct inhibition of transcription factor binding.  A study of the chromatin 
environment at LPS-inducible genes in macrophages showed that CGIs are relatively 
nucleosome-deficient in a manner that is independent of SWI/SNF chromatin 
remodelling activity [139], suggesting that CGI-associated loci are relatively ‘open’ for 
access by transcriptional machinery.  In line with this, primary immune response 
genes often have CGIs in their promoter regions, whereas secondary response 
genes can require SWI/SNF remodelling activating in order to allow transcription 
factor and RNA polymerase II binding [202].  Macrophage CGI regions also exhibit 
low histone H3 and H1 density (high density is usually antagonistic to transcription), 
as well as high levels of H3K4me3 and H3K36me2, which are characteristic of a 
transcriptionally permissive state.  Active CGI promoters are also often enriched for 
binding sites of the transcription factor Sp1 – including at the Irf5 locus [203] - as 
DNA binding by Sp1 can in turn recruit RNA polymerase II and TATA-binding protein 
(TBP) to the region (even in the absence of a TATA box) [204] to promote 
transcription.  As a consequence, the CGI present at the Irf5 locus if non-methylated 
could explain the high level of expression of IRF5 in M1 macrophages, compared to 
M2 macrophages [197] or monocyte precursors [196, 205].  In concordance with this, 
it has been shown that CGIs in the Irf7 promoter can become methylated in the 
2fTGH cell line, leading to Irf7 gene silencing [206]. 
 
In contrast to the human Irf5 gene, murine Irf5 is located on chromosome 6, and is 
primarily expressed as a full-length transcript, with only a single splice variant; which 
is detected at low levels in the bone marrow of C57BL/6J mice and contains a 288-
nucleotide deletion in the coding region resulting in impaired transcriptional activity 
[207].  The alternative murine Irf5 isoform also lacks the ability to be ubiquitinated, 
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unlike the full-length transcript [208].  In vitro, murine IRF5 can be activated by both 
TBK1 and MyD88 to form homodimers, and mediates transcription of Type I IFN and 
proinflammatory cytokines, like its human counterpart [207]. 
 
Figure 1.8: Alternatively-spliced isoform variants of IRF5 
Nine different splice variants of IRF5 have been identified, differing mainly in the 5’ UTR and Exon 6, 
and these are expressed in different cell types. Each isoform utilises one of three promoters (P-V1, P-
V2, P-V3) encoded by Exon 1A, 1B or 1C.  Some isoforms have short 30/48bp deletions in Exon 6, 
whereas others lack whole exons.  Figure adapted from [198] 
 
1.4.2 – Irf5 mRNA alternative splicing and turnover 
As well as the use of alternative promoter exons (see Section 1.4.1), some of the 
known Irf5 isoforms also exhibit distinctive insertion/deletion patterns in exon 6 as a 
result of alternative splicing events.  Alternative splicing is the processing of pre-
mRNA to mature mRNA transcripts via the removal of intronic sequences, leaving 
only the coding exons.  As part of the process, exons can also be excluded from the 
primary transcript by ‘exon skipping’, or the boundaries of exons can be altered by 
utilisation of alternative 3’ acceptor splice junctions (changes 5’ boundary of 
downstream exon) or 5’ donor splice junctions (changes the 3’ boundary of upstream 
exon).  In exon 6 of the Irf5 gene, there are two constitutively active 3’ acceptor 
splice sites, both of which have equal strength so equal amounts of the alternative 
transcripts are produced.  As shown in Figure 1.8, as a result of the use of these 
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alternative sites the Irf5 isoforms –v5 and –v6 contain 4 repeats of a CGGGG motif 
(described as an insertion), whereas –v1, -v3 and -v4 only contain 2 repeats of the 
same CGGGG motif (described as a deletion) [198].  This indel repeat motif encodes 
for a proline-rich region in the IRF5 protein, located in a putative PEST domain.  
Interestingly, these repeats have only expanded recently in evolution [198], as 
species other than humans only have a single CGGGG motif, which suggests the 
importance of this region, perhaps as a protein-protein interaction interface. 
 
Alternative splicing has also resulted in the severely truncated –v7, -v8 and –v9 
isoforms of Irf5 (Figure 1.8) [198].  The isoform –v7 lacks the majority of the DBD due 
to skipping of exon 2, and thus may function as an endogenous dominant negative 
(DN) mutant of full-length IRF5. The isoform –v8 has a large single deletion that 
spans most of exons 6 and 7.  An early termination codon was inserted in –v9, so 
this isoform lacks the entire C-terminus.  See Figure 5.9 for the structure of the IRF5 
isoform proteins as a result of the alternative splicing events.  Human Irf5 transcripts 
can also contain one or two polyA sites, resulting in short or long 3’ UTRs [209, 210].  
Longer transcripts contain two AU-rich elements, leading to rapid mRNA turnover; 
whereas shorter transcripts have a longer half-life, and are more upregulated in cells 
stimulated with Type I IFN [211]. 
 
1.4.3 – Association of Irf5 with autoimmune diseases 
Genome-wide association studies (GWAS) that compare the genome sequence 
between healthy and diseased cohorts are becoming a useful tool to identify gene 
mutations that predispose to pathogenesis.  Single-nucleotide polymorphisms 
(SNPs) – variation of a single nucleotide within a population that results in two 
different alleles (one associated with disease risk, and one with disease protection) 
at a particular genomic locus – have now been described for multiple diseases and 
ethnic groups, which has lead to the identification of many new susceptibility loci that 
can now be the focus of further study and therapeutic design.  SNPs in the Irf5 gene, 
which result in increased expression of IRF5 or expression of alternative isoforms of 
IRF5 have now been associated with many TH1/TH17-driven autoimmune diseases, 
highlighting the importance of regulation of IRF5 expression for a tightly controlled 
immune response.  Conversely, high expression of the Irf5 gene has been negatively 
associated with asthma, a TH2-driven disease [212].  Table 1.1 describes the SNPs 
published at the Irf5 locus that lead to increased susceptibility or protection to 
Rheumatoid Arthritis (RA) (see Section 1.4.3.1), Systemic Lupus Erythematosus 
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(SLE) (see Section 1.4.3.2), Inflammatory Bowel Disease (IBD), Multiple Sclerosis 
(MS), Primary Sjogren’s Syndrome (pSS), Asthma and Systemic Sclerosis (SSc). 
 
1.4.3.1 – IRF5 and Rheumatoid Arthritis (RA)  
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, with a 
prevalence of 1% in the population [213] and a disproportionately high incidence in 
older individuals and women compared to men (3:1 ratio) [214].  The target tissue in 
RA is primarily the synovial joints – often those of the hands, feet and knees - and 
clinical features comprise a syndrome of joint pain, stiffness and swelling, as well as 
increased susceptibility to infections, cardiovascular disease and lymphoma [214].  
RA joints are characterised by a massive leukocytic infiltrate into the synovium 
(synovitis); which leads to chronic inflammation, pannus formation and subsequent 
irreversible joint damage, due to cartilage degradation and erosion of juxta-articular 
bone [213, 215].  RA is believed to be initiated via the activation of CD4+ T-cells, 
which inappropriately recognise autoantigens and trigger an immune response [216].  
This immune response becomes auto-antigen independent (for reasons not yet 
understood) and sustained, therefore driving the disease unremittingly [217].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Comparison of normal and rheumatoid joints [218] 
In the healthy joint (left) the thin synovial membrane lines the non-weight-bearing aspects of the joint. In 
rheumatoid arthritis (right) the synovial membrane becomes hyperplastic and infiltrated by chronic 
inflammatory cells. Ultimately it develops into 'pannus', which migrates onto and into the articular 
cartilage and underlying bone. 
 
The inflamed RA synovium, as shown in Figure 1.9, consists largely of activated 
macrophages (30-40%) and T-cells (~30%); although B-cells and dendritic cells are 
also present [213, 215].  To sustain this increased tissue mass, angiogenesis is a 
prominent feature of arthritic joints [219].  Resident tissue cells, including activated 
synovial fibroblasts, chondrocytes and osteoclasts, have also been shown to 
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promote perpetuation of inflammation in the RA joint, as well as mediate the 
associated cartilage and bone damage [220].  RA synovial fluid contains a wide 
range of effector molecules, including pro-inflammatory cytokines (IL-1β, TNF, IL-6), 
chemokines (IL-8, IP-10, MCP-1, RANTES), and matrix metalloproteases (MMP-1, -
3, -9, -13); which interact with one another in a complex manner to result in the 
chronic and persistent inflammation associated with RA [83].  The recruitment, 
activation and function of each of the cell types present in the RA synovium are 
directed principally by this network of secreted effector molecules. 
 
The cytokine TNF was originally identified in 1975 as a factor isolated from serum of 
endotoxin-treated mice that induced necrosis of a methylcholanthrene-induced 
murine sarcoma [221]; however it soon became apparent that TNF also exhibited 
pro-inflammatory effects, due to its ability to induce signs and symptoms of shock 
and multi-organ damage [222].  TNF is now considered the prime inflammatory 
mediator in the RA joint, due to its ability to induce degradation of cartilage [223] and 
bone [224] in vitro via chondrocyte and osteoclast activation, and also the 
observation that TNF is spontaneously produced by dissociated RA synovial 
mononuclear cell cultures to chronic levels [225], along with IL-1β [225], IL-6 [226], 
IL-8 [227] and GM-CSF [228].  Importantly, if TNF activity is blocked in these 
cultures, spontaneous production of IL-1β protein and IL1b mRNA is significantly 
reduced [229], suggesting a hierarchy of control within the effector molecules 
associated with the RA synovium.  This is highlighted by the fact that TNF is 
produced very rapidly in response to noxious stimuli [230] - initially by cleavage of 
preformed membrane stores on macrophages, neutrophils and activated T-cells by 
TNF-converting enzyme (TACE) [231] - and is therefore present at early stages to 
regulate inflammation.  TNF levels are subsequently maintained via production by 
cells of the monocyte/macrophage lineage, although neutrophils, T-cells and 
endothelial cells can also contribute [213].  Consistent with the idea that TNF co-
ordinates the cytokine response in RA; TNF blockade also inhibited expression of IL-
6 and IL-8, and spontaneous production of GM-CSF (responsible for MHC class II 
expression on antigen-presenting cells) [228, 232].  TNF is therefore responsible for 
the induction of proinflammatory cytokine and chemokine production in the RA 
synovium, leading to recruitment of leukocytes from the blood, and maintenance of 
an inflammatory state.  
 
TNF research therefore suggested that by blocking a single cytokine, the 
downstream effects could have an important influence on the complex disease 
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process of RA.  Following this rationale, TNF-blocking therapeutics were developed 
at the Kennedy Institute of Rheumatology [213].  Administration of a specific 
monoclonal antibody against murine TNF after disease onset in the collagen-induced 
arthritis (CIA) murine model of RA, was shown to ameliorate both inflammation and 
joint damage [233].  Further to this, clinical investigations in which the activity of TNF 
in RA patients was blocked with intravenously-administered Infliximab, a chimeric 
anti-TNF monoclonal antibody, confirmed that TNF regulates the RA disease process 
by controlling signs and symptoms of disease in approximately two-thirds of patients 
[213].  Anti-TNF therapy is now a treatment option for RA, in combination with the 
commonly administered disease-modifying anti-rheumatic drug (DMARD) 
methotrexate; and efficacy has also been shown in other chronic inflammatory 
diseases, such as Crohn’s disease, psoriasis, psoriatic arthritis and ankylosing 
spondylitis [214].  Although blockade of TNF is beneficial, it is not curative; 
therapeutic effects are only partial and side effects can include increased 
susceptibility to Mycobacterium tuberculosis infection [214, 234].  TNF is clearly a 
useful target for therapy of inflammatory disease; however complete blockade of TNF 
activity is not always beneficial if the body requires other more balanced immune 
responses to occur.  A therapy that specifically controls regulation of TNF 
expression, for example on a transcriptional or translational level, to prevent 
excessive TNF presence in the joint but not absolute prevention of activity, would 
therefore be advantageous in terms of side effects. 
 
RA consists of both environmental and genetic components.  There is strong 
evidence that multiple genetic factors confer predisposition to RA, although 
geographic location and ethnicity play a factor in the strength of such associations.  
Variation in the human leukocyte antigen (HLA) gene is a crucial determinant of RA 
susceptibility, in particular the Shared Epitope (SE) – a molecular structure consisting 
of a conserved amino acid sequence at aa70-74 of the third hypervariable region of 
the DRB1 chain, which is found in both the HLA-DRB1*01 and *04 alleles - is 
strongly associated with RA [235].  The SE also determines greater disease severity 
with an increased incidence of bone erosion and earlier disease onset [236].  A 
majority of RA patients are positive for autoantibodies against the Fc portion of the 
IgG molecule (Rheumatoid Factor – RF), and the presence of RF correlates with a 
severe form of RA, although it sometimes can be detected in normal healthy 
individuals or patients with conditions other than RA [237].  RA patients also produce 
autoantibodies against cyclic citrullinated peptides (anti-CCP), and these are rarely 
detected in healthy individuals, therefore can be considered a more specific disease 
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marker than RF [238].  Anti-CCP antibodies can be detected years before the 
appearance of any RA clinical symptoms and are indicators of a greater degree of 
inflammation and a more destructive disease [238].  Smoking is associated with anti-
CCP positive RA, and anti-CCP antibodies display a strong association with the 
HLADRB1 SE, whereas anti-CCP negative RA is associated with HLADRB1*03 
allele, which suggests that there are at least two distinct diseases within the 
syndrome of RA [239]. 
 
IRF5 has been shown to be extremely important for increased and prolonged TNF 
production in M1 macrophages, compared to anti-inflammatory M2 macrophages 
[25, 197].  In line with this, multiple polymorphisms in the Irf5 locus have been 
associated with RA (see Table 1.1), and in particular the rs2004640 SNP, which 
creates a 5’ donor splice site in exon 1B resulting in expression of different isoforms 
of IRF5, has been identified in several case-control cohorts [240-242].  Equally 
however, there are also studies that do not agree with this association [243, 244].  Of 
the Irf5 SNPs that have been associated with RA, those cohorts that were 
phenotyped for the type of RA they were suffering, also showed inconsistent results.  
Multiple studies show association of Irf5 with anti-CCP negative or RF negative RA, 
suggesting a less severe form of the disease, however in terms of the degree of 
erosion associated with Irf5 SNPs the results are unclear [245, 246].  It is possible 
that IRF5 is involved in more acute inflammatory events, rather than the systemic 
inflammation characteristic of RA, and therefore increases the susceptibility of a 
patient to RA at the early stages of onset, rather than being a factor in prolonged 
disease status.  In line with this, the Udalova lab has shown the importance of IRF5 
in the acute Antigen-Induced Arthritis (AIA) murine model, with reduced swelling, pro-
inflammatory cytokine production and M1 macrophage presence in the methylated 
BSA immunised knee of Irf5-/- mice (manuscript in preparation). 
 
1.4.3.2 – IRF5 and Systemic Lupus Erythematosus (SLE)  
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune inflammatory 
disease that can result in patients experiencing a wide range of clinical phenotypes.  
Human SLE can consist of a facial butterfly rash (malar rash) or much more life-
threatening manifestations such as nephritis if the disease has progressed to 
become systemic [247].  Patients are predominantly women, and 95% possess anti-
nuclear antibodies (ANA), which recognise ‘self’ chromatin components including 
dsDNA, histones and nucleosomes, and as a result activate the innate immune 
system.  ANAs seem to be specific to SLE, and are not detected in other 
Chapter 1 - Introduction 
51 
autoimmune diseases [248].  Immune complexes involving ANAs are often deposited 
around the body, including on the renal glomerular basement membrane, which 
ultimately results in glomerulonephritis due to the inflammatory response that ensues 
[249].  Several genetic associations with SLE susceptibility have been identified, 
including Ptpn22 [250], the HLA genes [251], Stat4 [252], and importantly in this 
context – Irf5 (see Table 1.1).  The strongest association of the Irf5 locus with SLE is, 
like RA, with the rs2004640 SNP, which is consistently associated in worldwide 
cohorts including Europe, America and Japan [253-256].  Conversely only a weak 
association was observed in a case-control study from China [257].  Interestingly, 
MDDCs and macrophages from individuals possessing the rs2004640 SNP 
demonstrate increased TNF production on stimulation of TLR2 with its agonist MDP 
[258], further highlighting the increased inflammation associated with this mutation.  
European and South American SLE cohorts have also been associated with an indel 
upstream of Irf5 exon 1A, which adds an Sp1 binding site to the 5’ UTR [254, 259]. 
 
The importance of IRF5 in SLE development has been highlighted using murine 
models of the disease and Irf5-/- mice.  In the pristane model of murine SLE, Irf5-/- 
mice experienced poor lymphocyte activation and T-cells were differentiated to a TH2 
rather than TH1 phenotype, corresponding with reduced IL-12, IL-23 and in particular 
IFNα levels, which are critical for SLE disease pathogenesis [260].  A reduction in 
monocytes migrating to the peritoneal cavity has also been observed in the absence 
of IRF5, which is thought to be a key initial event in the pathogenesis of the pristane-
induced model [261].  Concordant with this, the FcγRIIB-/-Yaa and FcγRIIB-/- murine 
lupus models showed that IRF5 is crucial for disease development, in particular IFNα 
production [262], as was also the case for Irf5-/--MLR/lpr mice [263].   
 
A reduction in IgG class-switching in B-cells in the Irf5-/- mice was also observed 
upon pristane induction of SLE [264], which correlates with observations that IRF5 
also plays a crucial role in B-cell development.  Irf5-/- mice experience attenuated 
plasma cell development, resulting in splenomegaly due to accumulation of immature 
B-cells in the spleen.  This is due a lack of expression of the IRF5-target gene Prdm1 
(BLIMP1), a plasma cell commitment factor [265].  It has also been observed that 
IRF5 is required to drive Ikaros expression, which is responsible for IgG2a antibody 
production [266, 267].  A lack of mature B-cells and therefore antibodies means that 
fewer ANA immune complexes can form, which drive SLE pathogenesis.  It is 
therefore clear that the role of IRF5 in autoimmunity extends beyond cytokine 
production, although this is a prominent activity in macrophages in particular. 
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SNP Gene region R/P alleles Disease Population Cases/Controls Odds Ratio (95% CI) Probability Reference 
CGGGG 
in/del Promoter 4/3 repeats IBD Belgian (UC patients) 427/534 2.42 (1.76-3.34 p= 5.3x10
-8 [268] 
   MS Spanish 2337/2813 1.22 (1.05-1.41) p= 1.1x10
-2 [269] 
   pSS French Caucasian 185/157 2.00 (1.50-2.70) p= 6.6x10
-6 [270] 
   RA Japanese 1942/1598 1.20 (1.04-1.39) p= 0.2 [271] 
   RA Swedish (RF negative/anti-CCP negative) 2300/1836 
1.29 (1.14-1.16)     
1.27 (1.13-1.43) 
p= 7.9x10-5   
p= 7.3x10-5 [272] 
   SLE South American/Spanish/German/Italian 1488/1466 1.60 (1.44-1.80) p= 1.58x10
-19 [254] 
   SLE Swedish 485/563 1.69 (1.42-2.02) p= 4.6x10
-9 [259] 
  3/4 repeats Asthma UK 1467 (340 families) N/A p= 6.1x10
-3 [212] 
rs729302 Promoter A/C RA Japanese (anti-CCP negative) 1942/1598 1.22 (1.09-1.35) p= 4x10-3 [271] 
   RA Caucasian/Asian 6582/5375 0.881 (0.799-0.971) p= 6x10
-2 [240] 
rs752637 Promoter G/A RA Caucasian/Asian 6582/5375 0.915 (0.824-1.016) p= 3.3x10-2 [240] 
   SLE European 1383/1614 0.80 (0.71-0.90) p= 2.4x10
-4 [255] 
rs2004640 Promoter T/G JIA North American/European (RF negative) 440/756 1.60 (1.17-2.20) p= 3x10-3 [273] 
   pSS Caucasian 212/162 1.93 (1.15-3.42) p= 1x10
-2 [274] 
   RA Tunisian (anti-CCP positive/erosive) 140/185 
1.54 (0.92-2.59)     
1.71 (1.03-2.84) 
p= 4x10-2     
p= 1x10-2 [245] 
   RA Norwegian (RF negative/non-erosive) 1140 (380 families) N/A 
p= 1.1x10-2   
p= 5.1x10-3 [246] 
   RA Caucasian/Asian 6582/5375 0.901 (0.844-0.962) p= 0.168 [240] 
   RA Spanish (anti-CCP negative, SE positive) 4620/3741 0.88 (0.83-0.94) p= 6.5x10
-5 [241] 
   RA Swedish/Dutch (anti-CCP negative) 1530/881 N/A p= 3.6x10
-3 [242] 
   SLE Norwegian 154/756 1.95 (1.50-2.53) p= 3.75x10-7 [273] 
   SLE North American/Spanish/Swedish/Argentine 1661/2508 1.47 (1.36-1.60) p= 4.2x10
-21 [253] 
   SLE North American 370/462 1.68 (1.20-2.34) p= 8x10
-3 [275] 
   SLE South American/Spanish/German/Italian 1488/1466 1.54 (1.39-1.71) p= 2.38x10
-16 [254] 
   SLE European 1383/1614 0.73 (0.65-0.81) p= 4.3x10
-8 [255] 
   SLE Japanese/Korean 277/201 1.31 (1.14-1.49) p= 8.3x10
-5 [256] 
   SSc French Caucasian 881/760 1.58 (1.18-2.11) p=2x10
-3 [276] 
  G/T Asthma UK 1467 (340 families) N/A p= 6.9x10
-3 [212] 
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SNP Gene region R/P alleles Disease Population Cases/Controls Odds Ratio (95% CI) Probability Reference 
rs3757385 Promoter A/C RA Norwegian (RF negative/non-erosive) 1140 (380 families) N/A p= 4.2x10
-3   
p= 1.7x10-3 [246] 
   RA Swedish/Dutch (anti-CCP negative) 1530/881 N/A p= 2.2x10
-3 [242] 
rs3807306 Promoter A/C RA Swedish/Dutch (anti-CCP negative) 1530/881 N/A p= 9.1x10-5 [242] 
  T/G IBD Belgian (UC patients) 427/534 1.36 (1.12-1.64) p=1.8x10
-3 [268] 
   MS Spanish 2337/2813 1.25 (1.08-1.45) p= 3.7x10
-3 [269] 
rs4728142 Promoter A/G IBD Belgian (UC patients) 427/534 1.50 (1.24-1.83) p= 4.2x10-5 [268] 
   IBD European (UC patients) 6687/19718 1.07 (1.03-1.11) p= 1.74x10
-8 [277] 
   MS Spanish 2337/2813 1.25 (1.08-1.45) p= 2.9x10
-3 [269] 
rs2280714 3' region A/T RA Caucasian/Asian 6582/5375 0.927 (0.866-0.992) p= 0.317 [240] 
   SLE European 1383/1614 0.87 (0.77-0.99) p= 2.9x10
-2 [255] 
   SSc Japanese 281/477 1.42 (1.15-1.75) p= 1.2x10
-3 [278] 
rs10488631 3' region C/T RA European (anti-CCP positive) 6768/8806 1.25 (1.14-1.37) p= 2.8x10-6 [279] 
   RA Swedish  (anti-CCP negative) 2300/1836 1.27 (1.08-1.50) p= 4.1x10
-3 [272] 
   SLE European 1383/1614 2.02 (1.72-2.38) p= 7.8x10
-18 [255] 
rs10954213 3' region G/A RA Norwegian (RF negative/non-erosive) 1140 (380 families) N/A p= 1.4x10
-3   
p= 8.04x10-4 [246] 
   SLE South American/Spanish/German/Italian 1488/1466 1.35 (1.21-1.51) p= 3.49x10
-7 [254] 
Table 1.1: Association of SNPs in the Irf5 locus with autoimmune diseases 
Table describing the SNPs in the Irf5 locus (name, location, risk/protective alleles) associated with autoimmune diseases in a variety of case-control cohorts from multiple populations.  
The probability of each association (p-value) and odds ratio (strength of association within 95% confidence intervals – >1=strong association) is detailed.  RA= Rheumatoid Arthritis, SLE= 
Systemic Lupus Erythematosus, IBD= Inflammatory Bowel Disease, MS= Multiple Sclerosis, pSS= Primary Sjogrens Syndrome, SSc= Systemic Sclerosis, JIA= Juvenile Idiopathic 
Arthritis, UC= Ulcerative Colitis, CCP= Cyclic Citrullinated Peptide, RF= Rheumatoid Factor. 
Continued… 
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1.4.4 – Role of IRF5 in apoptosis and tumour suppression 
Apoptosis is a highly regulated process of cell suicide that occurs throughout 
development and during host defence.  Alongside the key roles for IRF5 in driving 
immune inflammatory responses, it has been observed that Irf5-/- fibroblasts are 
deficient in apoptosis during viral infection, which is beneficial for the viral pathogen as 
this enhances it’s ability to propagate in the host [280].  Interestingly, although the Irf5 
locus is a direct target for the apoptosis-associated transcription factor p53, which 
binds to a p53-binding site in Irf5 exon 2 [281], the apoptotic effects of IRF5 are 
independent of p53, as it is itself able to drive expression of pro-apoptotic genes such 
as p21 and Bax in response to DNA damage [282].  This is further highlighted by the 
fact that ectopic expression of IRF5 in p53-/- colon cancer cells also sensitises to DNA-
damage induced apoptosis [283].  The stimulus TRAIL has been shown to induce 
nuclear localisation of IRF5, which in turn sensitises tumour cells to undergo apoptosis 
[284].  Fas can also induce apoptosis via activation of IRF5 upstream of caspase-8 
activity [285].  In line with this, the Irf5 genomic locus is lost in many haematological 
cancers, including acute myeloid leukaemia (AML), which further suggests a role for 
IRF5 in tumour suppression.   
 
Interestingly, the Irf1 locus has also been associated with leukaemia development 
[286] and tumours of the gastrointestinal tract [287].  IRF1 and p53, like IRF5, have 
mainly been described as acting independently to induce apoptotic genes, except 
however at the p21 locus where IRF1 binds to p300, which in turn activates p53 [288].  
Loss of Irf1 on a p53-null background results in a more dramatic increase in tumour 
incidence than loss of p53 alone, suggesting that IRF1 also acts as a tumour 
suppressor [289].  Both DNA-binding and a C-terminal transcription enhancer domain 
are required for inhibition of tumour growth by IRF1 [290]. 
 
In conclusion, it is clear that IRF5 plays key roles in pro-inflammatory macrophage 
polarisation, tumour suppression and B-cell development. Dysregulation of Irf5 
expression is associated with autoimmune disease, however the signalling pathways 
and mechanisms by which IRF5 performs its diverse transcriptional functions are 
poorly understood.  The IRF family in general preferentially co-operates with co-factors 
in order to drive transcription of target genes, both in the formation of intra-family 
heterodimers and interactions with other non-related proteins.  A non-biased study to 
identify novel co-factors of IRF5 would be beneficial for learning more about cell-type 
specific IRF5 activity, with a view to developing specific inhibitors to dampen 
autoimmune inflammation. 
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1.5 – Hypothesis of investigation 
The initial focus of this study was to identify novel protein-protein interaction partners of 
IRF5, with the working hypothesis that “co-factors play an important role in IRF5-
mediated transcriptional activity”. 
 
1.5.1 – Specific aims for the IRF5 interactome study (Chapter 3) 
1) Optimise One-Strep affinity purification for demonstrating protein-protein 
interactions in HEK293-TLR4 cells and Irf5-/- murine macrophages 
2) Perform an interactome screen using One-Strep affinity purification coupled to 
mass spectrometry (LC-MS/MS) to identify novel co-factors of IRF5 
3) Validate any hits from the interactome screen by Western blotting and 
reciprocal immunoprecipitation 
 
During this part of the project I identified multiple novel protein-protein interaction 
partners of IRF5.  KAP1 (TRIM28) was identified with the most confidence from the 
screen and was validated by Western blotting.  I then hypothesised that “KAP1 plays 
a role in IRF5-mediated gene expression.” 
 
1.5.2 – Specific aims for investigating IRF5-KAP1 activity (Chapter 4) 
1) Determine the domain of IRF5 that interacts with KAP1 using truncated mutants 
of IRF5 and One-Strep affinity purification 
2) Determine whether KAP1 interacts with IRF5 in M1 macrophages 
3) If Aim 2 demonstrates an IRF5-KAP1 complex in M1 macrophages – look at the 
effect of KAP1 siRNA knockdown and overexpression on IRF5-regulated gene 
expression by qPCR, ELISA and luciferase reporter assay. 
4) Determine whether any effects in Aim 3 are due to direct transcriptional or 
ubiquitinating activities of KAP1 on IRF5  
5) If negative results from Aim 4, look at the effect of KAP1 depletion on the 
chromatin environment at IRF5 gene targets 
 
1.5.3 – Specific aims for the IRF5-RelA interaction (Chapter 5) 
1) Leading on from initial work in the Udalova group identifying NFκB RelA as a 
co-factor of IRF5 [197], investigate the effect of co-expression of both factors 
on inflammatory gene expression (qPCR, luciferase reporter assay), in line with 
on-going IRF5/RelA/Pol II ChIP-seq studies in the group. 
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2) Map the interaction interface involved in the IRF5-RelA interaction using 
truncated mutants of both proteins, and IRF5 alternatively spliced isoforms. 
3) Following on from Aim 2, look at the effect of co-expression of truncated 
mutants of IRF5 with full-length RelA on target gene expression – Tnf is an 
example of a gene where IRF5 is indirectly recruited to the DNA by RelA [197], 
along with other examples identified by the ChIP-seq study, in order to show 
the importance of the direct interaction to drive gene expression. 
4) Also following on from Aim 2, design short peptides from the IRF5-interacting 
domain sequence, and determine whether these are able to bind to RelA, with 
a view to blocking the protein-protein interaction.   
5) Investigate high-throughput methods to determine whether small 
molecules/peptides can block the IRF5-RelA interaction interface.  Specifically-
designed therapeutics such as these could be tailored to target enhanced 
inflammatory gene expression by IRF5, rather than completely blocking IRF5 
activity within the macrophage, which like blocking TNF with monoclonal 
antibodies could have an adverse effect on natural immune responses. 	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2.0 – Materials and Methods 
 
2.1 – Cell culture 
All cell lines were maintained at 37˚C, with 5% CO2 and 95% humidity. 
 
2.1.1 – Maintenance of cell lines 
Cell lines used in this study (see Table 2.1) were purchased from Invivogen USA, and 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; PAA, USA) 
supplemented with 10% v/v Foetal Bovine Serum (FBS; Gibco, UK) and 1% v/v 
Penicillin/Streptomycin (P/S; PAA, USA).  Additionally, HEK293-TLR4-CD14/Md2 
(HEK293-TLR4) cells were supplemented with 50 µg/ml Hygromycin B (Invivogen, 
USA) and 10 µg/ml Blasticidin S (Invivogen, USA) to maintain expression of the 
plasmids encoding the TLR4 receptor and its co-receptors.  Cells were stimulated as 
required with 1 µg/ml lipopolysaccharide (LPS; Alexis, USA). 
 
 
 
 
 
                
                
 
                 
                                                Table 2.1: Cell lines used in this study 
 
 
HEK293-TLR4 and HEK293-ET cells were maintained in flasks (Falcon, UK), whereas 
RAW264.7 cells were cultured in 10 cm tissue culture dishes (Falcon, UK).  Cells were 
passaged once a confluency of approximately 70% was achieved, up to a maximum of 
10 passages.  Culture media was aspirated from the flask/dish, and the cells washed 
gently with Dulbecco’s Phosphate Buffered Saline (PBS; PAA, USA) to remove any 
dead cells and traces of media.  Trypsin-EDTA (PAA, USA) was then added to the 
flask/dish and the cells incubated for 5-10 minutes at 37˚C until the adherent cells were 
resuspended.  RAW264.7 cells required additional gentle scraping with a cell lifter to 
achieve resuspension.  Cells were then washed in the appropriate media to remove 
any traces of trypsin, and re-seeded into flasks/dishes at a maximum 1:4 dilution in a 
suitable volume of media.  Alternatively, resuspended cells were counted and seeded 
for experiments as necessary. 
CELL LINE DESCRIPTION 
HEK293-TLR4-CD14/Md2 
Human Embryonic Kidney (HEK)-293 cells that 
stably express Toll-like Receptor 4 (TLR4) along 
with the co-receptors CD14 and Md2. 
RAW264.7 Mouse leukemic monocyte macrophage cell line 
HEK293-ET  
HEK293 EBNA T cells that constitutively express 
the SV40 large T antigen and EBNA1 protein 
from Epstein-Barr Virus to enhance ectopic gene 
expression 
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2.1.2 – Cryopreservation of cells 
For long-term storage, cell lines were resuspended in FBS supplemented with 10% v/v 
dimethylsulfoxide (DMSO; Invitrogen, USA) at a concentration of 1x107 cells/ml.  1 ml 
aliquots were then transferred into cryovials, which were subsequently placed at -80˚C 
overnight in an insulated container to ensure slow freezing.  Once frozen, the cryovials 
were moved to a liquid nitrogen storage tank. 
 
To re-culture, cells were thawed quickly by placing the cryovial in a water bath at 37˚C, 
then washed with media to remove any traces of DMSO before seeding as required. 
 
2.2 – Preparation of human primary myeloid cells 
All human primary cells were maintained at 37˚C, with 5% CO2 and 95% humidity. 
 
2.2.1 – Isolation of PBMCs from human blood 
Blood from healthy donors was obtained from the National Blood Service, Colindale, 
London.  Blood was diluted 1:1 in Hank’s Balanced Salt Solution (HBSS; PAA, USA) 
and layered over an equal volume of Ficoll-Hypaque LymphoprepTM (Axis-Shield, UK) 
in sterile 50 ml tubes (Falcon, UK).  Centrifugation was performed (Scanspeed 
1580MGR, GRS-750-4 rotor) at 1,800 revolutions per minute (rpm) for 20 minutes at 
room temperature, with a minimum deceleration setting on the brake.  The buffy layer 
formed at the interface between the diluted blood and Lymphoprep by density gradient 
centrifugation was collected and centrifuged at 1,800 rpm for 10 minutes.  The 
resulting cell pellet was washed twice with HBSS by resuspension and centrifugation.  
Peripheral blood mononuclear cells (PBMCs) were resuspended in 45 ml HBSS and 
passed through a cell strainer to ensure a single cell suspension in preparation for 
elutriation. 
 
2.2.2 – Isolation of monocytes from PBMCs 
Human monocytes were isolated from PBMCs (see Section 2.2.1) by elutriation in a 
Beckman JE6 elutriator (Beckman Coulter, UK), which separates cell populations 
based on size.  PBMCs were loaded into the elutriation chamber, where they were 
subjected to centrifugal force (2,500 rpm), which was counter-balanced by pumping 
Roswell Park Memorial Institute 1640 media supplemented with 2mM L-glutamine 
(RPMI; PAA, USA), and additionally supplemented with 1% v/v FBS (Gibco, UK) and 
1% v/v P/S (PAA, USA), through the chamber at a constant rate.  As a result, when the 
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flow rate exerted by the pump was gradually increased, cells of increasing size were 
ejected from the chamber and could be collected.  The composition of the cell 
populations being ejected from the elutriation chamber was determined by flow 
cytometry, comparing forward scatter (FSC - cell size) and side scatter (SSC - 
granularity).  Initially, T-lymphocytes were the first population available for collection, 
and as the flow rate was increased to between 18-23 ml/minute the monocytes were 
gradually ejected, followed by granulocytes.  Only fractions containing more than 70% 
monocytes and fewer than 5% granulocytes, as determined by flow cytometry, were 
collected for my experiments. 
 
2.2.3 – In vitro differentiation of human monocytes to macrophages 
Monocyte-enriched fractions derived from elutriation (see Section 2.2.2) were counted 
and resuspended in culture media (RPMI + 10% v/v FBS + 1% v/v P/S) before being 
seeded into 10cm tissue culture dishes (Falcon, UK) along with the appropriate 
cytokine for differentiation.  M1 macrophages were generated by the addition of 50 
ng/ml human GM-CSF (Peprotech, UK) to dishes of 1x107 monocytes per 10 ml of 
culture media, and M2 macrophages were generated by the addition of 100 ng/ml 
human M-CSF (Peprotech, UK) to dishes of 7x106 monocytes per 10 ml of media.   
 
After 5 days incubation, macrophages were harvested and adherent cells were 
detached by Versene-EDTA (PAA, USA), as necessary.  Macrophages were then 
resuspended in fresh culture media at 1x106 cells/ml and seeded as required.  
Macrophages were stimulated with 10 ng/ml LPS (Alexis, USA) when necessary. 
 
2.3 – Preparation of murine primary myeloid cells 
All murine primary cells were maintained at 37˚C, with 5% CO2 and 95% humidity. 
 
2.3.1 – Isolation of bone marrow progenitors 
Wild type or Irf5-/- mice (both on a C57BL/6 background) were euthanized by CO2 
inhalation and cervical dislocation, and then the femurs and tibias were dissected by 
cutting the bones at the ankle and pelvis.  Excess muscle surrounding the bone was 
removed initially using scissors, and then by soaking the bones in 70% v/v ethanol for 
5 minutes to make it easier to remove the muscle using a tissue (Kimtech, UK).  Both 
ends of each of the bones were then cut using scissors, and the bone marrow flushed 
out into a sterile 50 ml tube (Falcon, UK) using 10 ml of PBS (PAA, USA) in a syringe 
with a 27g needle.  All the bone marrow flushed from the bones of a single mouse was 
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pooled into the same 50 ml tube, and then centrifuged (Scanspeed 1580MGR, GRS-
750-4 rotor) at 1,500 rpm for 5 minutes at room temperature.  The resulting pellet was 
resuspended in 1 ml of bone marrow culture media – RPMI + 10% v/v FBS + 1% v/v 
P/S supplemented with 50 µM 2-Mercaptoethanol (2-ME; Gibco, UK), and 10 µl of the 
cell suspension was diluted 1:10 in 50% v/v Trypan Blue solution (Sigma, UK) for live 
cell counting by haemocytometer.  Bone marrow cells were then diluted to a final 
concentration of 5x105 cells/ml in bone marrow media. 
 
2.3.2 – In vitro differentiation of bone marrow cells 
A total of 5x106 bone marrow progenitor cells (see Section 2.3.1) were plated in 10 ml 
bone marrow media (RPMI + 10% v/v FBS + 1% v/v P/S+ 50 µM 2-ME) in bacterial 
petri dishes (Falcon, UK).  After 8 days of differentiation in the presence of cytokine, 
macrophages were harvested (using Versene-EDTA if necessary), counted and 
seeded as required in bone marrow media (no addition of cytokine required).  Tissue 
culture plates and dishes (Falcon, UK) were used for re-seeding once the cells were 
fully differentiated.  Macrophages were stimulated with 500 ng/ml LPS (Alexis, USA). 
 
M2 macrophages were generated by the addition of 100 ng/ml human M-CSF 
(Peprotech, UK) to the bone marrow progenitors on Day 0.  No further dosing with M-
CSF was required for the remainder of the 8-day differentiation period.   
 
M1 macrophages were generated by the addition of 20 ng/ml murine GM-CSF 
(Peprotech, UK) to the bone marrow progenitors at Day 0.  On day 3 of differentiation, 
a further 10 ml of bone marrow media supplemented with 20 ng/ml murine GM-CSF 
was added to each dish of cells (20 ml total volume after addition).  On day 6 of 
differentiation, 10 ml of media from each dish was substituted with fresh bone marrow 
media supplemented with 20 ng/ml GM-CSF.  This was carried out by removal of 10 ml 
of media from each dish, centrifugation (Scanspeed 1580MGR, GRS-750-4 rotor) at 
1,500 rpm for 5 minutes at room temperature to pellet the cells, then resuspension of 
the pellet in 10 ml of fresh bone marrow media, which could be returned to each dish. 
 
2.4 – Cloning and purification of expression constructs  
 
2.4.1 – Udalova laboratory gene reporter and expression constructs 
Multiple gene reporter and expression constructs were already available in the Udalova 
group for utilisation in this study, and these are detailed in Table 2.2.  All expression 
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constructs were either cloned in the ‘pBent2’ vector: a modified pENTR vector 
(Invitrogen, USA) containing the Cytomegalovirus (CMV) promoter and Internal 
Ribosome Entry Site (IRES)-linked Green Fluorescent Protein (GFP); or the ‘pBent2-
strepN’ vector: a further modified pBent2 vector that also contains the One-Strep tag 
sequence at the N-terminus of the Multiple Cloning Site (MCS).  Luciferase gene 
reporter constructs were cloned in the pGL3-Basic or pGL3-Promotor vectors 
(Promega, USA). 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
 
 
Table 2.2: Udalova laboratory gene reporter and expression constructs  
Description of the gene reporter and expression constructs that were available in the laboratory  
and relevant for this study.   All NFκB and IRF expression constructs were generated from  
human sequences. 	  
2.4.2 – Cloning One-Strep tag fused NFκB constructs 
In addition to those constructs already available in the Udalova group, I also subcloned 
the NFκB subunits RelA, cRel and p50 into the pBent2-strepN vector, in order to form 
One-Strep fusion constructs for these proteins (see Table 2.3 below).  
 
CONSTRUCT NAME DESCRIPTION VECTOR TAG 
Strep-RelA-Flag WT NFκB RelA 
pBent2-
strepN 
Strep at N-terminus 
Flag at C-terminus 
Strep-cRel-Flag WT NFκB cRel pBent2-
strepN 
Strep at N-terminus 
Flag at C-terminus 
Strep-p50-HA WT NFκB p50 
pBent2-
strepN 
Strep at N-terminus 
HA at C-terminus 
                Table 2.3: One-Strep NFκB fusion constructs 
                Description of the One-Strep NFκB fusion constructs generated during this study 
CONSTRUCT NAME DESCRIPTION VECTOR TAG 
RelA-Flag WT NFκB RelA pBent2 Flag at C-terminus 
RelA-HA WT NFκB RelA pBent2 HA at C-terminus 
RelB-HA WT NFκB RelB pBent2 HA at C-terminus 
cRel-HA WT NFκB cRel pBent2 HA at C-terminus 
cRel-Flag WT NFκB cRel pBent2 Flag at C-terminus 
p50-HA WT NFκB p50 pBent2 HA at C-terminus 
p52-HA WT NFκB p52 pBent2 HA at C-terminus 
HA-IRF5 WT IRF5 pBent2 HA at N-terminus 
BAP-Flag WT BAP pBent2 Flag at C-terminus 
Myc-IRF5 WT IRF5 p8 Myc at N-terminus 
Strep-HA-IRF5 WT IRF5 
pBent2-
strepN 
Strep/HA at N-terminus 
HA-IRF5ΔDBD 
IRF5 lacking DNA 
binding domain (aa1-
130) 
pBent2 HA at N-terminus 
Strep-HA-IRF5ΔDBD 
IRF5 lacking DNA 
binding domain (aa1-
130) 
pBent2-
strepN 
Strep/HA at N-terminus 
Tnf 5’WT/3’WT 
Human WT Tnf 
promoter (1171bp 5’) 
and 3’ region (1252bp 
3’)  
pGL3-
Basic n/a 
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2.4.2.1 - Restriction digestion and alkaline phosphatase reactions 
RelA-Flag, cRel-Flag and p50-HA DNA fragments were excised from pre-existing 
pBent2 constructs (see Table 2.2) using the restriction enzyme combinations 
BamHI/SpeI (SuRE/Cut Buffer M), BamHI/EcoRI (SuRE/Cut Buffer A) and EcoRI/SalI 
(SuRE/Cut Buffer H) respectively in combination with the appropriate SuRE/Cut buffer 
as detailed (Roche, USA) in a reaction volume of 20-50 µl.  The pBent2-strepN 
destination vector was also digested using the same restriction enzyme combinations.  
Restriction digests were performed for 2 hours at 37˚C. 
 
X µl       DNA (1 µg maximum) 
2 µl       10x SuRE/Cut Buffer (Roche, USA) 
0.5 µl    100x BSA (NEB, USA) 
1 µl       Restriction Enzyme A (Roche, USA) 
1 µl       Restriction Enzyme B (Roche, USA) 
X µl      Nuclease-Free H20 (Ambion, USA) 
20 µl . 
 
Once completed, 2 µl alkaline phosphatase (AP; New England Biolabs, USA) was 
added to the 20 µl restriction digest of the pBent2-strepN vector for 30 minutes at 37˚C 
to remove the 5’ phosphate groups.  This step reduces self-ligation of the vector (see 
Section 2.4.2.2) and therefore reduces the number of false-positive colonies, which 
lack the DNA insert, after bacterial transformation (see Section 2.4.2.3) 
 
2.4.2.2 – DNA fragment purification  
Post-digestion, DNA fragments were resolved by electrophoresis in a 1% w/v agarose 
gel made with 1x TAE buffer (Tris base, Acetic acid, EDTA).  DNA loading buffer (5x, 
Bioline, UK) and 10x SYBR Green I (Invitrogen, USA) were added to the samples 
before loading onto the gel, to enable monitoring of the extent of travel along the gel 
and also DNA visualisation by blue light.  Hyperladder I (Bioline, UK) was also loaded 
onto the gel, also with 10x SYBR green I to enable determination of fragment size.   
 
The required DNA fragments (RelA-Flag, cRel-Flag, p50-HA and pBent2-strepN) were 
excised from the agarose gel (see Figure 2.1) with a scalpel during DNA visualisation 
by blue light, and the DNA purified from the agarose using the Wizard® SV Gel and 
PCR Clean-Up System (Promega, UK), according to manufacturer’s instructions.  DNA 
concentration was determined using a NanoDropTM 1000 (Thermo Scientific, USA). 
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Figure 2.1: Restriction digest fragments of One-Strep fusion constructs 
Fragments generated by restriction digest were resolved by electrophoresis in a 1% w/v agarose gel 
containing ethidium bromide (EtBr) and visualised by UV excitation. 
 
2.4.2.3 – DNA ligation  
Ligation reactions were performed in a 10 µl volume using 1 µl of T4 ligase (NEB, 
USA) and 1 µl of the corresponding T4 ligase buffer (NEB, USA).  The insert to vector 
molar ratio for the reaction was 3:1, with 50 ng of restriction-digested pBent2-strepN 
vector used per ligation.  The amount of restriction-digested insert (RelA-Flag, cRel-
Flag, p50-HA) to use in the reaction was calculated by the formula: 
 
Mass of insert (ng) = mass of vector (ng) x length of insert (bp) 
    Length of vector (bp) 
 
Negative control ligations consisting of digested vector alone (no insert) were 
performed in parallel to determine whether self-ligation of the DNA vector was 
occurring.  Ligation was carried out overnight at 16˚C. 
 
2.4.2.4 – Generation of chemically competent cells 
TOP10 chemically competent cells (Invitrogen, USA) were thawed on ice (20 µl 
aliquot), mixed by gentle tapping and 300 µl pre-warmed SOC medium added, before 
shaking at 225 rpm for 1 hour at 37˚C in an Innovar 44 shaker (New Brunswick 
Scientific, USA).  100 µl of the culture was then plated onto a pre-warmed LB agar 
plate containing no selection antibiotic, and the plate incubated overnight at 37˚C.  The 
following day, a single colony was picked and grown in 5 ml LB broth (no selection 
antibiotic required) for 2-3 hours at 37˚C with vigorous shaking (300 rpm).  This starter 
culture was transferred to a flask containing 200 ml LB broth (no selection antibiotic 
required) and incubated at 37˚C with vigorous shaking until an absorbance of 0.6 A600 
was achieved (approximately 2 hours growth).  The culture was then placed on ice for 
15 minutes, transferred into 4 sterile 50 ml tubes (Falcon, UK) and centrifuged at 4000 
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rpm for 10 minutes at 4˚C (Sorvall RT7, RTH-250 rotor).  The resulting cell pellets were 
resuspended in 15 ml (60 ml total) sterile, ice cold 1M CaCl2 (Sigma, UK) by gentle 
pipetting, and incubated on ice for 15 minutes, before centrifugation (Sorvall RT7, 
RTH-250 rotor) at 4000 rpm for 10 minutes at 4˚C.  The resulting cell pellets were 
resuspended in 4 ml (16 ml total) sterile, ice cold 0.1M CaCl2 supplemented with 15% 
v/v glycerol (Sigma, UK) by gentle pipetting.  The cells were finally incubated on ice for 
4 hours, before divided into 200 µl aliquots in sterile 1.5 ml tubes (Eppendorf, UK), 
snap frozen in liquid nitrogen and stored at -80˚C. 
 
2.4.2.5 – Transformation of chemically competent cells 
A vial of library efficiency DH5α (Invitrogen, USA) or homemade TOP10 competent 
cells (see Section 2.4.2.4) were thawed on ice, then mixed in their tube by gentle 
tapping, and 50 µl aliquots transferred to pre-chilled tubes (Eppendorf, UK).  Any 
unused competent cells were refrozen on dry ice for 5 minutes, before being returned 
to -80˚C.  The DNA ligation reaction (see Section 2.4.2.3) was diluted 5-fold and 1 µl of 
the diluted reaction (1-10 ng) was added to the aliquoted competent cells, and mixed 
by gentle tapping.  Alternatively 1-10 ng of plasmid DNA was added to the cells if re-
transformation of a construct was required.  After 30 minutes on ice, the competent 
cells were heat-shocked for 30 seconds in a water bath at 42˚C, then immediately 
chilled on ice for 2 minutes.  500 µl of pre-warmed SOC medium (Invitrogen, USA) was 
then added to the cells, which were shaken at 225 rpm for 1 hour at 37˚C in an Innovar 
44 shaker (New Brunswick Scientific, USA).  100 µl of the culture was then spread onto 
pre-warmed LB agar plates containing the appropriate selection antibiotic (kanamycin 
for pBent2 constructs), and the plate incubated overnight at 37˚C. 
 
2.4.2.6 – Identification of positive clones 
Aliquots of LB broth (5 ml) containing appropriate selection antibiotic were inoculated 
with individual bacterial colonies from transformation plates (see Section 2.4.2.5) and 
grown overnight at 37˚C in an Innovar 44 shaker (New Brunswick Scientific, USA) set 
to 225 rpm.  The next day, 1 ml of each bacterial culture was transferred to a 
microcentrifuge tube (Eppendorf, UK) and the cells pelleted by centrifugation at 3,500 
rpm for 5 minutes at 4˚C (Heraeus Biofuge Fresco).  Plasmids were harvested by Mini-
Prep kit (Qiagen, Germany) as per the manufacturers instructions, and positive clones 
identified by diagnostic restriction digest followed by resolution of the resulting 
fragments by electrophoresis (see Section 2.4.2.2).  Plasmids containing an 
appropriately sized insert fragment, as visualised by UV excitation of the EtBr agarose 
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gel, were verified by sequencing (MWG Eurofins, UK).  The remaining 4 ml of bacterial 
culture was used for larger scale purification of the plasmid DNA (see Section 2.4.5). 
 
2.4.3 – Udalova laboratory IRF5 truncated mutant expression constructs 
Truncated mutants of IRF5, lacking one or more structural domains of the protein, were 
available in the Udalova laboratory as expression plasmids (see Table 2.4). 
 
NAME 	   CONSTRUCT	   VECTOR	   TAG RE’s FORWARD PRIMER	   REVERSE PRIMER	  
Strep-HA-
IRF5_N130 
WT IRF5  
aa1-130 
pBent2-
StrepN 
Strep/HA 
at  
N-terminus 
 
EcoRI 
SalI 
CGCGGGAAT
GAATTCATG
TATCCTTAT
GATGTTCCT
GATTATGCT
AACCAGTCC
ATCCCAGTG
GCT 
CGCGGGAAT
GTCGACTCA
GGAGTCTGT
GGGAGCAG
GGCCA 
Strep-HA-
IRF5_N220 
WT IRF5  
aa1-220 
pBent2-
StrepN 
Strep/HA 
at  
N-terminus 
 
EcoRI 
SalI 
CGCGGGAAT
GAATTCATG
TATCCTTAT
GATGTTCCT
GATTATGCT
AACCAGTCC
ATCCCAGTG
GCT 
CGCGGGAAT
GTCGACTCA
TGCAGGGGG
CAGGCTGGC
AGGCA 
Strep-HA-
IRF5_N395 
WT IRF5  
aa1-395 
pBent2-
StrepN 
Strep/HA 
at  
N-terminus 
 
EcoRI 
SalI 
CGCGGGAAT
GAATTCATG
TATCCTTAT
GATGTTCCT
GATTATGCT
AACCAGTCC
ATCCCAGTG
GCT 
AATGTCGAC
TTA 
GTCAGGCCA
TTCTTCCCC
AAAG 
 
Strep-HA-
IRF5_Δ219 
WT IRF5 
aa220-455 
pBent2-
StrepN 
Strep/HA 
at  
N-terminus 
 
EcoRI 
SalI 
CGCGGGAAT
GAATTCATG
TATCCTTAT
GATGTTCCT
GATTATGCT
GCAGGCGAA
CAGCTCCTG
CCAGA   
 
CGCGGGAAT
GTCGACTTA
TTGCATGCC
ACCTGGGTG
CA 
Table 2.4: IRF5 truncated mutant constructs 
Description of the Strep- and HA-tagged truncated IRF5 constructs available in the Udalova laboratory, 
generated by Dr Grigory Ryzhakov, including the primers used to amplify the fragments.  RE = restriction 
enzyme, restriction site highlighted in primer sequence by underlining, HA-tag highlighted in bold. 
 
The Strep-HA-IRF5ΔDBD construct, and the full-length Strep-HA-IRF5 construct 
previously described in Table 2.2 can also be used in combination with these IRF5 
truncated mutant constructs to complete the range of mutants available. 
 
2.4.4 – Cloning of NFκB RelA truncated mutant expression constructs 
In addition to the IRF5 truncated mutant constructs already available, I also cloned 
truncated mutants of the NFκB subunit RelA, in order to be able to map the IRF5-RelA 
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interaction from both sides of the interface.  Whereas the IRF5 mutants were Strep and 
HA tagged, the RelA mutants were Flag tagged in order to be able to carry out 
immunoprecipitations using the respective tags.  Table 2.5 describes the expression 
constructs in detail including the primers required to amplify the fragments.  Full length 
WT RelA-Flag, as described in Table 2.2 completes the range of RelA constructs. 
Table 2.5: NFκB RelA truncated mutant constructs 
Description of the Flag-tagged truncated NFκB RelA constructs generated during this study including the 
primers used to amplify the fragments.  RE = Restriction enzyme, restriction site highlighted in primer 
sequence by underlining, Flag-tag sequence highlighted in bold. 
 
2.4.4.1 – PCR amplification for RelA truncated mutant cloning 
A RelA-HA expression plasmid (see Table 2.2) was used as a DNA template for 
amplification of regions of NFκB RelA sequence using the primers described in Table 
2.5 and a high fidelity Phusion DNA polymerase (Finnzyme, Thermo Scientific, UK).  A 
50 µl PCR reaction was performed using the following reagents: 
 
0.5 µl   Template DNA (at 50 ng/µl) 
28 µl     dH20 
10 µl     5x Phusion buffer 
1 µl       dNTP (at 40 nM) 
0.5 µl    Phusion DNA polymerase 
5 µl       Forward primer (at 5 µM) 
5 µl       Reverse primer (at 5 µM) 
50 µl 
NAME	   CONSTRUCT	   VECTOR	   TAG RE’s FORWARD PRIMER	   REVERSE PRIMER	  
RelA_N186-
Flag 
WT RelA 
aa1-186 
pBent2 Flag at  
C-terminus 
BamHI 
SpeI 
CGCGGGAAT
ACTAGTATG
GACGAACTG
TTCCCCCTC
ATC 
CGCGGGAAT
CCTAGGTTA
CTTGTCATC
GTCATCCTT
GTAATCGTC
AAAGATGGG
ATGAGAAAG 
 
RelA_N292-
Flag 
WT RelA 
aa1-292 
pBent2 Flag at  
C-terminus 
BamHI 
SpeI 
CGCGGGAAT
ACTAGTATG
GACGAACTG
TTCCCCCTC
ATC 
CGCGGGAAT
CCTAGGTTA
CTTGTCATC
GTCATCCTT
GTAATCTGT
ATCTGGCAG
GTACTGGAA 
 
RelA_Δ186-
Flag 
WT RelA 
aa186-551 
pBent2 Flag at  
C-terminus 
BamHI 
SpeI 
CGCGGGAAT
ACTAGTATG
CGTGCCCCC
AACACTGCC
GAG 
 
CGCGGGAAT
CCTAGGTTA
CTTGTCATC
GTCATCCTT
GTAATCGGA
GCTGATCTG 
ACTCAGCAG 
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PCR reactions were performed on a thermocycler according to the programme below: 
1. 98°C for 30 seconds 
2. 98°C for 10 seconds (denaturation) 
3. 52°C for 30 seconds (annealing) 
4. 72°C for 90 seconds (elongation) 
5. 72°C for 10 minutes  
 
2.4.4.2 – TOPO TA cloning reaction 
The TOPO TA cloning reaction is a 5-minute ligation reaction between the pCR 4-
TOPO vector (Invitrogen, USA), which is linear with 5’ thymidine overhangs, and the 
PCR product with 3’ adenine overhangs.  The advantage of first cloning into the TOPO 
vector is that it is easier to perform a restriction digest on circular DNA than a linear 
PCR product.  The restriction digest of a vector can also be monitored more easily than 
digestion of a PCR product, as two fragments should be generated which can be 
visualised by agarose gel electrophoresis.  It is also possible to sequence DNA inserts 
from the TOPO vector, using specific primers against T3, T7 or M13.   
 
Following PCR amplification, the PCR product was immediately used in the TOPO 
cloning reaction.  Firstly, as the PCR product was blunt-ended, 3’ adenine overhangs 
were generated by adding 1 µl Taq DNA polymerase (Invitrogen, USA) to each PCR 
reaction on ice, then incubating at 72°C for 10 minutes.  No additional dATP or new 
buffers were needed for this part of the reaction.  Following this, the TOPO reaction 
was performed at room temperature for 5 minutes: 
 
2.5 µl   PCR product (with adenine overhangs) 
0.5 µl   pCR 4-TOPO vector 
0.5 µl   Salt (200 mM NaCl, 10 mM MgCl2) 
2.5 µl   dH20 
 6 µl   . 
 
The TOPO reaction (3 µl of total volume) was transformed by heat shock into 20 µl 
chemically competent TOP10 cells, then incubated at 37°C for 1 hour with 250 µl SOC 
medium, after which 100 µl was spread onto ampicillin LB agar plates, as described in 
Section 2.4.2.5.  Colonies were allowed to grow overnight at 37°C, before plasmids 
were isolated by Mini-Prep purification (Qiagen, Germany) and positive transformants 
identified by diagnostic digest with the appropriate restriction enzymes, followed by 
agarose gel electrophoresis and visualisation by UV light and EtBr (see Section 
Repeat steps 2-4 (x30 cycles) 
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2.4.2.6).  A minimum of 8 colonies were screened per plate.  Plasmid DNA isolated 
from positive clones were sent for sequencing (MWG Eurofins, UK), and upon 
verification the RelA truncation inserts were sub-cloned into the pBent2 vector, by 
restriction digestion, purification, ligation and transformation as described in Section 
2.4.2.  Once completed, large-scale purification was performed (see Section 2.4.5). 
 
2.4.5 – Purification of expression construct plasmid DNA 
Following growth of either a 5 ml starter culture alone or supplemented with 100 ml 
transduced E.coli in LB broth containing the appropriate selection antibiotic, small- or 
large-scale purification of constructs was performed using Mini-Prep (Qiagen, 
Germany) or Midi-Prep (Qiagen, Germany) kits respectively, according to 
manufacturers instructions.  Midi-Prep kits can generate up to 100 µg of plasmid DNA, 
whereas Mini-Prep kits can generate up to 20 µg plasmid DNA.  Following purification, 
plasmid DNA was resuspended in 1x TE buffer and the concentration determined via 
NanoDropTM 1000 (Thermo Scientific, USA).  The resulting construct concentrations 
were normalised and stored at either 4°C or -20°C for longer-term. 
 
2.4.6 – Generation of bacterial glycerol stocks 
An aliquot of bacterial culture (400 µl) was taken before the cells were centrifuged for 
plasmid purification by Midi-Prep (see Section 2.4.5).  100 µl of a 60% v/v solution of 
glycerol was added to the bacteria in a cryovial.  Cryovials were stored at -80°C.  
 
To regenerate a bacterial culture from glycerol stocks, a pipette tip was used to scrape 
a small amount of the glycerol stock, which could then be used to inoculate a starter 
culture of 5 ml LB broth (containing the appropriate selection antibiotic). 
 
2.5 – Cloning and purification of adenoviruses  
Cloning an adenoviral expression vector involves recombining an entry clone (pBent2 
mammalian expression plasmid) with the pAd/CMV-DEST destination vector 
(Invitrogen, USA), which encodes genes for the elements required for proper 
packaging and production of adenovirus.  The CMV promoter ensures high-level 
expression of gene of interest.  Recombination occurs via an LR recombination 
reaction with LR clonase II enzyme (Invitrogen, USA). 
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2.5.1 – Cloning of an expression construct into the pAdeasy vector 
Entry clone (150 ng) was added to destination vector (300 ng) in a total reaction 
volume of 8 µl with TE buffer.  2 µl of LR clonase II enzyme (Invitrogen, USA) was 
added and the reaction incubated at room temperature for 1 hour.  Following this, 1 µl 
Proteinase K (Invitrogen, USA) was added and the reaction incubated at 37°C for 10 
minutes.  3 µl of reaction was transformed into chemically competent TOP10 cells (see 
Section 2.4.2.5) and plated onto an LB agar plate containing ampicillin selection 
antibiotic.  Positive transformants were picked and cultured overnight in 5 ml LB broth 
with ampicillin before plasmid purification via Mini-Prep (Qiagen, Germany) (see 
Section 2.4.5).  Positive transformants were confirmed by fingerprint digest with a 
single restriction enzyme, the predicted fragments of which were determined by Vector 
NTI software (Invitrogen, USA). 
 
2.5.2 – Transfection of the pAdeasy construct 
The cloned pAdeasy construct (3 µg) from Section 2.5.1 was then digested with PacI 
restriction enzyme (see Section 2.4.2.1).  1 volume of phenol/chloroform (Sigma, UK) 
was added to the digest, which was then vortexed and centrifuged for 5 minutes at 
13,000 rpm (Heraeus Biofuge Fresco).  The upper-phase was recovered and 
transferred to a clean tube (Eppendorf, UK), then 2.5 volumes of ethanol and 0.1 
volumes of 3M sodium acetate pH5.2 (Sigma, UK) were added, and the mixture 
incubated at -20°C for 30 minutes.  The DNA was then pelleted by centrifugation at 
13,000 rpm for 10 minutes (Heraeus Biofuge Fresco) and the pellet washed with 70% 
v/v ethanol.  100 µl of Optimem media (Invitrogen, USA) was added to the pellet and 
then incubated for 30 minutes at 37°C.  A further 400 µl of Optimem plus 10 µl 
Lipofectamine 2000 (Invitrogen, USA) was added to the mixture and incubated at room 
temperature for 20 minutes.  The solution was finally added to 5x105 HEK293 cells 
cultured in a 6-well plate and incubated for 2 hours at 37°C before being replaced with 
1 ml DMEM + 10% v/v FBS and finally incubated overnight at 37°C. 
 
2.5.3 – Agarose overlay and picking viral plaques 
The day after transfection of the pAdeasy construct into HEK293 cells (see Section 
2.5.2), a solution was prepared containing 1.5 ml of 1.5% w/v melted and warmed 
seaplaque agarose, and 1.5 ml 2x MEM media (Invitrogen, USA) supplemented with 
4% v/v FBS and 2% v/v P/S.  The transfection media was removed from the 
transfected HEK293 cells and the agarose-containing solution added drop-wise into 
the well.  Following 7-8 days incubation at 37°C (in a level incubator), plaques formed 
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which were visible using a fluorescent GFP microscope.  1-2 µl was removed from the 
centre of each plaque and transferred to a 48-well plate containing 500 µl DMEM.  12 
plaques were picked for each construct in this manner, then the plate incubated at 
37°C overnight to allow the virus to elute into the media.  If plaques did not form after 8 
days, 1 ml DMEM was injected under the agarose layer and transferred to a 15 ml tube 
(Falcon, UK) along with the broken agarose.  The well was then washed with a further 
2 ml DMEM and added to the tube before centrifugation at 1,500 rpm for 5 minutes 
(Scanspeed 1580MGR, GRS-750-4 rotor).  The resulting supernatant was serially 
diluted (50 µl sup + 950 µl DMEM, 200 µl sup + 800 µl DMEM, 500 µl sup + 500 µl 
DMEM) and applied to HEK293 cells in a 6-well plate for 1-2 hours at 37°C.  
Supernatants were replaced with DMEM + 4% v/v FBS + 2% v/v P/S for 24 hours at 
37°C before overlaying as above.  
 
2.5.4 – Adenovirus large-scale grow up 
Adenoviral particles were expanded by gradual infection of HEK293 cells in increasing 
sizes of tissue culture plates/flasks, to generate a large quantity for stock purification. 
 
2.5.4.1 – 12-well plate 
Viral plaque particles generated in Section 2.5.3 were used to infect 5x105 HEK293 
cells in a 12-well plate, by addition of 500 µl of elution to the cells for 1-2 hours at 
37°C, followed by 500 µl of DMEM + 4% v/v FBS + 2% v/v P/S.  Cells were left to be 
infected for several days at 37°C until a full cytopathic effect was observed. 
 
2.5.4.2 – 6-well plate 
Viral lysate from the 12-well plate (Section 2.5.4.1) was then used to infect 2 wells of a 
6-well plate, each containing 1x106 HEK293 cells.  The first well was incubated with 
500 µl viral lysate plus 500 µl DMEM for 2 hours at 37°C, whilst the second well was 
incubated with 100 µl viral lysate plus 900 µl DMEM.  Both plates then had 1 ml DMEM 
+ 4% v/v FBS + 2% v/v P/S added, and while the first was left to incubate for 1-2 days 
at 37°C until the full cytopathic effect was observed; the second well was incubated 
only overnight at 37°C before removal of the supernatant the next day and cell lysis 
(see Section 2.8.2) and Western blotting to check viral expression.  The first well was 
freeze-thawed three times before the viral lysate was utilised in Section 2.5.4.3. 
 
2.5.4.3 – One T175 flask 
Viral lysate generated in Section 2.5.4.2 (1 ml) was then used to infect HEK293 cells in 
a T175 flask, along with 9 ml DMEM.  After incubation at 37°C for 1 hour, 10 ml DMEM 
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+ 4% v/v FBS + 2% v/v P/S was added to the flask, and incubated for 1-2 days at 37°C 
until a full cytopathic effect was achieved.  The flask was then tapped to resuspend all 
of the cells and the lysate transferred to four 10 ml cryovials (5 ml in each), before 
snap freeze/thawing three times with liquid nitrogen.  Two cryovials were aliquoted into 
1.5 ml screw-top microcentrifuge tubes and stored at -80°C for archive purposes. 
 
2.5.4.4 – Ten T175 flasks 
The other two cryovials generated in Section 2.5.4.3 (10 ml total) were then made up 
to 100 ml in DMEM and 10 ml added to each of ten T175 flasks containing 80% 
confluent HEK293 cells.  After incubation at 37°C for 1 hour, 10 ml DMEM + 4% v/v 
FBS + 2% v/v P/S was added to each flask, which was then incubated for 
approximately 40 hours at 37°C until an 80% cytopathic effect was achieved.  Flasks 
were then tapped to resuspend any cells that were still slightly adherent and the 
contents of the ten flasks transferred to four 50 ml tubes, which were subsequently 
centrifuged at 1,000rpm for 5 minutes (Scanspeed 1580MGR, GRS-750-4 rotor).  The 
resulting pellets were resuspended in 10 ml DMEM and pooled into one 50 ml tube 
before it was centrifuged again.  The final pellet was resuspended in 10 ml 0.1M Tris 
pH 8.0, divided between two cryovials and snap freeze/thawed three times. 
 
2.5.5 – Purification of high-titre adenovirus stocks 
Purification of high-titre adenovirus stocks was performed in a Class I hood with 
appropriate PPE and Microsol (Anachem, UK) solutions for clean-up.  Viral lysates 
from Section 2.5.4.4 were transferred to a clean 50 ml tube and passed through a 10 
ml syringe and blunt needle 4-5 times to shear the chromatin.  The lysate was then 
centrifuged at 2,000rpm for 5 minutes (Scanspeed 1580MGR, GRS-750-4 rotor) to 
pellet the cellular debris and the supernatant transferred to another clean 50 ml tube.  
The supernatant was made up to 11.4 ml with 0.1M Tris pH8.0, then 6.6 ml saturated 
caesium chloride (Sigma, UK) solution added and mixed well with a pipette.  The 
solution was transferred to two ultracentrifuge tubes (Sorvall, ThermoScientific, USA) 
using a blunt needle and 10 ml syringe until completely full with no air bubbles.  The 
collars were placed onto the tubes and screwed in place.  Tubes were ultracentrifuged 
(Sorvall, ThermoScientific, USA) overnight at 60,000rpm and 4°C (acc: 9, dec: 1).   
 
The following day, viral particle bands were collected from the ultracentrifuge tubes 
using a sharp needle and syringe to pierce the tube whilst immobilised in a clamp 
stand.  Viral particles from both tubes were pooled into a single clean ultracentrifuge 
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tube and topped up until full with 1.34 g/ml caesium chloride (Sigma, UK) solution.  
Once all bubbles were removed the tube was ultracentrifuged overnight as before. 
 
On the third day, the virus band was removed from the ultracentrifuge tube as 
described above, in a maximum volume of 2.5 ml.  The band was applied to a 
disposable PD-10 Desalting Column (GE Healthcare, USA) that had been pre-
equilibrated with 25 ml PBS 2+.  Virus was eluted from the column with 3.5 ml PBS 2+ 
into a bijou containing 10 drops of glycerol (Sigma, UK) – approximately 10% v/v final 
concentration, then mixed well and passed through both 0.44 µ and 0.22 µ filters using 
a Luer lock syringe.  Purified virus was then aliquoted into screw-top microcentrifuge 
tubes in 500 µl or 200 µl volumes and stored at -80°C. 
 
2.5.6 – Determination of titration and replication competency 
HEK293 cells cultured in a 12-well plate (5x105) were infected with 100 µl of serial 
dilutions of adenovirus, prepared from 10 µl of stock, in DMEM + 10% v/v FBS + 1% 
v/v P/S overnight at 37°C.  The following day, the titre of the virus was determined 
using the Adeno-XTM Rapid Titre Kit (Clontech, USA), according to the manufacturers 
protocol.  The remaining diluted adenovirus was applied to a T25 flask of Human Skin 
Fibroblasts (HSFs) and incubated for 2 hours at 37°C.  The adenovirus in the flask was 
then replaced with DMEM + 10% FBS and the cells were observed over 10 days at 
37°C to ensure a cytopathic effect did not occur (would mean the adenovirus is 
replication competent and would have had to be destroyed). 
 
2.6 – Transfection and adenoviral infection  
Cell lines were transduced in order to express or deplete proteins or peptides, 
according to experimental design. 
 
2.6.1 – Transduction of HEK293 cells (Lipofectamine 2000 reagent) 
HEK293-TLR4 or HEK293-ET cells were seeded in poly-L-lysine (Sigma, UK) coated 
10 cm dishes/ 6-well/ 12-well/ 96-well tissue culture plates and incubated overnight at 
37°C.  The following day when 70% confluency was achieved, cells were washed and 
transfection media (DMEM + 10% v/v FCS) added.  Mammalian expression plasmid 
DNA was added to Optimem media (Invitrogen, USA) then mixed with an equal volume 
of Optimem plus Lipofectamine 2000 reagent (Invitrogen, USA) as described in Table 
2.6.  Solutions were incubated at room temperature for 20 minutes before being added 
drop-wise to the cells.  Cells were incubated overnight at 37°C before being washed 
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twice with room temperature PBS prior to cell lysis (see Section 2.8.2 or 2.10.3).  
Transfection efficiency was determined by GFP-expression visualised via microscopy. 
  
  Table 2.6: Reagent volumes required for Lipofectamine 2000 transfection 
 
In order to transfect 3 wells of HEK293-TLR4 cells in a 96-well plate for a luciferase 
reporter assay (see Section 2.7.4), the reagent quantities and protocol below were 
required, before overnight incubation at 37°C.  
 
1. Prepare 600 ng total DNA plasmids in 88 µl Optimem media (Invitrogen, USA) 
2. Add 3.5 µl Lipofectamine 2000 reagent (Invitrogen, USA) in 88 µl Optimem 
media, and incubate for 20 minutes at room temperature 
3. Add 55 µl of this transfection mixture per well of 96-well plate (3 wells total) 
 
2.6.2 – Transduction of RAW264.7 cells (Lipofectamine LTX reagent) 
RAW264.7 cells were seeded in 96-well tissue culture plates (5x104 cells per well in 
100 ml media) and incubated overnight at 37°C.  No media change was required prior 
to the transfection protocol.  In order to transfect 6 wells of a 96-well plate, the reagent 
quantities and protocol below were required, before overnight incubation at 37°C.  
Cells were then lysed for use in a luciferase gene reporter assay (see Section 2.7.4).  
Transfection efficiency was determined by GFP-expression visualised via microscopy. 
 
1. Prepare 600 ng total DNA plasmid in 40 µl Optimem media (Invitrogen, USA) 
2. Add 1 µl Lipofectamine Plus reagent (Invitrogen, USA) in 19 µl Optimem media, 
and incubate for 15 minutes at room temperature 
3. Add 2 µl Lipofectamine LTX reagent (Invitrogen, USA) in 18 µl Optimem media 
and incubate for 30 minutes at room temperature 
4. Add 12.5 µl of this transfection mixture per well of 96-well plate (6 wells total) 
 
2.6.3 – Transduction of human primary macrophages (DharmaFECT I)  
Following isolation of PBMCs from human blood and elutriation to purify monocytes, 
cells were differentiated into macrophages using GM-CSF for 5 days (see Section 2.2).  
SIZE	   CELL NUMBER	   MEDIA VOLUME	   OPTIMEM VOLUME PLASMID AMOUNT LIPOFECTAMINE 2000 VOLUME	  
10cm dish 1x107 7.5 ml 1.5 ml + 1.5 ml Approx 10 µg 30 µl 
6-well plate 2x106 1.5 ml 250 µl + 250 µl Approx 1 µg 5 µl 
12-well plate 7x105 1 ml 50 µl + 50 µl Approx 500 ng 3 µl 
96-well plate 5x104 50 µl 25 µl + 25µl Approx 100 ng 0.5 µl 
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Following differentiation, cells were harvested with Versene-EDTA (PAA, USA) at 
37°C, and counted and resuspended in pre-warmed phenol-free RPMI media (PAA, 
USA) at a density of 1x105 cells per 30 µl.  Transduction was required in this cell type 
in order to deplete protein levels of KAP1/TRIM28 by RNA interference (siRNA 
knockdown).  The siRNA oligonucleotide (5’-UGACCAAGAUCCAGAAGCA-3’) was 
generated by MWG Eurofins, UK [291].  Negative control siRNA (Qiagen, Germany) 
was sourced as a control for non-specific effects of the KAP1 siRNA.  Half of the GM-
CSF differentiated macrophages were therefore subjected to transfection with KAP1 
siRNA whereas half were transfected with control siRNA.   
 
The following mixture was prepared per 1x105 cells and incubated at room temperature 
for 20 minutes: 
 
  0.5 µl DharmaFECT I reagent (Dharmacon, USA) 
17.5 µl Optimem media (Invitrogen, USA) 
  2.0 µl Oligonucleotide at 500 nM, final concentration 50 nM 
   20 µl 
 
The 20 µl transfection mixture was then added to the 30 µl of suspended cells in 
multiples according to the number of wells of a 96-well plate (RNA/ELISA) or 10 cm 
dishes (ChIP) required for the experiment.  Cells were transfected for 4 hours in a 50 
ml tube, rotating on a wheel shaker, before being pelleted at 1,500 rpm (Scanspeed 
1580MGR, GRS-750-4 rotor) for 5 minutes and resuspended in pre-warmed RPMI + 
10% v/v FBS (100 µl per 1x105 cells for 96-well plate, 10 ml per 1x107 cells for 10 cm 
dish).  Once plated, cells were incubated at 37°C for 3 days, before stimulation with 10 
ng/ml LPS (Alexis, USA) as required. 
 
2.6.4 – Cellular uptake of peptides using ProteoJuice reagent 
HEK293-ET cells were seeded in 12-well tissue culture plates coated with poly-L-lysine 
(Sigma, UK) at a density of 7x105 cells per well.  Following overnight incubation at 
37°C, cells were transfected with mammalian expression plasmids (see Section 2.6.1) 
before further incubation overnight at 37°C.  Per well that required peptide transfection, 
a sterile microcentrifuge tube was prepared containing 50 µl DMEM, 2.5 µl ProteoJuice 
reagent (Millipore, USA) and 2.5/5/7.5 µl peptide at a stock concentration of 1 mg/ml 
according to whether a 1:1, 1:2 or 1:3 ratio was required.  The contents of the tube 
were vortexed then incubated at room temperature for 20 minutes, before 450 µl of 
DMEM added.  Seeded cells were washed twice with DMEM then the transfection 
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mixture added drop-wise to the empty well.  Following incubation for 2 or 20 hours at 
37°C, cells were stimulated as required with 1 µg/ml LPS (Alexis, USA) then lysed for 
either RNA or protein extraction (see Sections 2.7.1 and 2.8.2). 
 
2.6.5 – Adenoviral transduction of HEK293-TLR4 cells 
HEK293-TLR4 cells (1x107) were plated onto 10 cm tissue culture dishes coated with 
poly-L-lysine (Sigma, UK).  Following overnight incubation at 37°C, the media was 
removed and replaced with 7 ml DMEM containing adenoviral particles at a multiplicity 
of infection (MOI) of 5.   
 
The volume of stock adenovirus required for the desired MOI can be calculated by 
determining the desired pfu (plaque-forming units): 
Number of cells x Desired MOI = Desired pfu 
 
           Desired pfu          x 1000 = µl adenovirus required 
Adenovirus titre (pfu/ml) 
 
Following 2 hours of serum-free infection, the adenovirus-containing media was 
washed from the 10 cm dishes and replaced with 10 ml pre-warmed DMEM + 10% v/v 
FCS + 1% v/v P/S and incubated overnight at 37°C.  The following day, cells were 
stimulated with LPS (Alexis, USA) at 1 µg/ml as required then washed twice with pre-
warmed media to ensure all adenoviral particles had been removed before cross-
linking and cell lysis (see Section 2.8.1 and 2.8.2).  Infection efficiency could be 
determined by GFP-expression via microscopy. 
 
2.6.6 – Adenoviral transduction of human and murine macrophages 
Human or murine macrophages (1x106 or 1x105) were plated in 6-well or 96-well plates 
respectively and incubated overnight at 37°C to allow the cells to adhere.  Media was 
changed to 7 ml /50 µl pre-warmed serum-free RPMI prior to adenoviral infection at an 
MOI of 100 (see Section 2.6.5) for 4 hours at 37°C.  After 4 hours, 7 ml /50 µl complete 
media was added to the dishes and the cells incubated overnight at 37°C.  The 
following day, cells were stimulated with LPS (Alexis, USA) at 10 ng/ml or 500 ng/ml as 
required then washed twice with pre-warmed media to ensure all adenoviral particles 
had been removed before RNA or protein extraction (see Section 2.7.1 or 2.8.2).  
Infection efficiency could be determined by GFP-expression via microscopy. 
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2.7 – Measuring gene expression and protein secretion  
 
2.7.1 – RNA extraction  
Total RNA was extracted from cells using an RNeasy Mini Kit (Qiagen, Germany) as 
per the manufacturers instructions.  Any contaminating genomic DNA was removed 
during this protocol using the RNase-Free DNase Set (Qiagen, Germany).  RNA 
concentration was quantified using the NanoDropTM 1000 (Thermo Scientific, USA) and 
normalised to 100 ng/µl maximum concentration before storage at -80°C.  RNA-
containing samples were routinely stored on ice to help prevent degradation. 
 
2.7.2 – cDNA synthesis 
cDNA was synthesised from 0.1-1 µg of total RNA (see Section 2.7.1) with a High 
Capacity cDNA Reverse Transcriptase Kit (Invitrogen, USA) in the following reaction: 
 
10  µl RNA 
2    µl 10x RT buffer 
0.8 µl 25x dNTPs (100 mM) 
2    µl 10x Random primers 
1    µl Reverse transcriptase 
4.2 µl Nuclease-free water 
20  µl 
 
A reagent master-mix for the total number of samples (plus two extra) was prepared.  
Before the reverse transcriptase enzyme was added to the master-mix, 9 µl was taken 
and added to 3x 3 µl pooled samples of RNA and made up to 20 µl with nuclease-free 
water as a ‘no-RT’ control for genomic DNA contamination.  The cDNA reaction was 
performed in a thermocycler, with the lid set at a constant temperature of 100°C 
according to the following programme: 
 
1. 25°C for 10 minutes 
2. 37°C for 120 minutes 
3. 85°C for 5 minutes 
 
Samples were diluted 1:4 in nuclease-free water and stored at -20°C until required for 
qPCR analysis (see Section 2.7.3). 
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2.7.3 – Quantitative Real-Time PCR (qPCR) analysis of gene expression 
Real-time PCR allows quantification of mRNA levels produced by cells using TaqMan 
primer probes (Life Technologies, USA) to amplify mRNA that had been previously 
reverse-transcribed to generate cDNA (see Section 2.7.2).  Gene expression was 
measured by the change-in-threshold (ΔΔCT) method. 
 
Taqman primer probes (Life Technologies, USA) bind to the cDNA target sequence 
and are cleaved by the 5’ nuclease activity of Taq DNA polymerase as the primer 
becomes extended.  This cleavage reduces the proximity of a 5’ reporter fluorescent 
dye on the probe from a 3’ quencher dye, resulting in increased fluorescence.  As 
additional Taqman probes are cleaved with each PCR cycle, increased fluorescence 
intensity in proportion to the amount of amplicon is produced.  Each real-time PCR 
reaction produces a sigmoid curve over time according to the degree of fluorescence 
produced during the reaction, with a region of exponential growth across which an 
arbitrary line is drawn.  The PCR cycle number at which the curve crosses the arbitrary 
line is the CT value for each sample (see Figure 2.2).  The ΔCT value for each gene is 
calculated by subtracting the CT value of a sample from the CT value of its related 
control sample (Sample B minus Sample A in Figure 2.2).  ΔΔCT is calculated by next 
subtracting the calculated ΔCT value of your gene of interest from the ΔCT value of a 
housekeeping gene.  In order to generate a positive value, the formula 2^-ΔΔCT  is 
then applied. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Calculation of ΔCT values in Real-Time Quantitative PCR (qPCR) 
The point at which the fluorescence curve crosses an arbitrary line whilst in the exponential phase is the 
CT value of the sample (PCR cycle number).  ΔCT is the difference between the CT value of a sample and 
the CT value of a related control sample for the same gene that is used for normalisation. 
 
  
 
Samples were prepared by adding 2.4µl diluted cDNA to the following master mix, in a 
6 µl total reaction volume: 
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3    µl Fast Blue qPCR Master Mix + dTTP (Eurogentec, UK) 
0.3 µl Nuclease-free water 
0.3 µl Taqman probe (see Table 2.7) 
3.6 µl .  
 
The following Taqman primer sets (Life Technologies, USA) were utilised in this study: 
 
 
 
 
 
 
 
 
 
 
 
 
                              Table 2.7:Taqman primer probes used in this study 
 
The qPCR reaction was performed in an ABI 7900HT (Life Technologies, USA) 
according to the following programme: 
 
1. 95°C for 5 seconds 
2. 95°C for 15 seconds 
3. 60°C for 45 seconds 
 
2.7.4 – Luciferase gene reporter assays 
Luciferase gene reporter assays determine whether transcription factors are involved 
in regulation of gene expression at a particular gene locus.  A plasmid DNA construct 
containing a DNA sequence such as a promoter or enhancer that is known to be a 
gene regulatory element, drives expression of the Firefly luciferase gene to show the 
extent of involvement of a particular exogenously expressed transcription factor.  The 
Firefly luciferase gene encodes a bioluminescent enzyme that catalyses the 
conversion of luciferin to oxyluciferin and light, which is measurable.  HEK293-TLR4 or 
RAW264.7 cells were transfected with 600 ng of DNA plasmids per 6 wells of a 96-well 
plate according to the protocols in Section 2.6.1 and 2.6.2. Firefly luciferase reporter 
construct (200 ng), transcription factor expression plasmid (200 ng, see Table 2.2) and 
GENE	   SPECIES	   PRODUCT CODE	  
HPRT Mouse Mm00446968_m1 
IL12B Mouse Mm01288990_m1 
IL10 Human Hs00174086_m1 
IL12A Human Hs00168405_m1 
IL12B Human Hs00233688_m1 
IL23A Human Hs00372324_m1 
IL27 Human Hs00377366_m1 
IRF5 Human Hs00158114_m1 
RPLP0 Human Hs99999902_m1 
TNF Human Hs00174128_m1 
TRIM28 Human Hs01076244_g1 
Repeat steps 2-3 (x45 cycles) 
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200 ng Renilla luciferase construct (to allow normalisation of samples for transfection 
efficiency, cytotoxic effects and differences in cell number) were introduced into the 
cells.  Following incubation of transfected cells overnight at 37°C, LPS stimulation was 
performed for 6 hours.  Supernatants were removed and plates were then stored at -
20°C if required, before analysis of luciferase expression using the Dual-Glo™ 
Luciferase Assay kit (Promega, USA).  PBS (25 µl) and Dual-Glo™ Luciferase 
Reagent (25 µl) were added to each well respectively, before the plate was placed on a 
shaker for 30 minutes at room temperature.  Samples were then transferred into 
luminometer plates and luciferase activity measured using a 1450 MicroBeta® JET 
(PerkinElmer, USA). Dual-Glo™ Stop & Glo® Reagent (25 µl) was then added to each 
well and after 10 minutes shaking at room temperature, Renilla luciferase activity was 
measured in the same manner.  Data was normalised by dividing Firefly/Renilla 
luciferase activity. 
 
2.7.5 – Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA allows quantification of proteins that have been secreted into the supernatant by 
cultured cells using antibodies to specifically capture a protein of interest.  Capture 
antibodies (see Table 2.8) were diluted in PBS to a volume of 50 µl per well and 
applied to 96-well plates that were then placed on a shaker overnight at 4°C.  The 
following day, the solution was removed and the plate was then washed once with 
PBS+0.05% Tween (Sigma, UK).  Plates were blocked with 150 µl PBS + 2% w/v BSA 
(Bovine Serum Albumin, Sigma, UK) on a shaker for 1 hour at room temperature, 
before 3 washes with PBS + 0.05% v/v Tween.  Supernatant samples were diluted 1:3 
in PBS+1% BSA, and a standard curve prepared of seven 1:3 dilutions of the purified 
protein of interest (see Table 2.9) in PBS + 1% w/v BSA (top concentration 10,000 
pg/ml).  Samples/standards were applied to the capture antibody-coated and blocked 
plates in a volume of 50 µl and incubated shaking for 2 hours at room temperature or 
overnight at 4°C. 
 
Following protein capture, plates were washed 3 times with PBS + 0.05% v/v Tween 
before subsequent addition of corresponding biotinylated-antibody conjugates 
ANTIGEN	   SPECIES	   CLONE	   PRODUCT CODE SUPPLIER DILUTION 
IL-10 capture Human JES3-19F1 554705 BD Bioscience 1:500 
IL-10 detect Human JES3-12G8 554499 BD Bioscience 1:500 
TNF capture Human MAb1 551220 BD Bioscience 1:125 
TNF detect Human MAb11 554511 BD Bioscience 1:1000 
           Table 2.8: Capture and detection antibodies used in ELISA assays 
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(detection antibodies, see Table 2.8), which also bind to the captured protein of 
interest.  Detection antibodies were diluted in PBS + 1% w/v BSA to a volume of 50 µl 
per well and incubated on the plates for 1 hour shaking at room temperature.  
Following 3 washes with PBS + 0.05% v/v Tween, Streptavidin-HRP was added (binds 
to the biotinylated detection antibody), at a 1:400 dilution in PBS + 1% w/v BSA (50 µl 
per well), shaking for 1 hour at room temperature.  After a final 3 washes with PBS + 
0.05% v/v Tween, an HRP-substrate (TMB Microwell Peroxidase Substrate, KP Inc, 
USA) was added to a final volume of 50 µl per well to induce a quantifiable colour 
change, relative to the amount of protein immobilised in each well.  Plates were 
monitored during the resulting blue colour change to ensure that samples did not 
develop darker than the standard curve colour.  The enzymatic reaction was 
terminated by addition of 50 µl 1M H2S04, which produces a colour change to yellow.  
Absorbance was read at 450 nm by a spectrophotometric ELISA plate reader 
(Labsystems Multiscan Biochromic) and analysed using Ascent Labsystems software.  
This analysis compares the amount of protein in each sample (triplicate wells) to the 
standard curve of known protein concentrations (duplicate wells), in order to infer the 
absolute concentration of secreted proteins.  
 
                         
 
 
 
                          Table 2.9: Recombinant proteins used as standards for ELISA 
 
2.8 – Immunoprecipitation and Western blotting 
Protein complexes were purified in this thesis from cell lysates by either One-Strep 
affinity purification or immunoprecipitation using antibodies.  Western blotting was 
performed to identify and semi-quantitate specific proteins within cell lysates and One-
Strep/IP eluates.  This technique is not fully quantitative due to varying affinities of 
antibodies for their protein antigen, which means that interaction affinities between 
different protein partners cannot be deduced by densitometry of eluate protein bands 
on a Western blot.  Western blotting can also be applied to detect protein post-
translational modifications such as phosphorylation, methylation and acetylation. 
 
2.8.1 – Cross-linking of protein complexes within cells 
Cross-linking was performed using the amine-reactive cross-linker dimethyl 3,3'-
dithiobispropionimidate (DTBP, Thermo Scientific, USA), which consists of an 8-atom 
spacer arm with imidoesters groups.  The central disulphide bond of DTBP can be 
PROTEIN	   SPECIES	   PRODUCT CODE SUPPLIER 
IL-10 Human 554611 BD Bioscience 
TNF Human 554618 BD Bioscience 
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cleaved with reducing agents in order to reverse cross-linking of complexes.  Following 
cell culture as required, cells in 10 cm dishes were washed with PBS and a freshly-
prepared 25 mM stock solution of DTBP added in PBS to the dish at a final 
concentration of 8 mM.  Following 20 minutes incubation at room temperature with 
gentle swirling of the dishes, 1M Tris pH7.5 was added to a final concentration of 20 
mM to quench the reaction.  Following protein complex purification by One-Strep 
affinity purification or immunoprecipitation (see Sections 2.8.3-2.8.7), cross-linking was 
reversed by addition of 1M DTT to a final concentration of 150 mM and incubation at 
37°C for 30 minutes. 
 
2.8.2 – Protein extraction, concentration and quantification 
Cell lysis was performed either within a tissue culture plate or following cell harvesting 
by scraping with a cell lifter and pelleting in a microcentrifuge tube by centrifugation at 
1,500 rpm (Heraeus Biofuge Fresco) for 5 minutes.  Total cell lysis was performed 
using whole cell lysis buffer (see Section 2.12), and fractionation of cytoplasmic and 
nuclear lysates was performed with a combination of cytoplasmic lysis buffer and RIPA 
nuclear lysis buffer (see Section 2.12) plus sonication.  Lysis buffers were prepared by 
chilling on ice and the addition of protease inhibitors (Complete protease inhibitor 
cocktail, Roche, USA).  Total cell lysis and cytoplasmic lysis was performed on ice for 
30 minutes, followed by centrifugation at 13,000 rpm or 3,000 rpm (Heraeus Biofuge 
Fresco) for 10 minutes or 5 minutes at 4°C respectively.  Supernatants were collected 
and stored temporarily on ice or at -80°C longer-term.  Following cytoplasmic lysis, 
chilled RIPA nuclear lysis buffer (plus protease inhibitors) was added to the nuclear 
pellet and sonicated using a Bioruptor sonicator (Diagenode, Belgium) at 4°C for 8 
minutes with a 30 second on/off cycle.  Sonication is performed to break intermolecular 
interactions and fragment DNA in order to produce a less viscous lysate.  Nuclear 
lysates were then cleared by centrifugation at 13,000 rpm (Heraeus Biofuge Fresco) 
for 10 minutes at 4°C and the supernatant collected and stored as described above. 
 
Protein lysates were concentrated using Vivaspin® 500 Centrifugal Conentrator 
columns (Sigma, UK) at 13,000 rpm (Heraeus Biofuge Fresco) for 15 minutes.  Using 
this protocol proteins were purified with a molecular weight cut-off (MWCO) of 5 kDa.  
Protein concentration of samples was quantified using a Qubit® Fluorometer 
(Invitrogen, USA) and the corresponding assay according to the manufacturers 
instructions. 
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2.8.3 – One-Strep affinity purification 
The One-Strep System of affinity purification (see Figure 2.3) enables rapid, single 
step purification of recombinant proteins from bacterial or mammalian cell lysates 
[292].  The system utilises the One-Strep tag, a short peptide tag with the sequence:  
 
NH2-WSHPQFEKGGGSGGGSGGGSWSHPQFEK-COOH 
 
The One-Strep tag has a strong binding affinity for the engineered streptavidin 
derivative Strep-Tactin [292]; therefore the generation and introduction of One-Strep-
fusion proteins into a cell system, enables bait protein purification from a complex 
mixture of proteins by exposure of the cell lysate to Strep-Tactin coated beads.  In 
order to enhance specificity of the purification; the elution of the One-Strep-fusion bait 
protein is achieved by the addition of biotin to the column, which competitively binds to 
the same binding pocket on the Strep-Tactin as the One-Strep tag, but with a higher 
affinity.  One-Strep-fusion proteins, in complex with any interaction partners, are 
therefore eluted from the column.  Bait and prey (interacting) proteins can then be 
separated by SDS-PAGE and subjected to Western blotting with specific antibodies, or 
Colloidal blue staining to visualise bands for identification by mass spectrometry.  
Experiments are carried out in parallel with a mock control (transfection of the One-
Strep tag alone) to show interaction specificity and to help rule out any false positives 
caused by non-specific binding or insufficient washing steps before elution.  
 
Cell lysates were applied to a 50% suspension of Strep-Tactin Macro-prep beads (IBA, 
UK) suspended in a Biospin chromatography column (Biorad, UK) pre-equilibrated with 
1 ml ice-cold lysis buffer, and allowed to flow through by gravity.  Columns were 
washed with seven/twelve 1 ml applications of ice-cold IP wash buffer (see Section 
2.12) for non-cross-linked or cross-linked samples respectively.  Elutions were 
performed by addition of six 50 µl applications of biotin elution buffer (see Section 
2.12), which were collected and pooled into the same tube.  Eluates were concentrated 
as required (see Section 2.8.2), before utilisation in SDS-PAGE (see Section 2.8.8) or 
storage at -80°C. 
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Figure 2.3: One-Strep affinity purification for identifying protein-protein interactions 
A: One-Strep fusion proteins are expressed in target cells where they form complexes with endogenous 
proteins, which can be cross-linked to stabilise.  B: Bait plus prey complexes are isolated from cell lysates 
by exposure to Strep-Tactin, subjected to wash steps to remove non-specifically bound proteins, then 
eluted with biotin (C).  D: Eluates are subjected to SDS-PAGE and Western blotting or mass spectrometry 
of trypsinised Colloidal blue/silver stained bands for interacting protein identifications. 
 
2.8.4 – Flag-Immunoprecipitation 
Flag-immunoprecipitation allows purification of Flag-tagged exogenously expressed 
proteins and their complexes from cell lysates using antibodies.  Microcentrifuge tubes 
of cell lysates were incubated with Anti-FLAG® M1 Agarose Affinity Gel (Sigma, UK) for 
1 hour rotating at 4°C.  Washes with 1 ml of the corresponding lysis buffer (chilled, with 
Roche protease inhibitors added) were then performed by rotating the tube for 5 
minutes followed by centrifugation at 2,000 rpm (Heraeus Biofuge Fresco) for 2 
minutes at 4°C to pellet the Flag-matrix.  This was repeated 3 times, disposing of the 
supernatant following each centrifugation step.  Elutions were performed in the same 
manner with 50 µl Flag peptide (Sigma, UK) at a dilution of 1:25 in corresponding lysis 
buffer.  Eluates were collected twice and pooled to 100 µl, before utilisation in SDS-
PAGE (see Section 2.8.8) or storage at -80°C. 
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2.8.5 – Myc-Immunoprecipitation 
Myc-immunoprecipitation allows purification of Myc-tagged exogenously expressed 
proteins and their complexes from cell lysates using antibodies.  Microcentrifuge tubes 
of cell lysates were incubated with 1 µg c-myc antibody (clone 9E10, Santa Cruz, USA) 
for 2 hours rotating at 4°C.  20 µl Protein-G Magnetic Dynabeads (Invitrogen, USA) 
were added and the samples rotated for a further 90 minutes at 4°C.  Washes with 1 
ml of the corresponding lysis buffer (chilled, with Roche protease inhibitors added) 
were then performed by rotating the tube for 5 minutes followed by magnetic isolation 
of bead complexes.  This was repeated 4 times, disposing of the supernatant following 
each centrifugation step.  Elutions were performed by addition of 50 µl of loading buffer 
(4x concentrated, see Section 2.12) and 50 µl of lysis buffer to each sample and 
heating them to 100°C for 5 minutes.  Samples were chilled on ice and centrifuged 
gently to collect condensation, and then eluates were removed from the beads using a 
magnet.  Samples were utilised in SDS-PAGE (see Section 2.8.8) or stored at -80°C. 
 
2.8.6 – HA-Immunoprecipitation 
HA-immunoprecipitation allows purification of HA-tagged exogenously expressed 
proteins and their complexes from cell lysates using antibodies.  Microcentrifuge tubes 
of cell lysates were incubated with Anti-HA affinity matrix (Roche, USA) for 90 minutes 
rotating at 4°C.  Washes with 1 ml of the corresponding lysis buffer (chilled, with Roche 
protease inhibitors added) were then performed by rotating the tube for 5 minutes 
followed by centrifugation at 2,000 rpm (Heraeus Biofuge Fresco) for 2 minutes at 4°C 
to pellet the HA-matrix.  This was repeated 4 times, disposing of the supernatant 
following each centrifugation step.  Elutions were performed by addition of 50 µl of 
loading buffer (4x concentrated, see Section 2.12) and heating to 100°C for 5 minutes.  
Samples were chilled on ice and centrifuged gently to remove condensation.  Samples 
were utilised in SDS-PAGE (see Section 2.8.8) or stored at -80°C. 
 
2.8.7 – Endogenous protein immunoprecipitation 
Endogenous immunoprecipitation allows purification of exogenous proteins and their 
complexes from cell lysates using antibodies.  Microcentrifuge tubes of cell lysates 
were incubated with 2 µg IRF5/KAP1 antibody (see Table 2.10) or a –Ab control for 2 
hours rotating at 4°C.  100 µl TrueBlot Anti-Rabbit Ig IP beads (eBioscience, USA) 
were added and the samples rotated for a further 1 hour at 4°C.  Washes with 1 ml 
chilled IP wash buffer (see Section 2.12) were then performed by rotating the tube for 5 
minutes followed by centrifugation at 2,000 rpm (Heraeus Biofuge Fresco) for 2 
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minutes at 4°C to pellet bead complexes.  This was repeated 3 times, disposing of the 
supernatant following each centrifugation step.  Elutions were performed by addition of 
50 µl of loading buffer (4x concentrated, see Section 2.12) and 50 µl of lysis buffer to 
each sample and heating them to 100°C for 5 minutes.  Samples were chilled on ice 
and centrifuged gently to collect condensation, then eluates were removed from the 
beads following centrifugation at 2,000 rpm (Heraeus Biofuge Fresco) for 2 minutes.  
Samples were utilised in SDS-PAGE or stored at -80°C. 
 
2.8.8 – SDS-PAGE  
Total protein (10 µg) from cell lysate (see Section 2.8.2) or an appropriate volume of 
eluate (see Sections 2.8.3-2.8.7) were mixed with an appropriate volume of 4x loading 
buffer (see Section 2.12) and heated to 100°C for 5 minutes.  The resulting denatured 
and reduced proteins were separated at 160 V on a pre-cast NuPAGE® Novex 4-12% 
Bis-Tris gel (Invitrogen, USA) immersed in NuPAGE® MOPS SDS Running buffer 
(Invitrogen, USA) for approximately 60 minutes until fully resolved.  A Full-Range 
Rainbow Molecular Weight Marker (GE Healthcare, UK) was run in parallel so that the 
molecular weight of visualised proteins could be estimated. 
 
2.8.9 – Protein transfer 
Following SDS-PAGE (see Section 2.8.8), resolved proteins were transferred to 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare, UK).  PVDF membranes 
were cut to a suitable size, dehydrated in methanol and then equilibrated in Transfer 
Buffer (see Section 2.12). The PVDF membrane was placed on top of the gel 
containing resolved proteins, then sandwiched between 4 pieces of Transfer Buffer-
soaked filter paper.  The assembly was then placed in a transfer cassette in between 
two Transfer Buffer-soaked sponges and inserted into a transfer tank filled with pre-
cooled transfer buffer.  A constant voltage of 72 V was applied for 2 hours at 4°C. 
 
2.8.10 – Western blotting 
After protein transfer (Section 2.8.9) membranes were incubated in blocking solution 
(PBS + 0.1% v/v Tween + 5% w/v Milk) on a shaker for at least 1 hour at room 
temperature. Primary antibodies (see Table 2.10) were diluted in PBS + 0.1% v/v 
Tween + 2% w/v BSA and incubated with the membranes overnight at 4°C with gentle 
agitation.  The following day, the membranes were washed three times with PBS + 
0.1% v/v Tween, rotating on a shaker for at least 10 minutes between each wash step.  
HRP-conjugated secondary antibodies (see Table 2.10) were diluted in blocking 
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solution and incubated with the membranes for at least 1 hour at room temperature 
with gentle agitation.  Immuno-complexes were detected using the chemiluminescent 
substrate solution ECL (GE Healthcare, UK), visualised using Hyperfilm MP 
(Amersham, UK) and developed using an AGFA Cruis-60 automatic film processor 
(AGFA-Gaevert, UK).  When multiple protein detections were required on the same 
membranes, antibodies were stripped from the membrane using ReBlot Plus Strong 
Antibody Stripping Solution (Chemicon, UK) as per the manufacturer’s instructions. 
 
Table 2.10: Antibodies used for Western blotting 
 
2.9 – Proteomic techniques  
 
2.9.1 – Colloidal blue staining of SDS-PAGE gels 
Once protein samples on SDS-PAGE gels were resolved by electrophoresis (see 
Section 2.8.8), the gels were fixed for 20 minutes (50% v/v methanol, 5% v/v acetic 
acid), before addition of Colloidal Blue staining solutions overnight as specified in 
manufacturers protocol (Invitrogen, USA).  Gels were washed for at least 3 hours in 
distilled water to remove any background staining.  All steps were carried out with 
gentle shaking at room temperature.  Protein bands were visualised on a light box for 
excision and stored in distilled water at 4°C. 
ANTIBODY	   SOURCE	   CONJUGATED? PRODUCT CODE SUPPLIER DILUTION 
Actin Mouse / A5441 Sigma 1:10,000 
IRF5 Goat / ab2932 Abcam 1:1,000 
IRF5 Rabbit / ab21689 Abcam 1:1,000 
KAP1 Rabbit / ab10483 Abcam 1:1,000 
SETDB1 Rabbit / ab12317 Abcam 1:1,000 
STAT1 Rabbit / 9172S Cell Signalling 1:1,000 
STAT3 Rabbit / 9132S Cell Signalling 1:1,000 
Runx1 Rabbit / ab23980 Abcam 1:1,000 
Lamin A/C Mouse / 612163 BD Biosciences 1:1,000 
c-myc Mouse / sc-40 Santa Cruz 1:1,000 
Flag M2 Mouse HRP A8592 Sigma 1:5,000 
HA Mouse HRP 12013819001 Roche 1:5,000 
Strep Mouse HRP 2-1509-001 IBA 1:5,000 
Biotin Goat HRP ab19221 Abcam 1:5,000 
Rabbit Trueblot / HRP 18-8816 eBioscience 1:5,000 
Goat Rabbit HRP P0499 Dako 1:5,000 
Mouse Rabbit HRP P0260 Dako 1:5,000 
Rabbit Donkey HRP NA934 GE Healthcare 1:5,000 
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2.9.2 – Silver staining of SDS-PAGE gels 
Silver staining was carried out according to the Shevchenko protocol [293], with gentle 
shaking at room temperature, unless specified.  Once protein samples on SDS-PAGE 
gels were resolved by electrophoresis (see Section 2.8.8), gels were fixed for 20 
minutes (50% v/v methanol, 5% v/v acetic acid), followed by washing for 10 minutes 
(50% v/v methanol) and a further 10 minutes (distilled water).  Gels were then 
sensitised with 200 µg/ml sodium thiosulphate (Sigma, UK) for 1 minute, followed by 
two 1 minute washes with water, and then stained with 1 mg/ml silver nitrate 
(ThermoFisher, USA) for 20 minutes at 4°C.  After two 1 minute washes with distilled 
water, gels were developed by sodium carbonate (Sigma, UK) with added 
formaldehyde (2 g Na2C03, 37 µl formaldehyde in 100 ml distilled water) for 30 seconds 
followed by fresh developing solution for 5-8 minutes.  Stop solution (5% v/v acetic 
acid) was added to cease staining.  Gels were visualised on a light box for band 
excision, and stored at 4°C in distilled water. 
 
2.9.3 – Mass spectrometry (LC-MS/MS) 
At the Kennedy Institute, in collaboration with Dr Robin Wait, excised protein bands 
from Colloidal blue or silver stained SDS-PAGE gels (Sections 2.9.1 and 2.9.2) were 
destained, reduced with DTT (Sigma, UK), alkylated with iodoacetamide (Sigma, UK) 
and subjected to enzymatic digestion with trypsin (Sigma, UK) using an Investigator 
Progest robot (Genomic Solutions, UK) in 96-well plates, and then samples freeze-
dried.  Proteolysis by trypsin occurs by cleavage at the carboxyl side of lysine and 
arginine residues (unless followed by a proline) to generate tryptic peptides that can be 
detected by mass spectrometry.  Samples were analysed by high performance liquid 
chromatography coupled to electrospray ionisation tandem mass spectrometry (HPLC 
ESI MS/MS), involving a CapLC liquid chromatography system (Waters, USA) and Q-
Tof spectrometer (Micromass, USA).  Proteins were identified by correlation of spectra 
to entries in SwissProt using a local installation of Mascot v2.2 software. 
   
Alternatively, excised protein bands were sent to Dr Mike Deery at the Cambridge 
Centre for Proteomics (CCP) facility, where they were subjected to trypsin digestion 
and LC-MS/MS using an Eksigent NanoLC-1D Plus (Eksigent Technologies, USA) 
HPLC system and an LTQ OrbitrapVelos mass spectrometer (ThermoFisher, USA).   
 
Chapter 2 – Materials and Methods  
	   88 
2.10 – Chromatin Immunoprecipitation (ChIP) 
Chromatin Immunoprecipitation (ChIP) demonstrates recruitment of DNA-binding 
factors and chromatin modifications at specific gene loci.  Cells are first fixed to cross-
link any proteins to their position at the DNA, and then lysed to obtain the nuclear 
contents.  Lysates are also sonicated to fractionate lengths of DNA into 500 bp pieces, 
which are optimal for determining recruitment to a specific region and also for PCR 
amplification.  Proteins are purified from the lysates by immunoprecipitation along with 
any bound DNA fragments, and then the cross-linking reversed to separate protein and 
DNA complexes.  Purified ChIP DNA is then subjected to qPCR using specific primers 
to determine specific DNA sequences at which the protein was recruited or histone 
protein was modified.  All ChIP experiments were performed in DNA Lo-Bind 
Eppendorfs (Sigma, UK) in order to maximise DNA retrieval at the end of the protocol. 
 
2.10.1 – Fixation of cells 
The ChIP protocol requires 5x106-1x107 cells per immunoprecipitation in order to 
obtain enough DNA material for analysis.  Following cell culture and stimulation of 
human M1 macrophages as required (see Section 2.2), cells were fixed in their dishes 
by addition of formaldehyde (37.5% v/v HCHO with 10% v/v methanol stock solution) 
to a final concentration of 1% formaldehyde in the cell culture media.  Dishes were 
mixed quickly and incubated for 10 minutes at room temperature.  1M Tris pH7.5 was 
then added to a final concentration of 125 mM in order to quench the reaction.  Cells 
were harvested using a cell scraper and washed 3 times with 10 ml PBS, centrifuging 
the cells at 1,500 rpm (Sorvall RT7, RTH-250 rotor) for 5 minutes between each wash 
to obtain a cell pellet.  After the final wash, pellets were either immediately lysed (see 
Section 2.10.3), or snap-frozen in liquid nitrogen and stored at -80°C. 
 
2.10.2 – Preparation of immunoprecipitation beads 
Per ChIP to be performed, 30 µl of Protein-G Magnetic Dynabeads (Invitrogen, USA) 
coated in 3 µg of antibody was required.  First, the total required volume of magnetic 
beads were blocked in 1 ml PBS + 0.5% w/v BSA, rotating for 1 hour at room 
temperature, then the supernatant removed by application of the microcentrifuge tube 
containing the beads onto a magnet.  The beads were washed twice more in this 
manner, rotating for 5 minutes in between, then resuspended in 100 µl PBS + 0.5% 
w/v BSA per original 30 µl beads.  3 µg of antibody (see Table 2.11) was then added to 
each 100 µl of blocked beads, and incubated rotating for 1 hour at room temperature.  
Following this, the antibody-coated beads were washed 3 times in 1 ml PBS + 0.5% 
Chapter 2 – Materials and Methods  
	   89 
w/v BSA, rotating for 5 minutes before the removal of supernatant from the beads, in 
order to wash away any non-bound excess antibody.  Finally, the antibody-coated 
beads were resuspended in 75 µl PBS + 0.5% w/v BSA per original 30 µl of beads in  
preparation for addition to nuclear cell lysates (see Section 2.10.4). 
 
 
 
                           
 
                                
 
                               Table 2.11: Antibodies used for Chromatin Immunoprecipitation 
 
2.10.3 – Cell lysis and sonication 
Lysis buffers (LB1, LB2, LB3 - see Section 2.12) were prepared by the addition of 4 µl 
protease inhibitors (P8340, Sigma, UK) per 1 ml of buffer and chilled on ice.  Each cell 
pellet from Section 2.10.1 was resuspended in 500 µl of LB1 per 1x107 cells and 
incubated on ice for 10 minutes.  Following centrifugation at 2,500 rpm (Heraeus 
Biofuge Fresco) for 10 minutes at 4°C, the supernatant was discarded and the nuclear 
pellet resuspended in 500 µl of LB2 per 1x107 cells.  Lysates were rocked gently on a 
shaker at room temperature for 10 minutes to wash the pellet before centrifugation 
once again at 2,500 rpm (Heraeus Biofuge Fresco) for 10 minutes at 4°C to pellet the 
nuclei.  Following centrifugation the supernatant was discarded, the nuclei 
resuspended in 500 µl of LB3 per 1x107 cells and divided between two microcentrifuge 
tubes (250 µl per tube).  Samples were sonicated in a Bioruptor sonicator (Diagenode, 
Belgium) for 4 minutes with 30 second on/off intervals at 4°C.  Sonication duration was 
previously determined by optimisation to produce an optimal DNA fragment size of 500 
bp in this cell type [197] (DNA size following sonication at multiple time-points was 
observed on a 1% w/v agarose gel by EtBr and UV excitation).  Sonicated fractions 
were then pooled together once again (500 µl total volume) and 50 µl of 10% v/v Triton 
X-100 added.  LB3 sonicated lysates were then centrifuged at 13,000 rpm (Heraeus 
Biofuge Fresco) for 10 minutes at 4°C to pellet debris.  Supernatants were transferred 
to clean tubes and 50 µl was stored separately at -20°C to become the ‘whole cell 
extract’ (WCE) DNA sample for normalisation. 
 
2.10.4 – Chromatin immunoprecipitation 
The LB3 lysate obtained from Section 2.10.3 was equally divided between each of the 
antibodies to be utilised for ChIP.  70 µl of appropriate antibody-coated beads (see 
Section 2.10.2) were added to each Eppendorf of lysate and rotated overnight at 4°C. 
ANTIBODY	   SOURCE	   PRODUCT CODE SUPPLIER 
Pol II (N20) Rabbit sc-899 Santa Cruz 
H3K9me3 Rabbit ab8898 Abcam 
IRF5 Rabbit ab21689 Abcam 
RelA (C20) Rabbit sc-372 Santa Cruz 
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2.10.5 – Washes, elutions, cross-linking reversal and DNA purification 
Following overnight incubation of ChIP samples (Section 2.10.4), tubes were placed in 
a magnetic rack and the supernatant removed.  1 ml ice cold ChIP Wash Buffer (see 
Section 2.12) was then added to each tube and rotated for 5 minutes.  This wash step 
was performed 5 times, followed by a final wash with 1 ml ice cold TE + 50mM NaCl in 
the same manner.  Beads were then resuspended in 60 µl ChIP Elution Buffer (see 
Section 2.12) and incubated at 65°C for 15 minutes, whilst being briefly vortexed every 
2 minutes to keep the beads in suspension.  Tubes were then place in a magnetic rack 
and the supernatant collected into a fresh Eppendorf, before this elution process was 
repeated to give a final elution volume of 120 µl.  Eluates, along with the WCE 
prepared in Section 2.10.3, then had the cross-linking reversed by overnight incubation 
at 65°C.  The following day, DNA was purified using a PCR Purification Kit (Qiagen, 
Germany), with the ChIP/WCE samples eluted in 60 or 200 µl TE buffer respectively.  
WCE samples were purified separately to avoid cross-contamination. 
 
2.10.6 – Real-time qPCR of ChIP DNA 
Following purification of ChIP and WCE DNA (see Section 2.10.5), qPCR was 
performed in an ABI 7900HT (Life Technologies, USA).  Primers utilised for ChIP-
qPCR in this study were synthesised by MWG Eurofins as detailed in Table 2.12.  
           Table 2.12: Primers used for qPCR following Chromatin Immunoprecipitation 
 
ChIP primers were designed in the Udalova group by Dr Thomas Krausgruber using 
Primer3 software (http://frodo.wi.mit.edu/primer3) according to the following guidelines: 
 
• Amplicon of 100-200bp 
• Primer length of 20-27bp (optimal 22) 
• GC content of 40-60% (optimal 50%) 
• TM 63-67°C (optimal 65°C) 
• TM of forward and reverse primer must not largely differ (max. 1°C) 
• Pairs should not have a complementary sequence of more than 2 bases at 3’ 
• Complementary sequence of more than 3 bases should not exist in the primer 	  
LOCUS	   SPECIES	   FORWARD PRIMER REVERSE PRIMER 
Tnf 5’ Human 5’-GGA AGC CAA GAC TGA AAC CAG CA-3’ 
5’-CCG GGA ATT CAC AGA 
CCC CAC T-3’ 
Tnf 3’ Human 5’-ATA TTC CCC ATC CCC CAG GAA ACA-3’ 
5’-CTG CAA CAG CCG GAA 
ATC TCA CC-3’ 
Intergenic (24kb 
upstream of Hla-b) Human 
5’-GGG CAC ACA GCA 
GAT CAG AGG-3’ 
5’-GAT GGA GGC TGA ATG 
GCC TTC-3’ 
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Primer pairs were also validated by Dr Thomas Krausgruber on fixed/sonicated 
genomic DNA (gDNA), to ensure they demonstrated a CT value of below 25 cycles 
which decreased according to gDNA dilutions (exponential function).  For example 
when gDNA was diluted 1:8 (23), the CT value should decrease by 3 cycles.  The melt 
curves for the primer pairs were also analysed for sequence specificity, which should 
be demonstrated by a single peak at around 85°C, and primer-dimer formation 
(multiple peaks). 	  
The following master mix was prepared and added to 3 µl purified ChIP/WCE DNA in a 
well of a 384-well plate to create a 10 µl reaction: 
 
 
5    µl SYBR® Premix Ex Taq™ II (Takara, France) 
0.8 µl Nuclease-free water 
0.2 µl ROX dye 
1    µl 1:20 dilution of Forward + Reverse primer mix (see Table 2.12) 
7    µl . 
 
The ChIP-qPCR reaction was performed in an ABI 7900HT (Life Technologies, USA) 
according to the following programme: 
 
1. 95°C for 30 seconds (denaturation) 
2. 95°C for 5 seconds 
3. 60°C for 34 seconds 
4. 95°C for 15 seconds (melt curve stage) 
5. 60°C for 60 seconds 
6. 95°C for 15 seconds 
 
Data was normalised to ‘input’ (the CT value obtained from WCE) and analysed using 
the ΔΔCT method (see Section 2.7.3) in order to show changes in recruitment of 
proteins to the chosen DNA sequence.  In instances where cells had been subjected to 
RNAi, the data was further normalised to unstimulated siCon samples in order to 
demonstrate fold changes in recruitment. 
 
 
Repeat steps 2-3 (x40 cycles) 
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2.11 – Genome-wide ChIP-sequencing (ChIP-seq) 
ChIP-seq experiments mentioned in this thesis were performed by Dr David Saliba 
(Udalova group) and analysed by Dr Andreas Heger (CGAT, University of Oxford).  
ChIP DNA was isolated according to the protocol described in Section 2.10, using 50, 
100 and 300x106 murine bone marrow-derived M1 macrophages as described in 
Section 2.3.  Macrophages were stimulated with LPS for 0, 0.5 or 2 hours with LPS 
prior to fixation and cell lysis.   Pol II, RelA and IRF5 antibodies (10 µg) respectively 
(see Table 2.11) were used for immunoprecipitation of nuclear cell lysates.  
Quantification of ChIP DNA was performed using a Qubit spectrophotometer 
(Invitrogen, USA), demonstrating yields of 10-20 ng, which was sequenced following 
the Illumina/Solexa protocol. 
 
2.11.1 – Analysis of ChIP-seq data 
Sequences were mapped to the mouse genome build 37 (NCBI and the Mouse 
Genome Consortium) using Bowtie version 0.12.7 [294].  Peaks were called with Zinba 
version 2.02.01 [295] using default options including a window size of 200 and a false 
discovery rate (FDR) of 10%, due to the ability of this software to identify both broad 
and narrow enriched binding regions.  Subsequent analyses were also performed at 
increased levels of stringency (1% FDR) and resulted in the same conclusions from the 
datasets.  At a 10% FDR, 14,322/18,436 RelA binding sites (RelA cistrome), 
35,839/11,247 IRF5 binding sites (IRF5 cistrome) and 9,992/14,173 Pol II binding sites 
were identified at 0.5 and 2 hours post LPS stimulation respectively.  Aligned reads 
and called peaks were visualised using the UCSC genome browser. 
 
To further annotate genes that were functionally related to genome-wide RelA, IRF5 
and Pol II binding events, based on knockout microarray datasets from the Udalova 
group [25], GREAT analysis was performed [296].  Comparative analysis of cistrome 
gene lists was performed using ToppCluster to evaluate functional differences between 
each list, as described by GO Molecular Function and GO Biological Processes 
categories. 
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2.12 – Preparation of Buffers 
 
The following buffers were prepared as follows for use in experiments in this thesis:  
 
ChIP Lysis Buffer LB1: 
50 mM HEPES-KOH 
(pH7.5) 
140 mM NaCl 
1 mM EDTA 
10% v/v Glycerol 
0.5% v/v NP-40 
0.25% v/v TX-100 
 
ChIP Lysis Buffer LB2: 
10 mM Tris-HCl (pH8.0) 
200 mM NaCl 
1 mM EDTA 
0.5 mM EGTA 
 
ChIP Lysis Buffer LB3: 
10 mM Tris-HCl (pH8.0) 
100 mM NaCl 
1 mM EDTA 
0.5 mM EGTA 
0.1% w/v  
Na-Deoxycholate 
0.5% v/v  
Na-Lauroylsarcosine 
 
ChIP Elution Buffer: 
2% w/v SDS (0.2 µ) in 
TE buffer 
 
ChIP Wash Buffer: 
50 mM HEPES-KOH 
(pH7.6) 
500 mM LiCl 
1 mM EDTA 
1% v/v NP-40 
0.7% w/v  
Na-deoxycholate 
 
Whole-Cell Lysis Buffer: 
1% v/v TX-100 
10% v/v Glycerol 
1 mM EDTA 
150 mM NaCl 
50 mM Tris (pH7.8) 
 
Cytoplasmic Lysis 
Buffer: 
5 mM PIPES (pH8.0 
add 400 mM NaOH) 
85 mM KCl  
0.5% v/v NP-40 
 
Transfer Buffer: 
25 mM Tris-base 
192 mM Glycine 
10% v/v Methanol 
 
 
RIPA Nuclear Lysis Buffer: 
0.1% v/v NP-40 
0.1% w/v SDS (0.2 µ) 
0.5% w/v  
Na-Deoxycholate 
in PBS 
 
 
 
IP Wash Buffer: 
1% v/v NP-40 
0.1% w/v SDS (0.2 µ) 
500 mM NaCl 
20 mM Tris (pH8.0) 
2 mM EDTA 
 
Biotin Elution Buffer: 
100 mM Tris (pH8.0) 
150 mM NaCl 
2 mM Biotin 
 
4x Loading Buffer: 
200 mM Tris (pH6.8) 
400 mM DTT 
8% w/v SDS (0.2 µ) 
0.4% w/v Bromophenol Blue 
40% v/v Glycerol
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3.0 - Development of an IRF5 Proteomic Screen  
 
3.1 – Introduction 
An understanding of protein function within a cell can be obtained by searching for 
interaction partners in a physiological context.  Protein-protein interactions are at the 
heart of cellular function; both in the form of brief encounters such as signalling 
cascades, and in the formation of more stable complexes such as the ribosome or 
proteasome.  Most cellular proteins are involved in protein-protein interactions at some 
point in their lifespan, and it is becoming clear that for the IRF family in particular an 
understanding of their interactome can give huge insight into mediation of activity.  For 
example, IRF8 is in most instances reliant on interactions with IRF1, IRF2 or PU.1 to 
bind to DNA [170], IRF3/IRF7 form an enhanceosome structure at the Ifnb1 promoter 
via interactions with NFκB, AP1 and CBP [131], and IRF9 forms the ISGF3 complex 
along with STAT1 and STAT2, which activates transcription in response to virus [128]. 
 
Numerous studies, including those from the Udalova laboratory, have identified several 
protein-protein interaction partners for IRF5.  For example, phosphorylated IRF5 can 
form activating complexes with histone acetyl transferase (HAT) molecules such as 
CBP/p300 to drive gene expression [297].  IRF5 can also interact with the transcription 
factor NFκB RelA to enhance pro-inflammatory cytokine expression in macrophages 
[197].  In contrast, in unstimulated cells, IRF5 is able to form inhibitory complexes with 
histone deacetylase (HDAC) molecules such as NCoR, Sin3a and SMRT to negatively 
regulate gene expression [297].  IRF5 itself can be activated by physical interactions 
with MyD88 and TRAF6 downstream of TLR4 signalling, and TRIF downstream of 
TLR3 signalling [192, 298]; and can be degraded the E3 ligase TRIM21 [299]. 
 
The initial goal of this study was to identify other novel interaction partners of IRF5, in 
order to learn more about IRF5 activity via its interactome.  By manipulating IRF5 
function at the level of protein-protein interactions, we hope to generate highly specific 
therapeutics, such as synthetic peptides or small molecule inhibitors, which could block 
adverse functions of IRF5 in inflammatory macrophages of autoimmune patients.   
 
The proteomic screen, generation of tools and optimisation carried out within this 
section of my study has paved the way for more detailed biochemical and functional 
investigation of IRF5 and its interaction partners, in particular KAP1/TRIM28 and NFκB 
RelA, in Chapters 4 and 5 of this thesis. 
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3.2 – Results 
 
3.2.1 – One-Strep Affinity Purification: Proof of Principle 
The One-Strep system of affinity purification enables rapid, single step purification of 
recombinant proteins and their complexes from bacterial or mammalian cell lysates 
[292], as described in Section 2.8.3 and Figure 2.3 of the Materials and Methods 
chapter of this thesis.  The main advantage of this system over conventional 
immunoprecipitation is the fact that the technique does not rely on antibodies; 
therefore precipitation of bait proteins is not limited by antibody-antigen affinity or 
specificity.  This also means that Colloidal blue-stained SDS-PAGE gels of resolved 
One-Strep eluates do not contain prominent heavy and light chain antibody bands, 
which can mask large regions of the gel and limit the study by hiding potentially 
interesting protein-protein interaction partners that run at the same size (see 
Supplementary Figure S9.1).  One-Strep affinity purification allows multiple interactions 
to be studied in parallel, without the need to optimise multiple antibodies and wash 
conditions, as all prey proteins are tagged with the same Strep-tag.  The ability of the 
Strep-tag to bind to a Streptactin matrix with high affinity enables stringent wash 
conditions to be employed, in order to wash away any non-specifically bound proteins 
from the Streptactin column and therefore reduce the number of ‘false positive’ 
interactors.  Protein complexes can be eluted from the Streptactin matrix with biotin, 
which binds to Streptactin with a higher affinity than the Strep-tag, and therefore 
outcompetes Strep-tagged protein complexes for the Streptactin binding pocket. 
A 	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Figure 3.1: One-Strep affinity purification proof of principle 
HEK293-TLR4/CD14/Md2 cells (2x106) were transfected with expression plasmids containing Strep-HA-
IRF5 (‘A’) or the Strep-tag alone (mock control, ‘B’) with Lipofectamine 2000 reagent, in order to induce 
exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed on ice for 30 
minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting lysates (‘input’) 
were cleared by centrifugation to remove cellular debris before being loaded onto a column containing 150 
µl of Streptactin beads. The protein lysates were allowed to pass through the columns by gravity flow to 
allow Strep-tagged proteins to bind to the Streptactin matrix.  The remaining proteins were collected as 
they emerged through the column (‘flow’).  The columns were then washed by the addition of seven 
individual 1 ml volumes of IP wash buffer, which were collected after passing through the column (‘1 ml 
washes’).  Tagged proteins were eluted from the column by the addition of six 50 µl volumes of biotin 
elution buffer, which were collected individually (’50 µl biotin elutions’).  Equal volumes of the described 
protein samples were prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE.  
Protein gels were subjected Western blotting with a Strep-tag specific antibody in the first instance (top 
panels).  The experiment was repeated and the gel subjected to silver staining to show the total protein 
bands in each sample (lower panels) * = Non-specific bands, WB = Western blot. 
 
In order to ensure that binding and elution of a bait protein (Strep-HA-IRF5) from the 
Streptactin matrix occurred in my hands, I examined the binding and retrieval of Strep-
HA-IRF5 by Western blotting and silver-staining of an SDS-PAGE gel (see Figure 3.1 – 
panel A).  Western blotting using a Strep-tag specific antibody showed that exogenous 
Strep-HA-IRF5 was present in the ‘input’ lysate and became bound to the Streptactin 
column, as no corresponding band was present in the ‘flow through’ sample (collected 
following gravitational flow of input lysate through the Streptactin matrix).  The Strep-
HA-IRF5 also remained bound to the column throughout the seven wash steps and 
began to be eluted upon the third biotin elution, as can be seen in both the Western 
blot and silver stained gel (band at approximately 60 kDa, not present in the mock 
control, Figure 3.1 – panel B).  This suggested that at least three 50 µl elution steps 
needed to be performed in order for Strep-tag fusion proteins to be retrieved.  Protein 
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identity for the band on the silver stained gel (panel A) could be further confirmed by 
band excision, enzymatic digestion and analysis by LC-MS/MS.  Differences observed 
in the amount of Strep-tagged IRF5 retrieved in the Western blot and silver stain 
experiments in panel A, are likely due to transfection efficiency variability between the 
two experiments, resulting in lower IRF5 expression levels in the silver stain 
experiment.  The striking protein bands observed in the Western blot can also be 
explained by the signal-amplification nature of the technique, therefore band intensity 
between Western blots and silver stains cannot be compared to deduce the amount of 
protein present in a sample.  The silver stained gel also showed that non-specifically 
bound proteins were washed away by the third wash step, however in order to ensure 
that this was the case, I continued in future experiments to do a minimum of six wash 
steps.  This was preferable because proteins may still be present after three washes 
that are below the detection limits of a silver stain but could be amplified by an 
antibody in a Western blot, leading to ‘false positive’ protein-protein interaction 
partners being identified. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: One-Strep-NFκB proof of principle 
HEK293-TLR4/CD14/Md2 cells (2x106) were transfected with expression plasmids containing Strep-RelA-
Flag (top panel), Strep-cRel-Flag (middle panel) or Strep-p50-HA (bottom panel) with Lipofectamine 2000 
reagent, in order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells 
were lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The 
resulting lysates (‘input’) were cleared by centrifugation to remove cellular debris before being loaded onto 
a column containing 150 µl of Streptactin beads. The protein lysates were allowed to pass through the 
columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The remaining 
proteins were collected as they emerged through the column (‘flow’).  The columns were then washed by 
the addition of seven individual 1 ml volumes of IP wash buffer, the final of which was collected after 
passing through the column (‘final wash’).  Tagged proteins were eluted from the column by the addition of 
six 50 µl volumes of biotin elution buffer, which were collected and pooled (’elution’).  Equal volumes of the 
described protein samples were prepared by heating to 100°C with loading buffer, then resolved by SDS-
PAGE, and subjected to Western blotting with a Strep-tag specific antibody following transfer to PVDF 
membrane. O/E = overexpression, WB = Western blot. 
O/E: Strep-p50-HA 
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3.2.2 – One-Strep Affinity Purification: Determination of Positive Controls 
The next step was to demonstrate that interactions between bait and prey proteins 
could be preserved using the One-Strep system.  I therefore needed to identify positive 
controls for protein-protein interactions that could be run in parallel with experimental 
affinity purifications to show that the system was working correctly.  As the One-Strep 
system was to be used in combination with Western blotting (to validate known and 
hypothesised interactions), and mass spectrometry (to identify novel co-factors of 
IRF5), I endeavoured to use both end points to demonstrate positive controls. 
 
3.2.2.1 – Demonstrating One-Strep Positive Controls by Western Blotting 
The NFκB family of transcription factors consists of five subunits (RelA, RelB, cRel, 
p50 and p52), which are active as both homodimers and heterodimers to regulate 
gene expression (see Section 1.2.2).  Dimeric NFκB molecules occur in a resting state 
in the cytoplasm, sequestered by inhibitor molecules (IκB); and in an active state 
following IκB phosphorylation when they are released to allow translocation to the 
nucleus [83, 300].  As members of the same family, the NFκB subunits have evolved 
together; therefore interactions between these proteins are well conserved and exhibit 
high affinity, compared to interactions between unrelated proteins.  The most common 
NFκB heterodimer is RelA-p50, although other NFκB combinations can also occur. 
 
Consequently, I attempted to show the dimeric interactions between the NFκB subunits 
RelA, cRel and p50 using the One-Strep system and Western blotting.  I 
overexpressed Strep-tagged RelA, cRel and p50 (bait) with either HA- or Flag-tagged 
RelA, cRel or p50 (prey) in HEK293-TLR4 cells by lipid transfection.  The different tags 
enabled me to distinguish easily between the bait and the prey proteins in the same 
sample.  The resulting cell lysates were applied to Streptactin columns, and then the 
columns were subjected to seven 1 ml washes with ice-cold IP wash buffer.  
Complexes were eluted from the columns by six 50 µl biotin elutions, which were 
pooled, and 10% of the total elution volume loaded onto SDS-PAGE gels for Western 
blotting.  A Strep-HRP antibody was used to show expression of Strep-tagged bait 
proteins in the lysates, and also to show retrieval of the bait proteins upon biotin 
elution.  HA-HRP and Flag-HRP antibodies were used to show expression of prey 
proteins in the lysates and the presence of prey proteins in the eluates (indicating that 
an interaction was occurring between the bait and prey proteins within the cell).  Prey 
proteins were also co-expressed with the Strep-tag alone, not fused to any other 
protein.  This acts as a negative control for the One-Strep system, to show that the 
prey proteins were not binding directly to the Streptactin column. 
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Figure 3.3:  One-Strep affinity purification of NFκB heterodimers of RelA, cRel and p50 
HEK293-TLR4/CD14/Md2 cells (2x106) were transfected with combinations of expression plasmids 
containing Strep-, HA- or Flag-tagged NFκB proteins by Lipofectamine 2000 reagent, in order to induce 
exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed on ice for 30 
minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting lysates were 
cleared by centrifugation to remove cellular debris before being loaded onto a column containing 150 µl of 
Streptactin beads. The protein lysates (‘input’) were allowed to pass through the columns by gravity flow to 
allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were then washed by the 
addition of seven individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein complexes were 
eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, which were collected 
and pooled (’eluates’).  Protein samples (5% total input volume, 10% total eluate volume) were prepared 
by heating to 100°C with loading buffer, then resolved by SDS-PAGE, and subjected to Western blotting 
with Strep-, Flag- or HA-tag specific antibodies as required following transfer to PVDF membrane.  Panel 
(A) shows interactions between Strep-RelA-Flag and NFκB, Panel (B) shows Strep-cRel-Flag and NFκB, 
Panel (C) shows Strep-p50-HA and NFκB. Bait and prey proteins were visualised in input lysates (top two 
rows) and eluates (lower two rows) WB = Western blot. 
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Figure 3.3 shows that Strep-tagged RelA is interacting with cRel and p50, Strep-tagged 
cRel is interacting with RelA and p50, and Strep-tagged p50 is interacting with RelA 
and cRel, as expected.  Interactions between Strep-p50-HA and cRel-Flag appear 
weak due to low initial cRel-Flag protein expression in input lysates.  Negative controls 
all showed no non-specific binding of the prey proteins to the Streptactin columns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4:  One-Strep affinity purification of the NFκB RelA-STAT3 complex 
HEK293-TLR4/CD14/Md2 cells (2x106) were transfected with combinations of expression plasmids 
containing HA-tagged STAT3, Strep-tagged RelA and the Strep-tag alone by Lipofectamine 2000 reagent, 
in order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed 
on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting 
lysates were cleared by centrifugation to remove cellular debris before being loaded onto a column 
containing 150 µl of Streptactin beads. The protein lysates (‘input’) were allowed to pass through the 
columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were 
then washed by the addition of seven individual 1 ml volumes of chilled IP wash buffer.  Prey and bait 
protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, 
which were collected and pooled (’eluates’).  Protein samples (5% total input volume, 10% total eluate 
volume) were prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE, and 
subjected to Western blotting with Strep- or HA-tag specific antibodies as required following transfer to 
PVDF membrane. WB = Western blot. 
 
In order to determine whether lower affinity protein-protein interactions could also be 
identified in this manner, I also sought to demonstrate a positive control involving an 
interaction between two proteins belonging to different families.  A literature search 
revealed that NFκB RelA is able to interact with the transcription factor STAT3, which 
for example is important for inhibition of Nos2 gene expression [301]. I therefore 
performed the same experiment as in Figure 3.3, however this time I co-expressed 
Strep-tagged RelA with HA-tagged STAT3 in HEK293-TLR4 cells.  In this way, I was 
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also able to demonstrate a lower-affinity inter-family protein-protein interaction between 
RelA and STAT3 (see Figure 3.4).  This gave me confidence in the One-Strep system 
for identification of both high and low affinity protein-protein interactions. 
 
3.2.2.2 – Demonstrating One-Strep Positive Controls by LC-MS/MS 
I next attempted to demonstrate some known protein-protein interactions involving 
RelA using One-Strep affinity purification in combination with mass spectrometry.  
Strep-RelA-Flag was overexpressed in HEK293-TLR4 cells by lipid transfection, and 
the resulting total cell lysates were employed in the One-Strep system as described in 
Section 3.2.2.1.  The obtained 300 µl eluate was concentrated to 50 µl by 
centrifugation in a Vivaspin column in order for all of the protein within the eluate to be 
loaded into the same well of an SDS-PAGE gel.  Protein bands were visualised by 
silver staining (see Figure 3.5), and bands that were clearly present in the Strep-RelA-
Flag eluates, and not in the mock control, were excised from the gel with a scalpel and 
trypsin-digested for subsequent identification of peptide sequences by LC-MS/MS, 
which was performed by my supervisor Dr Robin Wait (Kennedy Institute).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Identification Strep-RelA-Flag co-factors by One-Strep-AP and LC-MS/MS 
HEK293-TLR4/CD14/Md2 cells (6x107) were transfected with Strep-tagged RelA and the Strep-tag alone 
by Lipofectamine 2000 reagent, in order to induce exogenous expression of this protein/tag.  Following 24 
hours, the cells were stimulated for 0 or 2 hours with 1µg/ml LPS, then lysed on ice for 30 minutes with 1 
ml chilled total cell lysis buffer with added protease inhibitors.  The resulting lysates were cleared by 
centrifugation to remove cellular debris before being loaded onto a column containing 150 µl of Streptactin 
beads. The protein lysates were allowed to pass through the columns by gravity flow to allow Strep-tagged 
proteins to bind to the Streptactin matrix.  The columns were then washed by the addition of seven 
individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein complexes were eluted from the 
column by the addition of six 50 µl volumes of biotin elution buffer, which were collected and pooled.  
Protein samples (20% total eluate volume) were prepared by heating to 100°C with loading buffer, then 
resolved by SDS-PAGE, and subjected to silver staining to visualise protein content of the samples.  
Bands were excised, pooled between –LPS and +LPS lanes, trypsinised and the resulting peptides 
identified by LC-MS/MS.  Proteins corresponding to the peptides were identified by MASCOT database. 
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Identified peptides were correlated to the MASCOT database for protein identification.  
As the protein bands appeared identical between the –LPS and +LPS lanes (Figure 
3.5, lanes 1 and 2), bands of the same size were pooled from these two lanes in order 
to increase the amount of material available for detection by mass spectrometry.  The 
corresponding region of the same size in the mock control lanes (Figure 3.5, lanes 3 
and 4) was also excised to confirm that proteins identified as interacting with Strep-
RelA-Flag were not present in the negative control sample, and were therefore specific 
interactions. 
Figure 3.6: Identification of Strep-RelA-Flag peptides by mass spectrometry 
Amino acid sequence of NFκB RelA, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
Figure 3.5 shows interesting prey protein bands at approximately 100 kDa and 35 kDa, 
which were not present in the mock control lanes, and could therefore be described as 
proteins interacting specifically with Strep-RelA-Flag. The identity of the Strep-RelA-
Flag bait protein at 65 kDa was confirmed by mass spectrometry in this experiment 
with a high degree of peptide coverage (Figure 3.6). 
 
Figure 3.7: Identification of p100 peptides by mass spectrometry 
Amino acid sequence of p100, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
p100 (97kDa) 
2 peptides = 30/900 amino acids = 3% peptide coverage 
  
MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGA
SSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNL
GVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDG
SFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQ
AFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRK
RRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGG
GGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGV
TADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVI
TGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYP
VHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNT
PLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTC
STKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVD
TYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQS
VEQEAEKLGPPPEPPGGLCHGHPQPQVH 
NFκB RelA (60kDa) 
10 peptides = 147/551 amino acids = 27% peptide coverage 
  
MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGP
GTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQCVKKRDLEQAISQRIQTN
NNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLSHPIFDNRAPNTAELKICRVNRNSGS
CLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSQADVHRQVAIVFRTPPYADPSLQAPVRVSMQ
LRRPSDRELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSA
SVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAP
APVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEF
QQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDF
SALLSQISS 
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Figure 3.8: Identification of IκBα peptides by mass spectrometry 
Amino acid sequence of IκBα, with the peptides identified by LC-MS/MS and correlation with the MASCOT 
database highlighted in bold. 
 
The 100 kDa protein band was identified by mass spectrometry to be p100 (see Figure 
3.7), an NFκB precursor, which is proteolytically cleaved upon phosphorylation by IKKα 
to form the p52 subunit, in the same way that NFκB p105 is cleaved to form the p50 
subunit. In their non-processed forms, both p100 and p105 have been shown to inhibit 
NFκB by sequestering the Rel subunits in the cytoplasm to prevent them binding to 
DNA targets [302].  In this instance, it is clear that I detected p100 interacting with RelA 
and not the cleaved product p52 due the size of the protein band that was excised 
from the silver stained gel (approximately 100 kDa), which is too large to be p52 
protein (52 kDa).  Also, the corresponding tryptic peptides spanned the full length of 
p100, up to and beyond the first 454 amino acids that become p52 upon cleavage. 
 
The 35 kDa protein band was found to be IκBα (see Figure 3.8), a member of the IκB 
family of inhibitors, which binds directly to NFκB to mask its nuclear localisation 
sequence (NLS) in order to retain the transcription factor in the cytoplasm [303].  In this 
way, IκBα can also prevent NFκB from binding to the DNA and initiating transcription of 
target genes.  Upon activation of signalling pathways targeting NFκB, IκBα is 
phosphorylated by IKK kinase molecules and degraded, which allows NFκB dimers to 
translocate to the nucleus [300].  Members of the IκB family show different affinities for 
the various NFκB dimers; and IκBα in particular has been shown to specifically bind to 
complexes containing RelA protein [304].   
 
Both of the proteins identified as interacting with RelA in this experiment can be 
considered as related, due to their functional similarity and the presence of ankyrin-
repeat domains in both p100 and IκBα.  This experiment has therefore identified by the 
One-Strep system in combination with mass spectrometry, two physiologically relevant 
inhibitor proteins that bind to Strep-RelA-Flag in HEK293-TLR4 cells. 
IκBα  (36kDa) 
1 peptide = 10/317 amino acids = 3% peptide coverage 
  
MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEP
WKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAG
CDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLV
SLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQL
GQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL 
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3.2.3 – IRF5 Proteomics: Murine Bone Marrow-Derived Macrophages  
Following confirmation that protein-protein interactions could be demonstrated using 
the One-Strep system with both Western blotting and mass spectrometry as end-
points, I next endeavoured to further optimise the system for IRF5 proteomic studies. 
 
Although HEK293-TLR4 cells, which were used to determine One-Strep positive 
controls in Section 3.2.2, are responsive to bacterial stimuli (LPS); the use of a cell 
type that is more physiologically relevant to IRF5 function was considered 
advantageous for proteomic studies, in order to increase the chances of identifying 
immune-relevant interaction partners of IRF5.  IRF5 is highly expressed in pro-
inflammatory (M1) macrophages (differentiated by GM-CSF), where it functions to 
induce expression of M1-characteristic markers and inhibit expression of M2 markers 
such as IL-10, therefore driving macrophages toward a pro-inflammatory phenotype 
[196, 197].  As a result, macrophages were considered ideal for an IRF5 proteomic 
study, due to the diverse transcriptional activity of IRF5 described in this cell type, and 
the potential for co-factors to be involved in IRF5-mediated gene regulation. 
 
As large numbers of cells are often required for proteomic studies, it was decided that 
the number of peripheral blood mononuclear cells (PBMCs) obtained from a single 
human donor could be limiting for my experiments; therefore macrophages 
differentiated from murine bone marrow would be more suitable, as bone marrow from 
multiple mice of the same genotype could be pooled to further increase material 
availability.  Working with murine primary cells also provides the option to obtain M1 
bone marrow-derived macrophages from Irf5-/- mice (available in the Udalova 
laboratory), so that exogenous Strep-tagged IRF5 would not need to compete with 
endogenous IRF5 for interaction partners in this system.  The use of GM-CSF to 
differentiate Irf5-/- M1 macrophages from bone marrow also means that other 
endogenous proteins, which may like IRF5 be differentially expressed during M1 and 
M2 polarisation, would still be present within the knockout macrophage to interact with 
Strep-HA-IRF5.  It would also be possible to express Strep-HA-IRF5 to physiological 
levels in Irf5-/- M1 macrophages, as determined by Western blotting with an IRF5-
specific antibody that recognises both exogenous Strep-HA-IRF5 in Irf5-/- M1 
macrophages and endogenous IRF5 in wild-type M1 macrophages, to compare protein 
levels.  Physiological levels of Strep-HA-IRF5 expression would be advantageous, as 
high levels of bait protein expression can lead to ‘false positive’ interactions in 
proteomic studies. 
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3.2.3.1 – Optimising Lysis of Murine Primary Cells 
Identification of whether a protein-protein interaction occurs within the cytoplasm or the 
nucleus is a good starting point for functional studies.  Fractionation of cytoplasmic and 
nuclear cell lysates using different combinations of lysis buffers was therefore 
optimised for murine M1 bone marrow-derived macrophages (see Figure 3.9).  Cell 
pellets were first lysed on ice for 30 minutes with a lysis buffer considered to be 
cytoplasmic only, before centrifugation at 2,000 rpm (Heraeus Biofuge Fresco) to 
produce a nuclear pellet.  The resulting supernatant was collected as ‘cytoplasmic 
lysate’ and loaded in the left-hand lane for each buffer combination in Figure 3.9.  
RIPA lysis buffer was used for the second stage of the lysis protocol (lysis of the 
nuclear pellet) in each combination, due to the fact that SDS has stronger denaturing 
abilities than detergents such as NP-40 and TX-100, to ensure nuclear membrane 
disruption.  Following lysis of the nuclear pellet with RIPA and sonication for eight 30-
second pulses to disrupt chromatin, the sample was cleared by centrifugation at 
13,000 rpm (Heraeus Biofuge Fresco).  The supernatant was collected as ‘nuclear 
lysate’ and loaded in the right-hand lane for each buffer combination in Figure 3.9.   
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Optimising the lysis protocol for murine M1 bone marrow-derived macrophages 
1x106 murine M1 bone marrow-derived macrophages were lysed on ice with 500 µl of cytoplasmic lysis 
buffer with protease inhibitors, and the resulting nuclear pellet was then lysed with 300 µl RIPA lysis buffer 
and sonicated for 8x 30-second pulses.  Lysates were cleared by centrifugation.  10 µg of each 
‘cytoplasmic’ and ‘nuclear’ lysate generated (3 lysis buffer combinations were tested) as determined by the 
Qubit spectrophotometer was prepared by heating to 100°C with 4x loading buffer, then resolved by SDS-
PAGE.  Following transfer to PVDF membrane, the samples were subjected to Western blotting with 
Lamin A/C (cytoplasmic protein)- and Tubulin (nuclear protein)-specific antibodies to determine if 
cytoplasmic/nuclear compartmentalisation.  WB = Western blot. 
 
1% v/v TX-100 lysis buffer, used in lysis condition 3, is considered a total-cell lysis 
buffer (see Section 2.12), as confirmed by the presence of both tubulin (cytoplasmic) 
and lamin (nuclear) in the cell lysate, even before the addition of RIPA and sonication.  
0.1% v/v TX-100 lysis buffer is sometimes considered a cytoplasmic lysis buffer, 
however a weak lamin band can be seen on the Western blot for lysis condition 2, 
suggesting some nuclear lysis also occurs with this buffer.  In contrast, the combination 
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of cytoplasmic lysis buffer, and RIPA lysis buffer/sonication for nuclear lysis (Figure 
3.9, condition 1) resulted in good compartmentalisation of tubulin and lamin, so was 
used for cell lysis of murine M1 bone marrow macrophages in all future experiments. 
 
3.2.3.2 – Optimising Adenoviral Infection of Murine Primary Cells 
In order to introduce exogenous Strep-tagged bait proteins into murine primary cells, 
which are non-transfectable, adenoviruses were cloned and purified for each of the 
aforementioned One-Strep fusion proteins (IRF5 and NFκB subunits), as described in 
Section 2.5 of the Materials and Methods chapter of this thesis.  The more transient 
adenoviral infection was considered appropriate for a short time-frame transcription 
factor experiment, rather than longer-tem expression by lentiviral infection, in which 
DNA is incorporated into the genome.  In order to identify the optimal adenoviral MOI 
for introduction of Strep-HA-IRF5 bait protein into M1 bone marrow-derived 
macrophages, the MOI was titrated and expression levels determined by Western 
blotting with a HA-tag specific antibody (see Figure 3.10).  Following 2 hours serum-
free in the presence of viral particles, high levels of Strep-HA-IRF5 was were observed 
with an MOI of 250 and very low expression was achieved with MOI 75.  
 
Figure 3.10: MOI titration for adenoviral infection of murine M1 bone marrow-derived macrophages 
1x106 murine M1 bone marrow-derived macrophages were adenovirally-infected with Strep-HA-IRF5 or 
Empty virus for 2 hours serum-free with increasing MOI.  After 24 hours, cells were lysed with total cell 
lysis buffer plus protease inhibitors, on ice for 30 minutes and cleared by centrifugation.  10 µg of protein 
from each sample (as determined by Qubit spectrophotometer) was resolved by SDS-PAGE, then the 
samples transferred to PVDF membrane before Western blotting with HA-HRP antibody to show infection 
efficiency.  An antibody specific for β-actin was used for a protein loading control.  WB = Western blot. 
 
To further optimise the infection protocol, macrophages were lysed at different time-
points following infection (2/24/48 hours) to allow the Strep-HA-IRF5 longer to be 
translated and expressed as protein.  Figure 3.11 shows high bait protein expression 
at 24 hours following the initial 2 hours in the presence of viral particles, which begins 
to decline at 48 hours.  Transient protein expression by adenovirus is therefore 
maintained for a time period that covers transcription factor activity.  Protein levels 
obtained with MOI 75 were also improved after a 24-hour expression allowance. 
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Figure 3.11: Strep-HA-IRF5 expression over time following adenoviral transduction 
1x106 murine M1 bone marrow-derived macrophages were adenovirally-infected with Strep-HA-IRF5 or 
Empty virus for 2 hours serum-free with an MOI of 0/75/250.  Cells were lysed following 2 hours or 24/48 
hours (including 2 hours serum-free) with total cell lysis buffer plus protease inhibitors, on ice for 30 
minutes and cleared by centrifugation.  10 µg of protein from each sample (as determined by Qubit 
spectrophotometer) was resolved by SDS-PAGE, then the samples transferred to PVDF membrane before 
Western blotting with HA-HRP antibody to show infection efficiency.  An antibody specific for β-actin was 
used for a protein loading control.  WB = Western blot, Exp = exposure. 
 
3.2.3.3 – Optimising Bait Protein Expression for Colloidal Blue Staining 
Ideally, in order for a protein to be identified by mass spectrometry at the Kennedy 
Institute, the corresponding band needs to be visible on an SDS-PAGE gel by Colloidal 
blue staining (approximately 10 ng protein available).  In contrast, visibility of a protein 
band by silver stain only (approximately 1 ng protein available) suggests that the 
protein will be below the level of detection for the mass spectrometer.  As it was 
considered optimal for Strep-HA-IRF5 to be expressed at physiological levels, I first 
attempted a One-Strep proteomic screen with an MOI of 50, which is in the lower 
range of the MOI required for detection by Western blot.  1.5x108 wild-type M2 bone 
marrow-derived macrophages (express low levels of endogenous IRF5, used in this 
instance due to lack of availability of Irf5-/- mice at the time of the experiment) were 
exposed to viral particles at an MOI of 50 for 2 hours serum-free, then lysed after 24 
hours using the combination of cytoplasmic lysis buffer and RIPA nuclear lysis buffer 
followed by sonication.  The resulting lysates were applied to One-Strep columns and 
washed seven times with 1 ml ice-cold IP wash buffer to wash away any non-
specifically bound proteins.  One-Strep eluates were concentrated to 50 µl and the 
total eluate loaded onto an SDS-PAGE gel for electrophoresis.  Upon silver staining of 
the gel (see Figure 3.12, Panel A), very few protein bands were visible, and even the 
bait protein (approximately 60 kDa in size) was non-identifiable.  This suggests that in 
this instance antibody efficiency is not comparable to the efficiency of a silver stain. 
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As it was of utmost importance that Strep-HA-IRF5 was expressed by the bone marrow 
macrophages in order for the One-Strep system to work, I next increased the MOI for 
adenoviral infection to 250, to determine whether bait protein could be detected by gel 
staining using the highest possible MOI (MOI of 250 uses an entire batch of purified 
adenovirus, due to the large number of cells required for this proteomic study, so was 
considered to be the upper limit for adenoviral infection).  Despite the fact that such a 
high MOI could mean high expression of bait protein, as defined by Western blotting, it 
was felt at this point that it was more important to ensure the presence of bait in the 
system, and any ‘false positives’ caused by overexpression could be ruled out by 
stringent validation.  Upon increasing the MOI to 250, Strep-HA-IRF5 bait protein was 
observed by both Colloidal blue (data not shown) and silver-staining an SDS-PAGE gel 
of One-Strep eluates (Figure 3.12, Panel B).  Despite the improved bait expression, 
minimal ‘prey’ protein bands (IRF5-interacting proteins) were visible, and all were also 
present in the mock control lanes so could be deemed non-specific.  It seems that 
transduction efficiency of murine primary cells is a limiting factor for bait protein 
expression and prey protein affinity purification in One-Strep proteomic studies. 
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Figure 3.12: Silver stain of One-Strep eluates from murine M2 macrophages expressing Strep-IRF5 
M-CSF-differentiated (M2) wild-type murine bone marrow-derived macrophages (1.5x108) were 
transduced with Strep-tagged IRF5 and the Strep-tag alone by adenovirus at MOI 50 (A) or 250 (B), in 
order to induce exogenous expression of this protein/tag.  Following 2 hours serum-free in the presence of 
viral particles, the cells were incubated for 24 hours at 37°C, then lysed on ice for 30 minutes with 1 ml 
chilled cytoplasmic lysis buffer with added protease inhibitors.  The nuclear pellet was further lysed with 1 
ml RIPA lysis buffer plus protease inhibitors and sonicated for 8 30-second pulses.  The resulting lysates 
were cleared by centrifugation to remove cellular debris before being loaded onto a column containing 150 
µl of Streptactin beads. The protein lysates were allowed to pass through the columns by gravity flow to 
allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were then washed by the 
addition of seven individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein complexes were 
eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, which were collected, 
pooled and concentrated by Vivaspin column.  Protein samples (total eluate volume) were prepared by 
heating to 100°C with loading buffer, then resolved by SDS-PAGE, and subjected to silver staining to 
visualise protein content of the samples.  MOI = multiplicity of infection. 
 
3.2.4 – IRF5 Proteomics: HEK293-TLR4-CD14/Md2 Cells 
Due to the adenovirus transduction efficiency issues identified with murine bone 
marrow derived macrophages, I next returned to working with cell lines, as these cells 
are more numerous and easily transfectable so do not possess the same limitations as 
murine primary cells.  Ideally I would have liked to work with a macrophage-like cell 
line, such as RAW264.7 cells, but these are also relatively difficult to transfect.  I 
decided to perform my proteomic screen in HEK293-TLR4 cells, as this cell line is 
responsive to bacterial LPS, which has been shown to activate IRF5-regulated gene 
expression [192].  A screen in HEK293-TLR4 cells was therefore considered to be a 
good starting point, as any protein-protein interactions identified could then be 
validated in human or murine primary macrophages. 
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3.2.4.1 – Transfection of HEK293-TLR4 cells for One-Strep proteomics  
First attempts at a One-Strep proteomic screen in HEK293-TLR4 cells were performed 
using Lipofectamine 2000 transfection to introduce the Strep-HA-IRF5 bait protein into 
the cells.  My supervisor Dr Robin Wait (Kennedy Institute) performed LC-MS/MS for 
this experiment.  By this method of transduction, the HEK293-TLR4 cell screen did not 
yield many prey protein bands following One-Strep affinity purification, despite large 
amounts of starting material and concentrated eluates (see Figure 3.15).   
Figure 3.13: Identification of Strep-HA-IRF5 peptides by mass spectrometry 
Amino acid sequence of IRF5, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
Figure 3.14: Identification of Hsp70 peptides by mass spectrometry 
Amino acid sequence of Hsp70, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
IRF5 bait was identified from the silver-stained gel with high confidence (see Figure 
3.13).  The only specific interaction partner identified from Figure 3.15 by LC-MS/MS 
was heat-shock protein 70 (Hsp70) (see Figure 3.14), as this protein was not found to 
be present in the mock-control lane.  It is possible that despite being a ubiquitously 
expressed protein, Hsp70 is a true protein-protein interaction partner of IRF5 and not a 
contaminant protein present in the eluate due to insufficient wash steps.  However, a 
known function of Hsp70 is to act as a chaperone protein, binding to newly translated 
protein near the ribosome to prevent aggregation, which could render the new protein 
non-functional [305].  Once an entire protein is fully synthesised, Hsp70 is released 
and the protein is free to fold into its correct conformation.  Based on this information, 
an IRF5-Hsp70 interaction could simply be occurring due to high levels of unfolded 
IRF5 (56kDa) 
8 peptides = 115/498 amino acids = 23% peptide coverage 
  
MNQSIPVAPTPPRRVRLKPWLVAQVNSCQYPGLQWVNGEKKLFCIPWRHATRHGPSQDGDNTIFKA
WAKETGKYTEGVDEADPAKWKANLRCALNKSRDFRLIYDGPRDMPPQPYKIYEVCSNGPAPTDSQP
PEDYSFGAGEEEEEEEELQRMLPSLSLTEDVKWPPTLQPPTLRPPTLQPPTLQPPVVLGPPAPDPSP
LAPPPGNPAGFRELLSEVLEPGPLPASLPPAGEQLLPDLLISPHMLPLTDLEIKFQYRGRPPRALTISNP
HGCRLFYSQLEATQEQVELFGPISLEQVRFPSPEDIPSDKQRFYTNQLLDVLDRGLILQLQGQDLYAI
RLCQCKVFWSGPCASAHDSCPNPIQREVKTKLFSLEHFLNELILFQKGQTNTPPPFEIFFCFGEEWPD
RKPREKKLITVQVVPVAARLLLEMFSGELSWSADSIRLQISNPDLKDRMVEQFKELHHIWQSQQRLQP
VAQAPPGAGLGVGQGPWPMHPAGMQ 
Hsp70 (70kDa) 
1 peptide = 14/641 amino acids = 2% peptide coverage 
MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFD
AKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGY
PVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFD
VSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLS
SSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKV
QKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIK
RNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGI
LNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAV
EDEGLKGQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD 
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IRF5 protein in the cytoplasm of the HEK293-TLR4 cells following overexpression by 
lipid transfection.  Despite other functions of Hsp70, including protection of proteins 
from oxidative or thermal stress [305]; the IRF5-Hsp70 interaction was not investigated 
further in this thesis, as it was unlikely that Hsp70 was involved in transcriptional 
regulation by IRF5, which is of primary interest to the Udalova group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Silver stain of One-Strep-IRF5 eluates from HEK293-TLR4 cells (lipid transfection) 
HEK293-TLR4-CD14/Md2 cells (1x108) were transfected with Strep-tagged IRF5 and the Strep-tag alone 
by Lipofectamine 2000 reagent, in order to induce exogenous expression of this protein/tag.  Following 24 
hours at 37°C, the cells lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added 
protease inhibitors. The resulting lysates were cleared by centrifugation to remove cellular debris before 
being loaded onto a column containing 150 µl of Streptactin beads. The protein lysates were allowed to 
pass through the columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  
The columns were then washed by the addition of seven individual 1 ml volumes of chilled IP wash buffer.  
Prey and bait protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin 
elution buffer, which were collected, pooled and concentrated by Vivaspin column.  Protein samples (total 
eluate volume) were prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE, and 
subjected to silver staining to visualise protein content of the samples.  Bands were excised, trypsinised 
and the resulting peptides identified by LC-MS/MS.  Proteins corresponding to the peptides were identified 
by MASCOT database. 
 
3.2.4.2 – Adenoviral transduction of TLR4 cells for One-Strep proteomics  
As an alternative to lipid transfection, HEK293-TLR4 cells were also transduced by 
adenoviral infection, to see if this change in protocol further improved Strep-HA-IRF5 
bait protein expression.  This section of my results was performed in collaboration with 
Dr David Saliba, a post-doctoral scientist in the Udalova group, and the Cambridge 
Centre for Proteomics (CCP), who performed the mass spectrometry associated with 
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these experiments, so this section will be described in plural.  In an attempt to improve 
purification of protein complexes, we also utilised the chemical cross-linker dimethyl 
dithiobispropionimidate (DTBP) to stabilise any weak or transient protein complexes, 
and prevent any endogenous interaction partners being washed away during the wash 
steps of the One-Strep protocol.  Cells were cross-linked with DTBP for 20 minutes at 
room temperature prior to cell harvesting and lysis.  DTBP is a cleavable, membrane-
permeable cross-linker, consisting of amine-reactive imidoesters at either end of an 8-
atom spacer arm.  The imidoesters react with primary amines (such as the amino acid 
lysine) that are in close proximity, to form stable amidine bonds.  These bonds can be 
reversed prior to SDS-PAGE with DTT to ensure individual proteins are resolved. 
 
Figure 3.16 shows colloidal blue-stained gels of cytoplasmic and nuclear Strep-HA-
IRF5 One-Strep eluates.  The lysates used to perform these experiments were 
obtained from adenovirally transduced HEK293-TLR4 cells (MOI 5 for 2 hours serum-
free) that were stimulated with LPS for 0 or 2 hours and cross-linked with DTBP prior to 
cytoplasmic and nuclear lysis.  These gels were sent away to the CCP for band 
excision, trypsin digestion and LC-MS/MS, and the results returned to myself for 
analysis and validation.   
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Figure 3.16: Cytoplasmic and nuclear Strep-HA-IRF5 eluates from HEK293-TLR4 cells (adenovirus) 
HEK293-TLR4/CD14/Md2 cells (1x108) were transduced with Strep-tagged IRF5 and the Strep-tag alone 
by adenovirus at MOI 5 in order to induce exogenous expression of this protein/tag.  Following 2 hours 
serum-free in the presence of viral particles, the cells were incubated for 24 hours at 37°C, then stimulated 
with LPS at 500ng/ml for 0 or 2 hours at 37°C. Cells were then cross-linked with DTBP and lysed on ice 
for 30 minutes with 1 ml chilled cytoplasmic lysis buffer with added protease inhibitors (A).  The nuclear 
pellet was further lysed with 1 ml RIPA lysis buffer plus protease inhibitors and sonicated for 8 30-second 
pulses (B).  The resulting lysates were cleared by centrifugation to remove cellular debris before being 
loaded onto a column containing 150 µl of Streptactin beads. The protein lysates were allowed to pass 
through the columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The 
columns were then washed by the addition of twelve individual 1 ml volumes of chilled IP wash buffer.  
Prey and bait protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin 
elution buffer, which were collected, pooled and concentrated by Vivaspin column.  Protein samples (80% 
total eluate volume) were prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE, 
and subjected to colloidal blue staining to visualise protein content of the samples.  Bands were excised, 
trypsinised and the resulting peptides identified by LC-MS/MS at CCP.  Proteins corresponding to the 
peptides were identified by MASCOT database. MOI = multiplicity of infection. 
 
Several interaction partners of IRF5 were identified in Figure 3.16, including SF3b1 
and KAP1 in the cytoplasm, and RBBP4, THAP4 and RUVBL1/2 in the nucleus (see 
Figure 3.17 and Supplementary Figures S9.4-S9.8).  Following confirmation that the 
peptides detected by LC-MS/MS were from colloidal blue bands running at an 
appropriate size for the protein identified, literature searches were performed in order 
to determine whether the functions of the proteins were relevant to IRF5 activity.  It 
was found that most of the proteins identified by the One-Strep proteomic screen were 
involved in regulation of gene expression by chromatin modification, which is extremely 
relevant to the transcription factor IRF5. 
255 
150 
102 
76 
52 
38 
IRF5 
THAP4 
RBBP4 
Colloidal Blue stain 
RUVBL1/2 
Nuclear 
One-Strep 
Eluates 
B 
-LPS +LPS -LPS +LPS 
Strep-HA-IRF5 Strep-tag 
Chapter 3 – Results 
	   114 
RUVBL1 and RUVBL2 (Supplementary Figures S9.4-S9.5 are components of the 
INO80 and NuA4 transcription activating complexes, which possess nucleosome 
sliding and histone acetyltransferase activities respectively [306]. 
 
RBBP4 (Retinoblastoma Binding Protein 4, Supplementary Figure S9.6) is a 
component of many histone deacetylase complexes, and is thought to be involved in 
transcriptional repression of E2F-responsive genes [307].  
 
Little is known about THAP4 (THAP domain-containing 4, Supplementary Figure S9.7) 
itself, however members of the THAP family are implicated in transcriptional regulation 
and chromatin modification, for example THAP1 is capable of DNA-binding [308], and 
THAP7 interacts with HDAC3 to mediate transcriptional repression [309].  
 
Many papers describe KAP1 (Figure 3.17, Krüppel-associated protein 1, also known 
as TRIM28 – Tripartite motif-containing 28) as a transcriptional repressor for KRAB-
domain containing zinc finger proteins, due to its ability to recruit the histone 
methyltransferase SETDB1 (SET domain bifurcated 1) and the nucleosome 
remodelling and deacetylation complex (NuRD/Mi2α) to the chromatin [310, 311].  
Additionally other members of the TRIM family, including TRIM21 act as E3 ligases 
[312], which could explain the IRF5-KAP1 interaction in the cytoplasm.   
 
In contrast to the other identified proteins, SF3b1 (Supplementary Figure S9.8, Splicing 
Factor 3b, subunit 1) is a subunit of the U2 snRNP complex and acts as an anchor 
between the spliceosome and the pre-mRNA [313]. 
 
 
Figure 3.17: Identification of KAP1 peptides by mass spectrometry 
Amino acid sequence of KAP1, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
KAP1 (100kDa)       
8 peptides = 93/835 amino acids = 11% peptide coverage 
  
MAASAAAASAAAASAASGSPGPGEGSAGGEKRSTAPSAAASASASAAASSPAGGGAEALELLEH
CGVCRERLRPEREPRLLPCLHSACSACLGPAAPAAANSSGDGGAAGDGTVVDCPVCKQQCFSKD
IVENYFMRDSGSKAATDAQDANQCCTSCEDNAPATSYCVECSEPLCETCVEAHQRVKYTKDHTVR
STGPAKSRDGERTVYCNVHKHEPLVLFCESCDTLTCRDCQLNAHKDHQYQFLEDAVRNQRKLLA
SLVKRLGDKHATLQKSTKEVRSSIRQVSDVQKRVQVDVKMAILQIMKELNKRGRVLVNDAQKVTE
GQQERLERQHWTMTKIQKHQEHILRFASWALESDNNTALLLSKKLIYFQLHRALKMIVDPVEPHGE
MKFQWDLNAWTKSAEAFGKIVAERPGTNSTGPAPMAPPRAPGPLSKQGSGSSQPMEVQEGYGF
GSGDDPYSSAEPHVSGVKRSRSGEGEVSGLMRKVPRVSLERLDLDLTADSQPPVFKVFPGSTTE
DYNLIVIERGAAAAATGQPGTAPAGTPGAPPLAGMAIVKEEETEAAIGAPPTATEGPETKPVLMALA
EGPGAEGPRLASPSGSTSSGLEVVAPEGTSAPGGGPGTLDDSATICRVCQKPGDLVMCNQCEFC
FHLDCHLPALQDVPGEEWSCSLCHVLPDLKEEDGSLSLDGADSTGVVAKLSPANQRKCERVLLAL
FCHEPCRPLHQLATDSTFSLDQPGGTLDLTLIRARLQEKLSPPYSSPQEFAQDVGRMFKQFNKLTE
DKADVQSIIGLQRFFETRMNEAFGDTKFSAVLVEPPPMSLPGAGLSSQELSGGPGDGP 
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3.2.4.3 – Validation of the IRF5-KAP1 interaction in HEK293-TLR4 cells 
In order to prioritise which of the protein hits from the proteomic screen to validate, I 
first looked at whether the proteins were expressed in immune cells such as 
macrophages, or were more highly expressed in the HEK293 cell lines (Figure 3.18 
and Supplementary Figures S9.9-S9.13).  Such determination would give an indication 
as to whether the identified prey protein was a background contaminant from the cell 
line, present in the eluates due to insufficient wash steps or non-specific binding to the 
Streptactin matrix, so could be irrelevant to IRF5 function in myeloid cells.  It was 
discovered that THAP4 is more highly expressed in the HEK293 cell line than immune 
cells (Supplementary Figure S9.12), so was not investigated further.  Figure 3.17 
shows that KAP1 was identified not only with the highest peptide coverage of all the 
hits from the screen (8 peptides), but was also expressed in immune cells including 
macrophages (Figure 3.18), therefore KAP1 was considered the highest priority for 
validation from the One-Strep proteomic screen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Relative expression levels of KAP1/TRIM28 in various tissues 
KAP1/TRIM28 expression levels in various tissues according to MOPED (Model Organism Protein 
Expression Database) [314], accessible from www.genecards.org 
 
In order to confirm the identification of KAP1 as an interaction partner for IRF5 by mass 
spectrometry, the One-Strep proteomic screen shown in Figure 3.16 was repeated, 
however this time rather than performing colloidal blue-staining of the SDS-PAGE gel, 
the One-Strep eluates were utilised for Western blotting with a KAP1-specific antibody.  
Figure 3.19 shows IRF5 interacting with KAP1 in both the cytoplasmic and nuclear 
compartments of HEK293-TLR4 cells, rather than in just the cytoplasm as identified by 
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LC-MS/MS.  The heavy colloidal blue staining at 110 kDa (approximate KAP1 running 
size) of the nuclear One-Strep screen in Figure 3.16, suggests a large number of prey 
protein purified at this size, which could have resulted in masking of the KAP1 protein 
band, so explaining why this protein was not identified by LC-MS/MS in the nucleus of 
HEK293-TLR4 cells.  In contrast, amplification of the KAP1 protein by a specific 
antibody in Western blotting was able to exemplify the presence of KAP1 in the nuclear 
eluates, without the issue of background, due to the high sensitivity of the Western 
blotting technique.  The fact that KAP1 was not present in the mock control (Strep-tag 
only) lanes of the Western blot in Figure 3.19 confirms that KAP1 is specifically 
interacting with IRF5 and not binding non-specifically to the Streptactin matrix.  The 
fact that this validation was performed in the absence of DTBP cross-linking, which 
was used in the initial screen, shows that the IRF5-KAP1 interaction is not likely to be 
an artefact of the cross-linking process, and suggests a direct interaction between the 
two proteins, which does not need to be bridged and stabilised by cross-linking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Validation of IRF5-KAP1 interaction in HEK293-TLR4 cells by Western blotting 
HEK293-TLR4/CD14/Md2 cells (1x107) were transduced with Strep-tagged IRF5 and the Strep-tag alone 
by adenovirus at MOI 5 in order to induce exogenous expression of this protein/tag.  Following 2 hours 
serum-free in the presence of viral particles, the cells were incubated for 24 hours at 37°C.  The cells were 
then lysed on ice for 30 minutes with 1 ml chilled cytoplasmic lysis buffer with added protease inhibitors.  
The nuclear pellet was further lysed with 1 ml RIPA lysis buffer plus protease inhibitors and sonicated for 8 
30-second pulses.  The resulting lysates were cleared by centrifugation to remove cellular debris before 
being loaded onto a column containing 150 µl of Streptactin beads. The protein lysates were allowed to 
pass through the columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  
The columns were then washed by the addition of twelve individual 1 ml volumes of chilled IP wash buffer.  
Prey and bait protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin 
elution buffer, which were collected, pooled and concentrated by Vivaspin column.  Protein samples (total 
eluate volume) were prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE and 
transferred to PVDF membrane for Western blotting with KAP1-, Lamin-, and Strep-specific antibodies.  
The top two panels show protein expression in cell lysates (including lamin to show nuclear 
compartmentalisation) and the bottom two panels show retrieval of bait and prey proteins – Strep-IRF5 
interacting with endogenous KAP1.  WB = Western blot. 
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As a second form of validation for the IRF5-KAP1 interaction, I also purified the 
complex utilising KAP1 as the bait protein rather than IRF5, as was the case in Figures 
3.16 and 3.19, in order to show the reciprocal interaction.  KAP1-Flag and Strep-HA-
IRF5 were co-expressed in HEK293-TLR4 cells by lipid transfection and the complex 
purified by Flag-immunoprecipitation (Flag-IP).  The KAP1-Flag expression plasmid 
was a kind gift from Dr Alexey Ivanov (West Virginia University, USA).  Figure 3.20 
illustrates Strep-HA-IRF5 interacting with KAP1-Flag by Western blotting of the Flag-IP 
eluates with a Strep-HRP specific antibody, with no non-specific binding of Strep-HA-
IRF5 to the Flag matrix.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Reciprocal Flag-immunoprecipitation of IRF5-KAP1 interaction in HEK293-TLR4 cells 
HEK293-TLR4/CD14/Md2 cells (1x107) were transfected with Strep-tagged IRF5 in combination with 
KAP1-Flag or Empty vector by Lipofectamine 2000 reagent in order to induce exogenous expression of 
these proteins/tag. Following 24 hours, the cells were then lysed on ice for 30 minutes with 1 ml chilled 
total cell lysis buffer with added protease inhibitors. The resulting lysates were cleared by centrifugation to 
remove cellular debris before being added to anti-Flag affinity agarose gel, rotating for 1 hour at 4°C.  
Washes were performed (3 times) with 1 ml chilled total cell lysis buffer by rotating the tube for 5 minutes 
at room temperature then pelleting the matrix.  Protein complexes were eluted twice with 50 µl Flag 
peptide, pooled and concentrated by Vivaspin column.  Protein samples (total eluate volume) were 
prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE and transferred to PVDF 
membrane for Western blotting with Strep- and Flag-specific antibodies.  The top two panels show protein 
expression in cell lysates, and the bottom panel shows Strep-IRF5 interacting with KAP1-Flag in the IP 
eluates.  WB = Western blot. 
 
In conclusion, the IRF5-KAP1 interaction has been validated by reciprocal 
immunoprecipitation (both One-Strep-AP with endogenous prey and Flag-IP with 
exogenous prey) in HEK293-TLR4 cells, and can be considered a genuine interaction 
in this cell type and not an artefact of the experimental procedure.  Further work is 
required to determine the function of the IRF5-KAP1 interaction in a more 
physiologically relevant cell type to IRF5 activity.  
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3.3 – Conclusion 
The advent of genomics, including the Human Genome Project, has led to the 
publication of a wealth of information regarding gene expression in various healthy and 
disease contexts, and has in turn highlighted the necessity to understand the next level 
of organisation – the proteome.  Regulation at the genome level directly influences the 
proteome as ultimately gene targets are transcribed and translated into protein; 
however the complexity of the proteome is endless, with numerous variables that affect 
protein activity including cell type-specific expression and kinetics, post-translational 
modifications such as phosphorylation and ubiquitination, and protein-protein 
interactions (also known as the interactome).  The advantages of studying proteomics 
and the interactome are that once protein activity has been characterised, inhibition of 
protein function at the level of protein-protein interactions, for example, using small 
molecule inhibitors to block interactions from taking place, can enable tailoring of 
protein function in order to reduce adverse characteristics of that protein without 
completely disabling all function (including any beneficial activity).  For example, there 
are many instances where genomics has told us that a gene is a risk factor for a 
certain disease, however completely disabling the gene (knock-out mice) can often 
lead to other previously unknown phenotypes within the organism that are unrelated to 
the disease pathology in question.  Such an ‘all-or-nothing’ approach to therapy is 
therefore not always appropriate.  This principle has also been demonstrated at the 
level of therapy, for example in Rheumatoid Arthritis, where blocking the activity of 
excessive levels of TNF protein using antibodies (anti-TNF therapy) is extremely 
beneficial for inflammatory pathology in many cases, however some patients develop 
susceptibility to other infections such as M.tuberculosis due to a lack of baseline TNF 
activity to drive the immune response to this pathogen during anti-TNF treatment [234].  
By improving our understanding of the proteome and developing strategies to regulate 
only certain branches of protein function, more intelligent and intricate therapies can be 
developed with more limited unforeseen off-target effects.   
 
The field of proteomics offers numerous strategies for studying protein-protein 
interactions, each with their own advantages and disadvantages.  In my project, I have 
opted to study novel protein-protein interactions of IRF5 using affinity purification in 
combination with mass spectrometry (AP-MS).  The combination of protein purification 
with mass spectrometry is a powerful tool for proteomic studies; and provides the 
opportunity to tailor the system to enable optimal identification of protein-protein 
interactions.  For example, there are numerous purification techniques that can be 
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utilised, many of which I have used throughout this thesis and are described below.  
Mass spectrometry (MS) in proteomics enables de novo peptide sequence elucidation 
from a complex mixture of proteins, and is widely used for analysis of gel or 
chromatographically separated proteins isolated directly from cell lysates [315].  Using 
a ‘bottom-up’ approach to proteomics (tandem mass spectrometry, LC-MS/MS), 
digested peptides are introduced to the mass spectrometer and characterised by two 
rounds of MS to first identify the precursor ion, then characterise the product ions 
following fragmentation of the peptide; to enable determination of peptide sequence 
and infer specific protein presence within a complex lysate.  Post-translational 
modifications such as phosphorylation can also be identified in this manner [316].  The 
use of isotopic labelling strategies such as iTRAQ is also extremely useful to 
quantitatively distinguish proteomic differences between multiple samples, for example 
diseased patient tissues and healthy controls [317].   
 
Such benefits justify the choice of AP-MS for the proteomic screen in this thesis, 
however in terms of limitations of the technique, there is the potential for ‘false 
negatives’ to occur (interactions that should be, but are not, identified due to short-
comings of the technique).  For example, prey proteins could be significantly less 
abundant than other similarly-sized contaminant proteins within a sample, which can 
prevent detection by the mass spectrometer [316].  Alternatively, databases can lack 
both novel and previously identified proteins, which could mean identified peptides 
cannot be matched.  As a result, all proteomic techniques can be considered 
complementary, and a combination of approaches is always beneficial to increase the 
quality and confidence of a study.  In this thesis, interactions have been identified both 
by AP-MS, and validated using endogenous and exogenous immunoprecipitations in 
various cell types.  The Udalova laboratory is also currently optimising a mammalian 
two-hybrid (M2H) system (Promega Checkmate) as a protein-protein interaction 
validation method (see Supplementary Figure S9.17), and is embarking on a 
collaboration to utilise MAPPIT technology (a cytokine receptor-based two-hybrid 
approach for studying native protein-protein interactions within mammalian cells [318]) 
as an alternative proteomic method to compliment this study.  The mass spectrometry 
approach in this thesis could also be further improved by using a gel-free system, also 
known as a ‘shotgun’ proteomic approach [319], in which total cell lysates are 
fragmented without prior separation by SDS-PAGE, as this would remove the added 
limitation of visualising and excising protein bands prior to mass spectrometry, and 
therefore improve the sensitivity of the AP-MS screen. 
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In terms of affinity purification options for a proteomic screen, immunoprecipitation (IP) 
of endogenous bait proteins from cell lysates using antibodies is the most 
physiologically relevant purification technique, as no overexpression of recombinant 
bait protein is required.  However, disadvantages of IP include access to poor or non-
specific antibodies, which can cause other proteins to be purified along with the 
intended bait or no bait protein purification at all.  It can also be difficult to perform 
multiple endogenous IPs in parallel due to the requirement to optimise each antibody.  
A variation of IP that enables a more generic purification protocol is Flag-IP, in which 
Flag-fusion bait proteins are introduced into cells and then purified from lysates using a 
Flag-specific antibody-coated matrix.  The Flag-tag is a short epitope tag, which in 
many cases does not affect protein folding, and so allows the fusion protein to be 
present in the cell in the same conformation as the endogenous protein, and does not 
limit the ability of the fusion protein to form protein-protein interactions and function in a 
normal manner.  For example, the addition of a Flag-tag to the C-terminus of NFκB 
RelA does not affect the ability of the protein to drive a κB associated luciferase 
reporter construct (data not shown).  However, as the bait protein is overexpressed in 
Flag-IP, this may lead to ‘false positive’ interactions due to the high levels of bait 
protein causing association with chaperones, which could result in improper 
intracellular localisation.  This could therefore result in bait protein exposure to proteins 
in different cellular compartments, which may not normally come into contact.  
Stringent validation of identified interaction partners is therefore required.    Another 
disadvantage of both endogenous and Flag antibody-based purifications in novel 
interaction partner studies, is that the heavy and light chains of the antibodies are 
leached from purification beads into the eluates; therefore large bands corresponding 
to these chains are visible on colloidal blue-stained SDS-PAGE gels of eluates, 
masking potential interaction partners of the same size.   
 
Attempts were made to perform an endogenous proteomic screen for IRF5 interaction 
partners using an IRF5-specific antibody in murine M1 macrophages in this thesis 
(Supplementary Figure S9.1).  Using the same conditions and buffers as utilised for 
IRF5 chromatin immunoprecipitation (ChIP) routinely in the Udalova laboratory, 
colloidal blue and silver staining of SDS-PAGE gels of IP eluates appeared to show 
that no IRF5 bait protein was purified (no strong protein band present at 60 kDa).  This 
could be explained by the range of sensitivity of such protein stains, as was also the 
case for adenoviral transduction of murine macrophages (Figure 3.12), or by the 
strength of antibody-antigen affinity, meaning that some IRF5 was precipitated but it 
was below the limit of silver stain detection.  Alternatively, the heavy chain of the 
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antibody, which runs at a similar size to IRF5, could have been masking the bait 
protein band.  Minimal prey protein bands were obtained from this experiment, and 
those that were not present in the mock control (IgG) lanes were identified to be 
myosin and actin (Supplementary Figures S9.2 and S9.3), which are ubiquitously 
expressed proteins and therefore likely not to be physiologically relevant to IRF5 
function in M1 macrophages.  As a result of the poor success of this endogenous 
screen, my purification technique of choice for identifying novel interaction partners of 
IRF5 in Chapter 3 of this thesis was One-Strep affinity purification, in order to ensure 
that bait protein levels were not limiting.  IP will be used to validate identified IRF5 
interactions at an endogenous level; and Flag-IP will be used in combination with One-
Strep-AP to map the interface of protein-protein interactions using truncated mutants in 
Chapters 4 and 5 of this thesis. 
 
Rationale for choosing the One-Strep system for purification of protein complexes was 
because the system is non-antibody based; instead manipulating the high-affinity 
competitive interaction exhibited between Streptactin and the One-Strep tag/biotin (see 
Section 2.8.3).  The advantage of the One-Strep tag over earlier generations of Strep-
tag is its optimised structure – a short tag containing two 8 amino acid Strep-tag II 
sequences (WSHPQFEK) separated by a short linker region [320].  This structure 
enables the One-Strep bait protein to have two contact points with the Streptactin 
matrix, ensuring tight immobilisation of the fusion protein during the purification and 
therefore enabling more stringent washes to occur to remove any unbound 
contaminant proteins from the purification column.  As a result, not only will SDS-
PAGE gels not show heavy/light chain antibody bands, but also there should be less 
background in the mock control and hopefully fewer false positive interactions.  
Similarly to the Flag-tag, the One-Strep tag does not affect protein folding, is 
biochemically inert, resistant to cellular proteases and is easily fused to recombinant 
polypeptides [320].  As with all of the purification systems I have mentioned, 
optimisation is required as binding kinetics and affinity can still vary from complex to 
complex.  This can involve cell stimulation and harvesting at different time points; and 
also the use of a variety of lysis buffers, both to separate cytoplasmic and nuclear 
fractions, and to investigate alternative buffer conditions because some interactions 
may be more resistant to high levels of salt or detergents than others.   
 
As shown in this Chapter, the One-Strep system is capable of detecting both high 
affinity intra-family (NFκB heterodimers) and lower affinity inter-family (NFκB RelA-
STAT3) protein-protein interactions in combination with Western blotting, and NFκB-
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inhibitor interactions (NFκB RelA-IκBα and NFκB RelA-p100) in combination with LC-
MS/MS.  Following optimisation of cell lysis and bait protein transduction methods, the 
One-Strep system has been successfully utilised in this Chapter to identify novel 
interaction partners of IRF5 in HEK293-TLR4 cells.  In particular, this proteomic screen 
has identified the protein KAP1/TRIM28 as a co-factor of IRF5 with high confidence, 
and this interaction has been validated by reciprocal immunoprecipitation in HEK293-
TLR4 cells, using a KAP1 specific antibody for Western blotting of eluates.  The One-
Strep system has also been utilised to investigate candidate protein-protein 
interactions based on hypotheses generated in the Udalova laboratory.  
Supplementary Figures S9.14-S9.15 demonstrate protein-protein interactions between 
IRF5-STAT1, IRF5-STAT3 and IRF5-Runx1 by Western blotting of One-Strep-IRF5 
eluates with appropriate primary antibodies, using interactions with RelA as a positive 
control [301, 321]. 
 
The protein KAP1, encoded by the Trim28 gene, is best described as a transcriptional 
co-factor for Krüppel-associated box (KRAB) domain-containing proteins, such as 
KOX1 [322] and Kid-1 [323].  KAP1 functions at the level of the chromatin template, 
where it acts as a scaffold to recruit different enzymatic activities to loci occupied by 
DNA-binding transcription factors, such as those with a KRAB domain [322].  In most 
instances, KAP1 is associated with regions of heterochromatin and transcriptional 
repression.  This is due to its ability to interact with complexes that provide histone 
deacetylase (HDAC) and methyltransferase activity; including SETDB1 [310] which can 
methylate lysine 9 of histone 3 (H3K9), Mi2α of the nuclear remodelling and 
deacetylation complex (NuRD) [311] and the nuclear receptor co-repressor complex 
(N-CoR-1) [324].  KAP1 also interacts with members of the HP1 family [325], which 
function in the conversion of regions of euchromatin to heterochromatin structures and 
therefore gene silencing [326, 327].  KAP1 has previously been identified as an 
interaction partner for IRF1 via an intrinsically disordered domain towards the N-
terminus of IRF1 [328], and can negatively regulate STAT1-mediated expression of 
IRF1 [329].  An interaction between KAP1 and IRF7 has also been described, in which 
KAP1 acts as a SUMO E3 ligase.  The resulting degradation of IRF7 leads to negative 
regulation of its target gene expression, including Type I IFN [330].  The identification 
of KAP1 as an interaction partner for IRF5 therefore seems plausible, due to the 
previous links between KAP1 and other members of the IRF family, and function in 
epigenetic regulation of gene expression in combination with transcription factors.   
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Further validation of the IRF5-KAP1 interaction, including immunoprecipitation of the 
complex in IRF5-expressing M1 macrophages, is now required to confirm the 
interaction is not an artifact of performing the One-Strep proteomic screen in the 
HEK293-TLR4 cell line and overexpressing the IRF5 bait protein.  Following this, 
functional analysis of the IRF5-KAP1 interaction, in particular depletion of KAP1 protein 
expression in IRF5-expressing cells, will give an insight into the physiological 
significance of the IRF5-KAP1 interaction, and identify which of the described functions 
of KAP1 are relevant in the context of IRF5 activity.  Such studies are described in 
Chapter 4 of this thesis. 
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4.0 – KAP1: a novel co-factor of IRF5  
 
4.1 – Introduction 
The Tripartite Motif (TRIM) proteins comprise a large family with over 70 members, 
each characterised by the presence of an N-terminal RBCC domain, consisting of a 
RING (Really Interesting New Gene) domain followed by one or two zinc-binding B-
Box motifs and a coiled coil (CC) domain.  The RING domain confers E3 ubiquitin 
ligase activity to the TRIM proteins, and the associated B-box and coiled coil are 
thought to mediate protein-protein interactions and the formation of macromolecular 
complexes, such as PML nuclear bodies (ill-defined super-structures of the nucleus at 
which many functions including DNA replication and transcription are proposed to 
occur [331]) in the case of TRIM19 [332].  TRIM proteins are involved in a wide variety 
of cellular processes; but in terms of immunity they have attracted a lot of attention for 
their ability to restrict retroviruses [333] and also their capacity to interfere with IRF and 
NFκB activity.  For example, TRIM21 has been shown to interact with and 
polyubiquitinate IRF3 and IRF5, resulting in subsequent proteasomal degradation and 
inhibition of target gene induction, including IFNβ as a result of IRF3 degradation [312].  
TRIM21 can also interact with and ubiquitinate IRF8 in a manner not associated with 
degradation, therefore enhancing IRF8 expression in IFNγ/CpG activated 
macrophages, and increasing IL-12p40 levels [312, 334].  TRIM59 has also been 
described to inhibit NFκB activity and phosphorylation and dimerisation of IRF3/IRF7, 
resulting in transcriptional repression of target genes [335]. 
 
The identification of KAP1 (encoded by the Trim28 gene) as a protein-protein 
interaction partner of IRF5 in Chapter 3 of this thesis provides additional evidence that 
the IRF family co-operate with members of the TRIM family.  The diversity in activity 
associated with TRIM proteins – the ability to both positively and negatively regulate 
IRF activity – and in particular the described variety of KAP1 functions (both regulation 
of heterochromatin and E3 ligase activity), poses an interesting question as to what is 
the purpose of the IRF5-KAP1 interaction? 
 
In this chapter, I have taken a loss-of-function and gain-of-function approach to 
investigate the role of KAP1 in IRF5-expressing M1 macrophages.  I have also 
mapped the interaction interface between IRF5 and KAP1 using truncated mutants of 
IRF5, in order to further validate the protein-protein interaction. 
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4.2 – Results 
 
4.2.1 – KAP1 is highly expressed in human M1 macrophages  
KAP1 (TRIM28) was identified as a novel co-factor of IRF5 in Chapter 3 of this thesis, 
following a proteomic screen involving One-Strep affinity purification coupled to mass 
spectrometry (LC-MS/MS) in HEK293-TLR4 cells.  The interaction was validated in 
HEK293-TLR4 cells by One-Strep affinity purification followed by Western blotting with 
a KAP1-specific primary antibody, which confirmed the presence of the IRF5-KAP1 
complex in both cytoplasmic and nuclear compartments (Figure 3.19).  The reciprocal 
interaction was also demonstrated, using KAP1-Flag as bait protein to pull-down Strep-
HA-IRF5 in HEK293-TLR4 cells (Figure 3.20).  As KAP1 is described as being 
expressed in mononuclear blood cells, in particular monocytes (Figure 3.18), I next 
investigated KAP1 expression in human M1 and M2 macrophages, which show 
differential expression of IRF5.  Total cell lysates of human M1/M2 macrophages from 
6 healthy donors were Western-blotted with a KAP1-specific antibody (Figure 4.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: KAP1 protein expression in human M1 and M2 macrophages 
Human M1 and M2 macrophages were differentiated from elutriated monocytes from 6 healthy donors 
using GM-CSF and M-CSF respectively, then stimulated for 0/24 hours with 50 ng/ml LPS.  Cells were 
lysed on ice with total cell lysis buffer, before being cleared by centrifugation.  10 µg protein (determined 
by Qubit analysis) was loaded per lane of an SDS-PAGE gel, resolved by electrophoresis then transferred 
to PVDF membrane for Western blotting with KAP1-, IRF5- and actin- antibodies.  WB = Western blot. 
37 
102 
76 
	   05/12/2012 
	   -LPS 	   +LPS 	   -LPS 	   +LPS 	   
M2 	   M1 	   -LPS 	   +LPS 	   -LPS 	   +LPS 	   
M2 	   M1 	   
10/01/2013 
	   -LPS 	   +LPS 	   -LPS 	   +LPS 	   
M2 	   M1 	   
13/12/2012 
WB:  
Actin 
WB:  
IRF5 
WB:  
KAP1 
M2 M1 
-LPS 
102 	   	   	   	   	   	   
	   
76 
37 
-LPS +LPS +LPS 
28/09/2011 
WB:  
KAP1 
WB:  
IRF5 
WB:  
Actin 
	   -LPS 	   +LPS 	   -LPS 	   +LPS 	   
M2 	   M1 	   
29/11/2012 
	   -LPS 	   +LPS 	   -LPS 	   +LPS 	   
M2 	   M1 	   
21/11/2012 
Chapter 4 – Results 
	   126 
KAP1 was found to be expressed more highly in M1 compared to M2 macrophage 
lysates, which corresponds to increased levels of IRF5 expression, or expression of 
more IRF5 isoforms in the M1 macrophages (Figure 4.1) [197].  In some donors, both 
IRF5 and KAP1 expression was increased by LPS stimulation for 24 hours, however 
this was not a consistent observation.  KAP1 expression, like IRF5 expression is 
therefore also polarised toward a pro-inflammatory (M1) macrophage phenotype. 
 
4.2.2 – KAP1 interacts with IRF5 in M1 macrophages  
Following confirmation that both KAP1 and IRF5 are expressed in M1 macrophages, 
further validation of the interaction was performed, to demonstrate that the interaction 
also occurs in this cell type, where IRF5 has been described as functional [196].  
Human M1 macrophages differentiated from elutriated monocytes for 5 days in the 
presence of GM-CSF were transduced by adenovirus expressing either Strep-HA-IRF5 
or the Strep-tag alone.  M1 macrophages were chosen due to the presence of higher 
levels of KAP1 protein, despite the fact that endogenous IRF5 could compete with 
Strep-HA-IRF5 for binding.  Western blotting of One-Strep eluates with a KAP1-specific 
antibody determined that Strep-HA-IRF5 was purified in complex with endogenous 
KAP1 (Figure 4.2).  This further confirms the identification of KAP1 as a co-factor of 
IRF5, now in a physiologically relevant cell type to IRF5 activity. 
 
 
 
 
 
 
 
 
 
Figure 4.2: IRF5 interacts with KAP1 in human M1 macrophages 
Human M1 macrophages (2x107) differentiated from elutriated monocytes by GM-CSF were transduced 
with Strep-tagged IRF5 and the Strep-tag alone by adenovirus at MOI 50 in order to induce exogenous 
expression of this protein/tag.  Following 4 hours serum-free in the presence of viral particles, the cells 
were incubated for 24 hours at 37°C in complete media.  The cells were then cross-linked with 8 mM 
DTBP and lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors. 
The resulting lysates were cleared by centrifugation to remove cellular debris before being loaded onto a 
column containing 150 µl of Streptactin beads. The protein lysates were allowed to pass through the 
columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were 
then washed by the addition of twelve individual 1 ml volumes of chilled IP wash buffer.  Prey and bait 
protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, 
which were collected, pooled and concentrated to 50by Vivaspin column.  Cross-linking was then reversed 
by 150 mM DTT at 37°C for 30 minutes.  Protein samples (total eluate volume) were prepared by heating 
to 100°C with loading buffer, then resolved by SDS-PAGE and transferred to PVDF membrane for 
Western blotting with KAP1- and Strep-specific antibodies.  The bottom panel shows Strep-IRF5 
interacting with endogenous KAP1.  WB = Western blot. 
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Attempts were also made to purify the endogenous IRF5-KAP1 complex from murine 
M1 macrophages by immunoprecipitation using specific antibodies (Figure 4.3).  This 
experiment was performed using murine cells in order to ensure the availability of large 
cell numbers and therefore prevent limitation of the experiment due to a lack of cellular 
material.  Both IRF5 and KAP1 were immunoprecipitated by their respective antibodies 
from cytoplasmic lysates, as shown by Western blotting IP eluates with the same 
antibodies (Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: IRF5 and KAP1 endogenous immunoprecipitation from murine M1 macrophages 
Murine M1 macrophages (5x107) differentiated from bone marrow with GM-CSF were stimulated with LPS 
for 0/2 hours at 500 ng/ml then cross-linked with 8 mM DTBP.  The cells were then lysed on ice for 30 
minutes with 1 ml chilled cytoplasmic lysis buffer with added protease inhibitors.  The nuclear pellet was 
further lysed with 1 ml RIPA lysis buffer plus protease inhibitors and sonicated for 8 30-second pulses.  
The resulting lysates were cleared by centrifugation to remove cellular debris before being incubated with 
2 µg of either an IRF5- or KAP1- specific antibody (see Table 2.10) or –Ab as a negative control, for 2 
hours rotating at 4°C.  Trueblot IP beads were added for a further 1 hour, then washed 3x with 1 ml chilled 
IP wash buffer by rotating for 5 minutes then pelleting the beads and removing the supernatant.  Prey and 
bait protein complexes were eluted from the column by the addition of 50 µl loading buffer with 50µl lysis 
buffer. Cross-linking was then reversed by 150 mM DTT at 37°C for 30 minutes.  50% of the eluates were 
prepared by heating to 100°C with loading buffer, then resolved by SDS-PAGE and transferred to PVDF 
membrane for Western blotting with KAP1- and IRF5 -specific antibodies. All panels are taken from a 
single membrane and film exposure.  WB = Western blot, IP = immunoprecipitation, -Ab = no antibody. 
 
Despite KAP1 expression being detected in the nuclear input lysates, no nuclear KAP1 
protein seemed to be immunoprecipitated.  This could be due to a change of 
conformation of KAP1 in the nucleus that renders the antibody epitope unrecognisable, 
whereas the epitope can still be detected by the antibody on denatured protein in a 
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Western blot of nuclear cell lysates.  Figure 4.3 shows cytoplasmic and precipitated 
IRF5 bands as white due to high levels of protein and overexposure of the Western 
blot in order to visualise nuclear bands on the same Western.   
 
4.2.3 – IRF5 interacts with KAP1 via an intrinsically disordered region  
Using expression plasmids encoding Strep-tagged truncated mutants of the IRF5 
protein (cloned in the Udalova laboratory by Dr Grigory Ryzhakov), I next endeavoured 
to map the interaction interface of IRF5 with KAP1-Flag.  The IRF5 truncated mutants 
lack one or more structural domains of IRF5 (Figure 4.4, Panel B) – either the DNA-
binding domain (DBD: aa1-130) alone or in combination with a central linker region 
(aa130-220), or the IRF association domain and C-terminal serine rich region (IAD: 
aa219-395; SRR: aa395-498).  Studying the extent of KAP1-Flag binding upon IRF5 
domain omission in this manner enables identification of the domain required for an 
interaction with KAP1. 
 
The Strep-tagged IRF5 truncated mutants were expressed to equal levels in HEK293-
TLR4 cells in combination with KAP1-Flag (Figure 4.4, Panel A), and the resulting 
lysates subjected to One-Strep affinity purification in combination with Western blotting.  
An N-terminal region just outside of the DBD was found to be important for the 
interaction interface with KAP1-Flag, as shown by reduced binding of the Strep-HA-
Δ219 mutant to KAP1-Flag (Figure 4.4, Panel A, lower blot).  It is clear that the DBD, 
which is absent in both the Strep-HA-ΔDBD and -Δ219 mutants, is not the region of 
IRF5 that interacts with KAP1, as the Strep-HA-ΔDBD mutant shows intact binding to 
KAP1-Flag.  This suggests that aa131-220 (missing in Δ219) rather than aa1-130 
(missing in both ΔDBD and Δ219) is the region required for IRF5 binding to KAP1.  The 
fact that there is not complete abrogation of KAP1-Flag binding to Strep-HA-Δ219 
suggests that the mutant could be forming homodimers with endogenous IRF5 in the 
HEK293-TLR4 cells, as Strep-HA-Δ219 still possesses an IAD which allows for dimer 
formation amongst the IRF family.  This could therefore explain the residual KAP1-Flag 
binding to Strep-HA-Δ219; however as there is a marked decrease in the amount of 
KAP1-Flag purified in this instance compared to with full-length Strep-HA-IRF5, this still 
suggests that aa131-220 is a crucial region of IRF5 for the interface. 
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Figure 4.4: Mapping the IRF5-KAP1 interaction interface 
HEK293-TLR4/CD14/Md2 cells (1x107) were co-transfected with combinations of expression plasmids 
containing Strep-tagged truncated mutants of IRF5 and KAP1-Flag by Lipofectamine 2000 reagent, in 
order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells were cross-
linked with 8 mM DTBP and lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added 
protease inhibitors.  The resulting lysates were cleared by centrifugation to remove cellular debris before 
being loaded onto a column containing 150 µl of Streptactin beads.  The protein lysates were allowed to 
pass through the columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  
The columns were then washed by the addition of twelve individual 1 ml volumes of chilled IP wash buffer.  
Prey and bait protein complexes were eluted from the column by the addition of six 50 µl volumes of biotin 
elution buffer, which were collected and pooled.  Eluates were concentrated by Vivaspin column then the 
cross-linked reversed by 150 mM DTT for 30 minutes at 37°C.  Protein samples were prepared by heating 
to 100°C with loading buffer, then resolved by SDS-PAGE, and subjected to Western blotting with Strep- 
and Flag-specific antibodies as required following transfer to PVDF membrane. WB = Western blot, DBD = 
DNA-binding domain, IAD = IRF association domain, SRR = Serine-rich region. 
 
At the time of performing this experiment, another study identified KAP1 as an 
interaction partner of IRF1 [328].  A multiprotein-binding interface, just outside the IRF1 
DBD, was shown to be responsible for the interaction.  This region was shown to 
exhibit high intrinsic disorder and therefore a high degree of flexibility due to a poor 
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tertiary structure [328], which is advantageous for proteins that require co-factors, as 
these characteristics enable the region to be more accessible for protein-protein 
interactions.  Analysis of the IRF5 sequence by the DISOPRED2 disorder prediction 
server [336] demonstrated that the KAP1 binding interface of IRF5 also contained a 
region (aa121-172) with a high degree of intrinsic disorder (Figure 4.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: IRF5 exhibits intrinsic disorder at an N-terminal region outside the DNA binding domain  
Analysis of IRF5 using DISOPRED2 software [336] showing the probability of intrinsic disorder within the 
IRF5 sequence, predominantly between amino acids 121 and 172. 
 
Interestingly, the intrinsically disordered regions of IRF1 and IRF5 align immediately 
following their highly conserved DNA-binding domains (Figure 4.6), suggesting that an 
unstructured yet poorly conserved region following the DBD may be a common feature 
of members of the IRF family.  This interface may be important for numerous protein-
protein interactions of IRF5, extending beyond only KAP1, as this region shows more 
accessibility than even the IRF5 IAD (Figure 4.5), which is widely considered to be the 
main domain responsible for protein-protein interactions amongst the IRF family.  In 
fact, several interaction partners of IRF1 have already been mapped to its intrinsically 
disordered region [328].  The fact that the region is so close to the DBD also suggests 
that any interaction partners are more likely to be involved directly in transcriptional 
regulation by IRF1/IRF5, possibly even binding directly to the DNA. 
DBD IAD SRR 
121 172 
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Figure 4.6: Sequence alignment of the intrinsically disordered regions of IRF5 and IRF1 
ClustalW multiple sequence alignment showing alignment of the intrinsically disordered regions of IRF1 
(blue) and IRF5 (red), immediately after their highly conserved DNA binding domains. 
 
4.2.4 – Depletion of KAP1 levels in human M1 macrophages by RNAi 
In order to determine the functional role of the IRF5-KAP1 interaction in inflammatory 
macrophages, I attempted a loss-of-function approach in which KAP1 levels were 
depleted by RNA-interference in the form of siRNA.  As KAP1 had been successfully 
knocked-down in this manner in the literature (although in different cell types), I used 
the same siRNA oligo sequence as was used in other studies as a starting point [291].  
IRF5 siRNA knockdown is performed routinely in the Udalova laboratory, so I utilised 
this protocol (Dharmafect I transfection) with the custom KAP1 and control siRNA.   
 
Figure 4.7 shows by Western blotting that KAP1 knockdown was most evident in 
human M1 macrophages when the final concentration of siRNA was 50 nM (panel A).  
Densitometry of the 50 nM condition (10 µg protein loaded for the Western blot) 
confirmed knockdown of KAP1 protein levels to 45.4% compared to the level observed 
with the control siRNA (Figure 4.7, panel B).  A similar level of knockdown 
CLUSTAL W (1.83) multiple sequence alignment 
  
IRF1            --------MPITRMRMRPWLEMQINSNQIPGLIWINKEEMIFQIPWKHAAKHGWDINKD 
IRF5           MNQSIPVAPTPPRRVRLKPWLVAQVNSCQYPGLQWVNGEKKLFCIPWRHATRHGPSQDGD 
                         *  *:*::***  *:** * *** *:* *: :* ***:**::** . : * 
  
IRF1           ACLFRSWAIHTGRYKAGEKEPDPKTWKANFRCAMNSLPDIEEVKDQSRNKGSSAVRVYRM 
IRF5           NTIFKAWAKETGKYTEGVDEADPAKWKANLRCALNKSRDFRLIYDGPRDMPPQPYKIYEV 
                 :*::** .**:*. * .*.** .****:***:*.  *:. : * .*:  ... ::*.: 
  
IRF1           LPPLTKNQRKERKSKSSRDAKSKAKRKSCGDSSPDTFSDGLSSSTLPDDHSSYTVPGYMQ 
IRF5           CSNGPAPTDSQPPEDYSFGAGEEEEEEEELQRMLPSLSLTEDVKWPPTLQPPTLRPPTLQ 
                .  .    .:  .. * .* .: :.:.  :    ::*   . .  *  :..   *  :* 
  
IRF1           D----------------------------------LEVEQALTPALSPCAVSSTLPDWHI 
IRF5           PPTLQPPVVLGPPAPDPSPLAPPPGNPAGFRELLSEVLEPGPLPASLPPAGEQLLPDLLI 
                                                    :* .  **  * * .. ***  * 
  
IRF1           PVEVVPDSTSDLYNFQVSPMP---------------STSEATTDEDEEGKLPEDIMKLLE 
IRF5           SPHMLPLTDLEIKFQYRGRPPRALTISNPHGCRLFYSQLEATQEQVELFGPISLEQVRFP 
               . .::* :  ::     .  *               *  *** :: *     .     :  
  
IRF1           QSEWQPTN-----------VDGKGYLLNEPG----------------------------- 
IRF5           SPEDIPSDKQRFYTNQLLDVLDRGLILQLQGQDLYAIRLCQCKVFWSGPCASAHDSCPNP 
               ..*  *::           * .:* :*:  *                              
  
IRF1           VQPTSVYGDFSCKEEPEIDSPGGDIGLSLQRVFTDLKNMDATWLDSLLTPVRLPSIQAIP 
IRF5           IQREVKTKLFSLEHFLNELILFQKGQTNTPPPFEIFFCFGEEWPDRKPREKKLITVQVVP 
               :*       ** :.  :      .   .    *  :  :.  * *      :* ::*.:* 
  
IRF1           CAP--------------------------------------------------------- 
IRF5           VAARLLLEMFSGELSWSADSIRLQISNPDLKDRMVEQFKELHHIWQSQQRLQPVAQAPPG 
                *.                                                          
  
IRF1           ------------------ 
IRF5           AGLGVGQGPWPMHPAGMQ 
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(approximately 50%) was observed on the Trim28 mRNA level in 5 human donors 
throughout an LPS time-course (Figure 4.7, panel C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: KAP1 depletion in human M1 macrophages by RNAi 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides against KAP1 and a negative control sequence, which were 
transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well plates.  A: 
siRNA was initially optimised at 20nM, 50nM and 100nM to optimal knockdown efficiency.  Following 
incubation for 3 days at 37°C to allow knockdown to occur, cells were lysed in 100 µl total cell lysis buffer 
with added protease inhibitors on ice for 30 minutes.  Lysates were centrifuged to remove cellular debris 
then protein content quantified by Qubit assay.  1 µg, 5 µg or 10 µg protein was heated to 100°C in loading 
buffer and resolved on SDS-PAGE gel before transfer to PVDF membrane for Western blotting with KAP1- 
and Actin-specific antibodies.  B:  Optimal knockdown efficiency in Panel A was observed with 50 mM 
siRNA (10 µg loading), as demonstrated by densitometry using QuantityOne software.  C:  KAP1 siRNA 
knockdown was also demonstated on the mRNA level at 50 nM siRNA.  Following 3 days transfection, 
cells were stimulated with 10 ng/ml LPS over a 0-6 hour timecourse, after which mRNA was extracted and 
1 µg (determined by Nanodrop quantification) reverse transcribed into cDNA for analysis by qPCR using 
hTRIM28 and hRPLP0 (housekeeping gene) Taqman assays.  Mean of 5 donors normalised to hRPLP0, 
error bars show SEM.  WB = Western blot, AU = arbitrary units, siKAP1/siCon = KAP1/control siRNA. 
 
It was therefore considered that a suitable level of KAP1 knockdown was obtained in 
order to look at the effect of reduced KAP1 levels on IRF5-related activity in human M1 
macrophages. 
 
4.2.5 – KAP1 does not enable IRF5 to negatively regulate IL-10  
IRF5 has been shown to drive the pro-inflammatory M1 phenotype in macrophages, 
both by promoting the expression of characteristic M1 markers such as IL-12 and TNF, 
and inhibiting the expression of M2 markers such as IL-10 [196].  The Udalova 
laboratory has previously shown by chromatin immunoprecipitation (ChIP) in human 
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M1 macrophages that IRF5 is present at the human IL10 gene promoter at 0/1 hour 
LPS stimulation; however RNA polymerase II is only recruited to the locus after 4 hours 
LPS stimulation when IRF5 is no longer bound to the promoter [196].  Such diverse 
modes of transcriptional activity by IRF5 – both driving and inhibiting gene expression 
– suggest a need for co-factors in order to mediate these functions.  The fact that 
KAP1 is involved in the promotion of a heterochromatin environment led to the 
hypothesis that IRF5 could be recruiting such activities to the IL10 promoter and 
inhibiting RNA polymerase II recruitment sterically due to inaccessibility of the locus, 
therefore inhibiting expression of this M2 marker in M1 macrophages.  I next 
endeavoured to investigate the effect of KAP1 depletion on IL-10 levels in human M1 
macrophages in order to test this hypothesis. 
Figure 4.8: Effect of KAP1 depletion on IL10 gene expression in human M1 macrophages 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) 
reverse transcribed into cDNA for analysis by qPCR using hIL10 and hRPLP0 (housekeeping gene) 
Taqman assays.  A: Mean of 5 donors normalised to hRPLP0, error bars show SEM.  B/C: Each line 
represents data points from a single donor, statistical analysis by unpaired Student’s t-test. AU = arbitrary 
units, siKAP1/siCon = KAP1/control siRNA. 
 
Following siRNA knockdown of KAP1 in human M1 macrophages from 5 independent 
heterogeneous donors, IL10 mRNA levels were measured by qPCR.  Figure 4.8 shows 
a non-significant trend for reduced production of IL10 mRNA upon KAP1 depletion at 1 
and 6 hours LPS stimulation.  This trend is also mirrored on the level of protein 
secretion in two representative human donors, as measured by ELISA (Figure 4.9). 
 
Depletion of KAP1 therefore seems to have minimal effect on IL-10 production on both 
the mRNA and protein level by human M1 macrophages, which opposes the original 
hypothesis that KAP1 has a role in inhibiting IL-10 production via IRF5 interactions.  
KAP1 therefore does not aid IRF5 in its ability to negatively regulate M2 markers.   
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Figure 4.9: Effect of KAP1 depletion on IL-10 protein secretion by human M1 macrophages 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which supernatants were collected and IL-10 protein secretion measured by IL-10 
ELISA.  A and B show representative individual human donors, mean of triplicate wells plotted, error bars 
show SD.  siKAP1/siCon = KAP1/control siRNA. 
 
4.2.6 – KAP1 negatively regulates M1 markers following LPS stimulation 
Following investigation of the effect of KAP1 siRNA knockdown on IL10 expression 
(negatively regulated by IRF5), I next studied the effect of this depletion on M1 
markers (positively regulated by IRF5).  Figure 4.10 shows that as a result of reduced 
KAP1 levels, significantly increased Tnf mRNA expression was observed, with a 
notable difference in expression at later time-points following LPS stimulation. 
 
 
 
 
 
Figure 4.10: Effect of KAP1 depletion on TNF gene expression in human M1 macrophages 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) 
reverse transcribed into cDNA for analysis by qPCR using hTNF and hRPLP0 (housekeeping gene) 
Taqman assays.  A: Mean of 5 donors normalised to hRPLP0, error bars show SEM.  B/C: Each line 
represents data points from a single donor, statistical analysis by unpaired Student’s t-test, *P<0.05. AU = 
arbitrary units, siKAP1/siCon = KAP1/control siRNA. 
 
Across 5 independent heterogeneous donors, Tnf mRNA expression was found to be 
significantly higher in KAP1-depleted M1 macrophages at 2 hours and 4 hours post-
hIL10 protein secretion
0 1 2 4 6
0
200
400
600
800
IL
-1
0,
 p
g/
m
l
time after LPS, hours
siCon
siKAP1
hIL10 protein secretion
0 1 2 4 6
0
200
400
600
800
1000
IL
-1
0,
 p
g/
m
l
time after LPS, hours
siCon
siKAP1
A B 
hTNF mRNA
0 1 2 4 6
0
50
100
150
200
250
300
350
siCon
siKAP1
n=5
time after LPS, hours
m
R
N
A 
ex
pr
es
si
on
 (A
U
)
hTNF mRNA, 2h
siCon siKAP1
0
200
400
600 *
n=5
m
R
N
A 
ex
pr
es
si
on
 (A
U
)
hTNF mRNA, 4h
m
R
N
A 
ex
pr
es
si
on
 (A
U
)
siCon siKAP1
0
20
40
60
80
*
n=5
A B C 
Chapter 4 – Results 
	   135 
LPS stimulation (Figure 4.10).  This coincided with a significant increase in TNF 
secretion observed at 4 hours and 6 hours post-LPS stimulation, compared to cells 
treated with control siRNA (Figure 4.11).   
 
Figure 4.11: Effect of KAP1 depletion on TNF protein secretion by human M1 macrophages 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which supernatants were collected and TNF protein secretion measured by TNF ELISA.  
A shows TNF secretion by 4 donors, mean of triplicate wells, error bars show SEM.  B and C: Each line 
represents data points from a single donor, statistical analysis by unpaired Student’s t-test, **P<0.01. AU = 
arbitrary units, siKAP1/siCon = KAP1/control siRNA. 
 
Although TNF showed the most significant differences upon KAP1 siRNA knockdown, 
other M1 markers that are also positively regulated by IRF5 showed trends (although 
not always significant) for increased mRNA production in the absence of KAP1.  Figure 
4.12 shows that as a result of depleted KAP1 levels, there was a trend for increased 
production of IL12a mRNA following 4 hours LPS stimulation, and a significant 
increase in IL12a mRNA following 6 hours LPS stimulation (panel A).  Figure 4.12 also 
shows trends for increased production of IL23a and IL27 mRNA following depletion of 
KAP1 levels at 4/6 hours and 6 hours LPS stimulation respectively (panels B and C).  
No increase in expression was observed for IL12b following KAP1 knockdown (Figure 
4.12, panel D), suggesting that KAP1 is involved in the regulation of only a subset of 
IRF5-regulated M1 markers. 
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Figure 4.12: Effect of KAP1 depletion on IL12a/IL23a/IL27/IL12b expression in M1 macrophages 
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  A: Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) 
reverse transcribed into cDNA for analysis by qPCR using Taqman assays hIL12A and hRPLP0 
(housekeeping gene) Taqman assays.  Left panels shows mean of 5 donors normalised to hRPLP0, error 
bars show SEM.  Right panels show lines representing data points from a single donor, statistical analysis 
by unpaired Student’s t-test, *P<0.05. B: hIL23a.  C: hIL27.  D: hIL12b.  AU= arbitrary units, siKAP1/siCon 
= KAP1/control siRNA. 
 
Interestingly, the time points at which knockdown of KAP1 made the most difference to 
mRNA expression of Tnf, IL12a, IL23a and IL27 were immediately following the peak 
in the kinetics of expression, when mRNA levels were beginning to subside in 
response to LPS stimulation.  Figure 4.13 shows the kinetics of expression of these 
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markers under normal conditions, without any RNAi to deplete KAP1 levels.  It is clear 
that Tnf gene expression begins to subside following 2 hours LPS stimulation, and 
IL12a/IL23a following 4 hours LPS stimulation, which corresponds to the time-points in 
Figures 4.10 and 4.12, at which a lack of KAP1 caused increased mRNA production.   
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Kinetics of LPS-induced TNF/IL12A/IL23A mRNA expression by M1 macrophages  
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were stimulated 
with 10 ng/ml LPS over a 0-6 hour timecourse, after which mRNA was extracted and 1 µg (as determined 
by Nanodrop quantification) reverse transcribed into cDNA for analysis by qPCR using Taqman assays 
hIL12A, hTNF, hIL23A and hRPLP0 (housekeeping gene) Taqman assays.  Mean of 5 donors normalised 
to hRPLP0, error bars show SEM.  AU = arbitrary units. 
 
These results therefore suggest that KAP1 plays a role in the inhibition of gene 
expression of a subset of IRF5-regulated M1 markers, and KAP1 inhibitory function at 
these gene loci professes immediately following the peak of mRNA production in 
response to LPS stimulation.   This is consistent with the previously defined role of 
IRF5 in sustained production of TNF in myeloid cells [197]. 
 
4.2.7 – KAP1 does not alter IRF5 expression, protein turnover or activity  
Following the results in Section 4.2.6, I next investigated a role for KAP1 in regulation 
of IRF5 mRNA/protein, as decreased levels of IRF5 could explain the reduction in the 
Tnf, IL12a and IL23a observed late in the mRNA kinetics following LPS stimulation, in 
the presence of endogenous KAP1 in M1 macrophages.  It is possible that KAP1, as a 
nuclear protein that can be recruited to the chromatin via DNA-binding transcription 
factors, could be regulating the Irf5 gene itself in response to LPS stimulation.  
Alternatively, as a member of the TRIM family in which E3 ligase function is common, 
KAP1 could be ubiquitinating IRF5 protein for degradation following LPS stimulation, in 
order to cease the production of inflammatory mediators. 
 
No significant difference was observed in Irf5 mRNA levels in KAP1-depleted M1 
macrophages compared to those treated with a control siRNA, throughout an LPS 
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time-course (Figure 4.14).  This therefore ruled out a role for KAP1 in transcriptional 
regulation of the Irf5 gene itself in response to LPS stimulation.  Conversely, IRF5 
ChIP-seq data produced by Dr David Saliba in the Udalova laboratory (Section 2.11) 
shows no increased recruitment of IRF5 to the Trim28 (KAP1) locus in murine M1 
macrophages following 2 hours LPS stimulation (Figure 4.14), suggesting that IRF5 
does not itself activate KAP1 expression, which could have explained the lag-time in 
KAP1 activity at M1 marker loci.  The peaks in IRF5 recruitment that are visible at the 
Trim28 locus were not called with a 1% false discovery rate (FDR), therefore Trim28 
was not included in the list of genes that are regulated by IRF5 in the ChIP-seq data 
set (manuscript submitted). 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.14: KAP1 and IRF5 do not transcriptionally regulate each other  
Human M1 macrophages (1x105) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded into 96-well 
plates.  Following 3 days for transfection, cells were stimulated with 10 ng/ml LPS over a 0-6 hour 
timecourse, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) 
reverse transcribed into cDNA for analysis by qPCR using hIRF5 and hRPLP0 (housekeeping gene) 
Taqman assays.  A: Mean of 5 donors normalised to hRPLP0, error bars show SEM.  B: Each line 
represents data points from a single donor, statistical analysis by unpaired Student’s t-test.  C: IRF5 and 
RNA Pol II recruitment to the Trim28 locus following 2 hours LPS stimulation of murine M1 macrophages, 
taken from a genome-wide IRF5 ChIP-seq study by the Udalova group (manuscript submitted).  AU = 
arbitrary units, siKAP1/siCon = KAP1/control siRNA. 
 
I next investigated whether KAP1 reduces IRF5 protein levels, as this would have 
explained the increase in Tnf expression when KAP1 was knocked down (more IRF5 
present to drive gene expression in the absence of KAP1).  Overexpression of 
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exogenous KAP1-Flag in murine RAW264.7 macrophage cells and HEK293-TLR4 
cells did not alter endogenous or exogenous IRF5 protein levels (Figure 4.15), as 
determined by Western blotting.  Moreover, under these conditions (defined by 
physiological levels of ubiquitin-related modifiers rather than their forced 
overexpression), no sign of IRF5 ubiquitination was observed on the Western blots in 
the form of a high molecular weight smear detected by the IRF5 primary or Strep-HRP 
antibodies (Figure 4.15).  This suggests that in the case of IRF5, KAP1 was not acting 
as an E3 ligase and not promoting IRF5 proteosomal degradation by ubiquitination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: KAP1 does not alter protein levels of IRF5 by acting as an E3 ligase 
RAW264.7 cells (A) or HEK293-TLR4 cells (B) (7x105) were transfected with KAP1-Flag expression 
plasmid alone (A) or in combination with Strep-IRF5 expression plasmid (B) by Lipofectamine LTX and 
Plus or 2000 reagents respectively, in order to induce exogenous expression of these proteins.  Following 
24 hours incubation at 37°C, cells were stimulated with LPS for 0/1 hour at 1 µg/ml then lysed on ice for 
30 minutes with total cell lysis buffer with added protease inhibitors.  Lysates were centrifuged to pellet 
cellular debris, and then the protein content quantified using a Qubit assay.  10 µg protein was prepared 
by heating to 100°C in loading buffer, then loaded onto SDS-PAGE gels for electrophoresis followed by 
transfer to PVDF membrane for Western blotting with Strep-, Flag-, IRF5- and Actin- specific antibodies.  
Figure representative of 3 experiments.  WB = Western blot 
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Furthermore, the presence of exogenous KAP1 had no effect on IRF5-driven Tnf 
luciferase reporter activity in RAW264.7 macrophage cells or HEK293-TLR4 cells, 
which further supports the notion that neither IRF5 protein levels nor activity are being 
decreased by KAP1 (Figure 4.16).  Little effect was also observed by KAP1 
overexpression on LPS-induced activity of the Tnf luciferase reporter in RAW264.7 
cells, suggesting that the levels or activity of other endogenous transcription factors 
involved in regulation of the Tnf gene (i.e. NFκB [337-340]) were not significantly 
compromised in this system (Figure 4.16). 
 
Figure 4.16: KAP1 does not alter the activity of IRF5 in a Tnf luciferase reporter assay 
RAW264.7 cells (1x105) were transfected with KAP1-Flag expression plasmid in combination with Strep-
IRF5 (A) or alone (B) by Lipofectamine LTX and Plus reagents, in order to induce exogenous expression 
of these proteins.  Cells were transfected at the same time with a Tnf_luciferase reporter construct, 
consisting of the 5’ and 3’ regulatory regions of Tnf upstream of the Firefly luciferase gene, and with a 
Renilla luciferase expression plasmid (for normalisation of transfection efficiency between wells).  
Following 24 hours incubation at 37°C, panel B was additionally stimulated for 0/6 hours with 1 µg/ml LPS.  
Firefly and Renilla luciferase activity was measured by Dual Glo luciferase assay using a Micro BetaJet to 
measure fluorescence levels.  Error bars show SEM of n=2 or 3 experiments, each performed in triplicate.  
C: Same experiment as A, except using HEK293-TLR4/CD14/Md2 cells and Lipofectamine 2000 reagent.  
Statistical analysis by unpaired Student’s t-test. 
 
Taken together, these results suggest that the sustained endogenous Tnf expression 
(and other M1 markers to a lesser extent) observed in the absence of KAP1 in Section 
4.2.6, may be due to other activities of KAP1. 
 
4.2.8 – Low levels of H3K9me3 are present at the Tnf locus 
KAP1 is known to recruit the methyltransferase SETDB1 to chromatin, which causes 
deposition of trimethylation on lysine 9 of histone 3 (H3K9me3), resulting in regions of 
closed heterochromatin [310].  I therefore sought to investigate H3K9me3 deposition at 
the Tnf locus in human M1 macrophages.  Over an LPS time-course, a very low level 
of H3K9me3 was observed across the Tnf locus (both the promoter and 3’ of the gene) 
compared to the much higher level observed at the control intergenic region (Figure 
4.17), as determined by chromatin immunoprecipitation.  This was logical, as the 
A B C 
TNF_luc (RAW264.7) 
lu
ci
fe
ra
se
 a
ct
iv
ity
 (A
U
)
pB
en
t
KA
P1
pB
en
t
KA
P1
0
10
20
30
n=3
+IRF5
-IRF5p = 0.61
TNF_luc (RAW264.7)
lu
ci
fe
ra
se
 a
ct
iv
ity
 (A
U
)
pB
en
t
KA
P1
pB
en
t
KA
P1
0
50
100
150
200
n=3
+LPS
-LPS
p = 0.36
TNF_luc (HEK293-TLR4) 
lu
ci
fe
ra
se
 a
ct
iv
ity
 (A
U
)
pB
en
t
KA
P1
pB
en
t
KA
P1
0
5
10
15
20
n=2
+IRF5
-IRF5
p = 0.87
Chapter 4 – Results 
	   141 
intergenic region is located in a gene-sparse area of the genome so is unlikely to be 
transcriptionally active and therefore would exhibit a ‘closed’ heterochromatin 
environment.  In comparison, the Tnf locus is transcriptionally active in response to 
LPS and as a primary response gene has RNA polymerase II poised on its promoter in 
preparation for transcription even before stimulation has occurred [202].  However, 
when H3K9me3 levels were normalised to the 0 hours LPS time-point for each of the 
loci, it was clear that there were no changes in H3K9me3 over the time-course at either 
the Tnf promoter or intergenic region, but some modest changes in H3K9me3 
deposition were observed at the 3’ of the Tnf locus (Figure 4.17).  Interestingly, 
H3K9me3 was significantly reduced at the 3’ following 1 hour of LPS stimulation, and 
was significantly increased again by 8 hours LPS stimulation (Figure 4.17).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: H3K9me3 deposition at the Tnf locus over an LPS time-course 
Human M1 macrophages (1x107) were differentiated from elutriated monocytes by GM-CSF, then 
stimulated with 0, 1, 4 or 8 hours LPS at 50 ng/ml before fixation with formaldehyde.  Cells were then 
lysed sequentially with cytoplasmic (LB1 and LB2) and nuclear lysis buffers (LB3) with added protease 
inhibitors and the resulting nuclear lysate sonicated for 4 minutes (30-second intervals) at 4°C to fragment 
the chromatin to 500 bp in size.  Lysates were then incubated rotating overnight at 4°C with protein G 
magnetic beads that had been pre-coated in antibody specific to H3K9me3.  Following 
immunoprecipitation of protein-DNA complexes in this manner, beads were washed 5 times with ice-cold 
ChIP wash buffer and complexes eluted twice with 60 µl ChIP elution buffer at 65°C for 15 minutes.  
Eluates were pooled and the cross-linking reversed overnight at 65°C, along with non-immunoprecipitated 
lysate for ‘input’ control, before the DNA was purified from the samples.  qPCR reactions were performed 
in duplicate using primers designed against the human Tnf promoter, Tnf 3’ and an intergenic region, 
using Sybr Green master-mix.  Data was normalised to ‘input’ DNA samples in order to show changes in 
H3K9me3 throughout the LPS timecourse.  A: absolute levels of H3K9me3 at each of the loci, B: levels of 
H3K9me3 normalised to 0 hours for each locus.  Error bars show SEM.  Statistical analysis performed 
using a paired Student’s t-test, *P<0.05. 
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This suggests that while no changes are observed at the Tnf promoter, the 3’ of the 
gene becomes more ‘open’ immediately following LPS stimulation and ‘closes’ again 
by becoming more heterochromatin-like after 8 hours.  This is supported by the fact 
that H3K9me3 levels increase in an LPS time-course when RNA polymerase II levels 
are beginning to subside (8 hours) and vice versa (1 hour) (Figure 4.18). 
 
 
 
 
 
 
 
 
 
Figure 4.18: H3K9me3 deposition and RNA polymerase II recruitment at the 3’ Tnf locus 
Human M1 macrophages (1x107) were differentiated from elutriated monocytes by GM-CSF, then 
stimulated with 0, 1, 4 or 6 hours LPS at 50 ng/ml before fixation with formaldehyde.  Cells were then 
lysed sequentially with cytoplasmic (LB1 and LB2) and nuclear lysis buffers (LB3) with added protease 
inhibitors and the resulting nuclear lysate sonicated for 4 minutes (30-second intervals) at 4°C to fragment 
the chromatin to 500 bp in size.  Lysates were then incubated rotating overnight at 4°C with protein G 
magnetic beads that had been pre-coated in antibody specific to H3K9me3 and RNA Pol II.  Following 
immunoprecipitation of protein-DNA complexes in this manner, beads were washed 5 times with ice-cold 
ChIP wash buffer and complexes eluted twice with 60 µl ChIP elution buffer at 65°C for 15 minutes.  
Eluates were pooled and the cross-linking reversed overnight at 65°C, along with non-immunoprecipitated 
lysate for ‘input’ control, before the DNA was purified from the samples.  qPCR reactions were performed 
in duplicate using primers designed against the human Tnf 3’ using Sybr Green master-mix.  Data was 
normalised to ‘input’ DNA samples in order to show changes in H3K9me3 and RNA Pol II recruitment 
throughout the LPS timecourse. Error bars show SD, representative human donor. 
 
The fact that the levels of H3K9me3 observed are so low compared to the intergenic 
region makes sense, as a strong heterochromatin environment would take longer to 
reverse to allow accessibility of the transcription machinery, therefore Tnf would not be 
able to act as a primary response gene to infection.  A low level of H3K9me3 at the 3’ 
of the locus however still enables a degree of epigenetic control of TNF production. 
 
4.2.9 – H3K9me3 is reduced at the 3’ Tnf locus following KAP1 depletion  
I next endeavoured to investigate whether the sustained production of TNF observed 
in M1 macrophages upon KAP1 depletion by siRNA (Section 4.2.6) could be explained 
by changes in H3K9me3 levels at the Tnf locus.  Chromatin immunoprecipitation of 
H3K9me3 in M1 macrophages from 3 independent heterogeneous donors showed 
decreased levels of H3K9me3 at the Tnf 3’ when KAP1 was depleted by siRNA, 
compared to control siRNA (Figure 4.19 and Supplementary Figure S9.16 for individual 
donors).  This decrease was observed at 4 hours post-LPS stimulation, at a time when 
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Tnf mRNA is normally subsiding.  This data therefore correlates with the mRNA and 
protein expression data in Section 4.2.6.  No difference in H3K9me3 deposition was 
observed at a control intergenic region when KAP1 was depleted, which serves as a 
negative control for the chromatin immunoprecipitation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: H3K9me3 deposition at the 3’ Tnf locus in the presence and absence of KAP1 
Human M1 macrophages (1x107) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded 10 cm 
dishes.  A: Following 3 days for transfection, cells were stimulated 0 or 4 hours with LPS at 50 ng/ml 
before fixation with formaldehyde.  Cells were then lysed sequentially with cytoplasmic (LB1 and LB2) and 
nuclear lysis buffers (LB3) with added protease inhibitors and the resulting nuclear lysate sonicated for 4 
minutes (30-second intervals) at 4°C to fragment the chromatin to 500 bp in size.  Lysates were then 
incubated rotating overnight at 4°C with protein G magnetic beads that had been pre-coated in antibody 
specific to H3K9me3.  Following immunoprecipitation of protein-DNA complexes in this manner, beads 
were washed 5 times with ice-cold ChIP wash buffer and complexes eluted twice with 60 µl ChIP elution 
buffer at 65°C for 15 minutes.  Eluates were pooled and the cross-linking reversed overnight at 65°C, 
along with non-immunoprecipitated lysate for ‘input’ control, before the DNA was purified from the 
samples.  qPCR reactions were performed in duplicate using primers designed against the human Tnf 3’ 
and an intergenic region, using Sybr Green master-mix.  Data was normalised to ‘input’ DNA samples in 
order to show changes in H3K9me3 throughout the LPS timecourse.  A: fold changes in H3K9me3 
deposition (normalised to siCon 0 hours) at the Tnf 3’ and B: at an intergenic region.  Error bars show 
SEM of mean data from n=3 human donors.  Statistical analysis performed using an unpaired Student’s t-
test, *P<0.05. 
 
Interestingly, RNA polymerase II recruitment is increased at the Tnf 3’ following KAP1 
depletion and LPS stimulation for 4 hours (Figure 4.20), which explains the increased 
levels of Tnf mRNA in the absence of KAP1 – without KAP1 the 3’ of the gene is less 
heterochromatin-like and more accessible to the transcription machinery.  
Unfortunately due to multiple poor batches of RNA polymerase II antibody at the time 
of performing this experiment, and a lengthy optimisation process for new alternative 
antibodies, this experiment was only performed in M1 macrophages from a single 
human donor. 
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Figure 4.20: RNA polymerase II recruitment to the 3’ Tnf locus in the presence/absence of KAP1 
Human M1 macrophages (1x107) differentiated from elutriated monocytes by GM-CSF were subjected to 
RNA interference with siRNA oligonucleotides (50 nM) against KAP1 and a negative control sequence, 
which were transfected by Dharmafect I reagent for 4 hours at room temperature then seeded 10 cm 
dishes.  A: Following 3 days for transfection, cells were stimulated for 4 hours with LPS at 50 ng/ml before 
fixation with formaldehyde.  Cells were then lysed sequentially with cytoplasmic (LB1 and LB2) and 
nuclear lysis buffers (LB3) with added protease inhibitors and the resulting nuclear lysate sonicated for 4 
minutes (30-second intervals) at 4°C to fragment the chromatin to 500 bp in size.  Lysates were then 
incubated rotating overnight at 4°C with protein G magnetic beads that had been pre-coated in antibody 
specific to RNA Polymerase II.  Following immunoprecipitation of protein-DNA complexes in this manner, 
beads were washed 5 times with ice-cold ChIP wash buffer and complexes eluted twice with 60 µl ChIP 
elution buffer at 65°C for 15 minutes.  Eluates were pooled and the cross-linking reversed overnight at 
65°C, along with non-immunoprecipitated lysate for ‘input’ control, before the DNA was purified from the 
samples.  qPCR reactions were performed in duplicate using primers designed against the human Tnf 3’ 
region, using Sybr Green master-mix.  Data was normalised to ‘input’ DNA samples in order to show 
changes in RNA Polymerase II recruitment throughout the LPS timecourse.  Error bars show SD of mean 
data from a representative human donor. 
 
4.2.10 – IRF5 forms a complex with the methyltransferase SETDB1 
KAP1 itself does not possess methyltransferase activity, and therefore alters H3K9me3 
deposition indirectly by acting as a scaffold protein between DNA-binding transcription 
factors and methyltransferase enzymes such as SETDB1 [310].  I next investigated 
whether IRF5 could form a complex with SETDB1, which could be responsible for the 
changes in H3K9me3 at the Tnf locus. 
 
One-Strep affinity purification of cytoplasmic and nuclear HEK293-TLR4 cell lysates 
that were adenovirally transduced with Strep-HA-IRF5 or the Strep-tag alone showed 
an interaction occurring between Strep-HA-IRF5 and endogenous SETDB1 in the 
nucleus by Western blotting One-Strep eluates with a SETDB1-specific antibody 
(Figure 4.21).  The fact that the IRF5-SETDB1 interaction required DTBP cross-linking 
to preserve the interaction, whereas the IRF5-KAP1 interaction was detected both with 
and without the addition of a cross-linker, implies indirect binding of SETDB1 to IRF5 
via an adaptor protein (likely to be KAP1) in a larger complex.  This result raises the 
possibility that the recruitment of SETDB1 to an IRF5-KAP1 complex and subsequent 
deposition of H3K9me3 could be the mode of action utilised by KAP1, in order to 
impose its inhibitory activity at the IRF5-regulated Tnf gene. 
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Figure 4.21: IRF5 interacts with SETDB1 in HEK293-TLR4 cells 
HEK293-TLR4/CD14/Md2 cells (1x107) were transduced with Strep-tagged IRF5 and the Strep-tag alone 
by adenovirus at MOI 5 in order to induce exogenous expression of this protein/tag.  Following 2 hours 
serum-free in the presence of viral particles, the cells were incubated for 24 hours at 37°C.  The cells were 
then cross-linked with 8 mM DTBP, then lysed on ice for 30 minutes with 1 ml chilled cytoplasmic lysis 
buffer with added protease inhibitors.  The nuclear pellet was further lysed with 1 ml RIPA lysis buffer plus 
protease inhibitors and sonicated for 8 30-second pulses.  The resulting lysates were cleared by 
centrifugation to remove cellular debris before being loaded onto a column containing 150 µl of Streptactin 
beads. The protein lysates were allowed to pass through the columns by gravity flow to allow Strep-tagged 
proteins to bind to the Streptactin matrix.  The columns were then washed by the addition of twelve 
individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein complexes were eluted from the 
column by the addition of six 50 µl volumes of biotin elution buffer, which were collected, pooled and 
concentrated by Vivaspin column before cross-linking was reversed with 150 mM DTT at 37°C for 30 
minutes.  Protein samples (total eluate volume) were prepared by heating to 100°C with loading buffer, 
then resolved by SDS-PAGE and transferred to PVDF membrane for Western blotting with KAP1-, Lamin-, 
SETDB1- and Strep-specific antibodies.  The top two panels show protein expression in cell lysates 
(including lamin to show nuclear compartmentalisation) and the bottom two panels show Strep-IRF5 
interacting with endogenous KAP1 and SETDB1.  WB = Western blot. 
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4.3 – Conclusion 
Following on from Chapter 3 of this thesis, in which KAP1/TRIM28 was identified as a 
co-factor of IRF5 by a systematic screen for novel interaction partners, the functional 
importance of the IRF5-KAP1 interaction was investigated in this chapter.  Firstly, the 
protein-protein interaction was further validated in M1 macrophages, which like IRF5 
express higher levels of KAP1 than M2 macrophages. Subsequently, KAP1 levels 
were successfully depleted in M1 macrophages by siRNA knockdown to approximately 
50% of the normal mRNA and protein levels of KAP1.  KAP1 was then shown on both 
the mRNA and protein level to significantly inhibit expression of Tnf (an IRF5 target 
gene) at later time-points in response to LPS stimulation, by a KAP1 loss-of-function 
study in M1 macrophages.  Similar but non-significant trends were also observed for 
IL12a, IL23a and IL27 gene expression, but not IL12b, suggesting that KAP1 plays a 
role in the negative regulation of only a subset of IRF5-regulated M1 markers.  These 
results were initially surprising, as following a literature search that revealed KAP1 as a 
transcriptional co-repressor, the initial hypothesis relating to IRF5 would be that KAP1 
aids in the described IRF5-mediated inhibition of M2 markers such as IL-10 [196].  The 
Udalova laboratory has previously shown that IRF5 is present at the IL10 promoter in 
human M1 macrophages at the initial stages of LPS stimulation, however RNA 
polymerase II is not recruited until 4 hours of stimulation has occurred and IRF5 has 
moved away from the locus [196], suggesting that IRF5 inhibits the binding of 
transcription factors that positively regulate IL10 in some manner.  The fact that this 
study shows KAP1 depletion in M1 macrophages has no significant effect on IL10 
mRNA and protein levels shows that the function of the IRF5-KAP1 interaction does 
not extend to IL10 inhibition by IRF5.  This may be due to the fact that KAP1 activity at 
this locus is complicated, as it has also been observed that KAP1 seems to negatively 
regulate STAT3 signalling, as shown by increased levels of pSTAT3 in the nucleus 
upon KAP1 siRNA knockdown and increased expression of IL6 [341].  STAT3 also 
regulates IL-10 by binding to a STAT motif in the IL10 promoter upon LPS stimulation 
[342], therefore KAP1 could be inhibiting STAT3 activity at the IL10 locus as well as 
IL6 so any effect on the chromatin in this region could be masked by this activity. 
 
I went on to investigate a role for KAP1 in mediating inhibition of IRF5-driven Tnf 
expression, as this was the gene that showed the strongest effect of KAP1 knockdown.  
I first ruled out both IRF5 regulating Trim28 gene expression (which would explain the 
lag-time in activity of KAP1 in response to LPS stimulation) and KAP1 regulating Irf5 
gene expression.  I also observed no ubiquitination of IRF5 in the presence of 
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exogenous KAP1 and endogenous ubiquitin modifiers, so KAP1 was not acting as an 
E3 ligase (a common function of many members of the TRIM family [343]) in this 
instance in order to regulate IRF5 protein turnover and degradation by the proteosome.  
This is contrary to another study in which KAP1 was identified as an interaction partner 
of IRF7, and showed that KAP1 could SUMOylate IRF7 for degradation in the 
presence of exogenous ubiquitin-like modifiers [330].  Interestingly, the IRF7-KAP1 
interaction was mapped to the C-terminal IAD of IRF7, whereas in this study the IRF5-
KAP1 interaction was mapped to an N-terminal region just outside the DBD of IRF5 
(aa130-219).  The position of KAP1 binding within the IRF sequence could therefore 
be indicative of function, with C-terminal interactions being more important for 
regulation of IRF protein ubiquitination and degradation; whereas N-terminal 
interactions near the DBD could be more directly involved in IRF transcriptional activity 
independently of protein turnover.  KAP1 has also been shown to interact with IRF1, 
another member of the IRF family of transcription factors [328].  This interaction was, 
like IRF5, mapped to the N-terminus of IRF1, in particular a region that showed 
intrinsic disorder and was therefore a highly accessible interface for protein-protein 
interactions due to a poor tertiary structure [328].  This chapter has also identified the 
KAP1 binding region of IRF5 (aa130-219) to show high intrinsic disorder, even more so 
than the IAD, which is most commonly described as a protein-protein interaction 
interface for IRF family members and other proteins.  This interface in IRF1 has 
already been shown to be important for several other protein-protein interactions [328], 
which suggests that intrinsically disordered regions of the IRF family, including that of 
IRF5, would be an interesting subject for further proteomic studies. 
 
It is possible that the inhibitory action of KAP1 in our system is due to the previously 
described ability of KAP1 to prevent p300-binding and therefore acetylation and 
activation of NFκB RelA [291].  The Udalova group has previously shown that IRF5 is 
recruited to the Tnf locus at two regions: both at the 5’ of the gene promoter by direct 
DNA binding at an Interferon Stimulated Response Element (ISRE) consensus site, 
and at a κB site cluster at the 3’ of Tnf via protein-protein interactions with NFκB RelA 
[197].  It is possible that IRF5, whilst co-operating with RelA, is inadvertently binding to 
the inactive deacetylated form of RelA, or IRF5 is deacetylated itself when interacting 
with KAP1 (activated IRF5 can also interact with p300 [297]), which then has a 
negative effect on Tnf gene expression.  However the fact that IRF5 activity was not 
altered in a Tnf luciferase reporter assay in the presence of KAP1, and neither was the 
activity of endogenous activators of the Tnf luciferase reporter upon LPS stimulation; 
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suggests that the levels or activity of any transcription factors (NFκB) involved in Tnf 
gene regulation are not compromised in the presence of exogenous KAP1. 
 
The locus encompassing the Tnf gene is believed to be open to regulatory proteins 
even in resting macrophages [202], which enables rapid transcription of this primary 
response gene in response to inflammatory stimuli.  Consequently, relatively high 
levels of positive histone modifications including acetylation [139, 202] and 
accumulation of RNA polymerase II are observed at the Tnf promoter and transcription 
start site (TSS) prior to stimulation [139, 197, 202, 344].  However, upon LPS 
stimulation of macrophages a rapid and transient increase in the production of full-
length nascent human Tnf transcripts is observed, which subsides 2-4 hours post 
stimulation [197, 344].  This suggests that further activating mechanisms are required 
in order to drive Tnf gene expression, as prior RNA polymerase II presence and 
acetylation does not cause basal TNF production by macrophages in the absence of 
stimulation.   
 
Chapter 4 of this thesis has identified that stimulation of human M1 macrophages with 
LPS results in a decrease in H3K9me3 deposition at the 3’ of the Tnf gene, but not at 
the Tnf promoter or a control intergenic region.  This suggests that negative histone 
modifications, which result in a heterochromatin environment (H3K9me3) may still be 
active at the 3’ of Tnf in resting cells, and are further removed by LPS induction.  The 
kinetics of H3K9me3 deposition at this region show an increase following 6-8 hours 
LPS stimulation, corresponding to the time-points at which Tnf mRNA expression has 
subsided.  This therefore suggests that H3K9me3 is re-deposited at the locus following 
the Tnf LPS-induced response.  H3K9me3 has been previously described as present 
at inflammatory loci, such as IL12b in murine macrophages, although at an 
approximately 8-fold lower level to that observed at promoters known to be assembled 
in heterochromatin [345].  Similar data was also observed in this chapter, in which an 
intergenic region exhibited much higher absolute levels of H3K9me3 to those identified 
at the Tnf locus.  A mechanism that enables quick reversion to a closed chromatin 
state at inflammatory loci, for example low levels of a heterochromatin mark that would 
be relatively easy to remove and deposit, would prevent transcription of these loci for 
longer than necessary.  Enhanced or sustained production of pro-inflammatory 
cytokines is a well-defined characteristic of many auto-immune diseases including 
Rheumatoid Arthritis [346]; therefore a low level of epigenetic regulation to prevent 
primary response gene dysregulation would avoid detrimental physiological 
inflammatory responses. 
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This study proposes that KAP1 is important for maintaining the dynamic H3K9me3 
histone mark at the Tnf locus, and is recruited via protein-protein interactions with IRF5 
in M1 macrophages.  In support of this hypothesis is the fact that depletion of KAP1 
levels by siRNA in M1 macrophages leads to depletion of H3K9me3 deposition at the 
Tnf 3’, a region known to exhibit IRF5 recruitment [197].  RNA polymerase II 
recruitment has also been shown to subside at the Tnf 3’ as H3K9me3 deposition 
begins to increase, and increased RNA polymerase II has been observed at the same 
locus upon KAP1 depletion.  This co-incides with the higher and more sustained Tnf 
(and other M1 marker) mRNA expression demonstrated at later time-points following 
LPS stimulation in the absence of KAP1.  It therefore seems that H3K9me3 deposition 
via KAP1 at IRF5-regulated inflammatory loci is important for ensuring highly controlled 
and non-excessive gene expression.  A larger complex involving direct interactions 
between IRF5-KAP1 and KAP1-SETDB1 could be important for this mechanism 
(Figure 4.22), as SETDB1 is well described as the methyltransferase involved in 
H3K9me3 deposition via KAP1.  Further work is required to show the kinetics of KAP1 
and SETDB1 recruitment at the Tnf locus by chromatin immunoprecipitation, and the 
dependence of IRF5 to recruit the complex, which is currently limited by poor antibody 
availability (KAP1 ChIP-seq studies have been performed by overexpression in cell 
lines [347]).  It is also possible that other mechanisms are in play involving KAP1 and 
IRF5 at the Tnf locus; for example, KAP1 could exert inhibitory post-translational 
modifications on IRF5, or block binding sites of IRF5 co-factors or IRF5 dimerisation, 
both of which would result in reduced gene expression in the presence of KAP1. 
 
 
 
 
 
 
 
 
 
Figure 4.22: Proposed model of IRF5-KAP1 activity in M1 macrophages 
IRF5 recruits KAP1 to the chromatin of genes such as TNF when directly bound to an Interferon 
Stimulated Response Element in the DNA sequence, or indirectly bound to a κB site via protein-protein 
interactions with RelA.  When transcription of this region is coming to an end, IRF5 is indirectly via KAP1 
able to recruit SETDB1 methyltransferase activity to the locus, which results in deposition of a low level of 
trimethylation of lysine 9 of histone 3 (H3K9me3).  H3K9me3 marks the locus for conversion to 
heterochromatin via the recruitment of heterochromatin protein 1 (HP1) family members, however the low 
levels of H3K9me3 mean that the mark is easily removed upon future challenge of Toll-like receptors 
(TLRs), allowing the TNF gene to be easily and rapidly transcribed as per its role as a primary response 
gene in inflammation.   
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5.0 – Co-operation between IRF5 and NFκB RelA  
 
5.1 – Introduction 
IRF5 regulates pro-inflammatory cytokine expression, so much so that Irf5-/- mice are 
resistant to LPS-induced endotoxic shock due to reduced serum levels of TNF, IL-6 
and IL-12 [193].  The Udalova laboratory has previously shown that by mediating the 
expression of pro-inflammatory cytokines such as TNF, IL-12p40, IL-12p35 and IL-
23p19, and inhibiting the expression of the anti-inflammatory factor IL-10; IRF5 acts as 
a master regulator of macrophage plasticity, by driving macrophages toward a pro-
inflammatory (M1) phenotype and away from a homeostatic/anti-inflammatory (M2) 
phenotype [25].  Further investigation at the Tnf gene locus in particular, identified that 
IRF5 contributes to regulation of Tnf expression in M1 macrophages by co-operating 
with the RelA subunit of master inflammatory transcription factor NFκB.  This results in 
higher and more prolonged levels of Tnf expression compared to those produced by 
M2 macrophages, in which RelA also regulates Tnf, but there is no IRF5 protein to 
boost expression [197].  Modulating IRF5 activity, in particular this co-operation with 
NFκB RelA in Tnf expression may therefore provide an attractive alternative to current 
therapies for autoimmune diseases. 
 
It is well described that blocking TNF activity using neutralising antibodies can be 
effective in treatment of numerous autoimmune diseases such as RA, due to the 
placement of TNF in the hierarchy of cytokine production in the joint – TNF drives the 
production of multiple other inflammatory mediators by immune cells, which potentiates 
the inflammatory response [227, 228].  Although a great therapeutic breakthrough, 
anti-TNF therapy only seems to be effective in 70% of patients, and blocking TNF 
activity in the patient can in some cases lead to further infections including 
M.tuberculosis [234].  Tailored therapies that do not completely block TNF activity 
(baseline level of TNF is optimal for normal immune response) are advantageous. 
 
In this Chapter of my thesis, I aim to characterise the protein-protein interaction 
interface between IRF5 and RelA with a view to designing specific peptides that could 
block this interaction and therefore prevent transcriptional synergy and prolonged Tnf 
expression.  I also aim, in collaboration with Dr David Saliba in the Udalova group, to 
investigate whether such co-operation between IRF5 and RelA is specific to the Tnf 
locus, or extends genome-wide to other IRF5-regulated genes, in which case blocking 
IRF5+RelA synergy may be even more effective as a therapeutic strategy. 
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5.2 – Results 
 
5.2.1 – IRF5 and RelA cooperate to drive inflammatory gene expression  
The importance of both IRF5 and RelA in the regulation of Tnf expression is 
highlighted by the effect of ectopic expression of these transcription factors in HEK293-
TLR4 cells (see Figure 5.1).  Overexpression of IRF5 and RelA together by lipid 
transfection additively drives Tnf mRNA expression, compared to when either of these 
transcription factors is overexpressed alone.  In particular, a significant increase in Tnf 
mRNA is observed between the RelA only and IRF5+RelA conditions in the absence of 
LPS (Figure 5.1).  It is likely that LPS stimulation also activates other endogenous 
regulators of the Tnf gene, for example inhibitory NFκB p50 homodimers [348], which 
could mute the effect of ectopic IRF5 and RelA protein expression at the Tnf locus, 
resulting in the observed lower significance upon stimulation.  Alternatively, as LPS 
activation also increases Tnf mRNA expression in the presence of ectopic IRF5 or 
RelA alone, it is possible that endogenous IRF5 or RelA is co-operating with the 
exogenous IRF5 and RelA under these conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Ectopic IRF5 and NFκB RelA additively drive mRNA expression of Tnf  
HEK293-TLR4/CD14/Md2 cells (1x105) were co-transfected with combinations of Strep-IRF5, Strep-RelA 
and empty vector (pBent2) expression by Lipofectamine 2000 reagent, in order to induce exogenous 
expression of these proteins.  Following 24 hours at 37°C, cells were stimulated with 50 ng/ml LPS for 0/2 
hours, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) reverse 
transcribed into cDNA for analysis by qPCR using hTNF and hRPLP0 (housekeeping gene) Taqman 
assays.  A: Mean of 6 experiments using cells from different passages, each performed in triplicate, 
normalised to hRPLP0, error bars show SEM.  Statistical analysis by unpaired Student’s t-test, * P>0.05, 
*** P>0.005.  B: Following transfection, cells were lysed on ice by total cell lysis buffer with added 
protease inhibitors, and 7 µg protein (as determined by Qubit analysis) prepared by heating to 100°C in 
loading buffer before resolution on SDS-PAGE gel and transfer to PVDF membrane.  Western blotting was 
performed with Strep- and Actin-specific antibodies.  WB = Western blot. 
 
The Udalova group has previously described, by virtue of systematic ChIP across the 
Tnf locus, that IRF5 is recruited to both the 5’ promoter region of Tnf (where it binds 
directly to the DNA at an ISRE site) and a 3’ downstream region (where no ISRE sites 
are present for DNA binding) [197].  At the 3’ of the Tnf locus, IRF5 recruitment is 
dependent on NFκB RelA binding to a κB site [197], which suggests indirect 
recruitment of IRF5 to this region via RelA, without IRF5 interacting with the DNA.   
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This described overlap of IRF5 and RelA recruitment at the 3’ of the Tnf locus has also 
been demonstrated by a genome-wide ChIP-seq study in murine M1 macrophages 
performed by Dr David Saliba in the Udalova laboratory (manuscript submitted), as 
detailed in Section 2.11.  Upon studying ChIP-seq peaks of IRF5 and RelA recruitment 
following 2 hours of LPS stimulation, it is clear that IRF5 and RelA recruitment at the 
Tnf 3’ is aligned (Figure 5.2, grey boxes).  IRF5 and RelA co-recruitment is also 
observed at the 5’ promoter region, but this can be explained by the presence of both 
ISRE and κB sites to which direct binding can occur [197].  Recruitment of RNA 
polymerase II to the Tnf locus was also observed at this time-point, suggesting that the 
region was transcriptionally active in murine M1 macrophages whilst IRF5 and RelA 
were present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Recruitment of IRF5, NFκB RelA and RNA polymerase II to the murine Tnf locus 
 
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was performed by Dr David Saliba in 
murine M1 macrophages, differentiated from bone marrow by GM-CSF and stimulated with LPS for 2 
hours at 500 ng/ml, using antibodies against IRF5 (blue), RelA (green) and RNA polymerase II (red) as 
detailed in Table 2.11.  Sequencing was performed following the Illumina/Solexa protocol and was then 
mapped to the genome using Bowtie [294].  ZINBA software was applied to each dataset to identify 
enriched binding regions for each of the factors [295].  Datasets were visualised using the UCSC genome 
browser [349] to show peaks of recruitment for each of the factors at the Tnf locus.   
 
The additive effect of IRF5 and RelA on the production of Tnf mRNA in Figure 5.3 was 
also reciprocated by a luciferase reporter assay.  A luciferase reporter construct 
encoding the human Tnf 5’ and 3’ regulatory regions was ectopically expressed in 
HEK293-TLR4 cells, followed by LPS stimulation.  Significantly increased firefly 
luciferase levels were detected upon co-expression of IRF5 and RelA, compared to 
those induced by each of the transcription factors alone (Figure 5.3).  This confirms the 
additive effect of IRF5 and RelA on Tnf expression is due to direct transcriptional 
regulation at the locus by these transcription factors. 
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Figure 5.3: Ectopic IRF5 and NFκB RelA additively drive Tnf luciferase reporter activity 
HEK293-TLR4 cells (1x105) were transfected with combinations of Strep-IRF5, Strep-RelA and empty 
vector expression plasmids by Lipofectamine 2000, in order to induce exogenous expression of these 
proteins.  Cells were transfected at the same time with a Tnf_luciferase reporter construct, consisting of 
the 5’ and 3’ regulatory regions of Tnf upstream of the Firefly luciferase gene, and with a Renilla luciferase 
expression plasmid (for normalisation of transfection efficiency between wells).  Following 24 hours 
incubation at 37°C, the cells were additionally stimulated for 0/6 hours with 50 ng/ml LPS.  Firefly and 
Renilla luciferase activity was measured by Dual Glo luciferase assay using a Micro BetaJet to measure 
fluorescence levels.  Error bars show SEM of n=3 experiments, each performed in triplicate. Statistical 
analysis by unpaired Student’s t-test, * P>0.05, ** P>0.01, *** P>0.005, **** P>0.001. 
 
Interestingly, the same additive effect of IRF5 and RelA was also observed at the 
IL12b gene in HEK293-TLR4 cells, which was previously identified as being IRF5-
regulated by microarray studies in the Udalova laboratory (M2 macrophages +/- 
adenoviral transduction of ectopic IRF5) [25] and Irf5-/- studies [193].  Co-expression of 
IRF5 and RelA in HEK293-TLR4 cells resulted in significantly enhanced levels of IL12b 
mRNA compared to the levels produced in the presence of IRF5 or RelA alone (Figure 
5.4, panel A).  The ChIP-seq study by Dr David Saliba (manuscript submitted) also 
shows overlapping IRF5 and RelA peaks at the 5’ of IL12b following 2 hours LPS 
stimulation, which coincides with RNA polymerase II recruitment to suggest 
transcriptional activity at the locus (Figure 5.4, panel B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Ectopic IRF5 and NFκB RelA additively drive mRNA expression of IL12b  
A: HEK293-TLR4/CD14/Md2 cells (1x105) were co-transfected with combinations of Strep-IRF5, Strep-
RelA and empty vector (pBent2) expression by Lipofectamine 2000 reagent, in order to induce exogenous 
expression of these proteins.  Following 24 hours at 37°C, cells were stimulated with 50 ng/ml LPS for 0/2 
hours, after which mRNA was extracted and 1 µg (as determined by Nanodrop quantification) reverse 
transcribed into cDNA for analysis by qPCR using hIL12b and hRPLP0 (housekeeping gene) Taqman 
assays.  Mean of 6 experiments using cells from different passages, each performed in triplicate, 
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normalised to hRPLP0, error bars show SEM.  Statistical analysis by unpaired Student’s t-test, * P>0.05, 
*** P>0.005.  B: Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was performed by Dr 
David Saliba in murine M1 macrophages, differentiated from bone marrow by GM-CSF and stimulated 
with LPS for 2 hours at 500 ng/ml, using antibodies against IRF5 (blue), RelA (green) and RNA 
polymerase II (red) as detailed in Table 2.11.  Sequencing was performed following the Illumina/Solexa 
protocol and was then mapped to the genome using Bowtie [294].  ZINBA software was applied to each 
dataset to identify enriched binding regions for each of the factors [295].  Datasets were visualised using 
the UCSC genome browser [349] to show peaks of recruitment for each of the factors at the IL12b locus. 
 
IL12b therefore also seems to be co-operatively regulated by both IRF5 and NFκB 
RelA, which suggests that co-operation between IRF5 and RelA is not only important 
at the Tnf locus [197], but may extend to other IRF5-regulated genes. 
 
5.2.2 – Genome-wide transcriptional co-operation of IRF5 and NFκB RelA 
Further analysis of the IRF5 and RelA ChIP-seq datasets generated by Dr David 
Saliba (in collaboration with Dr Andreas Heger at MRC-CGAT, University of Oxford) 
demonstrated that there are in fact many genes that appear to be co-operatively 
regulated by these two transcription factors (manuscript submitted).  The IRF5 
cistrome was demonstrated to target mainly gene promoters rather than enhancers, in 
particular in a 1kb vicinity of the transcription start site (TSS), as determined by 
comparing IRF5 recruitment across the genome in murine M1 macrophages to 
H3K4me1 and H3K4me3 (promoter and enhancer chromatin marks respectively) 
deposition across the genome in murine M2 macrophages and GM-CSF differentiated 
dendritic cells [70, 72].  The IRF5 cistrome was also shown to overlay with the RelA 
cistrome at 927 loci when a 10% false discovery rate (FDR) was employed during 
ChIP-seq peak calling.  When overlapping IRF5+RelA peaks were correlated to 
microarray expression data from murine M1 macrophages stimulated with LPS for 2 
hours (the same conditions used in the ChIP-seq experiment), the overlapping peaks 
accounted for 66% of upregulated genes, including Ccl5, IL1a, IL1b, Tnfaip2, Tnfaip3, 
Nfkbia, Nfkbie, Ebi3 and Daxx (manuscript submitted).  This suggests that IRF5 and 
RelA co-operate to positively regulate gene expression on a genome-wide scale.  
Further examples of IRF5+RelA overlapping peaks can be seen in Figure 5.5.   
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Figure 5.5: Recruitment of IRF5, NFκB RelA and RNA polymerase II to the murine IL1a and Ccl5 loci  
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was performed by Dr David Saliba in 
murine M1 macrophages, differentiated from bone marrow by GM-CSF and stimulated with LPS for 2 
hours at 500 ng/ml, using antibodies against IRF5 (blue), RelA (green) and RNA polymerase II (red) as 
detailed in Table 2.11.  Sequencing was performed following the Illumina/Solexa protocol and was then 
mapped to the genome using Bowtie [294].  ZINBA software was applied to each dataset to identify 
enriched binding regions for each of the factors [295].  Datasets were visualised using the UCSC genome 
browser [349] to show peaks of recruitment for each of the factors at the A: IL1a and B: Ccl5 loci 
 
Following on from the observed dependence of IRF5 on RelA for recruitment to the 3’ 
of Tnf [197], the binding motif underneath the IRF5 and RelA ChIP-seq peaks was 
investigated in order to determine whether direct DNA binding was occurring at these 
regions.  The IRF5+RelA cistrome (overlapping peaks) was best described by 
consensus κB [350, 351] rather than ISRE [95, 352] binding sites, which suggests that 
RelA rather than IRF5 interacts directly with the DNA at these loci.  To this effect, IRF5 
recruitment to the IL1a and Ccl5 loci was compromised in RelA-depleted cells 
(manuscript submitted, data not shown), as was also the case for the Tnf locus [197].  
 
Interestingly, although RelA is important in driving inflammatory gene expression in M1 
macrophages, there is no difference in the level of RelA protein between the pro-
inflammatory M1 and homeostatic/anti-inflammatory M2 macrophages [197].  In 
comparison, IRF5 is differentially expressed, with much higher levels in pro-
inflammatory M1 macrophages (Figure 4.1).  Comparison of RelA recruitment to the 
genome in murine M1 macrophages (Dr David Saliba’s ChIP-seq data set) with murine 
M2 macrophages [353] in Figure 5.6 also shows no difference in RelA binding in the 
two macrophage phenotypes at loci shown to have overlapping IRF5+RelA peaks.  
This suggests that while RelA is important for driving expression of these genes in both 
M1 and M2 macrophages, high and/or sustained levels of gene expression observed in 
M1 macrophages [25, 197] is due to recruitment of other factors that are absent in M2 
macrophages.  Based on the synergy of IRF5+RelA in Tnf and IL12b expression 
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observed in Section 5.2.1 of this thesis, as well as the widespread overlap of 
IRF5+RelA across the genome in murine M1 macrophages (manuscript submitted), we 
propose that IRF5 is one of, if not the main factor responsible for this increased 
inflammatory gene expression.  The importance of protein-protein interactions of IRF5 
with RelA to modulate gene expression was therefore further highlighted by this ChIP-
seq study. 
 
 
 
 
 
Figure 5.6: Recruitment of RelA to the Tnf, IL12b, Ccl5 and IL1a loci in M1 and M2 macrophages 
 
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) was performed by Dr David Saliba in 
murine M1 macrophages, differentiated from bone marrow by GM-CSF and stimulated with LPS for 2 
hours at 500 ng/ml, using antibodies against RelA as detailed in Table 2.11.  Sequencing was performed 
following the Illumina/Solexa protocol and was then mapped to the genome using Bowtie [294].  ZINBA 
software was applied to each dataset to identify enriched binding regions for each of the factors [295].  
Datasets were visualised using the UCSC genome browser [349] to show peaks of recruitment for RelA at 
A: TNF, B: IL12b, C: Ccl5 and D: IL1a loci.  The dataset was compared to RelA recruitment in murine M2 
macrophages differentiated from bone marrow by M-CSF [353] 
 
5.2.3 – The IRF5 IAD forms the interaction interface with NFκB RelA 
The Udalova group has previously identified by endogenous immunoprecipitation that 
IRF5 is able to perform a protein-protein interaction with NFκB RelA [197], which would 
enable indirect IRF5 recruitment to the DNA in the IRF5+RelA cistrome.  
 
5.2.3.1 – Mapping the IRF5 interaction interface  
I next endeavoured to determine the domain of IRF5 that was important for the 
interaction interface with RelA.  Using expression plasmids that encode Strep-tagged 
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truncated mutants of IRF5 (cloned in the Udalova laboratory by Dr Grigory Ryzhakov) I 
performed One-Strep affinity purification to investigate the ability of Flag-tagged RelA 
protein to bind to each of the Strep-tagged truncated IRF5 mutant proteins.  As the 
IRF5 truncated mutants lack one or more structural domains of IRF5 (Figure 5.7, panel 
A), studying the extent of RelA-Flag binding upon IRF5 domain omission in this 
manner enables identification of the domain required for an interaction with RelA.  
HEK293-TLR4 lysates from cells exogenously expressing the Strep-tagged IRF5 
mutants in combination with Flag-tagged RelA by lipid transfection were applied to 
Streptactin columns for One-Strep affinity purification, followed by Western blotting of 
eluates with Flag-tag and Strep-tag specific antibodies.  As a positive control protein-
protein interaction, Strep-tagged NFκB p50 was also co-expressed in the HEK293-
TLR4 cells with RelA-Flag, as determined in Section 3.2.2 of this thesis.  As a negative 
control to show that Flag-tagged proteins were not binding non-specifically to the 
Streptactin column, RelA-Flag was co-expressed with the Strep-tag alone, and BAP-
Flag (bacterial alkaline phosphatase) was expressed with each of the Strep-tagged 
truncated IRF5 mutants, as this is a bacterial protein that under normal conditions 
would not encounter mammalian proteins for protein-protein interactions.   
 
Figure 5.7 shows that both Strep-p50 is interacting with RelA-Flag (positive control) 
and Strep-IRF5 is interacting with RelA-Flag, as previously demonstrated [197].  RelA-
Flag is not binding non-specifically to the Streptactin column (Strep-tag lane), and 
BAP-Flag is not interacting with any of the IRF5 mutants (negative controls).  It is clear 
from this experiment that the IRF5 N220 mutant, which lacks the C-terminus of IRF5 
from aa220 onwards, is not able to interact with RelA.  Consistent with this, the ΔDBD 
and Δ219 mutants of IRF5 are still able to interact with RelA, which suggests they 
contain the necessary domains of IRF5 for the interaction to occur.  I can therefore 
conclude that the C-terminus of IRF5 (aa220-498), rather than the DNA-binding N-
terminus (aa1-220) is crucial for the interaction interface with RelA. 
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Figure 5.7: Mapping the IRF5-RelA interaction with truncated mutants of IRF5 (One-Strep)  
HEK293-TLR4/CD14/Md2 cells (1x107) were co-transfected with combinations of expression plasmids 
containing Strep-tagged truncated mutants of IRF5 (A) and RelA-Flag/BAP-Flag by Lipofectamine 2000 
reagent, in order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells 
were lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The 
resulting lysates were cleared by centrifugation to remove cellular debris before being loaded onto a 
column containing 150 µl of Streptactin beads.  The protein lysates were allowed to pass through the 
columns by gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were 
then washed by the addition of six individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein 
complexes were eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, which 
were collected and pooled.  Eluates were concentrated by Vivaspin column and prepared by heating to 
100°C with loading buffer, then resolved by SDS-PAGE, and subjected to Western blotting with Strep- and 
Flag-specific antibodies as required following transfer to PVDF membrane. WB = Western blot, DBD = 
DNA-binding domain, IAD = IRF association domain, SRR = Serine-rich region. 
 
To compliment the One-Strep mapping exercise in Figure 5.7, Dr David Saliba also 
performed the converse of the experiment, in which Flag-tagged RelA acts as the bait 
protein and the Strep-tagged truncated mutants of IRF5 (Figure 5.8, panel A) act as 
the prey proteins.  The Strep-tagged proteins appear as doublet bands in Figure 5.8 
(panel A) as when they were cloned, start codons were present both before and after 
the N-terminal Strep tag (5’ of HA tag), so Western blotting with a HA-antibody detects 
both of these forms of the proteins. In this manner, the extent of Strep-tagged IRF5 
mutant binding to RelA-Flag will determine the domain of IRF5 important for the 
interaction with RelA.  In the same way as in Figure 5.7, the RelA-p50 interaction was 
used as a positive control for the experiment.  BAP-Flag was also used as a negative 
control to show any non-specific binding of the Strep-tagged IRF5 mutants.   
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Figure 5.8: Mapping the IRF5-RelA interaction with truncated mutants of IRF5 (Flag-IP) 
HEK293-TLR4/CD14/Md2 cells (1x107) were co-transfected with combinations of expression plasmids 
containing Strep-HA-tagged truncated mutants of IRF5 (A) and RelA-Flag/BAP-Flag by Lipofectamine 
2000 reagent, in order to induce exogenous expression of these proteins/tags.  Following 24 hours, the 
cells were lysed on ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  
The resulting lysates were cleared by centrifugation to remove cellular debris before being added to anti-
Flag affinity agarose gel, rotating for 1 hour at 4°C.  Washes were performed (3 times) with 1 ml chilled 
total cell lysis buffer by rotating the tube for 5 minutes at room temperature then pelleting the matrix.  
Protein complexes were eluted twice with 50 µl Flag peptide, pooled and concentrated by Vivaspin 
column.  Protein samples (total eluate volume) were prepared by heating to 100°C with loading buffer, 
then resolved by SDS-PAGE and transferred to PVDF membrane for Western blotting with HA- and 
Tubulin-specific antibodies.  The top two panels show cell lysate protein expression, and the bottom panel 
shows Strep-HA-IRF5 mutants interacting with RelA/BAP-Flag in the IP eluates.  WB = Western blot, 
DBD= DNA-binding domain, IAD= IRF association domain, SRR= Serine-rich region. 
 
HEK293-TLR4 cell lysates from cells co-expressing the described protein combinations 
were applied to a Flag-matrix for Flag-immunoprecipitation.  Complexes were eluted 
with Flag-peptide following stringent wash steps.  Figure 5.8 shows that in principle the 
technique was successful, as the RelA-p50 interaction was observed (positive control).  
There is some non-specific binding of the Strep-tagged IRF5 mutants to BAP-Flag in 
this experiment, however this is less than the extent of binding observed to RelA-Flag 
so can be considered as background.  Further wash steps in future could improve this.  
Complementary to Figure 5.7, Figure 5.8 shows that the Strep-tagged mutants N130 
and N220 that consist of the N-terminus of IRF5, do not bind to RelA-Flag.  The same 
Strep-tagged Δ219 mutant, that consists of the C-terminus of IRF5, shows preserved 
binding to RelA when compared to full-length IRF5, which highlights the importance of 
the C-terminus for the interaction interface.  This experiment also shows preserved 
binding of the Strep-tagged mutant N395 to RelA, which lacks the C-terminal Serine-
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Rich Region (SRR) of IRF5.  It can therefore be concluded that the IAD rather than the 
SRR is the C-terminal domain responsible for IRF5 interacting with RelA. 
 
Multiple isoforms of IRF5 (V1-V9) have been described that are generated by 
alternative splicing of Irf5 mRNA transcripts [198].  These isoforms are transcribed 
from different Irf5 promoters, encoded by exons 1A, 1B or 1C, and as a result some 
have whole exon deletions due to changes in open reading frame, or 30/48bp in-dels 
in exon 6.  In terms of the IRF5 protein, this results in a whole new range of truncated 
proteins to those cloned by Dr Grigory Ryzhakov (Figure 5.9 and Table 5.1).  Of note, 
the Udalova truncated mutants were cloned based on isoform v3/v4, which contains 
two short deletions in exon 6, as this is the predominant isoform expressed in myeloid 
cells [198].  Expression plasmids encoding the IRF5 isoforms fused to a Flag-tag were 
kindly gifted to us by Professor Betsy Barnes (New Jersey Medical School).   
 
Figure 5.9: Proteins encoded by the IRF5 alternatively spliced isoforms  
Protein regions encoded by each of the Irf5 exons (grey), as identified by the NCBI CCDS database.  
Regions deleted by alternative splicing of IRF5 isoforms V1-9 highlighted in red.  X= 30/45bp deletion. 
 
 
 
 
 
 
 
Table 5.1: Nucleotides and amino acids deleted by alternative splicing of IRF5 isoforms 
Isoform deleted regions (both nucleotides and amino acids) as shown diagrammatically in Figure 5.9. 
IRF5 Isoform Nucleotides Missing Amino acids Missing 
V1 571-600 190-200 
V2 482-528 161-176 
V3/V4 482-528, 571-600 161-176, 190-200 
V5 None None 
V6 482-528 190-200 
V7 1-208, 482-528 1-69, 161-176 
V8 482-804 190-268 
V9 509-1545 170-498 
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To further compliment the IRF5-RelA interaction mapping exercise, these Flag-tagged 
isoforms were co-expressed with HA-tagged RelA in HEK293-TLR4 cells and the 
resulting lysates used for HA-immunoprecipitation to investigate the extent of Flag-
tagged isoform (prey) binding to RelA-HA (bait).  The protein-protein interaction 
between RelA-HA and cRel-Flag (see Section 3.2.2) was used as a positive control for 
this experiment, and BAP-Flag was co-expressed with RelA-HA as a negative control 
for non-specific binding.  Western blotting of HA-IP eluates in Figure 5.10 shows that 
whilst isoforms V2-V8 showed the same extent of binding to RelA-HA, isoform V9 was 
unable to form a complex with RelA-HA.  As V9 is the only isoform that lacks the entire 
C-terminus of the IRF5 protein, this coincides with results in Figures 5.7/5.8 that the C-
terminal IAD of IRF5 is crucial for the interaction with RelA.  V1 appears to exhibit less 
affinity for RelA than the other long isoforms, however this may be due to lower 
expression levels of V1, as the top panel of Figure 5.10 is slightly overexposed.  
Interestingly, isoform V8 lacks a short portion of the IRF5 IAD (aa220-268), yet 
exhibited no reduced binding to RelA, which pinpoints the interface to aa268-395. 
 
Figure 5.10: Mapping the IRF5-RelA interaction using IRF5 alternatively spliced isoforms (HA-IP)  
HEK293-TLR4/CD14/Md2 cells (1x107) were co-transfected with combinations of expression plasmids 
containing Flag-tagged truncated mutants of IRF5 (A) and RelA-HA by Lipofectamine 2000 reagent, in 
order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed on 
ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting 
lysates were cleared by centrifugation to remove cellular debris before being added to anti-HA affinity 
matrix, rotating for 1 hour at 4°C.  Washes were performed (3 times) with 1 ml chilled total cell lysis buffer 
by rotating the tube for 5 minutes at room temperature then pelleting the matrix.  Protein complexes were 
eluted with 50 µl 4x loading buffer by heating to 100°C, then resolved by SDS-PAGE and transferred to 
PVDF membrane for Western blotting with HA- and Flag-specific antibodies.  The top two panels show cell 
lysate protein expression, and the bottom panel shows isoforms interacting with RelA.  WB = Western blot. 
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5.2.3.2 – The IRF5 IAD is crucial for IRF5+RelA mediated transcription  
Following identification of the IRF5 IAD as the domain of IRF5 that interacts with RelA, 
I next endeavoured to show the importance of this domain for the transcriptional co-
operation between IRF5 and RelA.  The 3’ of the Tnf gene was previously identified by 
the Udalova laboratory as a region where IRF5 is recruited to the DNA at a κB site via 
protein-protein interactions with RelA [197].  In order to highlight the importance of a 
protein-protein interaction between IRF5 and RelA to induce synergistic gene 
expression, I co-expressed truncated mutants of IRF5 and full-length RelA in 
RAW264.7 cells, along with a luciferase reporter construct driven by the 3’ region of 
the Tnf gene (Figure 5.11).  Co-expression of full-length IRF5 with full-length RelA 
strongly induced Tnf luciferase expression compared to full-length IRF5 or RelA alone.  
Interestingly, the Δ219 mutant of IRF5, which showed intact binding to RelA in Section 
5.2.3 of this thesis, was able to drive Tnf luciferase expression in combination with 
RelA to the same extent as the full-length IRF5 protein with RelA, in unstimulated 
conditions. Consistent with previous observations (Section 5.2.3), the N220 mutant of 
IRF5 was not able to synergise with RelA to drive Tnf luciferase expression, due to the 
lack of IAD in this IRF5 construct.  Statistical significance was achieved under 
unstimulated conditions in this experiment, however upon LPS-stimulation (data not 
shown) although the same trends were visible no significance was reached.  This may 
be due to the activation/contribution of endogenous proteins upon LPS-stimulation.   
 
 
 
 
 
 
 
 
 
Figure 5.11: IRF5 and Δ219 synergise with RelA to the same extent in Tnf luciferase reporter assay  
RAW264.7 cells (1x105) were transfected with RelA-Flag/empty vector expression plasmid in combination 
with Strep-tagged full-length IRF5 of truncated mutants (A) by Lipofectamine LTX and Plus reagents, in 
order to induce exogenous expression of these proteins.  Cells were transfected at the same time with a 
Tnf_luciferase reporter construct, consisting of the 3’ regulatory regions of Tnf upstream of the Firefly 
luciferase gene, and with a Renilla luciferase expression plasmid (for normalisation of transfection 
efficiency between wells).  Following 24 hours incubation at 37°C, cells were stimulated for 6 hours with 1 
µg/ml LPS.  Firefly and Renilla luciferase activity was measured by Dual Glo luciferase assay using a 
Micro BetaJet to measure fluorescence levels.  Error bars show SEM of n=4 from different cell passages, 
each performed in triplicate.  Statistical analysis by unpaired Student’s t-test, ** P>0.01, **** P>0.001. 
 
The importance of the IRF5 IAD for protein-protein interactions with RelA was therefore 
demonstrated by Tnf luciferase reporter assay.  In order to show that the significance 
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of the IRF5 IAD for protein-protein interactions extends further than just the Tnf locus, 
and is important at other loci shown in Section 5.2.2 to be targeted by the IRF5+RelA 
cistrome, I also investigated the effect of IRF5 truncated mutants on IL12b mRNA 
expression.  Murine M1 macrophages from Irf5-/- mice were adenovirally transduced 
with full-length IRF5 or the IRF5 ΔDBD mutant in combination with RelA.  Irf5-/- M1 
macrophages were chosen for this experiment due to their lack of endogenous IRF5 
that could interact with exogenous proteins and complicate the system.  The ΔDBD 
mutant is unable to bind to DNA but still possesses the C-terminal IAD, which I have 
identified as important for the protein-protein interaction with RelA.  Figure 5.12 shows 
that IRF5 ΔDBD in combination with RelA synergises to the same extent as full-length 
IRF5 in combination with RelA to drive mRNA expression of IL12b, under unstimulated 
conditions.  Unfortunately I was unable to see the same effect on Tnf mRNA 
expression in this system, which may be due to a spontaneous non-linked mutation in 
the Dock2 gene that had arisen in our Irf5-/- colony [354], which at the time had a great 
impact on our Irf5-/- phenotype (and has since been bred out of our colony). 
 
 
 
 
 
 
 
 
 
Figure 5.12: IRF5 and ΔDBD synergise with RelA to the same extent to drive IL12b expression  
Murine M1 macrophages derived from the bone marrow of Irf5-/- mice by GM-CSF differentiation were 
adenovirally transduced with IRF5 or ΔDBD in combination with either RelA or empty virus at an MOI of 50 
for 4 hours serum-free, before being left overnight at 37°C to allow for protein expression.  mRNA was 
extracted and 1 µg (as determined by Nanodrop quantification) reverse transcribed into cDNA for analysis 
by qPCR using mIL12b and mHPRT (housekeeping gene) Taqman assays.  A: Mean of 3 experiments 
using 3 different bone marrow extractions, each performed in triplicate, normalised to mHPRT, error bars 
show SEM.  Statistical analysis by unpaired Student’s t-test, * P>0.05, ** P>0.01.     
 
5.2.4 – The RelA DD forms the interaction interface with IRF5 
After identification of the region of IRF5 interacting with RelA, I next studied the IRF5-
RelA interaction from the other angle, in order to identify the region of RelA interacting 
with IRF5.  Flag-tagged truncated mutants of RelA, containing one or more of the main 
structural domains of RelA (Rel-homology domain: RHD, Dimerisation domain: DD, 
Transactivation domain: TAD), were cloned into mammalian expression plasmids 
(Figure 5.13) for lipid transfection into HEK293-TLR4 cells.   
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Figure 5.13: Flag-tagged truncated mutants of NFκB RelA  
Truncated mutants of RelA were by cloned PCR using primers specifically designed to the RelA sequence 
with a Flag-tag on the reverse primer.  The PCR products were subsequently cloned into a pBent2 vector.  
RHD= Rel homology domain, DD= Dimerisation domain, TAD= Transactivation domain.  
 
One-Strep affinity purification was performed on HEK293-TLR4 cell lysates co-
expressing Strep-tagged IRF5 (bait) in combination with the Flag-tagged truncated 
mutants of RelA (prey).  Once again, BAP-Flag was used as a negative control prey 
protein, in order to show no non-specific binding was occurring with Strep-tagged IRF5.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Mapping the IRF5-RelA interaction with truncated mutants of RelA (One-Strep AP) 
HEK293-TLR4/CD14/Md2 cells (1x107) were co-transfected with combinations of expression plasmids 
containing Flag-tagged truncated mutants of RelA and Strep-IRF5 by Lipofectamine 2000 reagent, in 
order to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed on 
ice for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting 
lysates were cleared by centrifugation to remove cellular debris before being loaded onto a column 
containing 150 µl of Streptactin beads.  The protein lysates were allowed to pass through the columns by 
gravity flow to allow Strep-tagged proteins to bind to the Streptactin matrix.  The columns were then 
washed by the addition of six individual 1 ml volumes of chilled IP wash buffer.  Prey and bait protein 
complexes were eluted from the column by the addition of six 50 µl volumes of biotin elution buffer, which 
were collected and pooled.  Eluates were concentrated by Vivaspin column and prepared by heating to 
100°C with loading buffer, then resolved by SDS-PAGE, and subjected to Western blotting with Strep- and 
Flag-specific antibodies as required following transfer to PVDF membrane. WB = Western blot. 
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Figure 5.14 shows that the N186 mutant of RelA, which consists of only the RHD and 
lacks the C-terminus, is unable to bind to IRF5.  In accordance with this, the Δ186 
mutant of RelA, which lacks the RHD, was still able to bind to IRF5, which suggests the 
RHD is not part of the interaction interface with RelA.  As the N292 mutant of RelA, 
which consists of the RHD and DD domains, was able to bind to IRF5, by process of 
elimination the RelA dimerisation domain (DD) is responsible for the IRF5 interaction. 
 
The dimerisation domain of RelA is part of the most evolutionarily conserved region of 
the NFκB proteins (their DNA-binding N-terminus) – as more NFκB subunits have 
evolved over time, this region of the proteins has remained relatively unchanged.  
Figure 5.15 shows the degree of conservation of the NFκB subunit residues aligned 
with aa186-292 of RelA (the region shown to be involved in the interaction interface 
with IRF5) by ClustalW analysis.   
 
RelA     N-RAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGP-----GWEAR 
RelB     K-KSTNTSELRICRINKESGPCTGGEELYLLCDKVQKEDISVVFSRA-----SWEGR 
cRel     N-RAPNTAELRICRVNKNCGSVRGGDEIFLLCDKVQKDDIEVRFVLN-----DWEAK 
p105     SSEAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGF 
p100     S-KSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENG--WQAF 
         . .:  :::*:* *::: .*   **:*::********:**.: *         *:. 
 
RelA     GSFSQADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDT 
RelB     ADFSQADVHRQIAIVFKTPPYEDLEIVEPVTVNVFLQRLTDGVCSEPLPFTYLPRD 
cRel     GIFSQADVHRQVAIVFKTPPYCKA-ITEPVTVKMQLRRPSDQEVSESMDFRYLPDE 
p105     GDFSPTDVHRQFAIVFKTPKYKDINITKPASVFVQEDKEEVQRKRRKALPTFSQPF 
p100     GDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLV 
         . ** :***:* ****:** * .  :  *. * : *:*      *:   * * *   
 
Figure 5.15: ClustalW alignment of the IRF5-interacting region of RelA with the NFκB subunits  
Alignment of an N-terminal region of the NFκB subunits (RelA aa186-292) by ClustalW to show 
conservation of these residues within the NFκB family. *=conserved residue, :=partially conserved residue 
 
The fact that IRF5 was previously shown by the Udalova group to specifically interact 
with RelA and not any of the other subunits of NFκB [197] was therefore very 
surprising due to the similarity of the proteins in this region.  In order to confirm this 
observation, immunoprecipitation of exogenously expressed bait and prey proteins 
was performed.  Myc-tagged IRF5 was co-expressed in HEK293-TLR4 cells with HA-
tagged subunits of NFκB and the resulting lysates utilised for myc-immunoprecipitation 
and Western blotting of the resulting eluates.  Figure 5.16 shows that myc-tagged IRF5 
was able to interact with HA-tagged RelA as expected, but also HA-tagged RelB and 
p52.  No protein-protein interactions were observed between IRF5/cRel, or IRF5/p50. 
 
Previous experiments by the Udalova laboratory that had shown the IRF5 interaction 
with NFκB to be specific to the RelA subunit [197] were conducted using antibodies 
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against endogenous NFκB proteins, and thus may have been subject to antibody 
affinity differences, as well as differences in endogenous expression of the NFκB 
proteins in the chosen cell type.  High affinity of the RelA antibody could therefore have 
made the experiment biased to show only the IRF5-RelA interaction.  Higher 
concentrations of the other NFκB primary antibodies, or even a longer exposure time 
when developing the Western blot may well have shown the other interactions.  As my 
experiment in Figure 5.16 utilised equally expressed HA-tagged NFκB subunits, only 
one antibody (HA-HRP) was required for Western blotting, which therefore removed 
any previous bias from the experiment. 
 
Figure 5.16: IRF5 interacts with the RelA, RelB and p52 subunits of NFκB (myc-IP)  
HEK293-TLR4/CD14/Md2 cells (2x106) were co-transfected with combinations of expression plasmids 
containing HA-tagged NFκB subunits and myc-IRF5/empty vector by Lipofectamine 2000 reagent, in order 
to induce exogenous expression of these proteins/tags.  Following 24 hours, the cells were lysed on ice 
for 30 minutes with 1 ml chilled total cell lysis buffer with added protease inhibitors.  The resulting lysates 
were cleared by centrifugation to remove cellular debris before being incubated for 2 hours rotating at 4°C 
with c-myc antibody and Protein G beads.  Following immunoprecipitation of protein complexes in this 
manner, beads were washed 4 times with ice-cold lysis buffer and complexes eluted with 50 µl loading 
buffer at 100°C.  Input protein samples were prepared by heating to 100°C with loading buffer, then 
resolved along with the eluates by SDS-PAGE and transferred to PVDF membrane for Western blotting 
with HA- and myc-specific antibodies.  The top two panels show cell lysate protein expression, and the 
bottom panel shows HA-tagged NFκB subunits interacting with myc-IRF5.  WB = Western blot 
 
We can now confidently state that IRF5 is able to interact with the RelA, RelB and p52 
subunits of NFκB.  The relevance of interactions with RelB and p52 on IRF5-mediated 
gene expression would therefore be interesting future work for the Udalova laboratory. 
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5.2.5 – Design of specific IRF5 peptides to block the IRF5-RelA interaction  
Direct inhibition of transcription factor complexes with small molecule inhibitors 
including peptides is becoming a more frequent strategy for modulating gene 
expression and signalling pathways, due to the specificity of this mode of inhibition.  
For example, peptides have been used to target the protein-protein interaction 
interface of the NOTCH transcription complex [355] and TCF/β-catenin [356].   
 
2.5.1 – IRF5 blocking peptide design 
Following characterisation of the IRF5-RelA interaction interface in Sections 5.2.3 and 
5.2.4 of this thesis by virtue of immunoprecipitation using truncated mutants, I next 
endeavoured to design specific IRF5 peptides that may bind to RelA.  By generating 
specific peptides that bind to the RelA interaction interface, I aim to sterically inhibit the 
protein-protein interaction between IRF5 and RelA proteins, which we hypothesise 
could reduce inflammatory gene expression in M1 macrophages. 
 
Figure 5.17 shows the overlapping strategy employed for designing IRF5 peptides.  By 
overlapping the peptides, I hope to be able to further pinpoint specific residues that are 
crucial for the interaction with RelA – if the overlapping residues between two peptides 
are important then both peptides should interact.  19 amino acid lengths of IRF5 
sequence were designed, which scan across the region aa224-411, encompassing the 
IRF5 IAD.  Each peptide was also designed to have a cysteine residue at the C-
terminus, as a thiol group is important for the conjugation process of to cell-penetrating 
peptides such as the penetratin sequence [357].  The peptides were also biotinylated 
at their N-terminus in order to be able to perform bio-layer interferometry using 
streptavidin probes (see Section 5.2.5.2 of this thesis).  Peptides were synthesised by 
Pepceuticals (Leicestershire, UK) to a minimum of 90% purity. 
Figure 5.17: IRF5 IAD biotinylated peptide design  
IRF5 amino acids 224-411 (encompassing the IRF5 IAD) highlighted in yellow, with the IRF5 IAD 
overlapping peptides highlighted by black arrows.  Each peptide is 19 amino acids in length and numbered 
1-13.  Bold residues are those that overlap between two adjacent peptides. 
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5.2.5.2 – Bio-layer interferometry to assess IRF5 peptide binding to RelA  
Bio-layer interferometry is a label-free technology for measuring bio-molecular 
interactions by means of analysing the interference pattern of white light reflected from 
two surfaces – a layer of immobilised protein on the tip of the biosensor, and an 
internal reference layer [358].  In collaboration with Dr Oleg Fedorov at the Structural 
Genomics Consortium (SGC, Oxford), this technique was utilised to determine whether 
the 20aa IRF5 IAD overlapping peptides designed in Figure 5.17 could bind to RelA 
protein.  The RelA protein (aa1-292) was purified by Dr Pavel Savitsky (SGC, Oxford). 
 
In terms of my experiment, a streptavidin biosensor was first coated in biotinylated 
IRF5 peptide, and then blocked with BSA to ensure the entire tip was coated and that 
minimal non-specific binding of RelA protein could occur.  The peptide-coated 
biosensors (one for each peptide designed in Figure 5.17) were then placed into wells 
of a 96-well plate containing free RelA protein in solution for a period of time to allow 
RelA protein to associate with the peptides.  A shift in the number of molecules bound 
to the biosensor tip leads to a shift in the interference pattern of white light compared 
to the internal reference.  Any change in the wavelength of white light observed is 
therefore a direct measurement of the change in thickness of the biological layer, in 
this case showing that RelA protein is binding to IRF5 peptide coating the biosensor.  
As real-time interactions are measured, association/dissociation rates are monitored.   
 
 
Figure 5.18: Binding of RelA protein to IRF5 peptides by bio-layer interferometry 
Association and dissociation of free RelA protein (21 µM) in solution to biotinylated IRF5 peptides (2 µM) 
immobilised on a streptavidin biosensor was measured over time by bio-layer interferometry (OctetRed 
384 platorm).  Reference = no peptide bound to biosensor (only BSA), D = IRF5 DBD peptide, A = Actin 
peptide (negative controls). 
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Figure 5.18 shows that RelA protein is able to bind to one of the IRF5 IAD peptides in 
particular: Peptide 11 (dark grey curve).  Association and dissociation curves for this 
peptide with RelA are clearly visible, as highlighted by presentation of the data for 
Peptide 11 alone in Figure 5.19.  Enhanced binding of RelA protein to Peptide 11 was 
observed in comparison to the negative controls, including a 20aa peptide of Actin 
sequence (light blue curve, Figure 5.19) and a 20aa peptide of IRF5 DBD sequence 
(light green curve, Figure 5.18), which was from the region of IRF5 shown not to 
interact with RelA in Section 5.2.3 of this thesis.  RelA-Peptide 11 binding was also 
clearly above the level of background associated with this experiment (no peptide 
curve in Figure 5.19), however this reference curve does show that some RelA protein 
was able to non-specifically bind to the streptavidin biosensors, as a small amount of 
association/dissociation is visible.  Despite this, RelA binding to Peptide 11 can be 
considered a true interaction due to the more apparent association observed. 
 
 
 
Figure 5.19: Binding of RelA protein to IRF5 IAD Peptide 11 by bio-layer interferometry 
Association and dissociation of free RelA protein (21 µM) in solution to biotinylated IRF5 IAD peptide 11 (2 
µM) immobilised on a streptavidin biosensor was measured over time by bio-layer interferometry 
(OctetRed 384 platorm).  No peptide = no peptide bound to biosensor (only BSA), Actin = 20aa 
biotinylated peptide of Actin sequence (negative controls). 
 
 
The location of Peptide 11 within the tertiary structure of the IRF5 IAD was determined 
by studying the published crystal structure of the IRF5 IAD [194] using the Cn3D 
software [359].  Peptide 11 (NH2-VKTKLFSLEHFLNELILFQC-COOH) is highlighted in 
yellow from several angles of the IRF5 IAD crystal structure in Figure 5.20, showing 
that it consists structurally of a α-helix and a β-sheet and is located on the exterior of 
the protein, rather than folded internally into the structure.  This means the Peptide 11 
region is very accessible for protein-protein interactions, making it a feasible region for 
the interaction interface with RelA.  The fact that Peptide 11 is located towards the C-
Actin 
No peptide 
Peptide 11 
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terminus of the IRF5 IAD also coincides with data in Section 5.2.3 of this thesis, which 
showed that IRF5 isoform v8, which lacks a portion of the N-terminus of the IRF5 IAD, 
was still able to interact with RelA. 
 
 
Figure 5.20: Peptide 11 highlighted in the IRF5 IAD crystal structure 
Crystal structure of the IRF5 IAD [194] with the Peptide 11 sequence (NH2-VKTKLFSLEHFLNELILFQC-
COOH) highlighted in yellow.  Image taken from the Cn3D software [359]. 
 
Co-crystallisation of IRF5 and RelA proteins, or Peptide 11 with RelA protein, would 
provide further insight into the 3D structure of the IRF5-RelA interaction interface.  This 
information could then be used to design other small-molecule inhibitors that would 
block any 3D binding pockets in the interface in order to prevent the IRF5-RelA 
interaction occurring. 
 
5.2.5.3 – IRF5 peptide cellular uptake (preliminary data) 
Preliminary attempts were made to investigate whether Peptide 11 has an inhibitory 
effect on IRF5+RelA controlled gene expression, as hypothesised.  In order for this to 
be tested, Peptide 11 needed to be able to penetrate cell membranes and therefore 
enter cells.  Peptide uptake into HEK293-ET cells was optimised using different ratios 
of ProteoJuice reagent:peptide and different transfection time points (2 hours or 20 
hours).  Uptake of peptide was determined following cell lysis with total cell lysis buffer, 
protein quantification and Western blotting with a Biotin-HRP antibody.  Figure 5.21 
shows that although the peptide itself could be detected by the Biotin-HRP antibody 
(far right lane), no band of the same size was visible in any of the cell lysate lanes, 
despite following the ProteoJuice protocol. 
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Figure 5.21: Biotinylated peptide cell penetration optimisation by ProteoJuice 
5x105 HEK293-ET cells were transfected with Peptide 11 by a 1:1, 1:2, 1:3 or 1:4 ratio of Proteojuice 
reagent to peptide (1 mg/ml) for 2 or 20 hours at 37°C.  Cells were lysed on ice for 30 minutes with total 
cell lysis buffer with added protease inhibitors and the lysates cleared by centrifugation to remove cellular 
debris.  Protein levels were quantified by Qubit assay. 10 µg protein/10µl Peptide 11 was prepared by 
heating to 100°C with loading buffer then loaded onto an SDS-PAGE gel along with and electrophoresed 
until fully resolved then transferred to PVDF membrane for Western blotting with Biotin and Actin-specific 
antibodies.  WB = Western blot. 
 
Interestingly, a biotinylated band was visible higher up the gel following 24 hours 
incubation for the transfection.  This band was the same size as RelA protein, to which 
the peptide is supposed to bind, however this may just be coincidental as samples are 
denatured and reduced prior to gel loading, so complex formation should have been 
inhibited before running the gel.   
 
In order to investigate whether the peptide was having an effect on gene expression, 
despite not being visible in cell lysates following transfection; the ProteoJuice protocol 
was repeated on HEK293-ET cells that had already been prior transfected with pBent2 
or IRF5+RelA expression plasmids by Lipofectamine 2000.  Following 20 hours 
incubation, the cells were stimulated with LPS for 2 hours and the RNA extracted for 
cDNA synthesis and qPCR.  Figure 5.22 shows no differences in Tnf/IL12b gene 
expression following the transfection of Peptide 11 or a control Peptide A into HEK293-
ET cells.  It was, however, not confirmed in either of these preliminary experiments that 
peptides were being successfully introduced into cells, so no firm conclusions as to the 
effect of peptides on gene expression can be made.  Further work to ensure 
penetrability of peptides is required, for example conjugating the peptide to fluorescent 
dye in order to visualise peptide location via fluorescent microscopy would be a good 
starting point.  It is also possible that the peptide was penetrating the cells, however 
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was being degraded by intracellular proteases, therefore approaches to protect 
peptides from degradation should be considered in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22: Effect of Peptide 11 on Tnf/IL12b gene expression in HEK293-ET cells 
5x105 HEK293-ET cells were transfected with pBent or IRF5+RelA expression plasmids with 
Lipofectamine 2000 overnight at 37°C.  The following day, cells were transfected with Peptide 11 by a 1:1, 
1:2, 1:3 or 1:4 ratio of Proteojuice reagent to peptide (1 mg/ml) for 20 hours at 37°C before stimulation 
with LPS for 2 hours at 50 ng/ml.  mRNA was extracted and 1 µg (as determined by Nanodrop 
quantification) reverse transcribed into cDNA for analysis by qPCR using hIL12b, hTNF and hRPLP0 
(housekeeping gene) Taqman assays.  Representative experiment, each performed in duplicate, 
normalised to hRPLP0, error bars show SD.  
 
In summary, IRF5 and NFκB RelA have been shown in this chapter to synergise in 
transcriptional regulation of a subset of genes in macrophages, leading to the 
identification of an IRF5+RelA cistrome.  IRF5 is able to physically interact with RelA 
via its IAD domain (aa268-395) and RelA in return interacts via its DD domain (aa198-
292) in order to mediate this synergistic activity.  Peptide 11 (NH2-
VKTKLFSLEHFLNELILFQC-COOH) has been identified as a short IRF5 IAD sequence 
with the ability to interact with the N-terminus of RelA, and therefore the potential to 
block the protein-protein interaction. 
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5.3 – Conclusion 
Following on from previous published work by the Udalova laboratory [196, 197], 
Chapter 5 of this thesis has further investigated the co-operative activity of IRF5 with 
the RelA subunit of the master inflammatory transcription factor NFκB.  I have 
demonstrated that transcriptional cooperation occurs between IRF5 and RelA in Tnf 
gene expression upon LPS stimulation, in terms of both mRNA and luciferase reporter 
activity, in line with previous studies [197].  ChIP-seq studies performed in the Udalova 
laboratory (manuscript submitted) have also identified an extensive list of other genes 
at which overlapping recruitment of IRF5 and RelA occurs, suggesting that such 
cooperation in gene expression occurs genome-wide and not just at the Tnf locus.  In 
line with this, I was also able to demonstrate IRF5+RelA synergy in IL12b expression 
on the mRNA level.  In total, 927 genomic regions (at 10% FDR threshold) have been 
identified in murine M1 macrophages that exhibit overlapping recruitment of IRF5 and 
RelA, of which 66% of peaks are in the vicinity of LPS-induced genes; suggesting that 
the primary mode of activity of the IRF5-RelA cistrome is up-regulation of target gene 
expression.  When comparative analysis of the gene lists for the IRF5+RelA, IRF5-only 
and RelA-only cistromes were performed; enrichment for the IRF5+RelA cistrome was 
observed for GO (gene ontology) molecular functions such as ‘cytokine activity’, 
‘cytokine receptor binding’ and ‘TNF receptor binding’, when compared to the 
individual cistromes.  As well as co-regulating numerous key immune genes, including 
cytokines and chemokines (Ccl4, Ccl5, IL1a, IL1b, IL12a, IL21, IL23a, IL27, IL6, Lta, 
Myd88, Traf2, Traf6, Tnf); the IRF5+RelA cistrome also co-regulates TLRs (Tlr1, Tlr2, 
Tlr4, Tlr8, Tlr9), chemokine receptors (Cx3cr1, Cxcr4, Ccr7, Ccr2) and c-type lectins 
(Clec4e, Clec2d, Clec4d, Clec16a).  This highlights the role of both IRF5 and RelA in 
regulating macrophage phenotype as well as establishing the macrophage pro-
inflammatory gene programme. 
 
It seems, based on re-ChIP experiments [197] and IRF5 ChIPs performed upon RelA 
depletion (manuscript submitted), that overlapping IRF5 and RelA ChIP-seq peaks are 
indicative of indirect recruitment of IRF5 to the DNA via protein-protein interactions with 
RelA.  This mechanism is further highlighted by the fact that the binding sites beneath 
IRF5+RelA ChIP-seq peaks were found to be more similar to consensus κB binding 
sites rather than ISREs (manuscript submitted).  The fact that many of the co-regulated 
gene loci exhibit the same RelA ChIP-seq binding profile in pro-inflammatory M1 
macrophages as in anti-inflammatory M2 macrophages (that do not express high 
levels of IRF5), suggests that any differences in gene expression levels between the 
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two macrophage phenotypes are more likely to be due to IRF5 activity than NFκB.  As 
NFκB is activated downstream of many PRRs once ligated by their corresponding 
PAMPs/DAMPs, it appears that IRF5 could be adding a degree of specificity to the 
innate immune response in macrophages, by only being involved in activation of a 
subset of genes downstream of a subset of PRRs.  In this manner, as gene targets are 
being doubly activated by both IRF5 and RelA, this results in higher and more 
sustained inflammatory gene expression in M1 macrophages, as IRF5 provides a 
transcriptional boost to NFκB activity. 
 
Interestingly, IRF5 and RelA have equally large independent functions, with 38% of 
total RelA peaks exhibiting RelA recruitment only, and 39% of total IRF5 peaks 
exhibiting IRF5 only.  Only 50% and 56% of these peaks respectively also coincided 
with RNA Polymerase II recruitment, suggesting that although together IRF5+RelA 
mainly positively regulate gene expression, alone they can both drive and inhibit gene 
expression (manuscript submitted).  This may be due to recruitment of a variety of co-
factors in the absence of each other.  Whilst the IRF5-only cistrome predominantly 
targets gene promoters (within 1 kb of the TSS), the RelA-only cistrome equally targets 
both promoter and enhancer regions across the genome.  These two cistromes 
intersect to form the IRF5+RelA cistrome at a limited number of promoters only, rather 
than enhancers (manuscript submitted).  It is likely that indirect IRF5 binding at 
promoters is preceded by RelA binding (or another factor in the absence of RelA), as 
NFκB requires nucleosome-free DNA in order to bind gene loci [350].  It is therefore 
unlikely that IRF5 is a causative factor in chromatin remodelling at promoters, despite 
the fact that it can interact with numerous enzymes and co-factors that affect the 
chromatin environment, including CBP/p300 [297] and KAP1/SETDB1 [360], as 
demonstrated in Chapter 4 of this thesis. 
 
IRF5 and RelA can physically interact via protein-protein interactions, as demonstrated 
both in this thesis and in previously published work [197], which explains how IRF5 can 
be recruited to κB sites in the DNA.  We hypothesise that via this interaction, at the Tnf 
locus in particular, the two transcription factors mediate intrachromosomal looping, 
which enables recycling of RNA polymerase II to reinitiate transcription.  A loop could 
form (see Figure 5.23) by IRF5 binding directly to an ISRE at the 5’ of the Tnf gene, 
whilst also interacting via protein-protein interactions with a molecule of RelA bound to 
a κB site at the 3’ of the locus [197].  Via such a mechanism, RNA polymerase II is 
returned to the TSS immediately after completion of transcriptional elongation, as the 
DNA is looped back to the start, in order to transcribe the gene again.  This could 
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explain the high and sustained expression of Tnf that is observed in M1 macrophages 
in the presence of both IRF5 and RelA compared to M2 macrophages that lack IRF5 
[197].  Such intrachromosomal looping has previously been identified at the Tnf locus 
in T-cells [361] (see Figure 5.23), however 3C-analysis is required of the locus in 
macrophages in order to confirm whether this topology is also relevant to pro-
inflammatory macrophages, which is currently being investigated in the Udalova group. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 – Model of intrachromosomal interactions at the Tnf locus  
A: Proposed model of IRF5-mediated circularisation of the Tnf locus in macrophages, via interactions with 
both an ISRE at the 5’ of the gene and with RelA at the 3’ of the locus. B: Diagram of the 
intrachromosomal interactions observed at the Tnf locus in T-cells [361]. 
 
Experiments in this chapter have demonstrated that IRF5 interacts with RelA via its C-
terminal IAD domain (in particular aa268-395).  This suggests that the protein-protein 
interaction occurs when IRF5 is in its active conformation, following phosphorylation, 
as until this occurs the SRR of IRF5 masks the IAD [194].  On the opposite side of the 
interface, RelA interacts with IRF5 via its N-terminal DD domain (aa186-292).  The fact 
that the DNA-binding N-terminus of RelA is highly conserved amongst the NFκB family 
(and accordingly IRF5 can also interact with RelB and p52), therefore suggests that the 
protein-protein interaction between IRF5 and RelA has a significant function and is 
likely to have been conserved over a period of evolution.  Interestingly, another 
member of the IRF family has also been shown to interact with RelA.  IRF3 is a 
component of the Ifnb enhanceosome, which involves interactions with an NFκB dimer 
containing RelA [132].  IRF3 has also been shown to interact directly with the N-
terminus of RelA (the RelA interface was defined as the RHD, but this can be further 
divided into the RHD and DD as was the case in this study, so IRF3 may interact via 
the same residues as IRF5) in the regulation of LPS-induced ISRE-dependent target 
genes [137].  The IRF3-RelA interaction can be inhibited by preferential binding of the 
glucocorticoid receptor (GR) DBD to the RelA RHD, thus resulting in negative 
regulation of the inflammatory response [137].  It would be interesting to investigate 
whether the IRF5-RelA interaction can also be inhibited by GR, and whether IRF5 or 
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IRF3 preferentially binds to RelA under LPS-stimulated conditions.  As RIG-I virally-
activated IRF3 inhibits IRF5-mediated induction of IL12b following bacterial infection 
[156], it is possible that IRF3 mediates this inhibitory activity via competing for RelA 
binding, as is the case for IRF4/IRF5 with the TLR adaptor protein MyD88 [160]. 
 
Following on from the interface mapping experiments in this Chapter, Peptide 11 was 
identified – a short region of the IRF5 IAD sequence with the ability to interact with the 
N-terminus of RelA, as determined by bio-layer interferometry.  The location of this 
peptide was shown to be on the exterior of the folded IRF5 IAD, which suggests good 
accessibility for the peptide as part of the interaction interface with RelA.  It is hoped 
that via this peptide, a strategy can be developed in which IRF5-RelA protein-protein 
interactions can be blocked, which in turn will have an inhibitory effect on the long list 
of pro-inflammatory macrophage genes that have now been identified as induced by 
the IRF5-RelA cistrome.  For example, sustained expression of Tnf by M1 
macrophages could be prevented, which may be beneficial for application as an 
autoimmune therapy.   
 
Classification of protein-protein interactions as druggable targets is a relatively new 
concept, and is most commonly approached using small molecule inhibitors; however 
there have been multiple successes documented utilising peptides as inhibitors.  For 
example, a helical p53 peptide has been shown to bind to HDMX, an inhibitory 
homologue of the p53-activating E3 ligase HDM2.  Upon peptide binding to HDMX, 
complexes between HDMX and full-length p53 are prevented, and p53-dependent 
transcriptional up-regulation is induced [362].  This is beneficial, as cancer cells often 
inactivate p53 in order to proliferate.  Peptides have also been shown to block the 
formation of the NOTCH transactivation complex, which is advantageous in T-cell 
acute lymphoblastic leukaemia, where inappropriate NOTCH activation is implicated in 
pathogenesis [355]. 
 
Alternative high-throughput routes to determining whether protein-protein interactions 
are inhibited, other than direct effects on mRNA expression or luciferase reporters, 
have also been considered in the Udalova group.  Preliminary work to optimise a 
Mammalian Two-hybrid system (M2H, Promega Checkmate) has been undertaken.  In 
this assay, the two potential interacting proteins are cloned into two vectors, resulting 
in one protein fused to a DNA-binding module, and one protein fused to a 
transactivation module upon expression.  If the two proteins interact, this brings 
together the added DNA-binding and transactivating domains to form a functional 
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transcriptional entity, which can induce luciferase expression from a co-transfected 
gene reporter construct.  In this way, luciferase activity is driven by the two proteins 
interacting, which is measurable.  Supplementary Figure S9.17 shows that although 
the positive control interaction (MyoD-Id) was demonstrated by the M2H system, no 
interaction was observed between IRF5 and RelA.  It is likely that the IRF5-RelA 
interaction is much weaker than the recommended positive control, therefore further 
work to improve the assay could be to clone some other proteins that are involved in 
lower affinity interactions, for example RelA-STAT3 (Figure 3.4), so that the IRF5-RelA 
interaction is more on scale.  It may also be beneficial to clone the truncated mutants 
of IRF5, as for example the Δ219 mutant has shown higher affinity RelA binding than 
the wild-type IRF5 by Flag-IP (see Figure 5.8). 
 
Alternatively to M2H, a protein-protein interaction ELISA (PPI-ELISA) has been 
investigated, as detailed in Figure 5.24.  In this assay, a bait lysate containing an 
exogenously-expressed One-Strep tagged protein is applied to a Streptactin-coated 
96-well plate.  Following this, a second lysate containing prey protein is applied.  If an 
interaction between the One-Strep tagged bait and Flag-tagged prey proteins occurs, a 
Flag-HRP detection antibody should enable in a luminescent signal, as is the end-point 
for a standard ELISA.  Supplementary Figure S9.18 shows that similarly to the M2H 
assay, the positive control (RelA-p50 interaction) was measurable in this manner, but 
the IRF5-RelA interaction was not detected, even with truncated IRF5 mutants.  This 
assay could be further optimised by use of purified proteins rather than lysates, which 
would reduce competition for binding to the Streptactin plate and therefore may enable 
weaker protein-protein interactions to be demonstrated.  Efficacy of high-throughput 
assays such as these would be beneficial to the Udalova laboratory as a platform for 
screening inhibitors for interaction modulating ability. 
 
 
Figure 5.24 – Development of a protein-protein interaction ELISA (PPI-ELISA) assay 
Interactions could be demonstrated by sequential application of cell lysates containing exogenously 
expressed bait (Strep-tagged) or prey (Flag-tagged) proteins, which can bind to the Streptactin plate and 
each other respectively.  Interactions would be detected using a Flag-HRP antibody and the assay 
developed according to the standard ELISA protocol. 
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6.0 – Discussion 
 
IRF5 is emerging as a key transcription factor that is involved in regulation of gene 
expression in several white blood cell types; including Type I IFN production in 
dendritic cells [363], developmental gene expression in B-cells [265], and of 
particular interest to the Udalova group: pro-inflammatory cytokine production in 
macrophages [193].  In line with this, multiple GWAS studies have identified 
polymorphisms in the Irf5 locus, leading to increased expression of Irf5 or expression 
of alternatively spliced isoforms of Irf5, that are associated with risk of autoimmune 
diseases such as SLE and RA in humans (see Table 1.1).  Accordingly, Irf5-/- mice 
demonstrate protection against LPS- and CpG-induced endotoxic shock due to 
reduced systemic production of pro-inflammatory cytokines [193].  My study provides 
an insight into the role of co-factors in regulation of IRF5 target gene expression 
downstream of TLR4 signalling in macrophages.  In particular, following a screen for 
novel protein-protein interaction partners of IRF5, I demonstrate the ability of 
previously undescribed IRF5 co-factors - namely the scaffold protein KAP1 and 
histone methyltransferase SETDB1 - to regulate the chromatin environment at the 
Tnf locus [360].  This study has also further investigated the importance and interface 
structure of the previously described IRF5- NFκB RelA interaction, resulting in the 
identification of a short IRF5 IAD peptide that can bind to the N-terminus of RelA. 
 
Chapter 3 of this thesis began with an interactome study consisting of One-Strep 
affinity purification coupled to mass spectrometry, in order to identify novel protein-
protein interaction partners of IRF5.  The ability of members of the IRF family to 
interact with intra- and inter-family co-factors, in particular via their C-terminal IAD1 or 
IAD2 domains, seems to be of utmost importance in regulation of their target gene 
expression.  Numerous complexes involving IRFs have now been described and 
implicated in both transcriptional induction and repression.  For example, complexes 
consisting of IRF proteins that positively regulate gene expression include the Ifnb1 
enhanceosome, in which IRF1/IRF3/IRF7 heterodimers can interact with NFκB, AP-1 
and HATs including p300 [99, 131]; the ISGF3 complex in which IRF9 interacts with 
STAT1 and STAT2 to drive gene targets such as Irf7 [128]; and IRF4/IRF8-PU.1 
complexes that can bind to IECS sites in the DNA and regulate target genes such as 
IL1b [185].  On the other hand, IRF complexes with the ability to inhibit gene 
expression include IRF2-p300, in which IRF2 acts as a substrate to inhibit histone 
acetylation at IRF1 target genes such as Type I IFNs [117]; the IRF8-IRF1/IRF2 
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complex that can also inhibit Type I IFN gene expression; and the IRF4-IRF8 
heterodimer that can inhibit Isg15 expression when bound to an ISRE at this locus 
[184].  Interestingly, prior to this study, the Udalova laboratory demonstrated that 
alongside the importance of IRF5 in driving expression of pro-inflammatory markers 
in macrophages, IRF5 was also able to inhibit expression of the anti-inflammatory M2 
marker IL-10 [25], which aids in the polarisation of macrophages to an M1 
phenotype.  It was observed that overexpression of IRF5 in M2 macrophages 
reduced their ability to secrete IL-10 upon LPS stimulation, and this inhibitory activity 
was dependent on the DBD of IRF5 as well as an ISRE site in the IL10 gene 
promoter [196, 364].  In line with this, ChIP studies showed that despite IRF5 binding 
to the promoter region of IL10 following LPS stimulation, RNA polymerase II 
recruitment was only detectable upon dissociation of IRF5 from the locus 4 hours 
later [25].  This suggests that the presence of IRF5, and likely some inhibitory co-
factors due to the well-described activity of IRF5 to induce transcription at other loci, 
inhibits the recruitment of the transcriptional machinery required to drive IL10 
expression.  In line with this, the Udalova laboratory has recently demonstrated that 
IRF5 binding to the IL10 promoter is dominant over pSTAT3 binding (manuscript 
submitted).  It may be that IRF5 itself prevents pSTAT3 from interacting with the 
DNA, due to the close proximity of ISRE and STAT binding motifs at the locus [342, 
364], or protein-protein interactions between IRF5-STAT3, as demonstrated in 
Chapter 3 of this thesis, may sterically hinder binding of pSTAT3 to the DNA.  Further 
studies into the chromatin environment at the IL10 locus in the presence and 
absence of IRF5 would give further insights into co-factors that may influence the 
epigenetic state of the locus, and increase our knowledge of the IRF5 interactome.  
 
A growing list of IRF5-interacting proteins is now appearing in the literature.  As a 
protein’s interactome gives key insights into the associated activity of that protein, we 
are now able to begin to unravel the determinants of IRF5’s key role in inflammation.  
My interactome study in Chapter 3 of this thesis has added several novel proteins to 
the IRF5 co-factor repertoire.  Figure 6.1 shows the proteins that have been linked to 
IRF5 to date, both those involved in IRF5 activation and transcriptional activity.  Of 
particular interest to this study, and the observations of the Udalova laboratory at the 
IL10 locus, is the fact that IRF5 interacts with both HDACs and HATs resulting in 
altered transactivation ability [297].  Phosphorylated IRF5 interacts with the HATs 
CBP/p300 in order to form a functional co-activator complex at ISRE-containing 
promoters such as Ifna1 [297].  HDAC-containing NCoR, Sin3a and SMRT co-
repressor complexes were also shown to interact with IRF5 in unstimulated cells 
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[297].  Interestingly, however it appears that HDACs can both sequester and 
enhance IRF5 transactivation ability, as HDAC1 is able to physically interact with 
IRF5 upon viral stimulation, and HDAC inhibitors can lead to inhibition of IRF5-
mediated transactivation of Ifna1 and IL6 promoter reporters in response to viral 
stimuli [297, 365].  It was also noted in this study that co-repressor proteins tended to 
associate with the IRF5 DBD, whereas co-activator proteins interacted with the IRF5 
IAD [297].  In line with this RelA (Chapter 5) binds to the IRF5 IAD and positively 
regulates gene expression, and KAP1 (Chapter 4) binds to the N-terminus of IRF5 
and negatively regulates gene expression.  Position of an interaction within the IRF5 
sequence therefore may well be indicative of co-factor function.  
Figure 6.1: The IRF5 interactome to date 
Summary of the IRF5-interacting proteins currently described in the literature, including the novel co-
factor KAP1 as described in Chapter 4 of this thesis. 
 
Chapter 4 of this thesis has further demonstrated that co-factors of IRF5 have the 
ability to modify the chromatin environment at target gene loci.  As a result of the 
IRF5 interactome study in Chapter 3 of this thesis, KAP1/TRIM28 was identified as a 
novel protein-protein interaction partner of IRF5 in pro-inflammatory M1 
macrophages [360].  This study demonstrates a role for KAP1 in maintenance of the 
characteristic heterochromatin mark H3K9me3 at the Tnf locus, in particular at the 3’ 
of the gene, where IRF5 is recruited to the DNA via protein-protein interactions with 
NFκB RelA [197].  A model is proposed in which a low level of H3K9me3 deposition 
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via KAP1 and the histone methyltransferase SETDB1 is required following LPS 
stimulation in order to ensure non-excessive production of primary response genes 
regulated by IRF5 (see Figure 6.2).  The Tnf locus in resting macrophages has been 
previously described as open to regulatory proteins, including RNA polymerase II, 
which accumulates at the TSS in preparation for rapid transcription following 
microbial stimulation and NFκB/IRF5 activation [139, 197, 202].  Accordingly, histone 
marks such as acetylation are also present, which are associated with regions of 
active chromatin [139] (see Figure 6.2).  Despite the fact that the Tnf locus is in this 
active conformation in resting cells, it is not until microbial stimulation occurs that 
nascent transcripts are rapidly produced [197, 344], suggesting that some level of 
regulation is in place that prevents poised RNA polymerase II in resting cells from 
transcribing the gene prematurely.  In this study, we observe, similarly to other 
inflammatory loci such as IL12b [345], a low level of H3K9me3 that seems to be 
removed from the 3’ of Tnf following LPS stimulation, before being re-deposited 
following 6-8 hours of LPS stimulation, corresponding to the time at which Tnf mRNA 
expression begins to subside.  Accordingly, KAP1 depletion in M1 macrophages 
results in higher and more sustained Tnf mRNA expression at later time points 
following LPS stimulation, and this trend extends to other IRF5-regulated 
inflammatory loci.  As KAP1 does not play a role in regulation of IRF5 expression, 
turnover or activity, we conclude that the primary mode of KAP1 activity at IRF5-
regulated loci is to manipulate the chromatin environment in order to regulate gene 
expression epigenetically.  Although IRF5 activity at the Tnf locus is most strongly 
associated with induction of transcription, it is logical that a mechanism is required to 
prevent excessive production of pro-inflammatory cytokines at which RNA 
polymerase II is poised in the basal resting state, otherwise they would be constantly 
undergoing transcription.  This is of particular importance for Tnf, which has been 
well characterised as able to drive production of many other pro-inflammatory factors 
during a potentiating immune response [204, 228].  Via protein-protein interactions 
with IRF5, it is therefore possible for KAP1 to mediate a quick reversion of 
inflammatory loci to a closed chromatin state, via deposition of a low level of 
heterochromatin-associated histone marks, that would be relatively easy to both 
deposit and remove in order to cease and reinitiate transcription respectively in a 
quick manner, and therefore drive gene expression for only a defined window of time 
(see Figure 6.2).  As prolonged production of pro-inflammatory cytokines is a 
characteristic of many autoimmune disorders, epigenetic regulation to prevent 
primary response gene dysregulation would avoid detrimental inflammatory 
responses.   
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The novel IRF5 protein-protein interaction partners KAP1/TRIM28 and SETDB1 can 
therefore be described as inhibitors of IRF5-mediated transcriptional activity in pro-
inflammatory M1 macrophages, although this activity does not extend to the IL10 
locus.  It would be interesting in the future to investigate the epigenetic state 
(H3K9me3 levels) of macrophages from autoimmune blood samples and compare 
this with healthy donors.  I would hypothesise that RA patients for example, blood 
samples from which are available at the Kennedy Institute, may exhibit reduced total 
H3K9me3 and KAP1 levels, associated with their characteristic increased cytokine 
production.  Microarray or RNA-seq studies upon KAP1 overexpression or depletion 
would also give an insight into the extent of KAP1-mediated heterochromatin 
regulation in M1 macrophages.  Following this, attempts to enhance KAP1 
expression or activity may be beneficial in terms of therapy to boost epigenetic 
regulation of pro-inflammatory gene loci.  There is increasing evidence that co-
operation between members of the IRF and TRIM families is a regular occurrence, 
with KAP1/TRIM28 shown to interact with IRF1/IRF5/IRF7 [328, 330, 360], TRIM21 
interacting with IRF3/IRF5/IRF8 [312, 334] and TRIM59 interacting with IRF3/IRF7 
[335].  Proteomic studies focussing on these two protein families in particular would 
be interesting to determine in more detail the extent of this relationship. 
 
Figure 6.2: Model of IRF5-related transcriptional activity at the Tnf locus 
The initial rapid induction of Tnf expression in M1 macrophages (A) is due to recruitment of NFκB to the 
locus, which is already acetylated and occupied by poised RNA polymerase II, following LPS-
stimulation.  Tnf mRNA expression remains high and sustained in M1 macrophages (B) following 
recruitment of IRF5 via direct DNA interactions at the 5’ and indirect recruitment via NFκB RelA/p65 at 
the 3’ of the gene.  Tnf expression begins to decline (C) when KAP1/SETDB1 are recruited to the 3’ of 
the locus, potentially via interactions with IRF5, leading to deposition of a low level of H3K9me3 
(heterochromatin mark) to ‘close’ the Tnf locus to transcription factor and RNA polymerase II activity. 
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To complement the One-Strep AP-MS study performed in Chapter 3 of this thesis, 
future work in the Udalova laboratory includes further IRF5 interactome studies in 
order to continue deciphering how IRF5 mediates its diverse transcriptional activities, 
in particular at the IL10 locus.  As no single interactome study can be extensive 
enough to demonstrate all interactions of a protein in a particular cell type, due to the 
prevalence of false positives/false negatives caused by background and 
shortcomings in equipment sensitivity, it is always beneficial to perform a variety of 
interactome studies in parallel to improve interactome coverage and increase the 
validity of results.  For example, to compliment my AP-MS study, techniques such as 
phage-display, yeast two-hybrid or mammalian-two hybrid could be performed.  It 
may also be beneficial, as colloidal-blue staining appeared to be a limiting factor in 
my protocol, to perform gel-free AP-MS studies to remove this variable.  The Udalova 
laboratory has entered into a collaboration to utilise MAPPIT technology (a cytokine 
receptor-based two-hybrid approach for studying native protein-protein interactions 
within mammalian cells [318]) in the future, as we feel that as phosphorylation is an 
important factor in IRF5 activation, studying IRF5 in its native conformation may 
enhance the validity of interacting protein hits.  It may also be beneficial to perform 
interactome studies with the alternatively spliced isoforms of IRF5, some of which 
have been identified in disease tissues, to investigate whether the range of co-factors 
available to the isoforms is indicative of enhanced or shortcomings of IRF5 activity. 
 
Further validation of the Chapter 3 interactome study is also required in the future, as 
the other proteins identified could also be valid transcription-regulating co-factors of 
IRF5 (see Figure 3.16).  For example, RUVBL1/RUVBL2 are members of 
transcription-activating complexes that possess nucleosome sliding and HAT 
activities [306] and RBBP4 is a member of HDAC complexes that are involved in 
transcriptional repression [307].  The reason that such validation was not embarked 
upon in this study was mainly due to current poor antibody availability, which may 
improve in future.   
 
Chapter 5 of this thesis has focussed on the pre-determined protein-protein 
interaction between IRF5 and NFκB RelA downstream of TLR4 signalling in 
macrophages [197].  The initial co-operation that was observed at the Tnf locus has 
in this study, by virtue of ChIP-seq studies performed by Dr David Saliba in parallel 
with my project, been demonstrated to in fact be one of many pro-inflammatory loci at 
which IRF5 interacts with RelA in order to be indirectly recruited to the DNA.  
Interestingly, IRF5 is uniquely recruited to only 1251 actively transcribed regions 
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(associated with RNA polymerase II) in M1 macrophages, whereas there are 2081 
additional IRF5 ChIP-seq peaks that directly overlap with regions of RelA binding 
(manuscript submitted).  This suggests that IRF5 preferentially co-operates with other 
transcription factors via physical interactions to positively regulate gene expression.  
There is also a subset of IRF5 ChIP-seq peaks that are located in regions with no 
RNA polymerase II recruitment, which suggests that without NFκB co-operation, 
IRF5 could primarily act as an inhibitor of gene expression, as is the case at the IL10 
locus [196].  Investigation of the binding motif underneath the IRF5+RelA cistrome 
identified a consensus sequence more similar to a κB site than an ISRE (manuscript 
submitted), which confirms that like at the Tnf locus, the primary mode of recruitment 
of IRF5 to these loci is via protein-protein interactions with RelA.  This is similar to 
DNA-binding activity of other IRF family members, which are able to bind to multiple 
consensus sites, including the GAS (IRF8) [178] and IECS in co-operation with PU.1 
(IRF4/IRF8) [173, 185].  It therefore seems that co-operation with other transcription 
factors to drive gene expression is a common feature of the IRF family. 
 
This study has provided strong evidence that IRF5 co-operates with NFκB RelA in 
macrophages.  Both the IRF and NFκB families of transcription factors are integral for 
the induction of many immune genes, however the fact that IRF5 only targets a 
specific subset of genes downstream of TLR activation, highlights the exciting 
possibility of specifically targeting IRF5-mediated pro-inflammatory function, in 
comparison to blockade of NFκB activity, which would be more detrimental to general 
macrophage function due to broader functional activities of NFκB.  Chapter 5 of this 
thesis has mapped in detail the protein-protein interaction interface between IRF5 
and NFκB RelA, leading to the identification of a short IRF5 IAD peptide (Peptide 11) 
with the ability to bind to RelA.  The location of Peptide 11 on the exterior of the IRF5 
protein structure, as determined by studying the published crystal structure of the 
IRF5 IAD, justifies the ability of this region to act as an interaction interface.  By 
potentially blocking the IRF5-RelA interaction using Peptide 11 or small-molecule 
inhibitors, we will be inhibiting a snapshot of IRF5 activity – transcription by IRF5 of 
the subset of genes regulated by IRF5+RelA cistrome.  As RelA should still be able 
to bind to the DNA at these loci, normal levels of expression associated with a 
regulated immune response will still be possible (more M2-like expression levels, 
rather than the boosted expression associated with IRF5 activity and an M1 
phenotype). 
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Drug targets are often members of large highly homologous protein families, and 
therefore possess very similar structural and functional characteristics, which makes 
drug selectivity at a molecular level very difficult.  For example, there are now many 
small molecule kinase inhibitors available, however there are many that result in off-
target effects [366].  Rather than targeting activation of a protein, for example, 
modulation of the protein interactome is an attractive option, as interaction interfaces 
between proteins are more unique, and can result in a more specific and tailored 
inhibition rather than pan blockade of activity.  Only 10% of critical interaction 
surfaces of human proteins possess the hydrophobic cavities that are required for 
small molecule design and high affinity binding [367].  A majority of interaction 
surfaces are relatively flat and distributed over a large contact surface area.  The use 
of peptides as protein-protein interaction inhibitors has several advantages over 
small molecules, including the potential for less toxicity and fewer side effects [368], 
but also the fact that peptides are modular and flexible in structure, which allows 
better complementation of interfaces and therefore more potency and selectivity in 
their inhibitory activity [369].  However, the fact that peptides exist as a population of 
conformers in solution, with an exposed unfolded backbone, means that they are 
prone to proteolysis and are often unable to cross membranes [369].  Recent 
developments that address this problem include hydrocarbon ‘stapling’ of peptides 
between successive turns of an alpha-helical structure – the most common element 
of protein structure present at interaction interfaces [370].  Preserving the peptide 
tertiary structure in this manner, by cross-linking between artificial amino acid 
residues that have been inserted into the peptide sequence, leads to increased 
protection of the peptide backbone and increased cell permeability [367].  Multiple 
instances of successful inhibition of protein-protein interactions using stapled 
peptides have now been described [355, 356, 362, 371], therefore stapling of IRF5 
Peptide 11 is a valid option to improve efficacy, especially as the peptide consists of 
an alpha-helical tertiary structure.  It is also possible to improve cell penetrability by 
conjugating Peptide 11 to a cell-penetrating peptide sequence, such as Penetratin 
(the homeodomain of the Drosophila transcription factor Antennapedia [372]) or Tat 
peptide from HIV-1 [357], which are thought to mediate cell-penetration mainly via 
endocytotic pathways.  The advantage of Tat peptide in terms of this study, is that it’s 
sequence contains a nuclear localisation sequence, so would enable Peptide 11 
once conjugated to Tat to target activated RelA in the nucleus.   
 
In line with the preliminary experiments in Section 5.2.5.3 of this thesis, future work 
involving Peptide 11 include RT-PCR and gene reporter assays to determine any 
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effect on target gene expression of the IRF5+RelA cistrome following cellular uptake.  
Parallel to this peptide approach for inhibition, the Udalova group has embarked on 
collaborations with Merck, who have performed an ALIS (Automated Ligand 
Identification System) [373] mass-spectrometry-based inhibitor screen for families of 
small molecules that are able to bind to IRF5 or RelA, and therefore may modulate 
transcriptional activity, although not necessarily by inhibiting protein-protein 
interactions.  Validation of the hits from the ALIS screen will also involve gene 
reporter assays and RT-PCR of target genes identified by microarray [25] and ChIP-
seq studies (manuscript submitted).  As structural information is crucial for designing 
specific inhibitory small molecules (the ALIS approach is more random, using large 
libraries of small molecules), future collaborations with the Structural Genomics 
Consortium (SGC, University of Oxford) to co-crystallise the IRF5 and RelA proteins 
will be of great importance.  We hope to learn more about the Peptide 11-RelA 
interaction in future collaborations with the SGC, by performing biophysical assays to 
determine the affinity of the interaction, and co-crystallisation of Peptide 11 to RelA in 
order to visualise the interaction and modify the peptide to improve binding. 
 
Other approaches for manipulating IRF5 activity include developing more of an 
understanding of Irf5 gene regulation and protein activation, in order to determine 
other angles from which IRF5 could be targeted.  For example, it is well documented 
that IRF5 needs to be phosphorylated in order to dimerise and translocate to the 
nucleus where is mediates transcription of target genes, however the kinase that 
activates IRF5 remains somewhat of a grey area.  Studies using arrays of kinase 
inhibitors may provide an insight.  It is also well known that GM-CSF polarises 
macrophages to an M1 IRF5-expressing phenotype, however the transcription 
factors downstream of CSF2R ligation by GM-CSF that drive Irf5 expression have not 
been determined.  Systematic studies of transcription factor binding sites present at 
the Irf5 locus could enlighten us in this area.  There could also be differences in the 
epigenetic state of the Irf5 locus during macrophage polarisation that modulate high 
or low expression of Irf5 in M1/M2 macrophages respectively.  
 
The ultimate test and validation of the role of IRF5 in autoimmunity must come from 
in vivo studies of infection and inflammatory disease models.  There are currently 
several papers demonstrating the importance of IRF5 in murine SLE models [260], 
endotoxic shock [193], and Antigen Induced Arthritis (AIA) (manuscript in 
preparation); and efficacy of blockade of IRF5-regulated cytokines like TNF, and 
IRF5-activating signals such as GM-CSF in murine Collagen Induced Arthritis (CIA)
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[374], suggests promise for inhibiting IRF5 activity in such models.  A major blocking 
point for investigating the roles of all members of the IRF family in autoimmunity 
however, despite many strong cases for IRF involvement in terms of in vitro data (see 
Chapter 1), is the availability of IRF cell-specific knockout mice (see Table 6.1).  The 
advantage of such animals is that as many of the IRFs have demonstrated activities in 
multiple cells types, pinpointing a particular activity may well be more beneficial in 
designing therapeutics in terms of off-target effects.  The Udalova laboratory is 
currently preparing mice in which IRF5 has been specifically ablated in macrophages 
(IRF5-Flox x LysM-Cre) for this purpose.  Amalgamation of cell-type specific knock-out 
in vivo studies with microarrays and genome-wide ChIP-seq studies (see Table 6.1) 
will provide a detailed picture of both IRF cell-type and gene target-specific effects and 
therefore insights into the scope of potential therapeutic activity in vivo. 
 
In conclusion, this study has made novel findings in terms of the IRF5 interactome, and 
will pave the way for novel investigations into therapeutics that target IRF5 activity via 
protein-protein interactions. 
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Table 6.1: Availability of IRF-related genome-wide and microarray datasets in myeloid cells and 
knockout mice 
 
 
IRF KO design Macrophage-related KO phenotype Myloid microarrays Genome-wide data  
IRF1 1) DBD targeted 
systemic KO  
 
 
2) Floxed  
(LoxP sites flanking 
Exon 3) 
Impaired induction of IL-12, 
iNOS and IFNβ by 
macrophages upon viral 
stimulation [109, 110, 113] 
IRF1 KO (peritoneal 
macrophages) [375] 
ChIP-seq BMDCs [70] 
 
 
ChIP-seq PBMCs [376] 
IRF2 1) DBD targeted 
systemic KO  
Impaired induction of IL-12 
by macrophages [119] 
N/A ChIP-seq BMDCs [70] 
IRF3 1) DBD targeted 
systemic KO  
Defective Type I Interferon 
production in by 
macrophages upon 
LPS/viral stimulation [130] 
IRF3 KO (dendritic cells 
and macrophages) [137, 
377] 
 
N/A 
IRF4 1) Systemic KO 
 
 
2) Floxed/GFP  
(LoxP sites flanking   
Exon 1 and 2) 
Regulates expression of 
M2 macrophage markers 
[188] 
 
High susceptibility to 
LPS/CpG-induced 
endotoxic shock [189] 
IRF4 KO (bone marrow-
derived macrophages) 
[378] 
ChIP-seq BMDCs [70] 
IRF5 1) Exon 2 targeted 
systemic KO 
 
 
 
2) Floxed  
(LoxP sites flanking 
Exon 2) 
Regulates expression of 
M1 macrophage markers 
[196, 197] 
 
 
Resistant to LPS/CpG-
induced endotoxic shock 
due to reduced cytokine 
levels in serum [193] 
IRF5 overexpression 
(bone marrow-derived 
macrophages) [196] 
 
IRF5 KO (dendritic cells) 
[377] 
ChIP-seq PBMCs [379] 
IRF7 1) Exon 1/2 targeted 
systemic KO  
 
 
 
2) Floxed  
(LoxP sites flanking 
Exon 2) 
Defective Type I Interferon 
production in by 
macrophages upon viral 
stimulation [130] 
IRF7 KO (dendritic cells) 
[377] 
N/A 
IRF8 1) Exon 2 targeted 
systemic KO 
 
2) Floxed 
(LoxP sites flanking 
Exon 2) 
Impaired macrophage 
differentiation, suffer from 
CMP [162] 
 
Defective IL-12 and iNOS 
production by macrophages 
[174, 175] 
IRF8 KO (peritoneal 
macrophages) [375] 
 
IRF8 KO (myeloid 
progenitor cells) [168] 
ChIP-Chip THP-1 [180] 
 
 
ChIP-Chip human 
macrophages [179] 
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7.0 – Abbreviations 
aa 
Ab 
APC 
AU 
BAP 
BCR 
bp 
BSA 
CBP 
CCP 
cDC 
ChIP 
CLP 
CML 
CMP 
CTL 
DAMP 
DBD 
DD 
DNA 
dsRNA 
DTBP 
DTT 
GAS 
G-CSF 
GM-CSF 
GWAS 
HA 
HAT 
HDAC 
HDM 
HMT 
HP1 
HRP 
IAD 
- amino acid 
- antibody 
- antigen presenting cell 
- arbitrary units 
- bacterial alkaline phosphatase 
- B-cell receptor 
- base pairs 
- bovine serum albumin 
- CREB-binding protein 
- cyclic-citrullinated peptide 
- conventional dendritic cell 
- chromatin immunoprecipitation 
- common lymphoid progenitor 
- chronic myeloid leukaemia 
- common myeloid progenitor 
- cytotoxic T-lymphocyte 
- damage-associated molecular pattern 
- DNA-binding domain 
- dimerisation domain 
- deoxyribonucleic acid 
- double-stranded RNA 
- dimethyl 3,3’-dithiobispropionimidate 
- dithiothreitol 
- gamma activation site 
- granulocyte colony-stimulating factor 
- granulocyte macrophage colony-stimulating factor 
- genome-wise association study 
- human influenza hemagglutinin 
- histone acetyltransferase 
- histone deacetylase 
- histone demethylase 
- histone methyltransferase 
- heterchromatin protein 1 
- horseradish peroxidase 
- IRF association domain
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IECS 
IFN 
IP 
IRF 
ISGF3 
ISRE 
JMJD3 
KAP1 
kB 
kDa 
LC-MS/MS 
LPS 
MCS 
M-CSF 
MHC 
MOI 
mRNA 
NFkB 
O/E 
PAMP 
PBMC 
pDC 
PEST 
PRR 
RA 
RF 
RHD 
RLR 
RNA 
RNAi 
rpm 
SD 
SE 
Ser 
SETDB1 
siRNA 
SLE 
- interferon-Ets composite sequence 
- interferon 
- immunoprecipitation 
- interferon regulatory factor 
- interferon-stimulated gene factor 3 
- interferon stimulated response element 
- Jumonji domain containing 3 
- Krüppel-associated protein 1 
- kilo base 
- kilo Dalton 
- liquid chromatography tandem mass spectrometry 
- lipopolysaccharide 
- multiple cloning site 
- macrophage colony-stimulating factor 
- major histocompatibility complex 
- multiplicity of infection 
- messenger RNA 
- nuclear factor kappa b 
- over-expression 
- pathogen-associated molecular pattern 
- peripheral blood mononuclear cell 
- plasmacytoid dendritic cell 
- proline, glutamic acid, serine, threonine 
- pathogen recognition receptor 
- rheumatoid arthritis 
- rheumatoid factor 
- Rel-homology domain 
- RIG-like receptor 
- ribonucleic acid 
- ribonucleic acid interference 
- revolutions per minute 
- standard deviation 
- standard error 
- serine residue 
- SET domain bifurcated 1 
- short interfering RNA 
- systemic lupus erythematosus 
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SNP 
SRR 
ssRNA 
STAT 
SUMO 
SWI/SNF 
TAD 
TCR 
TIR 
TLR 
TNF 
TRIM 
TSS 
UTR 
V(D)J 
vIRF 
WB 
- single nucleotide polymorphism 
- serine-rich region 
- single-stranded RNA 
- signal transducer and activator of transcription 
- small ubiquitin-like modifier 
- switch sucrose/non fermentable 
- trans-activation domain 
- T-cell receptor 
- Toll/interleukin 1 receptor 
- Toll-like receptor 
- tumour necrosis factor 
- tripartite motif 
- transcription start site 
- un-translated region 
- variable (diverse) joining 
- viral interferon regulatory factor 
- Western blot
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Supplementary Figure S9.1: IRF5 immunoprecipitation from murine M1 macrophages  
7.5x107 murine bone marrow-derived M1 (GM-CSF) macrophages were stimulated with LPS for 0/2 hours 
at 500 ng/ml.  Following cytoplasmic and nuclear lysis with ChIP buffers, lysates were incubated with 
Protein G beads coated in IRF5 antibody of IgG control for 1 hour then washed 12 times with ChIP wash 
buffer and protein complexes eluted in 4x loading buffer.  Following SDS-PAGE, gels were Colloidal 
Blue/silver-stained and bands excised for trypsin digestion and protein identification by mass spectrometry 
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Supplementary Figure S9.2: Identification of myosin peptides by mass spectrometry 
Amino acid sequence of myosin, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
 
 
 
 
Supplementary Figure S9.3: Identification of actin peptides by mass spectrometry 
Amino acid sequence of actin, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
 
 
 
 
 
Myosin-9 (227kDa) 
5 peptides = 91/1960 amino acids = 5% peptide coverage 
  
MAQQAADKYLYVDKNFINNPLAQADWAAKKLVWVPSDKSGFEPASLKEEVGEEAIVELVENGKK
VKVNKDDIQKMNPPKFSKVEDMAELTCLNEASVLHNLKERYYSGLIYTYSGLFCVVINPYKNLPIY
SEEIVEMYKGKKRHEMPPHIYAITDTAYRSMMQDREDQSILCTGESGAGKTENTKKVIQYLAYVA
SSHKSKKDQGELERQLLQANPILEAFGNAKTVKNDNSSRFGKFIRINFDVNGYIVGANIETYLLEK
SRAIRQAKEERTFHIFYYLLSGAGEHLKTDLLLEPYNKYRFLSNGHVTIPGQQDKDMFQETMEAM
RIMGIPEEEQMGLLRVISGVLQLGNIVFKKERNTDQASMPDNTAAQKVSHLLGINVTDFTRGILTP
RIKVGRDYVQKAQTKEQADFAIEALAKATYERMFRWLVLRINKALDKTKRQGASFIGILDIAGFEIF
DLNSFEQLCINYTNEKLQQLFNHTMFILEQEEYQREGIEWNFIDFGLDLQPCIDLIEKPAGPPGILA
LLDEECWFPKATDKSFVEKVMQEQGTHPKFQKPKQLKDKADFCIIHYAGKVDYKADEWLMKNM
DPLNDNIATLLHQSSDKFVSELWKDVDRIIGLDQVAGMSETALPGAFKTRKGMFRTVGQLYKEQ
LAKLMATLRNTNPNFVRCIIPNHEKKAGKLDPHLVLDQLRCNGVLEGIRICRQGFPNRVVFQEFR
QRYEILTPNSIPKGFMDGKQACVLMIKALELDSNLYRIGQSKVFFRAGVLAHLEEERDLKITDVIIGF
QACCRGYLARKAFAKRQQQLTAMKVLQRNCAAYLKLRNWQWWRLFTKVKPLLQVSRQEEEMM
AKEEELVKVREKQLAAENRLTEMETLQSQLMAEKLQLQEQLQAETELCAEAEELRARLTAKKQE
LEEICHDLEARVEEEEERCQHLQAEKKKMQQNIQELEEQLEEEESARQKLQLEKVTTEAKLKKLE
EEQIILEDQNCKLAKEKKLLEDRIAEFTTNLTEEEEKSKSLAKLKNKHEAMITDLEERLRREEKQRQ
ELEKTRRKLEGDSTDLSDQIAELQAQIAELKMQLAKKEEELQAALARVEEEAAQKNMALKKIRELE
SQISELQEDLESERASRNKAEKQKRDLGEELEALKTELEDTLDSTAAQQELRSKREQEVNILKKTL
EEEAKTHEAQIQEMRQKHSQAVEELAEQLEQTKRVKANLEKAKQTLENERGELANEVKVLLQGK
GDSEHKRKKVEAQLQELQVKFNEGERVRTELADKVTKLQVELDNVTGLLSQSDSKSSKLTKDFS
ALESQLQDTQELLQEENRQKLSLSTKLKQVEDEKNSFREQLEEEEEAKHNLEKQIATLHAQVADM
KKKMEDSVGCLETAEEVKRKLQKDLEGLSQRHEEKVAAYDKLEKTKTRLQQELDDLLVDLDHQR
QSACNLEKKQKKFDQLLAEEKTISAKYAEERDRAEAEAREKETKALSLARALEEAMEQKAELERL
NKQFRTEMEDLMSSKDDVGKSVHELEKSKRALEQQVEEMKTQLEELEDELQATEDAKLRLEVNL
QAMKAQFERDLQGRDEQSEEKKKQLVRQVREMEAELEDERKQRSMAVAARKKLEMDLKDLEA
HIDSANKNRDEAIKQLRKLQAQMKDCMRELDDTRASREEILAQAKENEKKLKSMEAEMIQLQEEL
AAAERAKRQAQQERDELADEIANSSGKGALALEEKRRLEARIAQLEEELEEEQGNTELINDRLKK
ANLQIDQINTDLNLERSHAQKNENARQQLERQNKELKVKLQEMEGTVKSKYKASITALEAKIAQLE
EQLDNETKERQAACKQVRRTEKKLKDVLLQVDDERRNAEQYKDQADKASTRLKQLKRQLEEAE
EEAQRANASRRKLQRELEDATETADAMNREVSSLKNKLRRGDLPFVVPRRMARKGAGDGSDE
EVDGKADGAEAKPAE 
Actin (40kDa) 
5 peptides = 86/375 amino acids = 23% peptide coverage 
  
MDDDIAALVVDNGSGMCKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKR
GILTLKYPIEHGIVTNWDDMEKIWHHTFYNELRVAPEEHPVLLTEAPLNPKANREKMTQIMFETFN
TPAMYVAIQAVLSLYASGRTTGIVMDSGDGVTHTVPIYEGYALPHAILRLDLAGRDLTDYLMKILT
ERGYSFTTTAEREIVRDIKEKLCYVALDFEQEMATAASSSSLEKSYELPDGQVITIGNERFRCPEA
LFQPSFLGMESCGIHETTFNSIMKCDVDIRKDLYANTVLSGGTTMYPGIADRMQKEITALAPSTMK
IKIIAPPERKYSVWIGGSILASLSTFQQMWISKQEYDESGPSIVHRKCF 
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Supplementary Figure S9.4: Identification of RUVBL1 peptides by mass spectrometry 
Amino acid sequence of RUVBL1, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
Supplementary Figure S9.5: Identification of RUVBL2 peptides by mass spectrometry 
Amino acid sequence of RUVBL2, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
Supplementary Figure S9.6: Identification of RBBP4 peptides by mass spectrometry 
Amino acid sequence of RBBP4, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
 
 
Supplementary Figure S9.7: Identification of THAP4 peptides by mass spectrometry 
Amino acid sequence of THAP4, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 
RBBP4 (48kDa) 
1 peptide = 10/425 amino acids = 2% peptide coverage 
  
MADKEAAFDDAVEERVINEEYKIWKKNTPFLYDLVMTHALEWPSLTAQWLPDVTRPEGKDFSIH
RLVLGTHTSDEQNHLVIASVQLPNDDAQFDASHYDSEKGEFGGFGSVSGKIEIEIKINHEGEVNR
ARYMPQNPCIIATKTPSSDVLVFDYTKHPSKPDPSGECNPDLRLRGHQKEGYGLSWNPNLSGHL
LSASDDHTICLWDISAVPKEGKVVDAKTIFTGHTAVVEDVSWHLLHESLFGSVADDQKLMIWDTR
SNNTSKPSHSVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLKLHSFESHKDEIFQV
QWSPHNETILASSGTDRRLNVWDLSKIGEEQSPEDAEDGPPELLFIHGGHTAKISDFSWNPNEP
WVICSVSEDNIMQVWQMAENIYNDEDPEGSVDPEGQGS 
THAP4 (63kDa) 
1 peptide = 12/577 amino acids = 2% peptide coverage 
  
MVICCAAVNCSNRQGKGEKRAVSFHRFPLKDSKRLIQWLKAVQRDNWTPTKYSFLCSEHFTKD
SFSKRLEDQHRLLKPTAVPSIFHLTEKKRGAGGHGRTRRKDASKATGGVRGHSSAATSRGAAG
WSPSSSGNPMAKPESRRLKQAALQGEATPRAAQEAASQEQAQQALERTPGDGLATMVAGSQ
GKAEASATDAGDESATSSIEGGVTDKSGISMDDFTPPGSGACKFIGSLHSYSFSSKHTRERPSV
PREPIDRKRLKKDVEPSCSGSSLGPDKGLAQSPPSSSLTATPQKPSQSPSAPPADVTPKPATEA
VQSEHSDASPMSINEVILSASGACKLIDSLHSYCFSSRQNKSQVCCLREQVEKKNGELKSLRQR
VSRSDSQVRKLQEKLDELRRVSVPYPSSLLSPSREPPKMNPVVEPLSWMLGTWLSDPPGAGTY
PTLQPFQYLEEVHISHVGQPMLNFSFNSFHPDTRKPMHRECGFIRLKPDTNKVAFVSAQNTGVV
EVEEGEVNGQELCIASHSIARISFAKEPHVEQITRKFRLNSEGKLEQTVSMATTTQPMTQHLHVT
YKKVTP 
RUVBL1 (50kDa) 
2 peptides = 27/456 amino acids = 6% peptide coverage 
  
MKIEEVKSTTKTQRIASHSHVKGLGLDESGLAKQAASGLVGQENAREACGVIVELIKSKKMAGRA
VLLAGPPGTGKTALALAIAQELGSKVPFCPMVGSEVYSTEIKKTEVLMENFRRAIGLRIKETKEV
YEGEVTELTPCETENPMGGYGKTISHVIIGLKTAKGTKQLKLDPSIFESLQKERVEAGDVIYIEANS
GAVKRQGRCDTYATEFDLEAEEYVPLPKGDVHKKKEIIQDVTLHDLDVANARPQGGQDILSMMG
QLMKPKKTEITDKLRGEINKVVNKYIDQGIAELVPGVLFVDEVHMLDIECFTYLHRALESSIAPIVIF
ASNRGNCVIRGTEDITSPHGIPLDLLDRVMIIRTMLYTPQEMKQIIKIRAQTEGINISEEALNHLGEIG
TKTTLRYSVQLLTPANLLAKINGKDSIEKEHVEEISELFYDAKSSAKILADQQDKYMK 
 
RUVBL2 (51kDa) 
2 peptides = 25/463 amino acids = 5% peptide coverage 
  
MATVTATTKVPEIRDVTRIERIGAHSHIRGLGLDDALEPRQASQGMVGQLAARRAAGVVLEMIRE
GKIAGRAVLIAGQPGTGKTAIAMGMAQALGPDTPFTAIAGSEIFSLEMSKTEALTQAFRRSIGVRIK
EETEIIEGEVVEIQIDRPATGTGSKVGKLTLKTTEMETIYDLGTKMIESLTKDKVQAGDVITIDKATG
KISKLGRSFTRARDYDAMGSQTKFVQCPDGELQKRKEVVHTVSLHEIDVINSRTQGFLALFSGDT
GEIKSEVREQINAKVAEWREEGKAEIIPGVLFIDEVHMLDIESFSFLNRALESDMAPVLIMATNRGI
TRIRGTSYQSPHGIPIDLLDRLLIVSTTPYSEKDTKQILRIRCEEEDVEMSEDAYTVLTRIGLETSLR
YAIQLITAASLVCRKRKGTEVQVDDIKRVYSLFLDESRSTQYMKEYQDAFLFNELKGETMDTS 
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Supplementary Figure S9.8: Identification of SF3b1 peptides by mass spectrometry 
Amino acid sequence of SF3b1, with the peptides identified by LC-MS/MS and correlation with the 
MASCOT database highlighted in bold. 	  	  	  
 	  	  	  	  
Supplementary Figure S9.9: Relative expression levels of RUVBL1 in various tissues 
RUVBL1 expression levels in various tissues according to MOPED, accessible from www.genecards.org 	  
SF3b subunit 1 (120kDa) 
4 peptides = 46/793 amino acids = 6% peptide coverage 
  
MPAGPVQAVPPPPPVPTEPKQPTEEEASSKEDSAPSKPVVGIIYPPPEVRNIVDKTASFVARNGP
EFEARIRQNEINNPKFNFLNPNDPYHAYYRHKVSEFKEGKAQEPSAAIPKVMQQQQQTTQQQLP
QKVQAQVIQETIVPKEPPPEFEFIADPPSISAFDLDVVKLTAQFVARNGRQFLTQLMQKEQRNYQ
FDFLRPQHSLFNYFTKLVEQYTKILIPPKGLFSKLKKEAENPREVLDQVCYRVEWAKFQERERKK
EEEEKEKERVAYAQIDWHDFVVVETVDFQPNEQGNFPPPTTPEELGARILIQERYEKFGESEEV
EMEVESDEEDDKQEKAEEPPSQLDQDTQVQDMDEGSDDEEEGQKVPPPPETPMPPPLPPTPD
QVIVRKDYDPKASKPLPPAPAPDEYLVSPITGEKIPASKMQEHMRIGLLDPRWLEQRDRSIREKQ
SDDEVYAPGLDIESSLKQLAERRTDIFGVEETAIGKKIGEEEIQKPEEKVTWDGHSGSMARTQQA
AQANITLQEQIEAIHKAKGLVPEDDTKEKIGPSKPNEIPQQPPPPSSATNIPSSAPPITSVPRPPTM
PPPVRTTVVSAVPVMPRPPMASVVRLPPGSVIAPMPPIIHAPRINVVPMPPSAPPIMAPRPPPMIV
PTAFVPAPPVAPVPAPAPMPPVHPPPPMEDEPTSKKLKTEDSLMPEEEFLRRNKGPVSIKVQVP
NMQDKTEWKLNGQVLVFTLPLTDQVSVIKVKIHEATGMPAGKQKLQYEGIFIKDSNSLAYYNMAN
GAVIHLALKERGGRKK 
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Supplementary Figure S9.10: Relative expression levels of RUVBL2 in various tissues 
RUVBL2 expression levels in various tissues according to MOPED, accessible from www.genecards.org 
 
 
 	  	  
 
Supplementary Figure S9.11: Relative expression levels of RBBP4 in various tissues 
RBBP4 expression levels in various tissues according to MOPED, accessible from www.genecards.org 
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Supplementary Figure S9.12: Relative expression levels of THAP4 in various tissues 
THAP4 expression levels in various tissues according to MOPED, accessible from www.genecards.org 	  	  	  	  	  
Supplementary Figure S9.13: Relative expression levels of SF3b1 in various tissues 
SF3b1 expression levels in various tissues according to MOPED, accessible from www.genecards.org 	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Supplementary Figure S9.14: Demonstration of IRF5-STAT1/STAT3 interactions  
1x107 HEK293-TLR4 cells were transduced with One-Strep IRF5, One-Strep RelA or the One-Strep tag 
alone using adenoviral vectors for 2 hours serum-free at an MOI of 5.  After 24 hours, the cells were lysed 
with cytoplasmic lysis buffer containing protease inhibitors.  Nuclear pellets were lysed with RIPA lysis 
buffer containing protease inhibitors, and subjected to sonication (30 second pulses for 8 minutes). One-
Strep affinity purification was carried out on the lysates, with 12x 1 ml washes using ChIP wash buffer and 
6x 50 µl elutions with biotin elution buffer (elutions pooled to 300 µl and concentrated to 50 µl).  100% of 
the total eluate was run on SDS-PAGE gel, followed by transfer to PVDF membrane and Western blotting 
with Strep, STAT1 and STAT3 specific antibodies.  WB = Western blot. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
Supplementary Figure S9.15: Demonstration of IRF5-Runx1 interactions  
1x107 HEK293-TLR4 cells were transduced with One-Strep IRF5 or the One-Strep tag alone using 
adenoviral vectors for 2 hours serum-free at an MOI of 5.  After 24 hours, the cells were lysed with total 
cell lysis buffer containing protease inhibitors.  One-Strep affinity purification was carried out on the 
lysates, with 12x 1 ml washes using ChIP wash buffer and 6x 50 µl elutions with biotin elution buffer 
(elutions pooled to 300 µl and concentrated to 50 µl).  100% of the total eluate was run on SDS-PAGE gel, 
followed by transfer to PVDF membrane and Western blotting with Strep and Runx1 specific antibodies.  
WB = Western blot. 
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Supplementary Figure S9.16: KAP1 promotes deposition of H3K9me3 at 3’ of human Tnf gene  
ChIP to show changes in deposition of H3K9me3 at the human Tnf 3’ locus and a negative control 
intergenic region in human M1 macrophages subjected to siRNA knock-down of KAP1 and LPS 
stimulation (see Figure 4.19).  Data from three individual human donors, error bars show mean +/- 
standard deviation. 	  
 
 
 
 
 
Supplementary Figure S9.17: Mammalian Two-hybrid optimisation 
IRF5 and RelA expression constructs (cloned into PAct and PBind vectors from the Checkmate kit, 
Promega) and reporter constructs were transfected into 1x105 HEK293-TLR4 cells by Lipofectamine 2000 
transfection and incubated overnight at 37°C.  Firefly luciferase levels (normalised to Renilla) were 
measured using a DualGo Luciferase assay (Promega, USA) to show the degree of interaction between 
expressed proteins.  Representative experiment, error bars show SD of triplicate wells) 	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Supplementary Figure S9.18: Protein-protein interaction ELISA optimisation 
 
HEK293-TLR4/CD14/Md2 cells (1x107) were transfected with expression plasmids containing Strep-or 
Flag-tagged proteins by Lipofectamine 2000 reagent, in order to induce exogenous expression of these 
proteins/tags.  Following 24 hours, the cells were lysed on ice for 30 minutes with 1 ml chilled total cell 
lysis buffer with added protease inhibitors.  The resulting lysates were cleared by centrifugation to remove 
cellular debris, then Strep-tagged bait proteins were applied to Streptactin plates for 1 hour at room 
temperature.  Following 3 washes with PBS + 0.05% v/v Tween, Flag-tagged prey lysates were applied, 
diluted in PBS + 1% w/v BSA, for 2 hours at room temperature.  Following 3 washes with PBS + 0.05% v/v 
Tween, Flag-HRP antibody was applied for 1 hour at room temperature, then the plate washed with PBS + 
0.05% v/v Tween.  Relative absorbance following addition of TMB substrate was measured to show the 
degree of interaction between Strep-tagged bait protein lysates and varying dilutions of Flag-tagged prey 
protein lysates.  Representative experiment. 	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